{"docstore/data": {"40c59cb6-ec27-4d2d-862a-c3f6edc23738": {"__data__": {"id_": "40c59cb6-ec27-4d2d-862a-c3f6edc23738", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call . ", "original_text": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65f1f320-e7bb-45f1-904f-79ff82bd6bf7", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad . ", "original_text": "Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall. "}, "hash": "2af6caa241bddb812b5669873aaf44332d365f9e9fc0978e71325676dc30f03d", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65f1f320-e7bb-45f1-904f-79ff82bd6bf7": {"__data__": {"id_": "65f1f320-e7bb-45f1-904f-79ff82bd6bf7", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad . ", "original_text": "Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40c59cb6-ec27-4d2d-862a-c3f6edc23738", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call . ", "original_text": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3262c248f76bbce871a924fe0fbe347fe50b19c42b6b4afc05ebda50e8a5c832", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f5a7aeb-ba46-4be2-8782-6976e4f59d70", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr . ", "original_text": "Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly. "}, "hash": "d50c3c70d91417d7cf50c3559a191a79b5b8cd99f0aeca69bdffbfb348999180", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall. ", "start_char_idx": 48, "end_char_idx": 218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f5a7aeb-ba46-4be2-8782-6976e4f59d70": {"__data__": {"id_": "4f5a7aeb-ba46-4be2-8782-6976e4f59d70", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr . ", "original_text": "Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65f1f320-e7bb-45f1-904f-79ff82bd6bf7", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad . ", "original_text": "Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1886c5bd7e3511ab6c88bc201c7d7ecf1cf3eab98078b0ba8b0937e52609c1b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b77c5f9f-c8c9-45af-9287-e8df0b9ac0ff", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference . ", "original_text": "However, you will have the opportunity to ask questions at the end of the call . "}, "hash": "89024a6bb3862803a2a6c42fb9d6ff36f858c80e6e35e8216af7488cb3865049", "class_name": "RelatedNodeInfo"}}, "text": "Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly. ", "start_char_idx": 218, "end_char_idx": 329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b77c5f9f-c8c9-45af-9287-e8df0b9ac0ff": {"__data__": {"id_": "b77c5f9f-c8c9-45af-9287-e8df0b9ac0ff", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference . ", "original_text": "However, you will have the opportunity to ask questions at the end of the call . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f5a7aeb-ba46-4be2-8782-6976e4f59d70", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr . ", "original_text": "Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d52f028d0099afe0cc81b1918abf37b69f89546e1099bed0b61d9e29dc4b022f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3092d54a-59d3-4c8d-ac78-5ad0e3d469f0", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n", "original_text": "This can be done \nby pressing star one on your telephone keypad . "}, "hash": "9908b727aa82bdbc9559b139fa64765434950785f528f1eaffed66fd228c21e5", "class_name": "RelatedNodeInfo"}}, "text": "However, you will have the opportunity to ask questions at the end of the call . ", "start_char_idx": 329, "end_char_idx": 410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3092d54a-59d3-4c8d-ac78-5ad0e3d469f0": {"__data__": {"id_": "3092d54a-59d3-4c8d-ac78-5ad0e3d469f0", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n", "original_text": "This can be done \nby pressing star one on your telephone keypad . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b77c5f9f-c8c9-45af-9287-e8df0b9ac0ff", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference . ", "original_text": "However, you will have the opportunity to ask questions at the end of the call . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d8a1320bd29b78b042687c7b5eb1a03302a61a8f816f14cc98ce795568345d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e029378-f87d-4f5c-901f-7208f3569a00", "node_type": "1", "metadata": {"window": "Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning. ", "original_text": "I will now hand over to your host, Mr . "}, "hash": "f0b0719ab7bf3d6ba21a1cecbcbc7770d8a44197663d0fde5ab17e43e6221abd", "class_name": "RelatedNodeInfo"}}, "text": "This can be done \nby pressing star one on your telephone keypad . ", "start_char_idx": 410, "end_char_idx": 476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e029378-f87d-4f5c-901f-7208f3569a00": {"__data__": {"id_": "1e029378-f87d-4f5c-901f-7208f3569a00", "embedding": null, "metadata": {"window": "Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning. ", "original_text": "I will now hand over to your host, Mr . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3092d54a-59d3-4c8d-ac78-5ad0e3d469f0", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n", "original_text": "This can be done \nby pressing star one on your telephone keypad . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c90c96da86b9da24dbc9cf44ca4e6234eb8c30f3a0a5d337ec0a74907f0e3e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c18cc781-3496-47eb-94c9-f5ccbcc3aed5", "node_type": "1", "metadata": {"window": "However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome. ", "original_text": "Kevin Mo ran, \nVP of Investor Relations, to begin today's conference . "}, "hash": "32bbc01b93876d1aa8d5b69140491f21dc53547c7c06f3775e82e0e9ad3e9187", "class_name": "RelatedNodeInfo"}}, "text": "I will now hand over to your host, Mr . ", "start_char_idx": 476, "end_char_idx": 516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c18cc781-3496-47eb-94c9-f5ccbcc3aed5": {"__data__": {"id_": "c18cc781-3496-47eb-94c9-f5ccbcc3aed5", "embedding": null, "metadata": {"window": "However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome. ", "original_text": "Kevin Mo ran, \nVP of Investor Relations, to begin today's conference . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e029378-f87d-4f5c-901f-7208f3569a00", "node_type": "1", "metadata": {"window": "Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning. ", "original_text": "I will now hand over to your host, Mr . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51507e72123946941acb4b18342a6f58ff732d495ab6f3dfc36c2e7e469a780c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66634b70-d7ee-43ee-9f66-0bbff9cd7545", "node_type": "1", "metadata": {"window": "This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook. ", "original_text": "Thank you.  \n \n"}, "hash": "675c26955d65b289c1e1195f9138a62fd8c915b9d0e0adb9b2afa36c547de552", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Mo ran, \nVP of Investor Relations, to begin today's conference . ", "start_char_idx": 516, "end_char_idx": 587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66634b70-d7ee-43ee-9f66-0bbff9cd7545": {"__data__": {"id_": "66634b70-d7ee-43ee-9f66-0bbff9cd7545", "embedding": null, "metadata": {"window": "This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook. ", "original_text": "Thank you.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c18cc781-3496-47eb-94c9-f5ccbcc3aed5", "node_type": "1", "metadata": {"window": "However, you will have the opportunity to ask questions at the end of the call .  This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome. ", "original_text": "Kevin Mo ran, \nVP of Investor Relations, to begin today's conference . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64cd4e5f72b564e24a1870ef0c9abbeac7dfdae6b5fcde9f4975e49a7d4dfa29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fd068f4-e07e-4a32-b36d-8a1607040c04", "node_type": "1", "metadata": {"window": "I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "original_text": "Kevin Moran :   Good morning. "}, "hash": "caf5bd70681bd536a587db6e65401d56fade282d0472d37c30057be8f96d0b5e", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 587, "end_char_idx": 602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fd068f4-e07e-4a32-b36d-8a1607040c04": {"__data__": {"id_": "6fd068f4-e07e-4a32-b36d-8a1607040c04", "embedding": null, "metadata": {"window": "I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "original_text": "Kevin Moran :   Good morning. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66634b70-d7ee-43ee-9f66-0bbff9cd7545", "node_type": "1", "metadata": {"window": "This can be done \nby pressing star one on your telephone keypad .  I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook. ", "original_text": "Thank you.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84568d6e13447de8da53b24ce957c4f2a53685da07ff940f07076438305a9123", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "327584de-bd37-4cda-90f3-cd945b22e8a8", "node_type": "1", "metadata": {"window": "Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n", "original_text": "And welcome. "}, "hash": "2ba9d67bf5a2cb8242bb42251d81f3ca81c522cc1c783112c53619c352826df8", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran :   Good morning. ", "start_char_idx": 602, "end_char_idx": 632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "327584de-bd37-4cda-90f3-cd945b22e8a8": {"__data__": {"id_": "327584de-bd37-4cda-90f3-cd945b22e8a8", "embedding": null, "metadata": {"window": "Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n", "original_text": "And welcome. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fd068f4-e07e-4a32-b36d-8a1607040c04", "node_type": "1", "metadata": {"window": "I will now hand over to your host, Mr .  Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "original_text": "Kevin Moran :   Good morning. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a37a69229db6869ca56e73871d575c3553918467e94b6fb64cc6dee2c96ebeb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e9141bc-fa23-4b4b-bce8-ceed288e1403", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements. ", "original_text": "Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook. "}, "hash": "82d364def821e9fb48117dd50654ef2569a3a75d35f19ea9bb8196d6cbc8436f", "class_name": "RelatedNodeInfo"}}, "text": "And welcome. ", "start_char_idx": 632, "end_char_idx": 645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e9141bc-fa23-4b4b-bce8-ceed288e1403": {"__data__": {"id_": "1e9141bc-fa23-4b4b-bce8-ceed288e1403", "embedding": null, "metadata": {"window": "Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements. ", "original_text": "Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "327584de-bd37-4cda-90f3-cd945b22e8a8", "node_type": "1", "metadata": {"window": "Kevin Mo ran, \nVP of Investor Relations, to begin today's conference .  Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n", "original_text": "And welcome. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72567de9d22d8a2bed0acf90e3a626d29d0095ec67d881f7ea9e87ff5d9eefd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d28c4d5-fd9c-4c14-b1c4-5efb1331ef65", "node_type": "1", "metadata": {"window": "Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com . "}, "hash": "8d4cc5896498776db774ecc507ecb98e295d5304d7e993ef7579c01526e02374", "class_name": "RelatedNodeInfo"}}, "text": "Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook. ", "start_char_idx": 645, "end_char_idx": 768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d28c4d5-fd9c-4c14-b1c4-5efb1331ef65": {"__data__": {"id_": "8d28c4d5-fd9c-4c14-b1c4-5efb1331ef65", "embedding": null, "metadata": {"window": "Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e9141bc-fa23-4b4b-bce8-ceed288e1403", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements. ", "original_text": "Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84ecda873240d3c978373755ba06fa6975d9e74c0213f49b6e4dd38ca420e511", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccdc05ae-47c7-4b56-9864-a40bb13cf39f", "node_type": "1", "metadata": {"window": "And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "original_text": "Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n"}, "hash": "6629224abfe63a4f26f999c5d75bf999a1d9c70740d32a785e03b3f938d9843d", "class_name": "RelatedNodeInfo"}}, "text": "You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "start_char_idx": 768, "end_char_idx": 891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccdc05ae-47c7-4b56-9864-a40bb13cf39f": {"__data__": {"id_": "ccdc05ae-47c7-4b56-9864-a40bb13cf39f", "embedding": null, "metadata": {"window": "And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "original_text": "Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d28c4d5-fd9c-4c14-b1c4-5efb1331ef65", "node_type": "1", "metadata": {"window": "Kevin Moran :   Good morning.  And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fb8053f5b081c51d5cf2a7ebb01f1e7473275e00a3938ee872cdd053923a4ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab5a43fe-253f-4033-a688-baa0511dcb18", "node_type": "1", "metadata": {"window": "Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call we will be making forward -looking statements. "}, "hash": "75ce31cf8f13a0b7ebdfaf42cba34984de944fda4189e75bb4462672d4e27b31", "class_name": "RelatedNodeInfo"}}, "text": "Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n", "start_char_idx": 891, "end_char_idx": 1105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab5a43fe-253f-4033-a688-baa0511dcb18": {"__data__": {"id_": "ab5a43fe-253f-4033-a688-baa0511dcb18", "embedding": null, "metadata": {"window": "Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccdc05ae-47c7-4b56-9864-a40bb13cf39f", "node_type": "1", "metadata": {"window": "And welcome.  Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "original_text": "Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec6bfa10371798460b91552137d13c2330ea3be0b8ee1d2e09177d567f99311e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51630290-54e3-4395-afe8-60b311f5b2ac", "node_type": "1", "metadata": {"window": "You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied . "}, "hash": "20f8275d11d2e616af355b1348e0221f81dadda8c0d5c46f40035e74d06f2e5e", "class_name": "RelatedNodeInfo"}}, "text": "During the call we will be making forward -looking statements. ", "start_char_idx": 1105, "end_char_idx": 1168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51630290-54e3-4395-afe8-60b311f5b2ac": {"__data__": {"id_": "51630290-54e3-4395-afe8-60b311f5b2ac", "embedding": null, "metadata": {"window": "You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab5a43fe-253f-4033-a688-baa0511dcb18", "node_type": "1", "metadata": {"window": "Today we will discuss Cardinal Health\u2019s  Second -\nQuarter Fiscal 2023 results along with updates to our full year outlook.  You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b70295c61b00dff79db547bf910a2b5e2ef6d415123a53b98a98d1d764fecb60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6f62471-5cb3-420b-8696-0272130e7647", "node_type": "1", "metadata": {"window": "Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. "}, "hash": "5603d4c4a4adbc11dec921ff47fcc514b3f780e23b17285b2a3c62dbe966ce26", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "start_char_idx": 1168, "end_char_idx": 1337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6f62471-5cb3-420b-8696-0272130e7647": {"__data__": {"id_": "c6f62471-5cb3-420b-8696-0272130e7647", "embedding": null, "metadata": {"window": "Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51630290-54e3-4395-afe8-60b311f5b2ac", "node_type": "1", "metadata": {"window": "You can find today\u2019s p ress \nrelease and earnings presentation on the IR section of our website at ir.cardinalhealth.com .  Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a46f3d8d2a0007d85b3ba975875d5905378bc8f14a4876c5e121b507a38417ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd452422-4bea-41e0-bc92-4d82791f9128", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. "}, "hash": "15a1c1b4fd7b77dbe7c672173fab888a04038221db1745e4ab81a1acea085492", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "start_char_idx": 1337, "end_char_idx": 1505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd452422-4bea-41e0-bc92-4d82791f9128": {"__data__": {"id_": "dd452422-4bea-41e0-bc92-4d82791f9128", "embedding": null, "metadata": {"window": "During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6f62471-5cb3-420b-8696-0272130e7647", "node_type": "1", "metadata": {"window": "Joining \nme today are Jason Hollar, our Chief Executive Officer,  Trish English,  our Interim Chief Financial \nOfficer, and Aaron Alt, who will take over as our Chief Financial Officer beginning February 10th.  \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f42ec17a0d24b4df7f35aec207e201d9bb4c6a0ef7c81386835d70e813a7336", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dd9cdc7-705d-451b-8ecd-b8874433755e", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n"}, "hash": "a30e0605d4cacfbf5fd5ce17938e1852e325bce1eae0a4fa012c36fa499bd78c", "class_name": "RelatedNodeInfo"}}, "text": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "start_char_idx": 1505, "end_char_idx": 1645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dd9cdc7-705d-451b-8ecd-b8874433755e": {"__data__": {"id_": "4dd9cdc7-705d-451b-8ecd-b8874433755e", "embedding": null, "metadata": {"window": "The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd452422-4bea-41e0-bc92-4d82791f9128", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff2bf5722a87c1c4fade8b4b392b6cbfd4c2ca4606cfb640c78eb6c2cffa756a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48d74772-2354-4594-ba84-029550fa729b", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  "}, "hash": "44da0c4d2ae313e4094a3b8825aa11f657ade0482d6df9c2c9ab3a8c64f8677f", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "start_char_idx": 1645, "end_char_idx": 1770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48d74772-2354-4594-ba84-029550fa729b": {"__data__": {"id_": "48d74772-2354-4594-ba84-029550fa729b", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dd9cdc7-705d-451b-8ecd-b8874433755e", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to risks and  uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c64b494a4c65d35b4e8c359b4dc0ce673069b070b3807ece93793d2a09de53f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f7f06fa-6cce-4390-9709-8b98134db78c", "node_type": "1", "metadata": {"window": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard. ", "original_text": "With that, I will now turn the call \nover the Jason.  \n \n"}, "hash": "a6bd0f52d22e978f11732309bf11ee1470e3bc0685f6759a16f6cb10edb2890c", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "start_char_idx": 1770, "end_char_idx": 1941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f7f06fa-6cce-4390-9709-8b98134db78c": {"__data__": {"id_": "4f7f06fa-6cce-4390-9709-8b98134db78c", "embedding": null, "metadata": {"window": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard. ", "original_text": "With that, I will now turn the call \nover the Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48d74772-2354-4594-ba84-029550fa729b", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.  ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6bd7e2172161aee4f4597c694fc69de0ea4d831b8e73b13f971263102c619cfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0215de7a-f500-43ef-99f4-2d6b0cb67192", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks. ", "original_text": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n"}, "hash": "6bc4cfeec1f603fce6475021c59a9ea28c40fc471fd2e720ee8a2e673b7ab423", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will now turn the call \nover the Jason.  \n \n", "start_char_idx": 1941, "end_char_idx": 1998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0215de7a-f500-43ef-99f4-2d6b0cb67192": {"__data__": {"id_": "0215de7a-f500-43ef-99f4-2d6b0cb67192", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks. ", "original_text": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f7f06fa-6cce-4390-9709-8b98134db78c", "node_type": "1", "metadata": {"window": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard. ", "original_text": "With that, I will now turn the call \nover the Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b69aa2fa2ad97bbfe0d35e063dd8c30c48a16ac9dfc41c128518cc279685640c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8905862-e7fa-47d7-a7a5-3689acaea323", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n", "original_text": "Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n"}, "hash": "60656bb1256267635e9ec8be35a4317fa5746d8c9fa2ff16abcd00cd3ca2c045", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "start_char_idx": 1998, "end_char_idx": 2062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8905862-e7fa-47d7-a7a5-3689acaea323": {"__data__": {"id_": "f8905862-e7fa-47d7-a7a5-3689acaea323", "embedding": null, "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n", "original_text": "Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0215de7a-f500-43ef-99f4-2d6b0cb67192", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks. ", "original_text": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "beca412527546008e7108cdc4bb9793e54c294540b8a12b159352976091f75d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aca04cea-8371-4a36-89aa-31c9a069b388", "node_type": "1", "metadata": {"window": "With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n", "original_text": "We\u2019re excited to have Aaron onboard. "}, "hash": "f70286d4cacc22a811dc081ab6f9359d6ce8cbad3fd1328e7dd115c0bc104906", "class_name": "RelatedNodeInfo"}}, "text": "Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n", "start_char_idx": 2062, "end_char_idx": 2193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aca04cea-8371-4a36-89aa-31c9a069b388": {"__data__": {"id_": "aca04cea-8371-4a36-89aa-31c9a069b388", "embedding": null, "metadata": {"window": "With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n", "original_text": "We\u2019re excited to have Aaron onboard. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8905862-e7fa-47d7-a7a5-3689acaea323", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to one question, \nso that we can try and give everyone in the queue an opportunity.   With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n", "original_text": "Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed56c0d799bdb89979e0c640ab19f2f4ec83d33992111e74aedc40f7e07dc1be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7f9ab1a-88fb-4c59-b9df-f7eb9d241148", "node_type": "1", "metadata": {"window": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry. ", "original_text": "He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks. "}, "hash": "5bb0c1289b14e6ef7a48ab091f07a00d7a18b77aea2d46228cfcaff7231993a0", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re excited to have Aaron onboard. ", "start_char_idx": 2193, "end_char_idx": 2230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7f9ab1a-88fb-4c59-b9df-f7eb9d241148": {"__data__": {"id_": "a7f9ab1a-88fb-4c59-b9df-f7eb9d241148", "embedding": null, "metadata": {"window": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry. ", "original_text": "He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aca04cea-8371-4a36-89aa-31c9a069b388", "node_type": "1", "metadata": {"window": "With that, I will now turn the call \nover the Jason.  \n \n Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n", "original_text": "We\u2019re excited to have Aaron onboard. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0de4418a1ffb28984b6aecbe677374de8e1521090dfacc09da0002f3bb6c300", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3421c8f5-d2ae-4e3a-a1db-9b2b870cac48", "node_type": "1", "metadata": {"window": "Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win. ", "original_text": "I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n"}, "hash": "b3d711edd0dc73518f1a5b82114690af2959bc9873d7fd73d703356777c58423", "class_name": "RelatedNodeInfo"}}, "text": "He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks. ", "start_char_idx": 2230, "end_char_idx": 2417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3421c8f5-d2ae-4e3a-a1db-9b2b870cac48": {"__data__": {"id_": "3421c8f5-d2ae-4e3a-a1db-9b2b870cac48", "embedding": null, "metadata": {"window": "Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win. ", "original_text": "I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7f9ab1a-88fb-4c59-b9df-f7eb9d241148", "node_type": "1", "metadata": {"window": "Jason Hollar :   Thanks, Kevin, and good morning, everyone.  \n \n Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry. ", "original_text": "He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d916c503982ddebb6973769d27d75c5dcc59c276dcd387754c8ce015dfa5ca7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c688c43-7107-4c63-b440-d3d8f758e413", "node_type": "1", "metadata": {"window": "We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "Aaron Alt:  Thanks Jason, and good morning.  \n \n"}, "hash": "141c3334958c424b0f4e68c1a9494097cc9362a858c1c51e4680dd890d3012fd", "class_name": "RelatedNodeInfo"}}, "text": "I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n", "start_char_idx": 2417, "end_char_idx": 2598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c688c43-7107-4c63-b440-d3d8f758e413": {"__data__": {"id_": "0c688c43-7107-4c63-b440-d3d8f758e413", "embedding": null, "metadata": {"window": "We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "Aaron Alt:  Thanks Jason, and good morning.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3421c8f5-d2ae-4e3a-a1db-9b2b870cac48", "node_type": "1", "metadata": {"window": "Before we dive in, I\u2019d like to take a moment to welcome Aaron Alt to Cardinal Health as our incoming \nChief Financial Officer.  \n \n We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win. ", "original_text": "I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e90fde5f27d7d17e5364938b03da54a8a2d33795ef6e2114f7daa65084ee17de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b613e4fc-d8ac-4aad-bc4e-d2eaa77247a6", "node_type": "1", "metadata": {"window": "He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry. "}, "hash": "2406a62ffb31e03c24b0fb6752967352b387061d0b0b5c517a510ecc8ce7d912", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  Thanks Jason, and good morning.  \n \n", "start_char_idx": 2598, "end_char_idx": 2646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b613e4fc-d8ac-4aad-bc4e-d2eaa77247a6": {"__data__": {"id_": "b613e4fc-d8ac-4aad-bc4e-d2eaa77247a6", "embedding": null, "metadata": {"window": "He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c688c43-7107-4c63-b440-d3d8f758e413", "node_type": "1", "metadata": {"window": "We\u2019re excited to have Aaron onboard.  He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "Aaron Alt:  Thanks Jason, and good morning.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825b23198b06c62ae81a4649d844014669225d105f3b19ae54f61f5e405542c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ef9cba6-7404-4ced-a52d-d32c58de4552", "node_type": "1", "metadata": {"window": "I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win. "}, "hash": "d5ec19b4f2dc3074ac609859bebe6dccfdb6a90a4c4ca1db47f8ac27ac793160", "class_name": "RelatedNodeInfo"}}, "text": "I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry. ", "start_char_idx": 2646, "end_char_idx": 2806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ef9cba6-7404-4ced-a52d-d32c58de4552": {"__data__": {"id_": "7ef9cba6-7404-4ced-a52d-d32c58de4552", "embedding": null, "metadata": {"window": "I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b613e4fc-d8ac-4aad-bc4e-d2eaa77247a6", "node_type": "1", "metadata": {"window": "He brings a breadth of financial and operational experience to \nour organization, including a background in distribution, and he\u2019s already hit the ground running in his \nfirst few weeks.  I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "040676bc7231bf31c469f0bb610258607391e34b9799e754f7f863c9621f5054", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7a0ad06-b541-49b7-83c2-fbea7acbf26f", "node_type": "1", "metadata": {"window": "Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "While still early "}, "hash": "6fc2bfc138b099610bf52c7ac5e3341053ed283602fbc37f01c2f09a93a0af0d", "class_name": "RelatedNodeInfo"}}, "text": "What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win. ", "start_char_idx": 2806, "end_char_idx": 2938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7a0ad06-b541-49b7-83c2-fbea7acbf26f": {"__data__": {"id_": "f7a0ad06-b541-49b7-83c2-fbea7acbf26f", "embedding": null, "metadata": {"window": "Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "While still early ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f2621361e47503ccf0c0de73ac6ec16011ca41bd81c0f089d3a7765a0434a13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ef9cba6-7404-4ced-a52d-d32c58de4552", "node_type": "1", "metadata": {"window": "I am confident he will be a valuable addition as the leader of our finance organization, \ncontributor to our Executive Committee, and a seamless fit with our compa ny culture .  \n \n Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba7751e02d19604e7cb831004b43cd9025660e15d727f9abc4d47c3184eac33d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a5e9ae7-34a0-4abf-9608-9a58ff73b2fe", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n", "original_text": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n"}, "hash": "e3d7783847e522e80b70bfe19990427dae2f1fff28266b4ba9129dfff039f125", "class_name": "RelatedNodeInfo"}}, "text": "While still early ", "start_char_idx": 2938, "end_char_idx": 2956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a5e9ae7-34a0-4abf-9608-9a58ff73b2fe": {"__data__": {"id_": "0a5e9ae7-34a0-4abf-9608-9a58ff73b2fe", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n", "original_text": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7a0ad06-b541-49b7-83c2-fbea7acbf26f", "node_type": "1", "metadata": {"window": "Aaron Alt:  Thanks Jason, and good morning.  \n \n I am excited to be part of the team here at Cardinal, particularly at such an important time, not only for \nour company but for the entire healthcare industry.  What attracted me to Cardinal Health w as the \nbroad portfolio, the overall culture and a leadership team that is motivated to win.  While still early ", "original_text": "While still early ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64e8f8d9eb7b2e970cf75a69e9efb16ec5eea34ab7fadcbc755fcf79caf78569", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6216ea0d-a1a1-477b-abc5-75d59248bc35", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n", "original_text": "I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n"}, "hash": "0b3d3113967b7865976910fcc3618c8caeb1625a96ed600d72d06d3ed9c9a07e", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n", "start_char_idx": 0, "end_char_idx": 195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6216ea0d-a1a1-477b-abc5-75d59248bc35": {"__data__": {"id_": "6216ea0d-a1a1-477b-abc5-75d59248bc35", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n", "original_text": "I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a5e9ae7-34a0-4abf-9608-9a58ff73b2fe", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n", "original_text": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f7dc4cb379562b3ac91174e2427df33569db82887e26bfeed81e1462b83a093", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af5be324-9283-45b0-9557-e3eddcb186a6", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness. ", "original_text": "Jason Hollar:   Thanks, Aaron. "}, "hash": "48f51c5ad4e8a918047ec9a267725ce22d70e4496ddf95688220239a3f564b5f", "class_name": "RelatedNodeInfo"}}, "text": "I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n", "start_char_idx": 195, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af5be324-9283-45b0-9557-e3eddcb186a6": {"__data__": {"id_": "af5be324-9283-45b0-9557-e3eddcb186a6", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness. ", "original_text": "Jason Hollar:   Thanks, Aaron. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6216ea0d-a1a1-477b-abc5-75d59248bc35", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n", "original_text": "I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f770c31bde10fa7c76940fdf1d6cc34f6e0cf40a2eec1e15257a3fdc8d5790d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e0ae0dc-ae82-44f8-9640-fa9be3ffaf44", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program. ", "original_text": "Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n"}, "hash": "8e2e37e2e33031fd8ef9d0e2d3bc678ddeba1e3efff2146b8aaca077d7b120bc", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:   Thanks, Aaron. ", "start_char_idx": 309, "end_char_idx": 340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e0ae0dc-ae82-44f8-9640-fa9be3ffaf44": {"__data__": {"id_": "8e0ae0dc-ae82-44f8-9640-fa9be3ffaf44", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program. ", "original_text": "Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af5be324-9283-45b0-9557-e3eddcb186a6", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness. ", "original_text": "Jason Hollar:   Thanks, Aaron. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77d5c09e9eec7758baccb479c6cebb6b7f364239a6fc5a0f91a52405cba4e44e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0c33dc3-6892-4e23-aac2-f055042a787d", "node_type": "1", "metadata": {"window": "I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus. ", "original_text": "Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n"}, "hash": "3eb8cd9da8ff12488e25ab4ab13c472591a8bf01ec46b2e9be81e6af5706ff4a", "class_name": "RelatedNodeInfo"}}, "text": "Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n", "start_char_idx": 340, "end_char_idx": 419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0c33dc3-6892-4e23-aac2-f055042a787d": {"__data__": {"id_": "d0c33dc3-6892-4e23-aac2-f055042a787d", "embedding": null, "metadata": {"window": "I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus. ", "original_text": "Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e0ae0dc-ae82-44f8-9640-fa9be3ffaf44", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program. ", "original_text": "Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d240f9885b3cfef4fc02a1ef852dd51367bb2a9925641193e91ad592750762b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21436b26-d3f9-476b-8dad-ac6f91cada08", "node_type": "1", "metadata": {"window": "Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains. ", "original_text": "In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness. "}, "hash": "3be8d282dbdda6a94f7642ca547191489bd3d9f2dface28fb5ede9f5a16d1c7c", "class_name": "RelatedNodeInfo"}}, "text": "Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n", "start_char_idx": 419, "end_char_idx": 499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21436b26-d3f9-476b-8dad-ac6f91cada08": {"__data__": {"id_": "21436b26-d3f9-476b-8dad-ac6f91cada08", "embedding": null, "metadata": {"window": "Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains. ", "original_text": "In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0c33dc3-6892-4e23-aac2-f055042a787d", "node_type": "1", "metadata": {"window": "I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus. ", "original_text": "Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "003ee957b8ea578c922f4bd64dea954f23f6ee890d3be2bc254e62326f5fce29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d18904c-7613-4a5c-a0de-d36740f8efea", "node_type": "1", "metadata": {"window": "Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n", "original_text": "In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program. "}, "hash": "7f94eac1adff88c659ee5f7df72ea8a089ca2fdb7e3ba3064e5ceb99ff4e63ef", "class_name": "RelatedNodeInfo"}}, "text": "In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness. ", "start_char_idx": 499, "end_char_idx": 605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d18904c-7613-4a5c-a0de-d36740f8efea": {"__data__": {"id_": "9d18904c-7613-4a5c-a0de-d36740f8efea", "embedding": null, "metadata": {"window": "Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n", "original_text": "In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21436b26-d3f9-476b-8dad-ac6f91cada08", "node_type": "1", "metadata": {"window": "Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains. ", "original_text": "In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70da2ad7a42709724a98c80179c5e368a4182191aebccad08bb3c8eaa085717e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6584d86-8286-4e51-a68d-588d345c3428", "node_type": "1", "metadata": {"window": "Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives. ", "original_text": "We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus. "}, "hash": "dde618251ef03f1e7d234700d066575923fe8cf6af6134b5f8b9f492b42855b9", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program. ", "start_char_idx": 605, "end_char_idx": 732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6584d86-8286-4e51-a68d-588d345c3428": {"__data__": {"id_": "b6584d86-8286-4e51-a68d-588d345c3428", "embedding": null, "metadata": {"window": "Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives. ", "original_text": "We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d18904c-7613-4a5c-a0de-d36740f8efea", "node_type": "1", "metadata": {"window": "Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n", "original_text": "In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9939625f21c169f4bbf8f498d25be283999725edba5903251f50c93d4730b60d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b84cb09-5b78-43a1-bef5-be35831cec0f", "node_type": "1", "metadata": {"window": "In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter. ", "original_text": "And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains. "}, "hash": "217f7720d92881aae7affcb8419b0e5a2384616ca1790b20cbcc6f2c4e555899", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus. ", "start_char_idx": 732, "end_char_idx": 834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b84cb09-5b78-43a1-bef5-be35831cec0f": {"__data__": {"id_": "6b84cb09-5b78-43a1-bef5-be35831cec0f", "embedding": null, "metadata": {"window": "In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter. ", "original_text": "And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6584d86-8286-4e51-a68d-588d345c3428", "node_type": "1", "metadata": {"window": "Overall, our Q 2 results demonstrated continued momentum against our plans.  \n \n In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives. ", "original_text": "We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e42d5b03c7e2cb64d59c41dfe660aa74bf1c6bffac88ff9b66a65ef2126ca3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b680782-520d-4109-8858-dc28d749c731", "node_type": "1", "metadata": {"window": "In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n", "original_text": "In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n"}, "hash": "8ffa2434e6797d1ced7b5e795f8d5309a8a6613b6847f465c7e8ec56264ad80d", "class_name": "RelatedNodeInfo"}}, "text": "And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains. ", "start_char_idx": 834, "end_char_idx": 943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b680782-520d-4109-8858-dc28d749c731": {"__data__": {"id_": "3b680782-520d-4109-8858-dc28d749c731", "embedding": null, "metadata": {"window": "In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n", "original_text": "In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b84cb09-5b78-43a1-bef5-be35831cec0f", "node_type": "1", "metadata": {"window": "In Pharma, we\u2019ve seen ongoing stability in the macro trends and underlying fundamentals of the \nbusiness.  In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter. ", "original_text": "And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "529158c1b9619a30c6dd3f285e65f36d44a3101c7281fb6dbbb2c31f4e98b877", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f1a02fc-5157-4f98-93f2-c24942e8666b", "node_type": "1", "metadata": {"window": "We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n", "original_text": "In Medical, we remain highly -focused on our Medical Improvement Plan initiatives. "}, "hash": "8bcd15f3da66c667b65784499f45030753eb8b831180df8555f86d509b798f99", "class_name": "RelatedNodeInfo"}}, "text": "In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n", "start_char_idx": 943, "end_char_idx": 1034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f1a02fc-5157-4f98-93f2-c24942e8666b": {"__data__": {"id_": "7f1a02fc-5157-4f98-93f2-c24942e8666b", "embedding": null, "metadata": {"window": "We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n", "original_text": "In Medical, we remain highly -focused on our Medical Improvement Plan initiatives. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b680782-520d-4109-8858-dc28d749c731", "node_type": "1", "metadata": {"window": "In the quarter, we saw particular strength in overall pharmaceutical demand and strong \nperformance from our generics program.  We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n", "original_text": "In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf4735dc43b9fcf2c36f5c981e851a9ffaf76f065c01182b48181152d7a32f03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "523b4030-9f3e-483a-90b2-a1d988e23a22", "node_type": "1", "metadata": {"window": "And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n", "original_text": "Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter. "}, "hash": "e1fe753d3c220ad4aa8638b437ecdf4e5773f75d30fd106ace1b4f7ea9e9624a", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, we remain highly -focused on our Medical Improvement Plan initiatives. ", "start_char_idx": 1034, "end_char_idx": 1117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "523b4030-9f3e-483a-90b2-a1d988e23a22": {"__data__": {"id_": "523b4030-9f3e-483a-90b2-a1d988e23a22", "embedding": null, "metadata": {"window": "And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n", "original_text": "Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f1a02fc-5157-4f98-93f2-c24942e8666b", "node_type": "1", "metadata": {"window": "We\u2019ve seen increasing contributions from specialty \nproducts, which is a key strategic area of focus.  And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n", "original_text": "In Medical, we remain highly -focused on our Medical Improvement Plan initiatives. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f91ca226b84219725ddbe7bc1f3efb5f043b53343a037f3e934f42b96f57589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5643e2ee-f753-4aac-a16a-9470e73bedab", "node_type": "1", "metadata": {"window": "In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value . ", "original_text": "We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n"}, "hash": "d561e46590cabd4a235672c35f6fd30bd49a401d4a4b6c225ba21bcd6ebaafa1", "class_name": "RelatedNodeInfo"}}, "text": "Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter. ", "start_char_idx": 1117, "end_char_idx": 1291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5643e2ee-f753-4aac-a16a-9470e73bedab": {"__data__": {"id_": "5643e2ee-f753-4aac-a16a-9470e73bedab", "embedding": null, "metadata": {"window": "In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value . ", "original_text": "We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "523b4030-9f3e-483a-90b2-a1d988e23a22", "node_type": "1", "metadata": {"window": "And, we continue to effectively manage through the \ninflationary headwinds affecting industry supply chains.  In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n", "original_text": "Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fb8e5a2aa5c75e0e84c3c26db5c66da0ff88b90694c9defe3d25087f0b52cc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f80f571-e349-4aab-8fcc-ff505c3eee90", "node_type": "1", "metadata": {"window": "In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n", "original_text": "At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n"}, "hash": "ef5d1cbd0b77d86e06d30b8f5e7c18346bdd105f1ac26e97a27b607067305635", "class_name": "RelatedNodeInfo"}}, "text": "We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n", "start_char_idx": 1291, "end_char_idx": 1424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f80f571-e349-4aab-8fcc-ff505c3eee90": {"__data__": {"id_": "1f80f571-e349-4aab-8fcc-ff505c3eee90", "embedding": null, "metadata": {"window": "In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n", "original_text": "At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5643e2ee-f753-4aac-a16a-9470e73bedab", "node_type": "1", "metadata": {"window": "In short,  Q2 was another data point that \nPharma is a resilient and growing business.  \n \n In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value . ", "original_text": "We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e11c4dc0737ce04fd00af56a4d3cc3ff65fa1d106bbf10ee22e43632235f04e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09da0c1c-c13a-4a99-bebb-260822d605f2", "node_type": "1", "metadata": {"window": "Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months. ", "original_text": "With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n"}, "hash": "017b4a8e141646121971c0056f93a43e4f29348c4d1d412aa606d89ed74228b4", "class_name": "RelatedNodeInfo"}}, "text": "At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n", "start_char_idx": 1424, "end_char_idx": 1575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09da0c1c-c13a-4a99-bebb-260822d605f2": {"__data__": {"id_": "09da0c1c-c13a-4a99-bebb-260822d605f2", "embedding": null, "metadata": {"window": "Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months. ", "original_text": "With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f80f571-e349-4aab-8fcc-ff505c3eee90", "node_type": "1", "metadata": {"window": "In Medical, we remain highly -focused on our Medical Improvement Plan initiatives.  Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n", "original_text": "At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "690724b2621310fbe6e4151d1447bd4d91c86e475c1fac4aa2ce944dffa5a039", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f54df3e5-0cf3-4996-aa36-02cb3f66e2ed", "node_type": "1", "metadata": {"window": "We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n", "original_text": "Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value . "}, "hash": "309623720601a2ebf98482b335014c719c501336fde7d3d576dd8d062ee392fb", "class_name": "RelatedNodeInfo"}}, "text": "With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n", "start_char_idx": 1575, "end_char_idx": 1720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f54df3e5-0cf3-4996-aa36-02cb3f66e2ed": {"__data__": {"id_": "f54df3e5-0cf3-4996-aa36-02cb3f66e2ed", "embedding": null, "metadata": {"window": "We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n", "original_text": "Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value . ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09da0c1c-c13a-4a99-bebb-260822d605f2", "node_type": "1", "metadata": {"window": "Overall, despite \nsome puts and takes, Medical\u2019s Q2 results were consistent with our prior commen tary, and we were \npleased to see a return to profitability in the quarter.  We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months. ", "original_text": "With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecf83318daf0ea6f449bb482ae32a5e2f84439e376250154e1fd4741c29dc7c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f84405eb-697f-4502-a4c8-1371425e5040", "node_type": "1", "metadata": {"window": "At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n", "original_text": "I will update you on th ese priorities \nin a few moments.  \n \n"}, "hash": "fa47933f9ac06ef2a517bc402839b2e7b1b80d0c4d529c280840018b0a0b58ec", "class_name": "RelatedNodeInfo"}}, "text": "Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value . ", "start_char_idx": 1720, "end_char_idx": 1976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f84405eb-697f-4502-a4c8-1371425e5040": {"__data__": {"id_": "f84405eb-697f-4502-a4c8-1371425e5040", "embedding": null, "metadata": {"window": "At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n", "original_text": "I will update you on th ese priorities \nin a few moments.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f54df3e5-0cf3-4996-aa36-02cb3f66e2ed", "node_type": "1", "metadata": {"window": "We continue to take actions to drive more \npredictable financial performance in -line with this business\u2019s underlying potential.  \n \n At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n", "original_text": "Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value . ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da2827241eef00b87f79d8758834d9598b665668e62b16f9dacf857aa6aa9945", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad8d91a4-d0f1-49b9-aaaf-dc21900eeb9b", "node_type": "1", "metadata": {"window": "With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n", "original_text": "Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months. "}, "hash": "6550dc05a4ffef54a040358d5b0c76079d17376d50ebdc0d5f8bfb9601818b84", "class_name": "RelatedNodeInfo"}}, "text": "I will update you on th ese priorities \nin a few moments.  \n \n", "start_char_idx": 1976, "end_char_idx": 2038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad8d91a4-d0f1-49b9-aaaf-dc21900eeb9b": {"__data__": {"id_": "ad8d91a4-d0f1-49b9-aaaf-dc21900eeb9b", "embedding": null, "metadata": {"window": "With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n", "original_text": "Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f84405eb-697f-4502-a4c8-1371425e5040", "node_type": "1", "metadata": {"window": "At an enterprise level, we continue to see benefits below the operating line from our capital \ndeployment actions and favorable capital structure.  \n \n With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n", "original_text": "I will update you on th ese priorities \nin a few moments.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15c27b8bd73f45e1aa20f80122aee5492ceab64a37eb9aa0ece709c6790b4486", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2f83f2d-324a-46b3-a618-03e1631e93c0", "node_type": "1", "metadata": {"window": "Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n", "original_text": "Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n"}, "hash": "9bd13241e1646f41ae5ce4559bebc0de7c9a2415c2a41727ac0c7c76bf300866", "class_name": "RelatedNodeInfo"}}, "text": "Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months. ", "start_char_idx": 2038, "end_char_idx": 2209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2f83f2d-324a-46b3-a618-03e1631e93c0": {"__data__": {"id_": "c2f83f2d-324a-46b3-a618-03e1631e93c0", "embedding": null, "metadata": {"window": "Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n", "original_text": "Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad8d91a4-d0f1-49b9-aaaf-dc21900eeb9b", "node_type": "1", "metadata": {"window": "With the first half of fiscal \u201823 behind us, we are pleased to raise our full year EPS guidance and \noutlook for the Pharmaceutical segment.  \n \n Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n", "original_text": "Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months. ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed3577d4804bcca8fbfb5b77cab1043663f19d32346b1e81ea173e6decbac5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37827ad2-2771-459b-9bdb-3d7af386f114", "node_type": "1", "metadata": {"window": "I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "Thanks, Trish.  \n \n"}, "hash": "7c73eab20a0edfe98a01babc0c52f0867c9419d3d7abf690e850c91095a2b8de", "class_name": "RelatedNodeInfo"}}, "text": "Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n", "start_char_idx": 2209, "end_char_idx": 2347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37827ad2-2771-459b-9bdb-3d7af386f114": {"__data__": {"id_": "37827ad2-2771-459b-9bdb-3d7af386f114", "embedding": null, "metadata": {"window": "I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "Thanks, Trish.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2f83f2d-324a-46b3-a618-03e1631e93c0", "node_type": "1", "metadata": {"window": "Our team remains fo cused on executing our 3 key strategic priorities of executing on the Medical \nImprovement Plan, building on the growth and resiliency of the Pharmaceutical segment, and \nmaintaining a relentless focus on maximizing shareholder value .  I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n", "original_text": "Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cabddecc1a5077eeda4589efec34dc3e62552c4e4ba963506f835becfd6f98e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c848f86-91d8-4805-a57f-f1887839c574", "node_type": "1", "metadata": {"window": "Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "Trish English :   Thank you Jason, and good morning everyone.  \n \n"}, "hash": "d36fbb226bc55b5a120a938fc1a845e06cf2d476599d3663ee225083e29505b8", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Trish.  \n \n", "start_char_idx": 2347, "end_char_idx": 2366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c848f86-91d8-4805-a57f-f1887839c574": {"__data__": {"id_": "6c848f86-91d8-4805-a57f-f1887839c574", "embedding": null, "metadata": {"window": "Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "Trish English :   Thank you Jason, and good morning everyone.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37827ad2-2771-459b-9bdb-3d7af386f114", "node_type": "1", "metadata": {"window": "I will update you on th ese priorities \nin a few moments.  \n \n Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "Thanks, Trish.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b70a3507d3d5abeed9f2e0a12eb175554485751e7248c850059b14fcd12e8f13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0f443ac-ab7e-41bf-8bb4-28e945fe228d", "node_type": "1", "metadata": {"window": "Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "I\u2019ll begin today with our consolidated second quarter results.  \n \n"}, "hash": "5b82964d45843f3106afb0da9479798d2abdac60b645f788bd84844c45eb48af", "class_name": "RelatedNodeInfo"}}, "text": "Trish English :   Thank you Jason, and good morning everyone.  \n \n", "start_char_idx": 2366, "end_char_idx": 2432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0f443ac-ab7e-41bf-8bb4-28e945fe228d": {"__data__": {"id_": "d0f443ac-ab7e-41bf-8bb4-28e945fe228d", "embedding": null, "metadata": {"window": "Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "I\u2019ll begin today with our consolidated second quarter results.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c848f86-91d8-4805-a57f-f1887839c574", "node_type": "1", "metadata": {"window": "Before I turn it over to Trish to review our results from the quarter and revised outlook, I\u2019d like to thank \nher for stepping in as interim CFO over the past six months.  Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "Trish English :   Thank you Jason, and good morning everyone.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adb95af90ffe906bce17fa3c6b3f84d9dbc5548ff2fe751f35bb2b5653d5d600", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cee39c0-b8f5-45c1-9375-882ac0fa3885", "node_type": "1", "metadata": {"window": "Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  "}, "hash": "a15ef581462ebfb0b0960d6c80a23e64296121a13920c54abc728af9d038a9df", "class_name": "RelatedNodeInfo"}}, "text": "I\u2019ll begin today with our consolidated second quarter results.  \n \n", "start_char_idx": 2432, "end_char_idx": 2499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cee39c0-b8f5-45c1-9375-882ac0fa3885": {"__data__": {"id_": "6cee39c0-b8f5-45c1-9375-882ac0fa3885", "embedding": null, "metadata": {"window": "Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3229cc4bec09eb0cebb186b87d2c60e377ec9d9ce6b60db3afee498da84ee563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0f443ac-ab7e-41bf-8bb4-28e945fe228d", "node_type": "1", "metadata": {"window": "Trish has brought leadership and \ncontinuity to the organization, and will be instrumental in ensuring a seamless transition with Aaron. \n Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "I\u2019ll begin today with our consolidated second quarter results.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dd5e277308167de6b0f6665f0b97fe389f0da23c9df260835611a8ea6ad636e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57fdb6c8-d778-40f6-8431-ff97bca14fe6", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n", "original_text": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs. "}, "hash": "8d29f49a4796ee65a678ddfc34ba5a4efd7ea9dc18717962848ecba28004224e", "class_name": "RelatedNodeInfo"}}, "text": "Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "start_char_idx": 2499, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57fdb6c8-d778-40f6-8431-ff97bca14fe6": {"__data__": {"id_": "57fdb6c8-d778-40f6-8431-ff97bca14fe6", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n", "original_text": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cee39c0-b8f5-45c1-9375-882ac0fa3885", "node_type": "1", "metadata": {"window": "Thanks, Trish.  \n \n Trish English :   Thank you Jason, and good morning everyone.  \n \n I\u2019ll begin today with our consolidated second quarter results.  \n \n Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "original_text": "Total company revenue increased 13 % and gross margin increased 3 %, both driven by the Pharma \nsegment.  ", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17f1090d906ce949216d405f2aff2c8cb8c36e8bd7e210081af13a22269767dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5f71a49-d78e-40cf-b65c-0a15b0d8a3ca", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents. ", "original_text": "Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n"}, "hash": "ca7a211910c773a6e1a5fe6ec07fe3b0a7a363c24c195be0a71287969e7bd3f9", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs. ", "start_char_idx": 0, "end_char_idx": 105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5f71a49-d78e-40cf-b65c-0a15b0d8a3ca": {"__data__": {"id_": "c5f71a49-d78e-40cf-b65c-0a15b0d8a3ca", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents. ", "original_text": "Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57fdb6c8-d778-40f6-8431-ff97bca14fe6", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n", "original_text": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab85305b76364e876392464437b72debacafcd7f70c1207e68e64d081e012304", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c8592bc-b53e-40ce-b8c8-88dcb4606d0d", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n", "original_text": "Operating earnings of $467 million  dollars  were in -line with the second quarter of last year. "}, "hash": "6440a445cb4ceb709eedf068277b827fa7e838a7709751c8ee689fdfdd43c2de", "class_name": "RelatedNodeInfo"}}, "text": "Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n", "start_char_idx": 105, "end_char_idx": 200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c8592bc-b53e-40ce-b8c8-88dcb4606d0d": {"__data__": {"id_": "2c8592bc-b53e-40ce-b8c8-88dcb4606d0d", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n", "original_text": "Operating earnings of $467 million  dollars  were in -line with the second quarter of last year. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5f71a49-d78e-40cf-b65c-0a15b0d8a3ca", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents. ", "original_text": "Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfce9784943270371ea5bf1b2d7f03b87a6ee22b3f80759d6271f4d56727c4fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9590ccac-c9dc-4044-b261-e6a2ed1be82b", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n", "original_text": "This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n"}, "hash": "3c61d31015cdc84221470e9f1edb4ffe00fa93997ce5e68d8da711f0ffc7c3e6", "class_name": "RelatedNodeInfo"}}, "text": "Operating earnings of $467 million  dollars  were in -line with the second quarter of last year. ", "start_char_idx": 200, "end_char_idx": 297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9590ccac-c9dc-4044-b261-e6a2ed1be82b": {"__data__": {"id_": "9590ccac-c9dc-4044-b261-e6a2ed1be82b", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n", "original_text": "This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c8592bc-b53e-40ce-b8c8-88dcb4606d0d", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n", "original_text": "Operating earnings of $467 million  dollars  were in -line with the second quarter of last year. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "849f33a807625f0977797d225adf3cb333e22631af5370edda111d4304836d11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4642057c-f645-4349-a396-423b72f23210", "node_type": "1", "metadata": {"window": "Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases. ", "original_text": "Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents. "}, "hash": "2605d0941614a1f150a0a924d31b3e492998340143ff1deca55edb7a7ef14534", "class_name": "RelatedNodeInfo"}}, "text": "This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n", "start_char_idx": 297, "end_char_idx": 422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4642057c-f645-4349-a396-423b72f23210": {"__data__": {"id_": "4642057c-f645-4349-a396-423b72f23210", "embedding": null, "metadata": {"window": "Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases. ", "original_text": "Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9590ccac-c9dc-4044-b261-e6a2ed1be82b", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n", "original_text": "This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4313eafb2bed0564c611aaac77eaff688c2b6bf382199bd2b35d1a15bc850b7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a021d24-0fd7-4634-bd17-e222dd4bbadf", "node_type": "1", "metadata": {"window": "Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date. ", "original_text": "As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n"}, "hash": "42c35047cd5c63f972d46880b5c390c86f51c6d0c945dc14996bc712998845d0", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents. ", "start_char_idx": 422, "end_char_idx": 584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a021d24-0fd7-4634-bd17-e222dd4bbadf": {"__data__": {"id_": "1a021d24-0fd7-4634-bd17-e222dd4bbadf", "embedding": null, "metadata": {"window": "Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date. ", "original_text": "As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4642057c-f645-4349-a396-423b72f23210", "node_type": "1", "metadata": {"window": "Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases. ", "original_text": "Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ce3f79fe7f30cda1bebf9b9a903ecdd811396a74facedf0deb4fdb3fd28002d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "256e1646-68a5-4e23-95bc-a212d7d7d1b3", "node_type": "1", "metadata": {"window": "This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n", "original_text": "Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n"}, "hash": "6cfb4436db63c4a46ca3d366f1de2658f6483019c644dee70169d22cc941f1ac", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n", "start_char_idx": 584, "end_char_idx": 691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "256e1646-68a5-4e23-95bc-a212d7d7d1b3": {"__data__": {"id_": "256e1646-68a5-4e23-95bc-a212d7d7d1b3", "embedding": null, "metadata": {"window": "This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n", "original_text": "Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a021d24-0fd7-4634-bd17-e222dd4bbadf", "node_type": "1", "metadata": {"window": "Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date. ", "original_text": "As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2237ae9ac27edf6d7aa3901c73f98cb6b5f3b300fed396a0ce94de7c51f289c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21109ba3-58e9-402c-bf6f-e83f6debc7c1", "node_type": "1", "metadata": {"window": "Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n", "original_text": "Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases. "}, "hash": "719b795517a0fb89ecf3d2caa37eae8ab4609bf03723d3c587b16397c7df3bce", "class_name": "RelatedNodeInfo"}}, "text": "Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n", "start_char_idx": 691, "end_char_idx": 885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21109ba3-58e9-402c-bf6f-e83f6debc7c1": {"__data__": {"id_": "21109ba3-58e9-402c-bf6f-e83f6debc7c1", "embedding": null, "metadata": {"window": "Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n", "original_text": "Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "256e1646-68a5-4e23-95bc-a212d7d7d1b3", "node_type": "1", "metadata": {"window": "This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n", "original_text": "Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcc9bc623940dbda5e52cf331d8c3d882a00d481ee1fe218ddf0fe6be0b564ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c2063ac-0f43-42ed-8769-d5e19bc07f6a", "node_type": "1", "metadata": {"window": "As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n", "original_text": "In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date. "}, "hash": "284547f3a686a7ef776dc2f1ffe58a0d6c8327f192b5f822d1ecdf27ab1a4f71", "class_name": "RelatedNodeInfo"}}, "text": "Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases. ", "start_char_idx": 885, "end_char_idx": 989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c2063ac-0f43-42ed-8769-d5e19bc07f6a": {"__data__": {"id_": "1c2063ac-0f43-42ed-8769-d5e19bc07f6a", "embedding": null, "metadata": {"window": "As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n", "original_text": "In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21109ba3-58e9-402c-bf6f-e83f6debc7c1", "node_type": "1", "metadata": {"window": "Moving below the line, Interest and Other decreased nearly 30 % to $18 million dollars, driven \nprimarily by increased interest income from cash and equivalents.  As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n", "original_text": "Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "affb8d18a1a7b92559906b8deece40d28fdcd445c90de95373bed40f0f85c29b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d659da2a-e8a9-472c-b4ad-5b979a55f6fd", "node_type": "1", "metadata": {"window": "Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n", "original_text": "We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n"}, "hash": "c70bddb9e537183d9dc95bf8c93718f7cd548048729e0bd82970722d40ee707c", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date. ", "start_char_idx": 989, "end_char_idx": 1205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d659da2a-e8a9-472c-b4ad-5b979a55f6fd": {"__data__": {"id_": "d659da2a-e8a9-472c-b4ad-5b979a55f6fd", "embedding": null, "metadata": {"window": "Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n", "original_text": "We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c2063ac-0f43-42ed-8769-d5e19bc07f6a", "node_type": "1", "metadata": {"window": "As a reminder, our debt is largely \nfixed rate, resulting in a net benefit from rising interest rates.  \n \n Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n", "original_text": "In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d0f26936f4e777798d2762406759b0b5ac40c3930ffde47ad5ec58b5c7b3c99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5664932-6758-4b77-968f-1602a93a275c", "node_type": "1", "metadata": {"window": "Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities . ", "original_text": "The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n"}, "hash": "aff0c7abe8a45fe134e0c4d7eca4ca98fd3b1fb4ca7b7c3bb2db379a43438df1", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n", "start_char_idx": 1205, "end_char_idx": 1371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5664932-6758-4b77-968f-1602a93a275c": {"__data__": {"id_": "d5664932-6758-4b77-968f-1602a93a275c", "embedding": null, "metadata": {"window": "Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities . ", "original_text": "The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d659da2a-e8a9-472c-b4ad-5b979a55f6fd", "node_type": "1", "metadata": {"window": "Our second quarter Effect ive Tax Rate finished at 23 %, approximately 3.5 percentage points higher \nthan prior year, primarily due to net positive discrete items in the prior -year period.  \n \n Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n", "original_text": "We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22411ff9104957154940f96b48a955e97a1f2cf1076d8df331ea28df9ce21b3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01f491f1-bc53-4186-96db-051bac17ecbc", "node_type": "1", "metadata": {"window": "In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n", "original_text": "Now, turning to the balance sheet.  \n \n"}, "hash": "b98ead42ff82e00541ff32053afe674a74a91807a445b13129289049eab606e1", "class_name": "RelatedNodeInfo"}}, "text": "The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n", "start_char_idx": 1371, "end_char_idx": 1451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01f491f1-bc53-4186-96db-051bac17ecbc": {"__data__": {"id_": "01f491f1-bc53-4186-96db-051bac17ecbc", "embedding": null, "metadata": {"window": "In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n", "original_text": "Now, turning to the balance sheet.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5664932-6758-4b77-968f-1602a93a275c", "node_type": "1", "metadata": {"window": "Diluted weighted average shares were 263 million, 6 % lower than a year ago due to share \nrepur chases.  In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities . ", "original_text": "The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f190c3e6278078739c45607cbdaae4a61c86baa92e6c08abac58c00162dba46a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8353d0d2-8500-4562-a842-a71e4a85cc91", "node_type": "1", "metadata": {"window": "We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n", "original_text": "We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n"}, "hash": "7a41a44cb7ae4133eac440d8d26f7a5d6caf26525e8fd2bf508bf717f83b1929", "class_name": "RelatedNodeInfo"}}, "text": "Now, turning to the balance sheet.  \n \n", "start_char_idx": 1451, "end_char_idx": 1490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8353d0d2-8500-4562-a842-a71e4a85cc91": {"__data__": {"id_": "8353d0d2-8500-4562-a842-a71e4a85cc91", "embedding": null, "metadata": {"window": "We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n", "original_text": "We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01f491f1-bc53-4186-96db-051bac17ecbc", "node_type": "1", "metadata": {"window": "In the second quarter, we completed our $1 billion dollar Accelerated Share \nRepurchase program and initiated a new $250 million dollar program, resulting in a total of $1.25 \nbillion dollars deployed year -to-date.  We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n", "original_text": "Now, turning to the balance sheet.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae089258c301b9abce668b2a292590d1bd95d868d692e98ee5b3ff29a0344b6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc67ec20-c3d3-4f5b-82d3-4deed5a83dcf", "node_type": "1", "metadata": {"window": "The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n", "original_text": "We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities . "}, "hash": "a46d88c40c8c9c1ecc443d7141751450be751375e450b176eef2b2f472da890b", "class_name": "RelatedNodeInfo"}}, "text": "We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n", "start_char_idx": 1490, "end_char_idx": 1645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc67ec20-c3d3-4f5b-82d3-4deed5a83dcf": {"__data__": {"id_": "fc67ec20-c3d3-4f5b-82d3-4deed5a83dcf", "embedding": null, "metadata": {"window": "The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n", "original_text": "We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities . ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8353d0d2-8500-4562-a842-a71e4a85cc91", "node_type": "1", "metadata": {"window": "We continue to expect $1.5 billion to $2 billion dollars in share \nrepurchases in fiscal \u201823, which reflects our continued focus on maximizing shareholder value.  \n \n The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n", "original_text": "We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50aa1df360b920cc8369cdf7890c5b47e12a1ce20955c8632b4ee56d3c0b93e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe60aac3-518b-4a4c-9465-6412b30dd445", "node_type": "1", "metadata": {"window": "Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars. ", "original_text": "As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n"}, "hash": "3b1da2d9bc54abd97f9b1a070cffb7d001f6843a42ba81dd21ad50f5c85a2fb4", "class_name": "RelatedNodeInfo"}}, "text": "We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities . ", "start_char_idx": 1645, "end_char_idx": 1770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe60aac3-518b-4a4c-9465-6412b30dd445": {"__data__": {"id_": "fe60aac3-518b-4a4c-9465-6412b30dd445", "embedding": null, "metadata": {"window": "Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars. ", "original_text": "As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc67ec20-c3d3-4f5b-82d3-4deed5a83dcf", "node_type": "1", "metadata": {"window": "The net result for the quarter was Earnings Per Share growth of 4% to $1.32. \n \n Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n", "original_text": "We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities . ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5125999c9aca860dec0112089de3941eb51322de85f01521699204a85858512b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0203552-2471-42ec-988d-fd2869f56716", "node_type": "1", "metadata": {"window": "We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n", "original_text": "Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n"}, "hash": "7c0d17d032da23a6e4818d92137b29ff6161e8e64205059fad5a6e7ea1c0d2da", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n", "start_char_idx": 1770, "end_char_idx": 1901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0203552-2471-42ec-988d-fd2869f56716": {"__data__": {"id_": "e0203552-2471-42ec-988d-fd2869f56716", "embedding": null, "metadata": {"window": "We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n", "original_text": "Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe60aac3-518b-4a4c-9465-6412b30dd445", "node_type": "1", "metadata": {"window": "Now, turning to the balance sheet.  \n \n We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars. ", "original_text": "As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e6aafb7027050365176e86662738276db68fea2dd10451f8777f73d6542c0e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9db249a5-5189-43ec-ae02-b4e9aad440fe", "node_type": "1", "metadata": {"window": "We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market. ", "original_text": "Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n"}, "hash": "d021114d693a9ea0de85fe74cb3708a3774586aa8d3f126b61be1015256774ad", "class_name": "RelatedNodeInfo"}}, "text": "Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n", "start_char_idx": 1901, "end_char_idx": 1982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9db249a5-5189-43ec-ae02-b4e9aad440fe": {"__data__": {"id_": "9db249a5-5189-43ec-ae02-b4e9aad440fe", "embedding": null, "metadata": {"window": "We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market. ", "original_text": "Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0203552-2471-42ec-988d-fd2869f56716", "node_type": "1", "metadata": {"window": "We generated se cond quarter adjusted free cash flow of $439 million dollars, bringing year -to-date \nadjusted free cash flow to $781 million dollars.  \n \n We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n", "original_text": "Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43d700ea9cf58f58008316227eef560c9aab5c540383348e80678900d6794ffd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df2b96da-a907-4687-bc98-5408fb1ab9ef", "node_type": "1", "metadata": {"window": "As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "Pharma segment profit increased 9 % to $464 million dollars. "}, "hash": "d8d88da8ba22505b030dc3471d0a422bfce5d1469b3c6d7e42dfac5e8f67e77c", "class_name": "RelatedNodeInfo"}}, "text": "Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n", "start_char_idx": 1982, "end_char_idx": 2146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df2b96da-a907-4687-bc98-5408fb1ab9ef": {"__data__": {"id_": "df2b96da-a907-4687-bc98-5408fb1ab9ef", "embedding": null, "metadata": {"window": "As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "Pharma segment profit increased 9 % to $464 million dollars. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9db249a5-5189-43ec-ae02-b4e9aad440fe", "node_type": "1", "metadata": {"window": "We ended the period with a cash position of $3.7 billion dollars, with no outstanding borrowings on \nour credit facilities .  As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market. ", "original_text": "Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edf2580d044f83c442d3e7eb555599a9d72c766828474d6551a639d1964145f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "654da6f2-b92c-46f5-954d-0d593f1ab661", "node_type": "1", "metadata": {"window": "Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n"}, "hash": "2b2b6871d639dd307d4b7316ac36d3a607919fa614680ba6a3f1f8ed33efb899", "class_name": "RelatedNodeInfo"}}, "text": "Pharma segment profit increased 9 % to $464 million dollars. ", "start_char_idx": 2146, "end_char_idx": 2207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "654da6f2-b92c-46f5-954d-0d593f1ab661": {"__data__": {"id_": "654da6f2-b92c-46f5-954d-0d593f1ab661", "embedding": null, "metadata": {"window": "Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df2b96da-a907-4687-bc98-5408fb1ab9ef", "node_type": "1", "metadata": {"window": "As a reminder, we continue to expect to pay down the $550 million dollars of \nMarch 2023 notes, at maturity with cash on hand.  \n \n Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "Pharma segment profit increased 9 % to $464 million dollars. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c061886413f7bae3838979adcddd358b339c11c01135588ad750778c0598eadb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e7bd50b-5e4a-4d08-949e-4c6ca1762aa1", "node_type": "1", "metadata": {"window": "Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market. "}, "hash": "a15096dc228373e61d6940577ad99af6a34f5a8d9e7fb1198b4dc8db9b9f98b5", "class_name": "RelatedNodeInfo"}}, "text": "This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n", "start_char_idx": 2207, "end_char_idx": 2375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e7bd50b-5e4a-4d08-949e-4c6ca1762aa1": {"__data__": {"id_": "7e7bd50b-5e4a-4d08-949e-4c6ca1762aa1", "embedding": null, "metadata": {"window": "Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "654da6f2-b92c-46f5-954d-0d593f1ab661", "node_type": "1", "metadata": {"window": "Now, I will cover our segment performance, beginning with Pharma on slide 5.  \n \n Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b477478fbcf22226486c232d7b8cc3982eaa8d36b2dda882923b98f5a755f61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06f06375-6dd0-4783-9af9-e30e2c2f9898", "node_type": "1", "metadata": {"window": "Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n "}, "hash": "41d54ba8c83d76fc9fbf6fa5789332dada10207bc06a0a43bae305a349102476", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market. ", "start_char_idx": 2375, "end_char_idx": 2521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06f06375-6dd0-4783-9af9-e30e2c2f9898": {"__data__": {"id_": "06f06375-6dd0-4783-9af9-e30e2c2f9898", "embedding": null, "metadata": {"window": "Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a2b864e644b389c95365b0da35ae51df09d3f039d7fed064d650a71c16030ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e7bd50b-5e4a-4d08-949e-4c6ca1762aa1", "node_type": "1", "metadata": {"window": "Second -quarter revenue increased 15 % to $48 billi on dollars, driven by brand and specialty \npharmaceutical sales growth from existing and net new customers.  \n \n Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0a9e4e047adb34e812dd576eab5c455043fbc00de4e632f47fb219fc40fb757", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07f7976b-8381-4ac3-8044-ea96eae61cf0", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations. ", "original_text": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see. "}, "hash": "ef68c8d445e99b96e4514c1c11d159c1f7781bd3b66be8abd00f6aa70282c4aa", "class_name": "RelatedNodeInfo"}}, "text": "To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "start_char_idx": 2521, "end_char_idx": 2732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07f7976b-8381-4ac3-8044-ea96eae61cf0": {"__data__": {"id_": "07f7976b-8381-4ac3-8044-ea96eae61cf0", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations. ", "original_text": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06f06375-6dd0-4783-9af9-e30e2c2f9898", "node_type": "1", "metadata": {"window": "Pharma segment profit increased 9 % to $464 million dollars.  This was driven by a higher contribution \nfrom brand and specialty products and generics program performance, partially offset by inflationary \nsupply chain costs.  \n \n During the quarter, we saw strong overall pharmaceutical demand, includ ing from our largest \ncustomers, reflecting their strength in the market.  To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "original_text": "To a lesser extent, we also saw year -over-year \ncontributions from the net new customers that we\u2019ve previously mentioned and more robust \nseasonality with cough, cold and flu products, as others have noted.  \n ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ef55f88bbca9aeae36164a34439d0c1f62f6e96a84ad0fc7fc7192df7711aa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4f0c547-fb2a-4acf-85af-26e2db6e1f3a", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n", "original_text": "This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n"}, "hash": "d20edc336004998bde353d2c49ace2f1a53c37c4cd011cfe54881da950a045a5", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see. ", "start_char_idx": 0, "end_char_idx": 142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4f0c547-fb2a-4acf-85af-26e2db6e1f3a": {"__data__": {"id_": "e4f0c547-fb2a-4acf-85af-26e2db6e1f3a", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n", "original_text": "This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07f7976b-8381-4ac3-8044-ea96eae61cf0", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations. ", "original_text": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "952f6194a7a5338cde838d49fec7c20da1f3848448a695a29e5d7a60c6d2210f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8a290a8-5600-4387-9daf-2998f2979f5e", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n", "original_text": "Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor. "}, "hash": "1712e6e902047ae939c0a83043e7b565c3a6093b3b4eb221d277311e84c38d55", "class_name": "RelatedNodeInfo"}}, "text": "This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n", "start_char_idx": 142, "end_char_idx": 290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8a290a8-5600-4387-9daf-2998f2979f5e": {"__data__": {"id_": "f8a290a8-5600-4387-9daf-2998f2979f5e", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n", "original_text": "Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4f0c547-fb2a-4acf-85af-26e2db6e1f3a", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n", "original_text": "This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e3d7a2ee7e8b1793462f0368e918075f7ff79ce610c19b61ccfebce11710c45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a5dabdb-86b1-46e6-9720-48e3769551bd", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes. ", "original_text": "In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations. "}, "hash": "059d37ac7922d12fe24c831f74f25cf226ef001d0e051c850600a5f0fc92d244", "class_name": "RelatedNodeInfo"}}, "text": "Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor. ", "start_char_idx": 290, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a5dabdb-86b1-46e6-9720-48e3769551bd": {"__data__": {"id_": "5a5dabdb-86b1-46e6-9720-48e3769551bd", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes. ", "original_text": "In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8a290a8-5600-4387-9daf-2998f2979f5e", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n", "original_text": "Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1e4905f7d0a834b654bb57d738b492cc4362298cea94b5bd7fa68420b753792", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a823d1a7-207f-475c-ae36-585b8c4526d7", "node_type": "1", "metadata": {"window": "This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n", "original_text": "Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n"}, "hash": "a1c46daede53d5340859c5dcea9f8daf7857b187472efe74a71cf72fd77a5f12", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations. ", "start_char_idx": 443, "end_char_idx": 544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a823d1a7-207f-475c-ae36-585b8c4526d7": {"__data__": {"id_": "a823d1a7-207f-475c-ae36-585b8c4526d7", "embedding": null, "metadata": {"window": "This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n", "original_text": "Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a5dabdb-86b1-46e6-9720-48e3769551bd", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes. ", "original_text": "In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d820e91588905384f85caa52358b0bca7fc765deb2a9deaaeb5df96a8688839f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "263cc231-0ec0-4b80-9144-0b977789828e", "node_type": "1", "metadata": {"window": "Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars . ", "original_text": "Okay, turning to Medical on slide 6.  \n \n"}, "hash": "90451d4d6a0d482ec219ef9f6204528ddfc6933ba17b9d6e034bbe6e9adee7f9", "class_name": "RelatedNodeInfo"}}, "text": "Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n", "start_char_idx": 544, "end_char_idx": 714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "263cc231-0ec0-4b80-9144-0b977789828e": {"__data__": {"id_": "263cc231-0ec0-4b80-9144-0b977789828e", "embedding": null, "metadata": {"window": "Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars . ", "original_text": "Okay, turning to Medical on slide 6.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a823d1a7-207f-475c-ae36-585b8c4526d7", "node_type": "1", "metadata": {"window": "This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n", "original_text": "Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24e60b9052fa6c96cee8092983b42d370dfaff3f61f7f0235eea257b2d16d658", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bbbe9d9-bf2b-4f0f-aa8a-25a305abf750", "node_type": "1", "metadata": {"window": "In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n", "original_text": "Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes. "}, "hash": "f6cf8b441e694743e5114c02d381511a112fc63802b39f2ed0e8efc33f9e044b", "class_name": "RelatedNodeInfo"}}, "text": "Okay, turning to Medical on slide 6.  \n \n", "start_char_idx": 714, "end_char_idx": 755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bbbe9d9-bf2b-4f0f-aa8a-25a305abf750": {"__data__": {"id_": "1bbbe9d9-bf2b-4f0f-aa8a-25a305abf750", "embedding": null, "metadata": {"window": "In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n", "original_text": "Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "263cc231-0ec0-4b80-9144-0b977789828e", "node_type": "1", "metadata": {"window": "Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars . ", "original_text": "Okay, turning to Medical on slide 6.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bafdcd7dd894733172e0c7cff897deae0b275fba279516a420d5d57ed193f2a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21890191-b2d1-4082-804c-a998555ec57f", "node_type": "1", "metadata": {"window": "Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %. ", "original_text": "Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n"}, "hash": "3e4a8d4fd5a819932319989f8547e65e985e0793f87119f6e89e6120fb4d74b5", "class_name": "RelatedNodeInfo"}}, "text": "Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes. ", "start_char_idx": 755, "end_char_idx": 903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21890191-b2d1-4082-804c-a998555ec57f": {"__data__": {"id_": "21890191-b2d1-4082-804c-a998555ec57f", "embedding": null, "metadata": {"window": "Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %. ", "original_text": "Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bbbe9d9-bf2b-4f0f-aa8a-25a305abf750", "node_type": "1", "metadata": {"window": "In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations.  Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n", "original_text": "Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b6f9b98dc7cb64fa8410bf329eb47e090d1c33a2ca2324da1f091bda1733f43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b246986-fb7a-4093-ac84-2ebed5cbecfd", "node_type": "1", "metadata": {"window": "Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n", "original_text": "Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars . "}, "hash": "f4307bfb2c4b248b463a3dce8467edb47efad9c8bd0c0748cd79cf345fc70855", "class_name": "RelatedNodeInfo"}}, "text": "Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n", "start_char_idx": 903, "end_char_idx": 998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b246986-fb7a-4093-ac84-2ebed5cbecfd": {"__data__": {"id_": "8b246986-fb7a-4093-ac84-2ebed5cbecfd", "embedding": null, "metadata": {"window": "Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n", "original_text": "Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars . ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21890191-b2d1-4082-804c-a998555ec57f", "node_type": "1", "metadata": {"window": "Similar to last quarter, this headwind was offset by \nyear-over-year tailwinds from our completed ERP technology enhancements and lower opioid -related \nlegal costs.  \n \n Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %. ", "original_text": "Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b865c79fff651675bc6691a0569ee6024a924838fa6b687a66bd22ae034c820", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "936a0f96-edc3-411a-91a3-29acdc2b6f53", "node_type": "1", "metadata": {"window": "Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business. ", "original_text": "This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n"}, "hash": "59ee0b4af807193474294b3be7fb982e660ce5ce5b836e97d0aedd0da076faf2", "class_name": "RelatedNodeInfo"}}, "text": "Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars . ", "start_char_idx": 998, "end_char_idx": 1109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "936a0f96-edc3-411a-91a3-29acdc2b6f53": {"__data__": {"id_": "936a0f96-edc3-411a-91a3-29acdc2b6f53", "embedding": null, "metadata": {"window": "Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business. ", "original_text": "This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b246986-fb7a-4093-ac84-2ebed5cbecfd", "node_type": "1", "metadata": {"window": "Okay, turning to Medical on slide 6.  \n \n Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n", "original_text": "Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars . ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a96fb8e0719430fe923e01edfdaa81df891b62513c865b813241088c81475f08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a553583-21e5-4dc6-b3d0-f7e81ce98301", "node_type": "1", "metadata": {"window": "Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products. ", "original_text": "During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %. "}, "hash": "86fb8fb13de254d4ac185cf3c58160f0151869ba7cc20a7ae87aa99232cd120b", "class_name": "RelatedNodeInfo"}}, "text": "This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n", "start_char_idx": 1109, "end_char_idx": 1261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a553583-21e5-4dc6-b3d0-f7e81ce98301": {"__data__": {"id_": "5a553583-21e5-4dc6-b3d0-f7e81ce98301", "embedding": null, "metadata": {"window": "Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products. ", "original_text": "During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "936a0f96-edc3-411a-91a3-29acdc2b6f53", "node_type": "1", "metadata": {"window": "Second -quarter revenue dec reased 7 % to $3.8 billion dollars driven by lower Products and \nDistribution sales, including PPE pricing and volumes.  Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business. ", "original_text": "This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33c4540f770e68a1e9440f2545f71b6e7a783b27e2a389263774837ea5575279", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed047fb5-e536-40b0-a889-55346ed34b02", "node_type": "1", "metadata": {"window": "Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis. ", "original_text": "This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n"}, "hash": "c1ca93ba9a0e4e911202bb87ced3cbd7e6221e5b1085c65db4bad79137b510dc", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %. ", "start_char_idx": 1261, "end_char_idx": 1400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed047fb5-e536-40b0-a889-55346ed34b02": {"__data__": {"id_": "ed047fb5-e536-40b0-a889-55346ed34b02", "embedding": null, "metadata": {"window": "Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis. ", "original_text": "This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a553583-21e5-4dc6-b3d0-f7e81ce98301", "node_type": "1", "metadata": {"window": "Continued strong growth in our at -Home \nSolutions business partially offset this decline.  \n \n Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products. ", "original_text": "During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39780979a2955e531e47023fcd3a375c6cf98eb2ebd4929def61de34697e5c56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5095139-98fd-4c19-aab0-83928355305f", "node_type": "1", "metadata": {"window": "This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n", "original_text": "On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business. "}, "hash": "2717c72a51b2d83e84903babb79efde9e2c4fe1ca16c66579d4ee725ca9db13e", "class_name": "RelatedNodeInfo"}}, "text": "This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n", "start_char_idx": 1400, "end_char_idx": 1608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5095139-98fd-4c19-aab0-83928355305f": {"__data__": {"id_": "a5095139-98fd-4c19-aab0-83928355305f", "embedding": null, "metadata": {"window": "This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n", "original_text": "On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed047fb5-e536-40b0-a889-55346ed34b02", "node_type": "1", "metadata": {"window": "Medical segment profit finished in -line with ou r prior commentary, decreasing 66 % to $17 million \ndollars .  This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis. ", "original_text": "This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15787633e6088c0d5d58ce2c14b9280c23b617a32962dfb57848ea1a0b9d68d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c68d6749-2db6-4031-84b2-3d1a51e9c91c", "node_type": "1", "metadata": {"window": "During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n", "original_text": "In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products. "}, "hash": "4628ee4d5ad1ac238bd2fd0195e4b5a38e5a06d405d9a2a3e60526071d5430f5", "class_name": "RelatedNodeInfo"}}, "text": "On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business. ", "start_char_idx": 1608, "end_char_idx": 1726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c68d6749-2db6-4031-84b2-3d1a51e9c91c": {"__data__": {"id_": "c68d6749-2db6-4031-84b2-3d1a51e9c91c", "embedding": null, "metadata": {"window": "During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n", "original_text": "In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5095139-98fd-4c19-aab0-83928355305f", "node_type": "1", "metadata": {"window": "This was primarily due to lower Products and Distribution volumes and net inflationary \nimpacts, partially offset by an improvement in PPE margins.  \n \n During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n", "original_text": "On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "914b015c3ee4f1552b513e0e8d6b789f1c10f1cc724680beb74d943716c2bea6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd86546a-3178-4f37-9e3f-256b67157ae9", "node_type": "1", "metadata": {"window": "This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n", "original_text": "With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis. "}, "hash": "999a71fae43649899172d13fb4c65023b1cc1eff7cd227edeca41aeb977abde2", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products. ", "start_char_idx": 1726, "end_char_idx": 1864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd86546a-3178-4f37-9e3f-256b67157ae9": {"__data__": {"id_": "cd86546a-3178-4f37-9e3f-256b67157ae9", "embedding": null, "metadata": {"window": "This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n", "original_text": "With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c68d6749-2db6-4031-84b2-3d1a51e9c91c", "node_type": "1", "metadata": {"window": "During the quarter, the net impact from inflation  was in -line with our expectations, and we achieved \ninflation mitigation of over 30 %.  This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n", "original_text": "In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "336aa7c81001ea502fafa8be033a5b2e4899de6b01f3446aed929cf2ca044073", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "571ed69f-f46d-4897-a4f2-53fb0379031a", "node_type": "1", "metadata": {"window": "On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n", "original_text": "Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n"}, "hash": "cb0224ad60ced7d1f10c99b343ad0defb5df6fe65f9f09efb512d4f46bc39309", "class_name": "RelatedNodeInfo"}}, "text": "With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis. ", "start_char_idx": 1864, "end_char_idx": 1955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "571ed69f-f46d-4897-a4f2-53fb0379031a": {"__data__": {"id_": "571ed69f-f46d-4897-a4f2-53fb0379031a", "embedding": null, "metadata": {"window": "On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n", "original_text": "Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd86546a-3178-4f37-9e3f-256b67157ae9", "node_type": "1", "metadata": {"window": "This sequential improvement from the first quarter was driven by the \ncontinued acceleration of our mitigation efforts, including the implementation of additional product \npricing actions in the quarter.  \n \n On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n", "original_text": "With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61e7f3cfdff8a4bfe32679df456ac744bc4d6b1e3e45d1bb3e7a2167dff81a6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95759236-358f-40ba-b4a3-ba5a3c3c9123", "node_type": "1", "metadata": {"window": "In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n", "original_text": "Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n"}, "hash": "3f8098551e84618f8bc4228b75d108db26e01b807cd359273238dc8edcea52b6", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n", "start_char_idx": 1955, "end_char_idx": 2120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95759236-358f-40ba-b4a3-ba5a3c3c9123": {"__data__": {"id_": "95759236-358f-40ba-b4a3-ba5a3c3c9123", "embedding": null, "metadata": {"window": "In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n", "original_text": "Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "571ed69f-f46d-4897-a4f2-53fb0379031a", "node_type": "1", "metadata": {"window": "On our last two earnings calls, we have discussed overall volume softness in our Products and \nDistribution business.  In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n", "original_text": "Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e35356bfc15f63cbbe9a7addacbb59e39e1d6cdf38316b6cb09d5eed74ebf16d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e50899a3-adee-48a2-88fb-e8b699b1e638", "node_type": "1", "metadata": {"window": "With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n"}, "hash": "f81a185384335c8872befc46e38424cadbbb248e5c12af0e6539d842ed678a8a", "class_name": "RelatedNodeInfo"}}, "text": "Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n", "start_char_idx": 2120, "end_char_idx": 2187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e50899a3-adee-48a2-88fb-e8b699b1e638": {"__data__": {"id_": "e50899a3-adee-48a2-88fb-e8b699b1e638", "embedding": null, "metadata": {"window": "With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95759236-358f-40ba-b4a3-ba5a3c3c9123", "node_type": "1", "metadata": {"window": "In the second quarter, we saw generally consistent overall volumes on a \nsequential basis, including our C ardinal Health Brand products.  With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n", "original_text": "Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "affc6a47f19b24a2e5ad7f7e42a17ba79e9049c699b46ab76ab56d3568be5d12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "779e1dcd-3f69-4c5c-8d89-90b5ab667ea2", "node_type": "1", "metadata": {"window": "Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n"}, "hash": "48c919450b604258ea5ae23ad75b840dc7461c35fbe3eeb5c00e370f1f1fd1fa", "class_name": "RelatedNodeInfo"}}, "text": "We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n", "start_char_idx": 2187, "end_char_idx": 2393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "779e1dcd-3f69-4c5c-8d89-90b5ab667ea2": {"__data__": {"id_": "779e1dcd-3f69-4c5c-8d89-90b5ab667ea2", "embedding": null, "metadata": {"window": "Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e50899a3-adee-48a2-88fb-e8b699b1e638", "node_type": "1", "metadata": {"window": "With respect to PPE, we did see \nsome slight improvement in volumes on a sequential basis.  Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "078c7ff92cf2ff399cb2f576982c3e0639dcc962a424adfc4ec682e52674843e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bc40fd3-7fc9-4419-8052-c519a93196fd", "node_type": "1", "metadata": {"window": "Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n"}, "hash": "cfd16c947c7e99e12706eb8c457220bbae4e7202ccb8df94051d2bb51c72bec1", "class_name": "RelatedNodeInfo"}}, "text": "This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n", "start_char_idx": 2393, "end_char_idx": 2495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bc40fd3-7fc9-4419-8052-c519a93196fd": {"__data__": {"id_": "1bc40fd3-7fc9-4419-8052-c519a93196fd", "embedding": null, "metadata": {"window": "Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "779e1dcd-3f69-4c5c-8d89-90b5ab667ea2", "node_type": "1", "metadata": {"window": "Additionally, we\u2019ve made significant \nprogress in selling through higher cost inventory on our balance sheet, leading to normalized PPE \nmargins in the quarter.  \n \n Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df9adee5c4f2417e5d85a21ce54f68e55f29b951f91915de5deb73de8f4f3e39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4220628-6ad6-4ec2-8404-1e1ea7f2703f", "node_type": "1", "metadata": {"window": "We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "Our expectations for the remaining items listed on slide 8 remain unchanged.  \n "}, "hash": "8a9f547f72e23c432a56d4b8eb9f27c1149cd03ce1634c805cc79acc830313d5", "class_name": "RelatedNodeInfo"}}, "text": "We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n", "start_char_idx": 2495, "end_char_idx": 2675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4220628-6ad6-4ec2-8404-1e1ea7f2703f": {"__data__": {"id_": "c4220628-6ad6-4ec2-8404-1e1ea7f2703f", "embedding": null, "metadata": {"window": "We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a7de5a17325fe7c03f52bfe3a41e51a294ffbb8b95490b9eebf50afac78fe55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bc40fd3-7fc9-4419-8052-c519a93196fd", "node_type": "1", "metadata": {"window": "Now, for our updated fiscal \u201823 outlook, beginning on slide 8.  \n \n We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf66ce65801297b21bbc29c98b89e3b2347129e91152f91b536e71b86308b797", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85c52a78-3f76-4cca-b0e0-740e26a9bc4f", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n", "original_text": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n"}, "hash": "fe5f5dd8f2a6628bdd801c5bdff5126903db02acedb23ee818a38e45cc522f00", "class_name": "RelatedNodeInfo"}}, "text": "Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "start_char_idx": 2675, "end_char_idx": 2755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85c52a78-3f76-4cca-b0e0-740e26a9bc4f": {"__data__": {"id_": "85c52a78-3f76-4cca-b0e0-740e26a9bc4f", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n", "original_text": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4220628-6ad6-4ec2-8404-1e1ea7f2703f", "node_type": "1", "metadata": {"window": "We are raising our EPS guidance by $0.15  at the lower end and $0.10  at the higher end to a new \nrange of $5.20 dollars to $5.50 dollars , which represents 6% year -over-year growth at the mid -point.  \n \n This update reflects improved outlooks for the Pharmaceutical segment and for Interest and Other.  \n \n We now expect Interest and Other in the range of $115 to $130 million dollars, with the improvement \nprimarily driven by the increased interest income on cash and equivalents.  \n \n Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "original_text": "Our expectations for the remaining items listed on slide 8 remain unchanged.  \n ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b9d33e402d1af581165fc7dfcd0c4b2d016897dc598fdcdbe804b6f4aef549b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "287c82ee-1617-4c71-b4c6-4711a50bb580", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight. ", "original_text": "As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n"}, "hash": "9250349cd5bc3841ef3348b7d06e5468767f542655cef07113544e3045c6459b", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n", "start_char_idx": 0, "end_char_idx": 276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "287c82ee-1617-4c71-b4c6-4711a50bb580": {"__data__": {"id_": "287c82ee-1617-4c71-b4c6-4711a50bb580", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight. ", "original_text": "As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85c52a78-3f76-4cca-b0e0-740e26a9bc4f", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n", "original_text": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e20cfbdcdb402218bfd0fea44ece5958abd0d2dad29b56a9e79500aefbac23b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "944d0c3a-4aa3-4038-86e3-f5d3f650a975", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n", "original_text": "Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n"}, "hash": "999cf07c7cd842140a234f1b42dc011dccf7cff6cd4c568cc0815d7bcb78df43", "class_name": "RelatedNodeInfo"}}, "text": "As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n", "start_char_idx": 276, "end_char_idx": 432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "944d0c3a-4aa3-4038-86e3-f5d3f650a975": {"__data__": {"id_": "944d0c3a-4aa3-4038-86e3-f5d3f650a975", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n", "original_text": "Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "287c82ee-1617-4c71-b4c6-4711a50bb580", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight. ", "original_text": "As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87ec32f230bb306b0030afaf6ccbb944bd24a4770ad256f78ca1f010a3536849", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dd4a69a-8d82-4c07-b1db-8469c9e53644", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n", "original_text": "With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n"}, "hash": "c2b79da621098571032f09ee31e5680d175527c45cbc105421e26b549f93610b", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n", "start_char_idx": 432, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dd4a69a-8d82-4c07-b1db-8469c9e53644": {"__data__": {"id_": "7dd4a69a-8d82-4c07-b1db-8469c9e53644", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n", "original_text": "With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "944d0c3a-4aa3-4038-86e3-f5d3f650a975", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n", "original_text": "Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6322659f4f59a87e9b754f78530bfdccdc3bf725cae7e5c7aed6a47e29ba9441", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "466706cd-33a1-4107-9d50-5e8f4d4218d2", "node_type": "1", "metadata": {"window": "As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit. ", "original_text": "On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight. "}, "hash": "fd7ea0b41314a16fea5d6be04c24261e5a4e0745a09009acd0244e7e2c1fb1da", "class_name": "RelatedNodeInfo"}}, "text": "With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n", "start_char_idx": 568, "end_char_idx": 752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "466706cd-33a1-4107-9d50-5e8f4d4218d2": {"__data__": {"id_": "466706cd-33a1-4107-9d50-5e8f4d4218d2", "embedding": null, "metadata": {"window": "As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit. ", "original_text": "On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dd4a69a-8d82-4c07-b1db-8469c9e53644", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n", "original_text": "With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b6a5eb058204385501ee891075bb621c9c197079a72619d56cac97699724f6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c6e2e84-2507-460d-9e41-d2a17818d7ea", "node_type": "1", "metadata": {"window": "Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter. ", "original_text": "As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n"}, "hash": "42ffbf117a1dd337745769d65fbf99e4cf93da849ec49f100dbf01bb70bfefa1", "class_name": "RelatedNodeInfo"}}, "text": "On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight. ", "start_char_idx": 752, "end_char_idx": 906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c6e2e84-2507-460d-9e41-d2a17818d7ea": {"__data__": {"id_": "9c6e2e84-2507-460d-9e41-d2a17818d7ea", "embedding": null, "metadata": {"window": "Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter. ", "original_text": "As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "466706cd-33a1-4107-9d50-5e8f4d4218d2", "node_type": "1", "metadata": {"window": "As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit. ", "original_text": "On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1e4eda3c9cce42297958c88e462f5238d53b81a3898d665b05562bf059ac900", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a37ca68f-869d-4c30-a713-80404760763a", "node_type": "1", "metadata": {"window": "With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n", "original_text": "Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n"}, "hash": "f4284ddd95392737a9d059a1f45e20b1e5299396e61f7f46e84fefa31a62f2b9", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n", "start_char_idx": 906, "end_char_idx": 1106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a37ca68f-869d-4c30-a713-80404760763a": {"__data__": {"id_": "a37ca68f-869d-4c30-a713-80404760763a", "embedding": null, "metadata": {"window": "With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n", "original_text": "Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c6e2e84-2507-460d-9e41-d2a17818d7ea", "node_type": "1", "metadata": {"window": "Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter. ", "original_text": "As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a36fbccb5097cd22a710959ec2c43025c2ac9b432eed5d883917c8a3e910dd8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6665a55-482f-431d-bd48-a1d100368f9b", "node_type": "1", "metadata": {"window": "On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment. ", "original_text": "And finally, no changes to the expected cadence of Medical segment profit. "}, "hash": "bbd42331499b24b077a202f96b1c6dd02d793c51b895d5b37b6495c1e7da35fe", "class_name": "RelatedNodeInfo"}}, "text": "Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n", "start_char_idx": 1106, "end_char_idx": 1217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6665a55-482f-431d-bd48-a1d100368f9b": {"__data__": {"id_": "c6665a55-482f-431d-bd48-a1d100368f9b", "embedding": null, "metadata": {"window": "On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment. ", "original_text": "And finally, no changes to the expected cadence of Medical segment profit. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a37ca68f-869d-4c30-a713-80404760763a", "node_type": "1", "metadata": {"window": "With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n", "original_text": "Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36b3446e715212274a3373328cca3bcfa9921c6bb69195df1690fc2f93ea8d84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2965d487-b0c1-4bd0-8467-f1baf24379ea", "node_type": "1", "metadata": {"window": "As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date. ", "original_text": "We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter. "}, "hash": "41c09effeadc92fb5d55f3b91aa60bea668f632d179ff09a865f34c0f9e01007", "class_name": "RelatedNodeInfo"}}, "text": "And finally, no changes to the expected cadence of Medical segment profit. ", "start_char_idx": 1217, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2965d487-b0c1-4bd0-8467-f1baf24379ea": {"__data__": {"id_": "2965d487-b0c1-4bd0-8467-f1baf24379ea", "embedding": null, "metadata": {"window": "As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date. ", "original_text": "We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6665a55-482f-431d-bd48-a1d100368f9b", "node_type": "1", "metadata": {"window": "On the cost side, while still at elevated levels, we\u2019ve seen a general stabilization across most areas, \nalong with improvement in international freight.  As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment. ", "original_text": "And finally, no changes to the expected cadence of Medical segment profit. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d29b6e64943832b9f6d7c2681d2c11143a008da48cf8bf4861c83c3fdab1bcd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aefce484-dc81-4e96-a21e-32da3a72ebf7", "node_type": "1", "metadata": {"window": "Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand. ", "original_text": "This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n"}, "hash": "6e4bf2db137ad20be04371a76604e45e24ba6e757a3f126d0f605d0c7ec497bb", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter. ", "start_char_idx": 1292, "end_char_idx": 1411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aefce484-dc81-4e96-a21e-32da3a72ebf7": {"__data__": {"id_": "aefce484-dc81-4e96-a21e-32da3a72ebf7", "embedding": null, "metadata": {"window": "Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand. ", "original_text": "This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2965d487-b0c1-4bd0-8467-f1baf24379ea", "node_type": "1", "metadata": {"window": "As a reminder, thes e product costs are capitalized \ninto inventory, and in the current environment of elongated supply chains, reflected in our P&L results \non an approximate two -quarter delay.  \n \n Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date. ", "original_text": "We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77f071d16c1f1a5546741bc2bd6c1e8ade2104690be25c61a7b4fae2693f63df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "211a0c81-5ea9-46ab-a1b7-799fd5012dec", "node_type": "1", "metadata": {"window": "And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n", "original_text": "For the enterprise, a key factor continues to be the overall utilization an d demand environment. "}, "hash": "4d5a25d48952eef397bf7c465f66a222153e1483200c779167c62bb6cb391d1e", "class_name": "RelatedNodeInfo"}}, "text": "This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n", "start_char_idx": 1411, "end_char_idx": 1635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "211a0c81-5ea9-46ab-a1b7-799fd5012dec": {"__data__": {"id_": "211a0c81-5ea9-46ab-a1b7-799fd5012dec", "embedding": null, "metadata": {"window": "And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n", "original_text": "For the enterprise, a key factor continues to be the overall utilization an d demand environment. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aefce484-dc81-4e96-a21e-32da3a72ebf7", "node_type": "1", "metadata": {"window": "Importantly, we continue to expect to exit the year with a run rate of at least 5 0% inflation mitigation.  \n \n And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand. ", "original_text": "This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4eb43a703da1417c9417fa5146d5acd81f5866a747b8c9459bd4fe17aa0e9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0abf00a4-e2dc-4ac9-a518-874739a105c3", "node_type": "1", "metadata": {"window": "We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n", "original_text": "In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date. "}, "hash": "48ee559b319042f00af60947c136fe6ea8872261ab2cee90a7a56d5f516ec7ba", "class_name": "RelatedNodeInfo"}}, "text": "For the enterprise, a key factor continues to be the overall utilization an d demand environment. ", "start_char_idx": 1635, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0abf00a4-e2dc-4ac9-a518-874739a105c3": {"__data__": {"id_": "0abf00a4-e2dc-4ac9-a518-874739a105c3", "embedding": null, "metadata": {"window": "We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n", "original_text": "In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "211a0c81-5ea9-46ab-a1b7-799fd5012dec", "node_type": "1", "metadata": {"window": "And finally, no changes to the expected cadence of Medical segment profit.  We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n", "original_text": "For the enterprise, a key factor continues to be the overall utilization an d demand environment. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c065e3703dd7cd0bf7eb844c919e24be062441f1e7b480db3fabd734513e9171", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c0a1095-05f5-404c-97bd-c3b5cc93df7b", "node_type": "1", "metadata": {"window": "This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish. ", "original_text": "In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand. "}, "hash": "f80442ad93189c7618ace7643ecb1f9c2d4952b25690dd665e84f89c4fb1ad7c", "class_name": "RelatedNodeInfo"}}, "text": "In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date. ", "start_char_idx": 1733, "end_char_idx": 1884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c0a1095-05f5-404c-97bd-c3b5cc93df7b": {"__data__": {"id_": "8c0a1095-05f5-404c-97bd-c3b5cc93df7b", "embedding": null, "metadata": {"window": "This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish. ", "original_text": "In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0abf00a4-e2dc-4ac9-a518-874739a105c3", "node_type": "1", "metadata": {"window": "We continue to expect \nsegment profit to improve sequentially and be particularly weighted towards the fourth quarter.  This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n", "original_text": "In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1036a52cf390fad94d2c61eda8f5878042e9724b2f2c30b4025e851e37e11ed3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c82249a-d493-44f7-af17-aee950329313", "node_type": "1", "metadata": {"window": "For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n", "original_text": "Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n"}, "hash": "8822bfef3ed90c9f8fdac2c70904fe8b1d169f58028b2cc8a69ae82bf81be289", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand. ", "start_char_idx": 1884, "end_char_idx": 1988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c82249a-d493-44f7-af17-aee950329313": {"__data__": {"id_": "6c82249a-d493-44f7-af17-aee950329313", "embedding": null, "metadata": {"window": "For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n", "original_text": "Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c0a1095-05f5-404c-97bd-c3b5cc93df7b", "node_type": "1", "metadata": {"window": "This \nsequencing primarily reflects o ur assumptions around the net impact of inflation, and to a lesser \nextent, a gradual improvement in overall volumes and the continued implementation of our cost \nsavings measures .  \n \n For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish. ", "original_text": "In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29c8f99b0a7269e688b3d909028e5f726e622445f7beb282ec5699804f3dd2d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cb36767-7ed1-46fd-ad59-02adb2f18414", "node_type": "1", "metadata": {"window": "In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n", "original_text": "With that, I\u2019ll now turn it over to Jason.  \n \n"}, "hash": "a753d98f732a613018566f3a25c7098d1f384333c6742937a51ea008de9c9306", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n", "start_char_idx": 1988, "end_char_idx": 2226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cb36767-7ed1-46fd-ad59-02adb2f18414": {"__data__": {"id_": "2cb36767-7ed1-46fd-ad59-02adb2f18414", "embedding": null, "metadata": {"window": "In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n", "original_text": "With that, I\u2019ll now turn it over to Jason.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c82249a-d493-44f7-af17-aee950329313", "node_type": "1", "metadata": {"window": "For the enterprise, a key factor continues to be the overall utilization an d demand environment.  In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n", "original_text": "Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad3baa400b77bfddefe64d013868efea6f51108628b2e55c4238df1f8e6ec9fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2433049a-7780-4c3f-a414-9bb22ab40dc3", "node_type": "1", "metadata": {"window": "In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability. ", "original_text": "Jason Hollar :   Thanks Trish. "}, "hash": "5cb2e4ca5c69120f38a248826be917e40213b5b5184735988fad980272e45dc5", "class_name": "RelatedNodeInfo"}}, "text": "With that, I\u2019ll now turn it over to Jason.  \n \n", "start_char_idx": 2226, "end_char_idx": 2273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2433049a-7780-4c3f-a414-9bb22ab40dc3": {"__data__": {"id_": "2433049a-7780-4c3f-a414-9bb22ab40dc3", "embedding": null, "metadata": {"window": "In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability. ", "original_text": "Jason Hollar :   Thanks Trish. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cb36767-7ed1-46fd-ad59-02adb2f18414", "node_type": "1", "metadata": {"window": "In \nPharma, we expect continued strength in overall pharmaceutical demand in the second half, albeit at \na more moderate rate than we\u2019ve seen to date.  In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n", "original_text": "With that, I\u2019ll now turn it over to Jason.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b3b8660cd040b7d1733a3c0ddf1504a58e288a052bc314393ab2df4a96108ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b66430dd-3355-4498-bd7d-42b493f8a2a1", "node_type": "1", "metadata": {"window": "Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n"}, "hash": "8db5c2586ec5578a9ebabb427f29a5dc59b99799e38c4fbafee21dc14539058f", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :   Thanks Trish. ", "start_char_idx": 2273, "end_char_idx": 2304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b66430dd-3355-4498-bd7d-42b493f8a2a1": {"__data__": {"id_": "b66430dd-3355-4498-bd7d-42b493f8a2a1", "embedding": null, "metadata": {"window": "Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2433049a-7780-4c3f-a414-9bb22ab40dc3", "node_type": "1", "metadata": {"window": "In Medical, we expect a gradual improvement in \noverall volumes, including with Cardin al Health Brand.  Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability. ", "original_text": "Jason Hollar :   Thanks Trish. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48992c0b319c3a1dd01214956a924169eda4e71076153c307a15129557d7dfc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2bd6145-5347-4685-9657-1f327e6f97b1", "node_type": "1", "metadata": {"window": "With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "First, executing our Medical Improvement Plan initiatives.  \n \n"}, "hash": "30e72b69520b6cf8e0ca9234a7be59cf81dc76169ab7f003e28ad4545f5801c1", "class_name": "RelatedNodeInfo"}}, "text": "Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n", "start_char_idx": 2304, "end_char_idx": 2391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2bd6145-5347-4685-9657-1f327e6f97b1": {"__data__": {"id_": "a2bd6145-5347-4685-9657-1f327e6f97b1", "embedding": null, "metadata": {"window": "With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "First, executing our Medical Improvement Plan initiatives.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b66430dd-3355-4498-bd7d-42b493f8a2a1", "node_type": "1", "metadata": {"window": "Therefore, if the trends from the first half of the \nyear continue, we would anticipate segment profit more towards the upper end of our range in the \nPharma segment and more towards the lower end of our range in the Medical segment.  \n \n With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62043d64a16e873178273600d78d8f80c6cbe0d0d07f34e5944d6d9bd9eae4a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bb2278b-a1f6-4f1a-b8bc-373de35e3043", "node_type": "1", "metadata": {"window": "Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability. "}, "hash": "771f9108fb900673661a10dd266b2257edcaab76a9ee4932e35dfa8e63ac8861", "class_name": "RelatedNodeInfo"}}, "text": "First, executing our Medical Improvement Plan initiatives.  \n \n", "start_char_idx": 2391, "end_char_idx": 2454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bb2278b-a1f6-4f1a-b8bc-373de35e3043": {"__data__": {"id_": "8bb2278b-a1f6-4f1a-b8bc-373de35e3043", "embedding": null, "metadata": {"window": "Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2bd6145-5347-4685-9657-1f327e6f97b1", "node_type": "1", "metadata": {"window": "With that, I\u2019ll now turn it over to Jason.  \n \n Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "First, executing our Medical Improvement Plan initiatives.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "351e9e953ace99776e6fdcb6eaa3fdbd9d07a17e086681ba14880371cd0f907a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7f03c2e-efcb-4bbc-b5e7-0a5745be9f00", "node_type": "1", "metadata": {"window": "Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n "}, "hash": "e98ed6326fb3d7bb8985229f3800e05eb5545d712205e2f3544d128fee78111b", "class_name": "RelatedNodeInfo"}}, "text": "Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability. ", "start_char_idx": 2454, "end_char_idx": 2659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7f03c2e-efcb-4bbc-b5e7-0a5745be9f00": {"__data__": {"id_": "a7f03c2e-efcb-4bbc-b5e7-0a5745be9f00", "embedding": null, "metadata": {"window": "Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e144196d2cad4dfc3cbd03958761ffbe2fdebf3d4483ad4559803a2c0fa24287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bb2278b-a1f6-4f1a-b8bc-373de35e3043", "node_type": "1", "metadata": {"window": "Jason Hollar :   Thanks Trish.  Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability. ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6643d346be1eb5bb96eb1b3cd05d05e4680955144ae7069d085835ad8420689a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed36ceba-aab9-4fbe-8a2c-e97fdf49464a", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew. ", "original_text": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories. "}, "hash": "86173d60631841e8361477b0e550907b6918eb207ece2d1fa412618abf6004e3", "class_name": "RelatedNodeInfo"}}, "text": "I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "start_char_idx": 2659, "end_char_idx": 2808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed36ceba-aab9-4fbe-8a2c-e97fdf49464a": {"__data__": {"id_": "ed36ceba-aab9-4fbe-8a2c-e97fdf49464a", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew. ", "original_text": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7f03c2e-efcb-4bbc-b5e7-0a5745be9f00", "node_type": "1", "metadata": {"window": "Let me now provide a few updates on our 3 key strategic priorities for \nfiscal \u201823. \n \n First, executing our Medical Improvement Plan initiatives.  \n \n Importantly, we remain on track with our mi tigation actions for inflation and global supply chain \nconstraints , the number one  key to returning the business to a more normalized level of profitability.  I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "original_text": "I \nam pleased with the incremental progress achieved in the second quarter, as we mitigated over 30 % \nof the gross impact to our business in Q2.  \n ", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "798c6059a00bed7b7ec25dff8df3799ac83ec7cb385f243f418bd6a0cc93cddc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ad1bc6f-ed62-4a31-bc7f-38cdcf4d6999", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics. ", "original_text": "We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n"}, "hash": "3d7b426a11c5cd08ddead7c3f43307f1270d92c7cabba7d9b6c2311b4c3a7971", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories. ", "start_char_idx": 0, "end_char_idx": 191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ad1bc6f-ed62-4a31-bc7f-38cdcf4d6999": {"__data__": {"id_": "4ad1bc6f-ed62-4a31-bc7f-38cdcf4d6999", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics. ", "original_text": "We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed36ceba-aab9-4fbe-8a2c-e97fdf49464a", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew. ", "original_text": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a33eefc2e7f6271e531ee4e951ba89de1a16796ab5f80f045ac6c8bcc60fb011", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1eaba84-7ad9-4af0-9bad-5a7b8cc8038f", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n", "original_text": "We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions. "}, "hash": "f291c8893402082677ca8e550fb538d16c6d8f73a8f2273075b4de87eebf3497", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n", "start_char_idx": 191, "end_char_idx": 388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1eaba84-7ad9-4af0-9bad-5a7b8cc8038f": {"__data__": {"id_": "e1eaba84-7ad9-4af0-9bad-5a7b8cc8038f", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n", "original_text": "We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ad1bc6f-ed62-4a31-bc7f-38cdcf4d6999", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics. ", "original_text": "We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1664c3c19ea21bebb8c7a9fc6de65ad44d7b61e121dccc04a008329fb46c2892", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b730af6f-5a0e-49f3-b4a6-d2a12b0aef6b", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio. ", "original_text": "Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew. "}, "hash": "a34e1dce12c3034697b45ef08bb990ba99f08860f39d1b6200ef58922097583e", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions. ", "start_char_idx": 388, "end_char_idx": 543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b730af6f-5a0e-49f3-b4a6-d2a12b0aef6b": {"__data__": {"id_": "b730af6f-5a0e-49f3-b4a6-d2a12b0aef6b", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio. ", "original_text": "Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1eaba84-7ad9-4af0-9bad-5a7b8cc8038f", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n", "original_text": "We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee55be9da5361d7c2b7f2706bfa9e26d73778f54aa6ed392551aeddd9662c0ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e3a9a0c-00cb-4928-82ec-8a3d7758c719", "node_type": "1", "metadata": {"window": "We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters. ", "original_text": "We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics. "}, "hash": "c84549aa611497d7cd79be6c3a73f549f2ce1635589fef94a0fc8b8047d4748f", "class_name": "RelatedNodeInfo"}}, "text": "Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew. ", "start_char_idx": 543, "end_char_idx": 735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e3a9a0c-00cb-4928-82ec-8a3d7758c719": {"__data__": {"id_": "6e3a9a0c-00cb-4928-82ec-8a3d7758c719", "embedding": null, "metadata": {"window": "We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters. ", "original_text": "We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b730af6f-5a0e-49f3-b4a6-d2a12b0aef6b", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio. ", "original_text": "Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19cc49318ebfa0252b402536107b6456b82f6b3a8c74bf56504992d71cfcb013", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "924c03aa-07ff-4159-93c2-241784d61c3b", "node_type": "1", "metadata": {"window": "We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n", "original_text": "We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n"}, "hash": "d1f23928a288d6e3e457ce13386bbdd02ac1567667ace0fe733a6464c0849c80", "class_name": "RelatedNodeInfo"}}, "text": "We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics. ", "start_char_idx": 735, "end_char_idx": 849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "924c03aa-07ff-4159-93c2-241784d61c3b": {"__data__": {"id_": "924c03aa-07ff-4159-93c2-241784d61c3b", "embedding": null, "metadata": {"window": "We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n", "original_text": "We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e3a9a0c-00cb-4928-82ec-8a3d7758c719", "node_type": "1", "metadata": {"window": "We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters. ", "original_text": "We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "392729fde9cf0e95b6e2db9a3672017f1e685eed95f77bb477b8a59562d95f00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c7856f1-d33e-41cc-bb1d-e520f514261a", "node_type": "1", "metadata": {"window": "Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet. ", "original_text": "Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio. "}, "hash": "408afa1f1feb7055ef2eb716d09b39b3212d7373594ccc224aae15fdf577f62b", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n", "start_char_idx": 849, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c7856f1-d33e-41cc-bb1d-e520f514261a": {"__data__": {"id_": "7c7856f1-d33e-41cc-bb1d-e520f514261a", "embedding": null, "metadata": {"window": "Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet. ", "original_text": "Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "924c03aa-07ff-4159-93c2-241784d61c3b", "node_type": "1", "metadata": {"window": "We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n", "original_text": "We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4842266a9e075c13b8d0551260474de3f58a016145a7c244b81a44b293616e73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93c54aad-3982-4ee2-9382-6f65bced9545", "node_type": "1", "metadata": {"window": "We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n", "original_text": "As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters. "}, "hash": "f6a20263ce88c6ccf64c4ffd6b157033eac7f71f59f5fa1370c99b44f3e143cb", "class_name": "RelatedNodeInfo"}}, "text": "Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio. ", "start_char_idx": 1007, "end_char_idx": 1121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93c54aad-3982-4ee2-9382-6f65bced9545": {"__data__": {"id_": "93c54aad-3982-4ee2-9382-6f65bced9545", "embedding": null, "metadata": {"window": "We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n", "original_text": "As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c7856f1-d33e-41cc-bb1d-e520f514261a", "node_type": "1", "metadata": {"window": "Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew.  We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet. ", "original_text": "Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6750a0ddddcad704bd46887936e16eac7750370fb29c00da89984ea5b8b84ae9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3346f407-38d4-4d9a-a40b-169687e229f7", "node_type": "1", "metadata": {"window": "We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home. ", "original_text": "Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n"}, "hash": "0ce0dfe5c7d5aa8cc7590176dd41235cc0de5df02cf885be60c6c4901e1b83c2", "class_name": "RelatedNodeInfo"}}, "text": "As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters. ", "start_char_idx": 1121, "end_char_idx": 1243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3346f407-38d4-4d9a-a40b-169687e229f7": {"__data__": {"id_": "3346f407-38d4-4d9a-a40b-169687e229f7", "embedding": null, "metadata": {"window": "We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home. ", "original_text": "Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93c54aad-3982-4ee2-9382-6f65bced9545", "node_type": "1", "metadata": {"window": "We a re also including language that allows \nfor greater flexibility to respond to future macroeconomic dynamics.  We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n", "original_text": "As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "120d033b8e3bdfb655c29b5d08cba4258241b34e9a15db49c4adb4f8184566a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8494921-a3b5-4c25-90bc-f81a979d5811", "node_type": "1", "metadata": {"window": "Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n", "original_text": "For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet. "}, "hash": "c920096fd2980c8825a78365b2f930c98b5234acb746f0c03826ee3d581aacc9", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n", "start_char_idx": 1243, "end_char_idx": 1508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8494921-a3b5-4c25-90bc-f81a979d5811": {"__data__": {"id_": "d8494921-a3b5-4c25-90bc-f81a979d5811", "embedding": null, "metadata": {"window": "Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n", "original_text": "For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3346f407-38d4-4d9a-a40b-169687e229f7", "node_type": "1", "metadata": {"window": "We continue to expect to exit the \nyear with a run rate of at least 50 % inflation mitigation, and to fully mitigate inflation by the end of \nfiscal \u201824.  \n \n Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home. ", "original_text": "Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1421ac1def0161069ab994276fbe3f2f83678882dbb0cfedaca749b42effa10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "949e6cdf-8cf4-4503-94fb-6b743c041c93", "node_type": "1", "metadata": {"window": "As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n", "original_text": "This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n"}, "hash": "09c6d5a861127092d207f604fad85bb5b184234f5f8c915eb4834467d1289e1d", "class_name": "RelatedNodeInfo"}}, "text": "For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet. ", "start_char_idx": 1508, "end_char_idx": 1671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "949e6cdf-8cf4-4503-94fb-6b743c041c93": {"__data__": {"id_": "949e6cdf-8cf4-4503-94fb-6b743c041c93", "embedding": null, "metadata": {"window": "As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n", "original_text": "This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8494921-a3b5-4c25-90bc-f81a979d5811", "node_type": "1", "metadata": {"window": "Outside of our mitigation actions, we are focused on optimizing and growing our Cardinal Health \nBrand portfolio.  As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n", "original_text": "For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f9bcef07df1bfcea18c4b9a68f16fed3a87232a27dfe1e74e4be87b9fc2e8e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7075fef9-e235-48e6-a65a-6e2ffa6cdc93", "node_type": "1", "metadata": {"window": "Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n", "original_text": "We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home. "}, "hash": "98d9d87169a178b05bb9fde6c6dcaf5af46010f7e834381f6e0bd423c0bbc96e", "class_name": "RelatedNodeInfo"}}, "text": "This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n", "start_char_idx": 1671, "end_char_idx": 1936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7075fef9-e235-48e6-a65a-6e2ffa6cdc93": {"__data__": {"id_": "7075fef9-e235-48e6-a65a-6e2ffa6cdc93", "embedding": null, "metadata": {"window": "Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n", "original_text": "We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "949e6cdf-8cf4-4503-94fb-6b743c041c93", "node_type": "1", "metadata": {"window": "As Trish indicated, the market demand environment in Medical has been relatively \nstagnant over the last couple quarters.  Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n", "original_text": "This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e02e4e91670dc0b101bcc29cbb2783ec1aecd61dbdc5f8081a337aee1415d0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "663d233b-7f87-433d-bc28-da6c3c3d7e35", "node_type": "1", "metadata": {"window": "For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n", "original_text": "Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n"}, "hash": "a35337c28d84c8ffa0dc8fcc7636515030054f70e41307f10440e874960c1103", "class_name": "RelatedNodeInfo"}}, "text": "We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home. ", "start_char_idx": 1936, "end_char_idx": 2118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "663d233b-7f87-433d-bc28-da6c3c3d7e35": {"__data__": {"id_": "663d233b-7f87-433d-bc28-da6c3c3d7e35", "embedding": null, "metadata": {"window": "For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n", "original_text": "Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7075fef9-e235-48e6-a65a-6e2ffa6cdc93", "node_type": "1", "metadata": {"window": "Additionally, som e of our higher -margin Cardinal Health Brand \ncategories remain under -penetrated, which we are addressing through targeted investments to \nincrease product availability, new product innovation and a continual focus on commercial excellence.  \n \n For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n", "original_text": "We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96af6f5eabfbfe16a92510af2dcf8b10e0a48b9c6cda3e7647ffc189e929b3d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "033d60d5-f355-4342-a8ae-41ec3a7048d1", "node_type": "1", "metadata": {"window": "This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care. ", "original_text": "And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n"}, "hash": "3d37bff1518d27cbcd0734e2fe757cd78fbb59b3f2af11acafedc2e3b6b33a51", "class_name": "RelatedNodeInfo"}}, "text": "Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n", "start_char_idx": 2118, "end_char_idx": 2386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "033d60d5-f355-4342-a8ae-41ec3a7048d1": {"__data__": {"id_": "033d60d5-f355-4342-a8ae-41ec3a7048d1", "embedding": null, "metadata": {"window": "This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care. ", "original_text": "And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "663d233b-7f87-433d-bc28-da6c3c3d7e35", "node_type": "1", "metadata": {"window": "For example, we  recently expanded our Sustainable TechnologiesTM manufacturing facility in \nRiverview, Florida, doubling the size to roughly 100,000 square feet.  This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n", "original_text": "Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d53fe0a99bffd940cb1d85b53ad5ed835cd3cb3e22a5aa737f4b7eb5fde4597c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "053d3036-b3d5-47cc-82fb-2e55064f2eab", "node_type": "1", "metadata": {"window": "We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n"}, "hash": "768fb8578dda73918882586ed941f9cbaf442726ba8f3100f3e6f99e9b8c6a28", "class_name": "RelatedNodeInfo"}}, "text": "And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n", "start_char_idx": 2386, "end_char_idx": 2652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "053d3036-b3d5-47cc-82fb-2e55064f2eab": {"__data__": {"id_": "053d3036-b3d5-47cc-82fb-2e55064f2eab", "embedding": null, "metadata": {"window": "We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "033d60d5-f355-4342-a8ae-41ec3a7048d1", "node_type": "1", "metadata": {"window": "This facility will enable us to \nbetter meet increasing demand for single -use device collections, reprocessing,  and recycling services  \nsupporting future growth while also delivering supply resiliency, sustainable solutions, and cost \nsavings for customers.  \n \n We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care. ", "original_text": "And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3636982eaa259dacc06d461cc5c1bdd8b959afbe47852f473fcdae91a14fba6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b1cada1-b67c-427a-9346-670f171b5831", "node_type": "1", "metadata": {"window": "Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n"}, "hash": "a0216db5b21a412b7ae008439b2dbd57f2e36e024b68824b9747ff5f465a8337", "class_name": "RelatedNodeInfo"}}, "text": "Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n", "start_char_idx": 2652, "end_char_idx": 2865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b1cada1-b67c-427a-9346-670f171b5831": {"__data__": {"id_": "0b1cada1-b67c-427a-9346-670f171b5831", "embedding": null, "metadata": {"window": "Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "053d3036-b3d5-47cc-82fb-2e55064f2eab", "node_type": "1", "metadata": {"window": "We are also investing to accelerate our growth businesses, primarily at -Home Solutions, where we\u2019ve \nseen stro ng growth fueled by the secular trend of care shifting into the home.  Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d27b3063e0e16d10837164c667e89c346936a09d77c00dc6316ccbf138b57684", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "273820e0-3cff-4f91-b748-088ca15fb25c", "node_type": "1", "metadata": {"window": "And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care. "}, "hash": "c787b56eca36d8437f57b964350d27ac9bcfd729c94b37c920ba6d5f6f106d0b", "class_name": "RelatedNodeInfo"}}, "text": "In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n", "start_char_idx": 2865, "end_char_idx": 3035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "273820e0-3cff-4f91-b748-088ca15fb25c": {"__data__": {"id_": "273820e0-3cff-4f91-b748-088ca15fb25c", "embedding": null, "metadata": {"window": "And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b1cada1-b67c-427a-9346-670f171b5831", "node_type": "1", "metadata": {"window": "Our new, central Ohio \ndistribution center, equipped with robotics and automation technology, will be fully operational soon \nas we continue to expand our footprint to match the sustained growth of home healthcare we are \nseeing in the industry and our business .  \n \n And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2bf0c486425ab359c118d8f4630453946f0cab2220b4d26e5b094b88e2fe575c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11028dd9-6e17-4b45-8ec4-73cb4bbb5c34", "node_type": "1", "metadata": {"window": "Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  "}, "hash": "95f62e44b5807803f5182d4818c268d0565b333f1c0e2a9c16e69a6637bdcaa7", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care. ", "start_char_idx": 3035, "end_char_idx": 3151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11028dd9-6e17-4b45-8ec4-73cb4bbb5c34": {"__data__": {"id_": "11028dd9-6e17-4b45-8ec4-73cb4bbb5c34", "embedding": null, "metadata": {"window": "Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cc92038ee9a5874f873c316cc42752e4e54a835491d5807bc2e86cbf9ee2158", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "273820e0-3cff-4f91-b748-088ca15fb25c", "node_type": "1", "metadata": {"window": "And, in our higher -margin Medical Services business, OptiFreight Logistics recently expanded its \nofferings with TotalVuetm Tracking, a new capability offering healthcare providers real-time shipment \ntracking to enhance supply chain visibility and resiliency.  \n \n Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0bdbf65ccf0f571ed79732744c8eac3cdb309e0f3dcd497c350dca1e0bb54dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5703d9b-ec88-477d-b8f9-3e137197953f", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n", "original_text": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships. "}, "hash": "cb562fa5fce2ad5124d140551fe4059336a0ca61a2c7284afc9c1e36988b5e46", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "start_char_idx": 3151, "end_char_idx": 3307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5703d9b-ec88-477d-b8f9-3e137197953f": {"__data__": {"id_": "d5703d9b-ec88-477d-b8f9-3e137197953f", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n", "original_text": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11028dd9-6e17-4b45-8ec4-73cb4bbb5c34", "node_type": "1", "metadata": {"window": "Second, moving to the Pharma segment, where we\u2019re building upon the growth and the resiliency of \nthe business, we\u2019re focused on executing in the core and accelerating our growt h areas, primarily \nSpecialty.  \n \n In the first couple months, we\u2019ve already seen efficiency and effectiveness gains from our recently \ncombined Pharmaceutical and Specialty Distribution organization.  \n \n We\u2019ve seen strong growth across Specialty Distribution, i ncluding within acute health systems and \nalternate care.  Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "original_text": "Additionally, our recent acquisition of the Bendcare GPO and investment in their \nmanaged services organization has been positively received by customers.  ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5279c761e8a16ff148a97f81a4cb45ecd62c59180b2ccdabb2fe55c476df3196", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c323ff84-04ee-4db5-b6eb-282cf0a2c0b7", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n", "original_text": "This includes strategic sourcing,  along with the high \ndemand area of manufac turer services. "}, "hash": "4dffaa2210ed647af9186b375d312364690f9a3bd49dec5c629460fb7c8381a0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships. ", "start_char_idx": 0, "end_char_idx": 244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c323ff84-04ee-4db5-b6eb-282cf0a2c0b7": {"__data__": {"id_": "c323ff84-04ee-4db5-b6eb-282cf0a2c0b7", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n", "original_text": "This includes strategic sourcing,  along with the high \ndemand area of manufac turer services. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5703d9b-ec88-477d-b8f9-3e137197953f", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n", "original_text": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4878a09ee4a2ddbd2a67b545d0a2b4c0716b845cf4190a0f8dc88777a7ae7a43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65f3e828-8259-4b84-b961-851a56b1aef6", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base. ", "original_text": "In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal. "}, "hash": "19a816b781b3678d27ba94ffd97b7a874a6fe61803dc8599f3be70f8467bb061", "class_name": "RelatedNodeInfo"}}, "text": "This includes strategic sourcing,  along with the high \ndemand area of manufac turer services. ", "start_char_idx": 244, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65f3e828-8259-4b84-b961-851a56b1aef6": {"__data__": {"id_": "65f3e828-8259-4b84-b961-851a56b1aef6", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base. ", "original_text": "In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c323ff84-04ee-4db5-b6eb-282cf0a2c0b7", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n", "original_text": "This includes strategic sourcing,  along with the high \ndemand area of manufac turer services. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce6e8720022ebd532c290a33e301e07e1efc303daf6551a79ca4b291d6e244c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90d4a0ba-76a2-439d-a8ce-2ab638a5cbed", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n", "original_text": "And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n"}, "hash": "dad3d3a2aea877609eb5b16752b9de29e2e214f2366d0d7b1f54c64f97dd1aac", "class_name": "RelatedNodeInfo"}}, "text": "In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal. ", "start_char_idx": 339, "end_char_idx": 550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90d4a0ba-76a2-439d-a8ce-2ab638a5cbed": {"__data__": {"id_": "90d4a0ba-76a2-439d-a8ce-2ab638a5cbed", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n", "original_text": "And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65f3e828-8259-4b84-b961-851a56b1aef6", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base. ", "original_text": "In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b80d28958dbaa769dc446c4124e97d04861c833c5ab98ee7322f766a38c05050", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e94d6552-dd70-4495-874c-b72b8e16863c", "node_type": "1", "metadata": {"window": "This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients. ", "original_text": "We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n"}, "hash": "1ddf22eb4c016158ba1fba73a23b17a145e5a9cbc421bf411ee062a4aaa3689f", "class_name": "RelatedNodeInfo"}}, "text": "And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n", "start_char_idx": 550, "end_char_idx": 774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e94d6552-dd70-4495-874c-b72b8e16863c": {"__data__": {"id_": "e94d6552-dd70-4495-874c-b72b8e16863c", "embedding": null, "metadata": {"window": "This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients. ", "original_text": "We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90d4a0ba-76a2-439d-a8ce-2ab638a5cbed", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n", "original_text": "And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79100a31251dd9548e11c3e30e7c7ef87a12f0bf40420bdaa3acf9c9ad2e6c05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2b9229b-df27-4253-8be5-c6f805db1efa", "node_type": "1", "metadata": {"window": "In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n", "original_text": "We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base. "}, "hash": "e31db3ef698ff6c58b07d46553ad40a26f1a04e803bae7568e9aa9ebfde543c4", "class_name": "RelatedNodeInfo"}}, "text": "We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n", "start_char_idx": 774, "end_char_idx": 925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2b9229b-df27-4253-8be5-c6f805db1efa": {"__data__": {"id_": "f2b9229b-df27-4253-8be5-c6f805db1efa", "embedding": null, "metadata": {"window": "In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n", "original_text": "We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e94d6552-dd70-4495-874c-b72b8e16863c", "node_type": "1", "metadata": {"window": "This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients. ", "original_text": "We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174d33d9416c92e7233ac03987e8ef1dc5a8a91f30492d1aaf69083297df6921", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed36589b-eadc-458e-82d3-2ee48ebcfd47", "node_type": "1", "metadata": {"window": "And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n", "original_text": "For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n"}, "hash": "be1ad453731704440fb0eb36cc0097aaeaf41714ff7ce17aae489bdbcba0ecb5", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base. ", "start_char_idx": 925, "end_char_idx": 1044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed36589b-eadc-458e-82d3-2ee48ebcfd47": {"__data__": {"id_": "ed36589b-eadc-458e-82d3-2ee48ebcfd47", "embedding": null, "metadata": {"window": "And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n", "original_text": "For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2b9229b-df27-4253-8be5-c6f805db1efa", "node_type": "1", "metadata": {"window": "In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n", "original_text": "We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb87050379db5891a37b32d4f9cacd1dcd06c306305896174cece5dd5d9e869", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d6f587d-4722-41ea-adfe-81917db4ea69", "node_type": "1", "metadata": {"window": "We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n", "original_text": "By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients. "}, "hash": "f467ac378ddbe5a1d97fe7ef6d606500f3fda4f683ab6ea7dcad3c783fbb60fe", "class_name": "RelatedNodeInfo"}}, "text": "For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n", "start_char_idx": 1044, "end_char_idx": 1236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d6f587d-4722-41ea-adfe-81917db4ea69": {"__data__": {"id_": "1d6f587d-4722-41ea-adfe-81917db4ea69", "embedding": null, "metadata": {"window": "We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n", "original_text": "By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed36589b-eadc-458e-82d3-2ee48ebcfd47", "node_type": "1", "metadata": {"window": "And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n", "original_text": "For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ccca4b5b5ecdfd5a9b2f5021eaaa1921b16beb858bda5ec58f195b7841719408", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9353a27a-4114-402a-bde3-6654432552b8", "node_type": "1", "metadata": {"window": "We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n", "original_text": "We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n"}, "hash": "e8ec4050b440dbf4c4d471df9cfbb356a2f5a65adb10a48de5b16c3548a5038b", "class_name": "RelatedNodeInfo"}}, "text": "By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients. ", "start_char_idx": 1236, "end_char_idx": 1405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9353a27a-4114-402a-bde3-6654432552b8": {"__data__": {"id_": "9353a27a-4114-402a-bde3-6654432552b8", "embedding": null, "metadata": {"window": "We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n", "original_text": "We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d6f587d-4722-41ea-adfe-81917db4ea69", "node_type": "1", "metadata": {"window": "We are investing in automation and enhancing technology across our su pply chain today in order to \ndrive operational productivity for the future.  \n \n We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n", "original_text": "By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0d2728d7e01146b1701472434813baf3a39c836b6ef0fa3aedf7e7f99bdbd54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a917898a-2a78-4453-b477-1875fa2eb444", "node_type": "1", "metadata": {"window": "For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n", "original_text": "And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n"}, "hash": "c208a7d8db4e431bef7b1d3da9bf862429acc5353351922ff7d740a97ccc6432", "class_name": "RelatedNodeInfo"}}, "text": "We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n", "start_char_idx": 1405, "end_char_idx": 1707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a917898a-2a78-4453-b477-1875fa2eb444": {"__data__": {"id_": "a917898a-2a78-4453-b477-1875fa2eb444", "embedding": null, "metadata": {"window": "For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n", "original_text": "And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9353a27a-4114-402a-bde3-6654432552b8", "node_type": "1", "metadata": {"window": "We\u2019re striving to deliver a flawless end -to-end customer experience supporting our strong and diverse \ncustomer base.  For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n", "original_text": "We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3dc6ef5861a550ed5add670d7eab1497d784f53a6bd11d8b42c946ffc5a7ed33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "797c013e-6e12-4392-89a4-b600fe5ed5e3", "node_type": "1", "metadata": {"window": "By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week. ", "original_text": "In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n"}, "hash": "9c522a78fb21db08ca9edf05e62e75b7708628601f3ccb227896e793f48a14f3", "class_name": "RelatedNodeInfo"}}, "text": "And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n", "start_char_idx": 1707, "end_char_idx": 1800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "797c013e-6e12-4392-89a4-b600fe5ed5e3": {"__data__": {"id_": "797c013e-6e12-4392-89a4-b600fe5ed5e3", "embedding": null, "metadata": {"window": "By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week. ", "original_text": "In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a917898a-2a78-4453-b477-1875fa2eb444", "node_type": "1", "metadata": {"window": "For example, our recently -announced collaboration with Palanti r will offer customers \na solution that connects diagnostic and clinical data with real -time purchasing and consumption data. \n By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n", "original_text": "And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "834cd9ece2be5d63f10a1e00d5f5d25b1a4f72a7cb10ea5d6d5e14b5083aa2d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "828a1472-664d-4af4-b05c-e935801f5491", "node_type": "1", "metadata": {"window": "We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives. ", "original_text": "Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n"}, "hash": "4bd35b6f613330b8ebf5c24efff9b7f987d0bca2104a19440cab8b5796ca6c5b", "class_name": "RelatedNodeInfo"}}, "text": "In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n", "start_char_idx": 1800, "end_char_idx": 2103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "828a1472-664d-4af4-b05c-e935801f5491": {"__data__": {"id_": "828a1472-664d-4af4-b05c-e935801f5491", "embedding": null, "metadata": {"window": "We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives. ", "original_text": "Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "797c013e-6e12-4392-89a4-b600fe5ed5e3", "node_type": "1", "metadata": {"window": "By leveraging AI and machine learning, our customers will be empowered to make better purchasing \nand inventory management decisions  for their businesses and patients.  We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week. ", "original_text": "In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1efa81577973109533dbe91a4e94238b8a2eb671aa4e6c425d10f353f59c037", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81bbaad6-0194-4231-a967-834aba4722cf", "node_type": "1", "metadata": {"window": "And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders. ", "original_text": "We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n"}, "hash": "d85ef8eecf93b5d9dd7b7f588acf9f02e49b7f8835abdbc39b89237f0e8856ba", "class_name": "RelatedNodeInfo"}}, "text": "Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n", "start_char_idx": 2103, "end_char_idx": 2274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81bbaad6-0194-4231-a967-834aba4722cf": {"__data__": {"id_": "81bbaad6-0194-4231-a967-834aba4722cf", "embedding": null, "metadata": {"window": "And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders. ", "original_text": "We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "828a1472-664d-4af4-b05c-e935801f5491", "node_type": "1", "metadata": {"window": "We are privileged to serve \nand partner with leaders across the various classes of trade such as retail pharmacy chains, mail \norder and grocery, as well as retail independents, long -term care and health systems, all of wh om \nprovide essential healthcare access for their respective communities.  \n \n And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives. ", "original_text": "Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a99565946083c51f88406ed5b29f3a0d72f9d13a1c61e8db0a1ade7b7d1fc4a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f5cc462-bc27-466d-9cf1-1e0916f6a17a", "node_type": "1", "metadata": {"window": "In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n", "original_text": "Before I wrap up, I want to touch on our new ESG report, which was released just last week. "}, "hash": "a76dd62ed23df4afdef11966998dd881e59ed8255ef39be00668da2cc9a7fa19", "class_name": "RelatedNodeInfo"}}, "text": "We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n", "start_char_idx": 2274, "end_char_idx": 2531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f5cc462-bc27-466d-9cf1-1e0916f6a17a": {"__data__": {"id_": "8f5cc462-bc27-466d-9cf1-1e0916f6a17a", "embedding": null, "metadata": {"window": "In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n", "original_text": "Before I wrap up, I want to touch on our new ESG report, which was released just last week. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81bbaad6-0194-4231-a967-834aba4722cf", "node_type": "1", "metadata": {"window": "And lastly, a brief update regarding our relentless focus on shareholder value creation.  \n \n In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders. ", "original_text": "We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eceed3b38146967596619afd5100425bd891914a6ea9cba6d9d8431f2d5bd9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f53742c4-df74-4fe2-89ad-e4295126752a", "node_type": "1", "metadata": {"window": "Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead. ", "original_text": "This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives. "}, "hash": "902570fbe25dda89890a0fe15cad353893cf2853f7daebd095b9992b0dc9fc49", "class_name": "RelatedNodeInfo"}}, "text": "Before I wrap up, I want to touch on our new ESG report, which was released just last week. ", "start_char_idx": 2531, "end_char_idx": 2623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f53742c4-df74-4fe2-89ad-e4295126752a": {"__data__": {"id_": "f53742c4-df74-4fe2-89ad-e4295126752a", "embedding": null, "metadata": {"window": "Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead. ", "original_text": "This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f5cc462-bc27-466d-9cf1-1e0916f6a17a", "node_type": "1", "metadata": {"window": "In addition to the shareholder value creation initiatives we\u2019ve already announced, such as our \ngovernance enhancements and simplification actions, we continue to place a strong emphasis on \nresponsible capital deployment, including the return of capital to shareholders through share \nrepurchases.  \n \n Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n", "original_text": "Before I wrap up, I want to touch on our new ESG report, which was released just last week. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94b02de4ed577745b445f571ff905d8a554ee4d062e58140efa54dd3b9b8b85b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb261727-b74b-4314-b7fe-f19ff1d8c521", "node_type": "1", "metadata": {"window": "We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders. "}, "hash": "caa3a5f451f3f216a16231a25b69d2d0d4e4a8409c2817e1330b8dd36e33fd64", "class_name": "RelatedNodeInfo"}}, "text": "This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives. ", "start_char_idx": 2623, "end_char_idx": 2810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb261727-b74b-4314-b7fe-f19ff1d8c521": {"__data__": {"id_": "bb261727-b74b-4314-b7fe-f19ff1d8c521", "embedding": null, "metadata": {"window": "We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f53742c4-df74-4fe2-89ad-e4295126752a", "node_type": "1", "metadata": {"window": "Our Business Review Committee continues to work t hrough the comprehensive review of our \ncompany\u2019s strategy, portfolio, capital allocation framework, and operations.  \n \n We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead. ", "original_text": "This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef8cf7d9c03a0994e515b374a7d989e2e74f5f36f87e145169f890fa47b0e179", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc70c947-66bd-4575-9feb-92c59e505791", "node_type": "1", "metadata": {"window": "Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n"}, "hash": "42ed08a746eb38b05ba4ecabefb83bb73bf20751d4efed10a1bd477369cd084b", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders. ", "start_char_idx": 2810, "end_char_idx": 2930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc70c947-66bd-4575-9feb-92c59e505791": {"__data__": {"id_": "bc70c947-66bd-4575-9feb-92c59e505791", "embedding": null, "metadata": {"window": "Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb261727-b74b-4314-b7fe-f19ff1d8c521", "node_type": "1", "metadata": {"window": "We plan to hold an Investor Day on June 8th in New York City, where among other topics, we will \nprovide an update on our company\u2019s long -term financial outlook, detail our growth strategies, and \nshare any relevant conclusions from the ongoing review.  \n \n Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6071f89f9f0d72fb2453955a62567c44f4a9fb1007d1df38005a83bbdfc5396d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d29562e-1275-4a96-a72a-85abf8241d2c", "node_type": "1", "metadata": {"window": "This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead. "}, "hash": "fac340a445728ef9892182aca25eb824a8cdb2e4f47d7552e7f2ff59fea171c0", "class_name": "RelatedNodeInfo"}}, "text": "We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n", "start_char_idx": 2930, "end_char_idx": 3047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d29562e-1275-4a96-a72a-85abf8241d2c": {"__data__": {"id_": "3d29562e-1275-4a96-a72a-85abf8241d2c", "embedding": null, "metadata": {"window": "This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc70c947-66bd-4575-9feb-92c59e505791", "node_type": "1", "metadata": {"window": "Before I wrap up, I want to touch on our new ESG report, which was released just last week.  This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d2ef99d8b11db4a6ead1784bb85366e167e048c4150aa27213e3050c6d6f5dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a17554f-6a4e-45b9-b097-84ed38e083d6", "node_type": "1", "metadata": {"window": "We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "I want to thank our dedicated Cardinal Health employees who "}, "hash": "7be2684b6fdc52ec5aa5dddd0b688b70785626e4afbdcac7545804d0fe86a38e", "class_name": "RelatedNodeInfo"}}, "text": "In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead. ", "start_char_idx": 3047, "end_char_idx": 3182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a17554f-6a4e-45b9-b097-84ed38e083d6": {"__data__": {"id_": "5a17554f-6a4e-45b9-b097-84ed38e083d6", "embedding": null, "metadata": {"window": "We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "I want to thank our dedicated Cardinal Health employees who ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c71bed9-073f-4af1-9867-c47cb7248707", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d53bc20f56a3b622defe326ae6ffaf75b83e6131b3c47e7b937d440f181141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d29562e-1275-4a96-a72a-85abf8241d2c", "node_type": "1", "metadata": {"window": "This \nexpanded report outlines the steps we are taking to operate in a more sustainable and equitable \nworld through our established ESG and diversity, equity and inc lusion initiatives.  We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c128130110d63739ef2a022789c8cc1b9532ba0259c6aa559628197530cf1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1e82e1d-7bb7-47b9-b522-96ab989e300f", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two. ", "original_text": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n"}, "hash": "a452b63d1d613793394f107a833dcb609c40e0d4e2c2d2d2c01e2e6e220767f2", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank our dedicated Cardinal Health employees who ", "start_char_idx": 3182, "end_char_idx": 3242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1e82e1d-7bb7-47b9-b522-96ab989e300f": {"__data__": {"id_": "b1e82e1d-7bb7-47b9-b522-96ab989e300f", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two. ", "original_text": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a17554f-6a4e-45b9-b097-84ed38e083d6", "node_type": "1", "metadata": {"window": "We continue to \nmake progress against our long -term targets and are committed to regularly updating our \nstakeholders.  We believe that we can simultaneously drive ESG improvements in support of our \nongoing business transformation.  \n \n In closing, while there remains work to do, I am encouraged by our team\u2019s progress to date and \nexcited about the opportunities ahead.  I want to thank our dedicated Cardinal Health employees who ", "original_text": "I want to thank our dedicated Cardinal Health employees who ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5f2ec611318e1fe45b1fa711a15a21dd3585e07cc16cb04481b808addc3417d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fd4e993-9e9f-472f-9834-49e53f4c9609", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan. ", "original_text": "With that, we will take your questions.  \n \n"}, "hash": "d3bc00ab2e765448b895b1f557a697efde869de86f40cf0b3d7af41feb142109", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n", "start_char_idx": 0, "end_char_idx": 162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fd4e993-9e9f-472f-9834-49e53f4c9609": {"__data__": {"id_": "0fd4e993-9e9f-472f-9834-49e53f4c9609", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan. ", "original_text": "With that, we will take your questions.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1e82e1d-7bb7-47b9-b522-96ab989e300f", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two. ", "original_text": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94c596bcf59404df1471eaee7e5b413c837f8446755dcc67d09963e926c75856", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11b284ec-3c0b-4288-b530-57b6c0654ee5", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n", "original_text": "Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad. "}, "hash": "d6fdaaa926cd724d77b7b1f46f68455a703a086d930d665a0888356b0f44e5b1", "class_name": "RelatedNodeInfo"}}, "text": "With that, we will take your questions.  \n \n", "start_char_idx": 162, "end_char_idx": 206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11b284ec-3c0b-4288-b530-57b6c0654ee5": {"__data__": {"id_": "11b284ec-3c0b-4288-b530-57b6c0654ee5", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n", "original_text": "Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fd4e993-9e9f-472f-9834-49e53f4c9609", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan. ", "original_text": "With that, we will take your questions.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec514b6be485e2e210bc5549c577e82cd87120f375d713da8a0f3d1532b74509", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8202855-051e-4406-91c6-c1222deebe83", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much. ", "original_text": "To withdraw your question, plea se press star two. "}, "hash": "0bfbbdec430488e864e1cf57277ea33e11bc6d6a5a2133ddab92eec2a3f3d7b2", "class_name": "RelatedNodeInfo"}}, "text": "Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad. ", "start_char_idx": 206, "end_char_idx": 320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8202855-051e-4406-91c6-c1222deebe83": {"__data__": {"id_": "b8202855-051e-4406-91c6-c1222deebe83", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much. ", "original_text": "To withdraw your question, plea se press star two. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11b284ec-3c0b-4288-b530-57b6c0654ee5", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n", "original_text": "Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b889f8e04029c2cdf9f27f6a659418772d3b51ad3900c10eb80abdead04889d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3d4cebe-aa1b-4340-a4e3-1f546bcde761", "node_type": "1", "metadata": {"window": "With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason. ", "original_text": "The first question comes from the line of  \nLisa Gill calling from JPMorgan. "}, "hash": "f99a50cdd51614a9e1c4f19c935c65433aa6db93994b990298fd802cf105c79a", "class_name": "RelatedNodeInfo"}}, "text": "To withdraw your question, plea se press star two. ", "start_char_idx": 320, "end_char_idx": 371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3d4cebe-aa1b-4340-a4e3-1f546bcde761": {"__data__": {"id_": "b3d4cebe-aa1b-4340-a4e3-1f546bcde761", "embedding": null, "metadata": {"window": "With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason. ", "original_text": "The first question comes from the line of  \nLisa Gill calling from JPMorgan. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8202855-051e-4406-91c6-c1222deebe83", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much. ", "original_text": "To withdraw your question, plea se press star two. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8cd06f926966ee8f39e2859ce3a8bfdc3a9051d4829bab3b5d3189c8a753180", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "221af547-cafc-4819-b5ad-166a417c435b", "node_type": "1", "metadata": {"window": "Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes . ", "original_text": "Please go ahead.  \n \n"}, "hash": "6ce541b88913a4e4baa34442bac77dd57077bfdd5ea4d4bfad446a6a3c69d010", "class_name": "RelatedNodeInfo"}}, "text": "The first question comes from the line of  \nLisa Gill calling from JPMorgan. ", "start_char_idx": 371, "end_char_idx": 448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "221af547-cafc-4819-b5ad-166a417c435b": {"__data__": {"id_": "221af547-cafc-4819-b5ad-166a417c435b", "embedding": null, "metadata": {"window": "Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes . ", "original_text": "Please go ahead.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3d4cebe-aa1b-4340-a4e3-1f546bcde761", "node_type": "1", "metadata": {"window": "With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason. ", "original_text": "The first question comes from the line of  \nLisa Gill calling from JPMorgan. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bde6be100ac5b3bbbd8a9b27480365cb97ff89f4aa80d6c63db7fe81b44bdc02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b176d3b1-f42b-42e4-ad6e-069df00a74f0", "node_type": "1", "metadata": {"window": "To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?  ", "original_text": "Lisa Gill:   Thanks very much. "}, "hash": "030ce3cb878c8cf5ac706f3a53ae38ab9f3300958bca776da6d86d65ceba3ffb", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 448, "end_char_idx": 469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b176d3b1-f42b-42e4-ad6e-069df00a74f0": {"__data__": {"id_": "b176d3b1-f42b-42e4-ad6e-069df00a74f0", "embedding": null, "metadata": {"window": "To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?  ", "original_text": "Lisa Gill:   Thanks very much. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "221af547-cafc-4819-b5ad-166a417c435b", "node_type": "1", "metadata": {"window": "Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes . ", "original_text": "Please go ahead.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f1884e0a6296ef5e72f5f66756eb61b641963cb2ff2ce8ccecba4bd3c4ec330", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "588b7cc8-29d9-4dc0-847f-c8ea801bd283", "node_type": "1", "metadata": {"window": "The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?  ", "original_text": "And thanks for all the details, Jason. "}, "hash": "b1b4e189f4e944edcc75a2afaef8adb4708701245fb54a08d0fcf94858a55181", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:   Thanks very much. ", "start_char_idx": 469, "end_char_idx": 500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "588b7cc8-29d9-4dc0-847f-c8ea801bd283": {"__data__": {"id_": "588b7cc8-29d9-4dc0-847f-c8ea801bd283", "embedding": null, "metadata": {"window": "The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?  ", "original_text": "And thanks for all the details, Jason. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b176d3b1-f42b-42e4-ad6e-069df00a74f0", "node_type": "1", "metadata": {"window": "To withdraw your question, plea se press star two.  The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?  ", "original_text": "Lisa Gill:   Thanks very much. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "131e2134dfbf6414c17b8ceea895fe533e782d06b083572c1a344dd6158ff516", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e67499bc-1870-496b-9ac7-8ffb440f6efc", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n", "original_text": "Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes . "}, "hash": "2334ee47b7fd2cafd7c3a1160a780593d48f1a377833e3da1989af73764a55cf", "class_name": "RelatedNodeInfo"}}, "text": "And thanks for all the details, Jason. ", "start_char_idx": 500, "end_char_idx": 539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e67499bc-1870-496b-9ac7-8ffb440f6efc": {"__data__": {"id_": "e67499bc-1870-496b-9ac7-8ffb440f6efc", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n", "original_text": "Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "588b7cc8-29d9-4dc0-847f-c8ea801bd283", "node_type": "1", "metadata": {"window": "The first question comes from the line of  \nLisa Gill calling from JPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?  ", "original_text": "And thanks for all the details, Jason. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d7165770fc6d9ec8f26549fac1fd756c1a6b311b651f21cb7b2cd169dc35757", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf75db4f-3d0a-4d0d-980c-fab8ed025023", "node_type": "1", "metadata": {"window": "Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah. ", "original_text": "So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?  "}, "hash": "a2c6566be3297fa6b84b1b68c607ee54df5c648417dbc83a33e01b956378a1b3", "class_name": "RelatedNodeInfo"}}, "text": "Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes . ", "start_char_idx": 539, "end_char_idx": 698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf75db4f-3d0a-4d0d-980c-fab8ed025023": {"__data__": {"id_": "bf75db4f-3d0a-4d0d-980c-fab8ed025023", "embedding": null, "metadata": {"window": "Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah. ", "original_text": "So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?  ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e67499bc-1870-496b-9ac7-8ffb440f6efc", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n", "original_text": "Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0d199a7dc367aef8c7eeeee94e2db6d6313a28b0124e26d19561831af68cdd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5d1cc88-a2fa-4393-ad3d-a94bc32c2098", "node_type": "1", "metadata": {"window": "And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa. ", "original_text": "And \nsecondly, has part of the issue on the hospital side been staffing issues?  "}, "hash": "c1035a1b89c636fd1af664bc4b8c47d0044ddc742a867c30cb74c5e65726f824", "class_name": "RelatedNodeInfo"}}, "text": "So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?  ", "start_char_idx": 698, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5d1cc88-a2fa-4393-ad3d-a94bc32c2098": {"__data__": {"id_": "b5d1cc88-a2fa-4393-ad3d-a94bc32c2098", "embedding": null, "metadata": {"window": "And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa. ", "original_text": "And \nsecondly, has part of the issue on the hospital side been staffing issues?  ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf75db4f-3d0a-4d0d-980c-fab8ed025023", "node_type": "1", "metadata": {"window": "Lisa Gill:   Thanks very much.  And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah. ", "original_text": "So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?  ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edd668d4605a325efcd5776941efc087007114eea23e365bd8abff0ebee46fa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd41bb40-f23d-497d-9588-f9f2d7b218cd", "node_type": "1", "metadata": {"window": "Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there. ", "original_text": "And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n"}, "hash": "9c13c0299c90d4d9c4a31d7c18fe6676a5c675a5f064c1a614a7875e87c6fa0a", "class_name": "RelatedNodeInfo"}}, "text": "And \nsecondly, has part of the issue on the hospital side been staffing issues?  ", "start_char_idx": 857, "end_char_idx": 938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd41bb40-f23d-497d-9588-f9f2d7b218cd": {"__data__": {"id_": "cd41bb40-f23d-497d-9588-f9f2d7b218cd", "embedding": null, "metadata": {"window": "Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there. ", "original_text": "And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5d1cc88-a2fa-4393-ad3d-a94bc32c2098", "node_type": "1", "metadata": {"window": "And thanks for all the details, Jason.  Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa. ", "original_text": "And \nsecondly, has part of the issue on the hospital side been staffing issues?  ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7976d8b3f7774ec96071510efa63a2560183bc0da91ef98bf645634ae99c3c14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ef5d208-2079-47ec-8d1b-45c94831cd98", "node_type": "1", "metadata": {"window": "So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there. ", "original_text": "Jason Hollar:   Yeah. "}, "hash": "875357f5a1de5c2c4b9841baf674e1eeebc97bee638f3b839fa519348f83d642", "class_name": "RelatedNodeInfo"}}, "text": "And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n", "start_char_idx": 938, "end_char_idx": 1023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ef5d208-2079-47ec-8d1b-45c94831cd98": {"__data__": {"id_": "9ef5d208-2079-47ec-8d1b-45c94831cd98", "embedding": null, "metadata": {"window": "So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there. ", "original_text": "Jason Hollar:   Yeah. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd41bb40-f23d-497d-9588-f9f2d7b218cd", "node_type": "1", "metadata": {"window": "Just on the Medical side, one of \nthe things that stuck out to me is you t alked about the improvement, and you talked about needing \nimprovement in volumes .  So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there. ", "original_text": "And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85a54fc8f9c76bb81e6f867aebf653450b6d2fd72d5cc095a26f0244ab627d27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2865a0f-51e8-46cc-87e1-27d671f2dc6c", "node_type": "1", "metadata": {"window": "And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical. ", "original_text": "Hi, Lisa. "}, "hash": "d47d6485197be6c0c49de45f72439acd977bd28be32e4ebbe4d720faa565972d", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:   Yeah. ", "start_char_idx": 1023, "end_char_idx": 1045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2865a0f-51e8-46cc-87e1-27d671f2dc6c": {"__data__": {"id_": "a2865a0f-51e8-46cc-87e1-27d671f2dc6c", "embedding": null, "metadata": {"window": "And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical. ", "original_text": "Hi, Lisa. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ef5d208-2079-47ec-8d1b-45c94831cd98", "node_type": "1", "metadata": {"window": "So, as we think about that, can you maybe talk about your expectations \naround surgical procedures as we move into calendar 2023, the back half of your year?   And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there. ", "original_text": "Jason Hollar:   Yeah. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "898bf89a7b2cb2461cddc0675a550e81ffd596be4a09735f8d49d34f7f896c42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a993f51-f564-4c7d-8cd7-64b0bd2fcf30", "node_type": "1", "metadata": {"window": "And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing. ", "original_text": "I think you're connecting all the right points there. "}, "hash": "67e7926a93b22395944ff30c7ebf7b357668d9efccc62ee9b633b6c5f9d94cd9", "class_name": "RelatedNodeInfo"}}, "text": "Hi, Lisa. ", "start_char_idx": 1045, "end_char_idx": 1055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a993f51-f564-4c7d-8cd7-64b0bd2fcf30": {"__data__": {"id_": "9a993f51-f564-4c7d-8cd7-64b0bd2fcf30", "embedding": null, "metadata": {"window": "And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing. ", "original_text": "I think you're connecting all the right points there. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2865a0f-51e8-46cc-87e1-27d671f2dc6c", "node_type": "1", "metadata": {"window": "And \nsecondly, has part of the issue on the hospital side been staffing issues?   And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical. ", "original_text": "Hi, Lisa. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c112cba6287380f41cce8290cab2231a3e9b267ac856f4e56b742f775ed5fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9a5e6df-d0e0-47cf-9ca5-61c994339900", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear. ", "original_text": "You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there. "}, "hash": "f892c247ecfb148fbb93adad596e99e208c3fba9e61bc327df368d5f302281f3", "class_name": "RelatedNodeInfo"}}, "text": "I think you're connecting all the right points there. ", "start_char_idx": 1055, "end_char_idx": 1109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9a5e6df-d0e0-47cf-9ca5-61c994339900": {"__data__": {"id_": "b9a5e6df-d0e0-47cf-9ca5-61c994339900", "embedding": null, "metadata": {"window": "Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear. ", "original_text": "You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a993f51-f564-4c7d-8cd7-64b0bd2fcf30", "node_type": "1", "metadata": {"window": "And as they start to resolve \nthat, will things get better for Cardinal as well?  \n \n Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing. ", "original_text": "I think you're connecting all the right points there. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c6c6ca85fd5d1f7d8ae715af36db4ffb1f9572922d33d216ea1479c1e4eb17b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76fbe46f-c81b-43db-981b-1f2dabd55772", "node_type": "1", "metadata": {"window": "Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth . ", "original_text": "And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical. "}, "hash": "28dcbdcd0b482573aabe68d9021138306e7278c20ad2d9f4032810df9e8ef62c", "class_name": "RelatedNodeInfo"}}, "text": "You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there. ", "start_char_idx": 1109, "end_char_idx": 1299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76fbe46f-c81b-43db-981b-1f2dabd55772": {"__data__": {"id_": "76fbe46f-c81b-43db-981b-1f2dabd55772", "embedding": null, "metadata": {"window": "Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth . ", "original_text": "And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9a5e6df-d0e0-47cf-9ca5-61c994339900", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah.  Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear. ", "original_text": "You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae275daf2ed67a0403e395323f3d8f866fb3a82608219c595b15b71580736cb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5a255fd-5513-40a3-bec7-33d50138a758", "node_type": "1", "metadata": {"window": "I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n", "original_text": "You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing. "}, "hash": "68eb58048595d3186ce313281e608a40b1a729c2befea8a81cd1a0eb8e699da9", "class_name": "RelatedNodeInfo"}}, "text": "And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical. ", "start_char_idx": 1299, "end_char_idx": 1408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5a255fd-5513-40a3-bec7-33d50138a758": {"__data__": {"id_": "d5a255fd-5513-40a3-bec7-33d50138a758", "embedding": null, "metadata": {"window": "I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n", "original_text": "You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76fbe46f-c81b-43db-981b-1f2dabd55772", "node_type": "1", "metadata": {"window": "Hi, Lisa.  I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth . ", "original_text": "And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b82bed8b47adf7b80714193c2270592590b569f8b4bde658d93b0981014808d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0db8a74-78fe-4504-8572-794ae9f5f831", "node_type": "1", "metadata": {"window": "You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed. ", "original_text": "To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear. "}, "hash": "98cd188b616aad2cb8e6aa96a1a01d2e666c7efc7c4ee06340aeb491f2bc3451", "class_name": "RelatedNodeInfo"}}, "text": "You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing. ", "start_char_idx": 1408, "end_char_idx": 1513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0db8a74-78fe-4504-8572-794ae9f5f831": {"__data__": {"id_": "b0db8a74-78fe-4504-8572-794ae9f5f831", "embedding": null, "metadata": {"window": "You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed. ", "original_text": "To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5a255fd-5513-40a3-bec7-33d50138a758", "node_type": "1", "metadata": {"window": "I think you're connecting all the right points there.  You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n", "original_text": "You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a877dd1293ebe47425718a89691a9ed0500b690c3211bf8cb09f3cf761fd8f45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1c303e0-c318-42eb-aff3-e67d24603458", "node_type": "1", "metadata": {"window": "And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end . ", "original_text": "So not sign ificant but getting back to closer to more normali zed level of growth . "}, "hash": "f8a4e3f863599f27abbe66425153321e1dfcaa42709f3bd12aecf511e785543e", "class_name": "RelatedNodeInfo"}}, "text": "To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear. ", "start_char_idx": 1513, "end_char_idx": 1731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1c303e0-c318-42eb-aff3-e67d24603458": {"__data__": {"id_": "a1c303e0-c318-42eb-aff3-e67d24603458", "embedding": null, "metadata": {"window": "And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end . ", "original_text": "So not sign ificant but getting back to closer to more normali zed level of growth . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0db8a74-78fe-4504-8572-794ae9f5f831", "node_type": "1", "metadata": {"window": "You know, that's \nwhat we hear from our customers and broadly from our peers in the industry is that there continues to \nbe some constraints as to getting to the free level of demand there.  And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed. ", "original_text": "To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fba8fe4257743ac40ff9b23b290452a5d9d7db5cdb81240b6f8d665180d66028", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0f1636f-bc0f-45bb-842f-9204888e486f", "node_type": "1", "metadata": {"window": "You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n", "original_text": "As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n"}, "hash": "94dbedd2b94b34a4dea58dc7d39272842b77e1b430dfaec2b0cc3e0a2a7042db", "class_name": "RelatedNodeInfo"}}, "text": "So not sign ificant but getting back to closer to more normali zed level of growth . ", "start_char_idx": 1731, "end_char_idx": 1816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0f1636f-bc0f-45bb-842f-9204888e486f": {"__data__": {"id_": "a0f1636f-bc0f-45bb-842f-9204888e486f", "embedding": null, "metadata": {"window": "You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n", "original_text": "As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1c303e0-c318-42eb-aff3-e67d24603458", "node_type": "1", "metadata": {"window": "And we do think that's a \ncomponent of what's impacting the lack of growth that we're seeing within Medical.  You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end . ", "original_text": "So not sign ificant but getting back to closer to more normali zed level of growth . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faf292e13a1e0f86d74e77badbc90335958cb3b304f28f12cdf1f2827613d6ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc0bcc7d-e973-4983-92a2-ebc0c7a89529", "node_type": "1", "metadata": {"window": "To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ? ", "original_text": "So, you're talking about a couple of percent type of growth and that would be more normali zed. "}, "hash": "f1f4625815908abcb80a3b06a8bbac0aca1c6b4295c7f573be5ff5b7283f0a35", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n", "start_char_idx": 1816, "end_char_idx": 2123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc0bcc7d-e973-4983-92a2-ebc0c7a89529": {"__data__": {"id_": "bc0bcc7d-e973-4983-92a2-ebc0c7a89529", "embedding": null, "metadata": {"window": "To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ? ", "original_text": "So, you're talking about a couple of percent type of growth and that would be more normali zed. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0f1636f-bc0f-45bb-842f-9204888e486f", "node_type": "1", "metadata": {"window": "You know, it's \nimpossible to tell definitively, but that's the ane cdotal feedback that we are hearing.  To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n", "original_text": "As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c1cf0e66aaee8fa672903689c88d14e4e554bf5a6ff1dc06d79c5703d7c883c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da32364a-e8c4-4d25-8891-1a852d61662e", "node_type": "1", "metadata": {"window": "So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n", "original_text": "And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end . "}, "hash": "d8ab8f7e2f3f3eeae4fe0dc159537478ddc19d5254c9c1a4a20a053349437bca", "class_name": "RelatedNodeInfo"}}, "text": "So, you're talking about a couple of percent type of growth and that would be more normali zed. ", "start_char_idx": 2123, "end_char_idx": 2219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da32364a-e8c4-4d25-8891-1a852d61662e": {"__data__": {"id_": "da32364a-e8c4-4d25-8891-1a852d61662e", "embedding": null, "metadata": {"window": "So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n", "original_text": "And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc0bcc7d-e973-4983-92a2-ebc0c7a89529", "node_type": "1", "metadata": {"window": "To help provide a \nlittle bit of color around the impact, that's why Trish had made some comments within her \ncommentary there, highlighting that we do anticipate that gradual improvement over the course of the \nyear.  So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ? ", "original_text": "So, you're talking about a couple of percent type of growth and that would be more normali zed. ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "064358e5399ff4eb1501516ecd7499504be7b10ee69e47fe29793ae18937efaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a80b0cc-ee8a-4ece-a85c-0816b9506876", "node_type": "1", "metadata": {"window": "As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right . ", "original_text": "And that's why Trish had provided that type of clarity.  \n \n"}, "hash": "4b397ed8187c124cf4eac9ee9ad0fa34f8eaeb28f2de1de984d4647b751b449e", "class_name": "RelatedNodeInfo"}}, "text": "And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end . ", "start_char_idx": 2219, "end_char_idx": 2342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a80b0cc-ee8a-4ece-a85c-0816b9506876": {"__data__": {"id_": "8a80b0cc-ee8a-4ece-a85c-0816b9506876", "embedding": null, "metadata": {"window": "As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right . ", "original_text": "And that's why Trish had provided that type of clarity.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da32364a-e8c4-4d25-8891-1a852d61662e", "node_type": "1", "metadata": {"window": "So not sign ificant but getting back to closer to more normali zed level of growth .  As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n", "original_text": "And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75e1fb81685810d7822ed40d6f824776fd69f1f99c38324d1b7be857826f6fcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44d8c1e0-ad7a-4bc9-934c-933a355ce64a", "node_type": "1", "metadata": {"window": "So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions . ", "original_text": "Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ? "}, "hash": "d1de1cc6a86557196fde211003f347acf5ed07ee45c2110dafa4803490d48179", "class_name": "RelatedNodeInfo"}}, "text": "And that's why Trish had provided that type of clarity.  \n \n", "start_char_idx": 2342, "end_char_idx": 2402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44d8c1e0-ad7a-4bc9-934c-933a355ce64a": {"__data__": {"id_": "44d8c1e0-ad7a-4bc9-934c-933a355ce64a", "embedding": null, "metadata": {"window": "So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions . ", "original_text": "Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ? ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a80b0cc-ee8a-4ece-a85c-0816b9506876", "node_type": "1", "metadata": {"window": "As a reminder, \nwhen we provided our Medical improvement plan, we highlighted, you know, a 3% CAGR  total \nvolume growth over the three -year period and we anticipated that about half that would be market \ngrowth, about half that would be our own innovation and capacity expansion plans for our products . \n So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right . ", "original_text": "And that's why Trish had provided that type of clarity.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64a74ed8bc075a89852f1e0ec9a370edc7d794410e0a24b101a53f8191fa1dab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1f9ee80-8845-4a07-91b7-67c937172d7e", "node_type": "1", "metadata": {"window": "And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market . ", "original_text": "Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n"}, "hash": "c61a546dd55db27ea4ab9fdc38b7cc3660a241691527f5ab42c5338d00db6a07", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ? ", "start_char_idx": 2402, "end_char_idx": 2678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1f9ee80-8845-4a07-91b7-67c937172d7e": {"__data__": {"id_": "c1f9ee80-8845-4a07-91b7-67c937172d7e", "embedding": null, "metadata": {"window": "And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market . ", "original_text": "Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44d8c1e0-ad7a-4bc9-934c-933a355ce64a", "node_type": "1", "metadata": {"window": "So, you're talking about a couple of percent type of growth and that would be more normali zed.  And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions . ", "original_text": "Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ? ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfe5f36554d7149e22d19867a3bdaa5112b9544798d6c26cd71bf485ea34a6f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e369788-8113-4fdb-b896-557ea220a626", "node_type": "1", "metadata": {"window": "And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n", "original_text": "Jason Hollar:  Yeah, no, I think you have it a generally right . "}, "hash": "1629cf287ba0552ede7171bc76b8f960ece88c1e5a98f1e2201e8ba95937a555", "class_name": "RelatedNodeInfo"}}, "text": "Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n", "start_char_idx": 2678, "end_char_idx": 2782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e369788-8113-4fdb-b896-557ea220a626": {"__data__": {"id_": "3e369788-8113-4fdb-b896-557ea220a626", "embedding": null, "metadata": {"window": "And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n", "original_text": "Jason Hollar:  Yeah, no, I think you have it a generally right . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1f9ee80-8845-4a07-91b7-67c937172d7e", "node_type": "1", "metadata": {"window": "And \nthat kind of differentiator between our mo re of a midpoint of our guidance to what would be more in \nthe lower end .  And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market . ", "original_text": "Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fac345a56f3a6098b5c1155d0b9a1c824c516ad71c023dc147612fa01e0c9fd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "433dd27c-cdc7-419d-86b0-bc795da8364c", "node_type": "1", "metadata": {"window": "Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes . ", "original_text": "Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions . "}, "hash": "8dcecdb6fa50d07a477c909658d31473388a5c36b12e1baef3179f48ed084447", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah, no, I think you have it a generally right . ", "start_char_idx": 2782, "end_char_idx": 2847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "433dd27c-cdc7-419d-86b0-bc795da8364c": {"__data__": {"id_": "433dd27c-cdc7-419d-86b0-bc795da8364c", "embedding": null, "metadata": {"window": "Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes . ", "original_text": "Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e369788-8113-4fdb-b896-557ea220a626", "node_type": "1", "metadata": {"window": "And that's why Trish had provided that type of clarity.  \n \n Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n", "original_text": "Jason Hollar:  Yeah, no, I think you have it a generally right . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a225151a84481c4555a397f0c1318647e40b0ed7a405012e8564e9e5974efdc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e3afc69-e76f-45d1-b80d-da255c82a459", "node_type": "1", "metadata": {"window": "Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part . ", "original_text": "And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market . "}, "hash": "d25c66844c89461480b5825459eb3788d6a231b2842b350ce1d66920980f6c57", "class_name": "RelatedNodeInfo"}}, "text": "Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions . ", "start_char_idx": 2847, "end_char_idx": 2963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e3afc69-e76f-45d1-b80d-da255c82a459": {"__data__": {"id_": "2e3afc69-e76f-45d1-b80d-da255c82a459", "embedding": null, "metadata": {"window": "Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part . ", "original_text": "And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "433dd27c-cdc7-419d-86b0-bc795da8364c", "node_type": "1", "metadata": {"window": "Lisa Gill:   So is the right way to think about that kind of half of its Jason, you feel like you have some \nlevel of control because it's new products that you're bringing to the market, and the other half is you're \ngoing to have to wait to see if those volumes come back ?  Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes . ", "original_text": "Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b75391285df0bf5e525cdfeb9d73d3f3d22467bf395b3fdb84bd9f0c0301168", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0000b7fd-6042-46b3-b6e2-6b3ff445a27c", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "So we didn't ever \nindicate it was a linear type of plan .  \n"}, "hash": "ce823c93c6e55ca5d436086e3e95e361b8a5ef565f1657f481be344bd1eb6df6", "class_name": "RelatedNodeInfo"}}, "text": "And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market . ", "start_char_idx": 2963, "end_char_idx": 3188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0000b7fd-6042-46b3-b6e2-6b3ff445a27c": {"__data__": {"id_": "0000b7fd-6042-46b3-b6e2-6b3ff445a27c", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "So we didn't ever \nindicate it was a linear type of plan .  \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e3afc69-e76f-45d1-b80d-da255c82a459", "node_type": "1", "metadata": {"window": "Or do you feel like you really, truly have \nvisibility around the whole 3% that you're talking about?  \n Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part . ", "original_text": "And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5518fb349ba456f6e6acc4d10eee86e817a8377f07026eb3fa296053eb41277", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4faaf20e-f4a4-456f-bbb7-6d6a2d96838f", "node_type": "1", "metadata": {"window": "Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes . "}, "hash": "17d53cdb99b87ba93ae714794a9a52717791237c4bba63bb0fd276b630087979", "class_name": "RelatedNodeInfo"}}, "text": "So we didn't ever \nindicate it was a linear type of plan .  \n", "start_char_idx": 3188, "end_char_idx": 3249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4faaf20e-f4a4-456f-bbb7-6d6a2d96838f": {"__data__": {"id_": "4faaf20e-f4a4-456f-bbb7-6d6a2d96838f", "embedding": null, "metadata": {"window": "Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0000b7fd-6042-46b3-b6e2-6b3ff445a27c", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, no, I think you have it a generally right .  Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "So we didn't ever \nindicate it was a linear type of plan .  \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "744c73f9cc1c61c59de55af7e84fe5bbc9e9f656cd2e8204fa10573d05df5e2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a921f115-5d6b-4372-bf99-6f35e38530a7", "node_type": "1", "metadata": {"window": "And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "Obviously down during the beginning of the pandemic and \nhas come back for the most part . "}, "hash": "e4ef1619d001d88e4d51bdbb689ec2b3b523ae9c4a20cb9dc91ee165758597ab", "class_name": "RelatedNodeInfo"}}, "text": "And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes . ", "start_char_idx": 3249, "end_char_idx": 3400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a921f115-5d6b-4372-bf99-6f35e38530a7": {"__data__": {"id_": "a921f115-5d6b-4372-bf99-6f35e38530a7", "embedding": null, "metadata": {"window": "And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "Obviously down during the beginning of the pandemic and \nhas come back for the most part . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4faaf20e-f4a4-456f-bbb7-6d6a2d96838f", "node_type": "1", "metadata": {"window": "Now, remember that a lot of the part that \nwe have control over is new product innovation and capacity expansions .  And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "517a4712c5081e0c5aedfc4161e9d7962ab55d1bb741c05b5fac59f7326edc5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d9f792f-bec8-4b35-bed5-88dc22faf274", "node_type": "1", "metadata": {"window": "So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "The last couple of quarters have been very predictable, very "}, "hash": "ff7a02b76c10e4514812248340abe2f9b6b5e09bd0d7d468ac994e31e3232efc", "class_name": "RelatedNodeInfo"}}, "text": "Obviously down during the beginning of the pandemic and \nhas come back for the most part . ", "start_char_idx": 3400, "end_char_idx": 3491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d9f792f-bec8-4b35-bed5-88dc22faf274": {"__data__": {"id_": "1d9f792f-bec8-4b35-bed5-88dc22faf274", "embedding": null, "metadata": {"window": "So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "The last couple of quarters have been very predictable, very ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "addff1423829700608048302c53f58fc17a77f6042b76bc944f98cfce260ea08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a921f115-5d6b-4372-bf99-6f35e38530a7", "node_type": "1", "metadata": {"window": "And  that\u2019s always an element \nof the three -year plan, I would expect to be weig hted a little bit more towards the later end because it \ntakes time to spool up those investments and getting those products into the market .  So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "Obviously down during the beginning of the pandemic and \nhas come back for the most part . ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0db0f36dec0cec56edea1fe1674aa361b1d2f9f702336e579af18e91d6ee92a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67def20d-9ea9-4e7d-b4ae-89c5aad6203a", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great . ", "original_text": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears . "}, "hash": "5b64ff7c97aa5805e602294cd63e1d148cbfdb1a871e5c97b72924bfaa59cc7a", "class_name": "RelatedNodeInfo"}}, "text": "The last couple of quarters have been very predictable, very ", "start_char_idx": 3491, "end_char_idx": 3552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67def20d-9ea9-4e7d-b4ae-89c5aad6203a": {"__data__": {"id_": "67def20d-9ea9-4e7d-b4ae-89c5aad6203a", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great . ", "original_text": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d9f792f-bec8-4b35-bed5-88dc22faf274", "node_type": "1", "metadata": {"window": "So we didn't ever \nindicate it was a linear type of plan .  \n And volumes, we had to be careful too, that we had a peri od here the last two to three years that's been \nincredibly choppy in terms of the volumes .  Obviously down during the beginning of the pandemic and \nhas come back for the most part .  The last couple of quarters have been very predictable, very ", "original_text": "The last couple of quarters have been very predictable, very ", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11a96fd85c2f47f38a36d7df9eec26e56988e70631dd25577a0f09d29ebb2d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de78e4c8-32f0-4440-933d-5b3a9f4ab736", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n", "original_text": "So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n"}, "hash": "ea5d26da71de569ecb2e44bf809d50b6770e5f517bb787129b36d566bfa25c5c", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears . ", "start_char_idx": 0, "end_char_idx": 131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de78e4c8-32f0-4440-933d-5b3a9f4ab736": {"__data__": {"id_": "de78e4c8-32f0-4440-933d-5b3a9f4ab736", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n", "original_text": "So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67def20d-9ea9-4e7d-b4ae-89c5aad6203a", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great . ", "original_text": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa025e720670e9227d29e73ac0b747e9f408c5c9d2717186cfa8ec6dd0d74f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "302df498-ad0e-47d0-bb98-83f8ee0569b4", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question . ", "original_text": "Lisa Gill:  Okay . "}, "hash": "af19bdb868b58713c8a9f51460e844d77920f91ee7fe8618473067289bb02a7e", "class_name": "RelatedNodeInfo"}}, "text": "So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n", "start_char_idx": 131, "end_char_idx": 365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "302df498-ad0e-47d0-bb98-83f8ee0569b4": {"__data__": {"id_": "302df498-ad0e-47d0-bb98-83f8ee0569b4", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question . ", "original_text": "Lisa Gill:  Okay . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de78e4c8-32f0-4440-933d-5b3a9f4ab736", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n", "original_text": "So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b382a2a5f6c5fe3e88cb7a457b8d05525edf76f3bf9c22fa150a3f622706319", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4d4ee26-2813-4158-ac1b-749b4d9fcf20", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes. ", "original_text": "Great . "}, "hash": "b4ff409a95f1e5180673b4e1134196f86aa0f2303ab4f7c1584673fcf03ed528", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Okay . ", "start_char_idx": 365, "end_char_idx": 384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4d4ee26-2813-4158-ac1b-749b4d9fcf20": {"__data__": {"id_": "c4d4ee26-2813-4158-ac1b-749b4d9fcf20", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes. ", "original_text": "Great . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "302df498-ad0e-47d0-bb98-83f8ee0569b4", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question . ", "original_text": "Lisa Gill:  Okay . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a678bbcb80d7ddf0f3af3c317fb9bf50b7c3c675c18975a4fdc6556b53afdf61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ace5f03-e90a-4ee9-bfe6-ca5a25f45e00", "node_type": "1", "metadata": {"window": "So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n", "original_text": "Thank you.  \n \n"}, "hash": "dd848b4415f006bee4c658210956cf353bde229222a9f86218635b07e0b0861f", "class_name": "RelatedNodeInfo"}}, "text": "Great . ", "start_char_idx": 384, "end_char_idx": 392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ace5f03-e90a-4ee9-bfe6-ca5a25f45e00": {"__data__": {"id_": "8ace5f03-e90a-4ee9-bfe6-ca5a25f45e00", "embedding": null, "metadata": {"window": "So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n", "original_text": "Thank you.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4d4ee26-2813-4158-ac1b-749b4d9fcf20", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes. ", "original_text": "Great . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55da03fa6860a716fe0ea36404f396ecd757e868da8c22f9535726b799afce14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d710224b-15a3-47e7-a057-83b0f0a90912", "node_type": "1", "metadata": {"window": "Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore . ", "original_text": "Jason Hollar:  Next question . "}, "hash": "f0c24f3e6b42588d3b1f042ab06f948eb886f365d3014ebbe3be3cf368ef2c32", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 392, "end_char_idx": 407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d710224b-15a3-47e7-a057-83b0f0a90912": {"__data__": {"id_": "d710224b-15a3-47e7-a057-83b0f0a90912", "embedding": null, "metadata": {"window": "Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore . ", "original_text": "Jason Hollar:  Next question . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ace5f03-e90a-4ee9-bfe6-ca5a25f45e00", "node_type": "1", "metadata": {"window": "So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n", "original_text": "Thank you.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a60a4e69122f3cfe634b2d604fbffd2199ee160ae7b15d2559f82b31a7fa4de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b78b9865-348f-4b1d-b537-9aea758349ff", "node_type": "1", "metadata": {"window": "Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n", "original_text": "Yes. "}, "hash": "de535b6448ae9c3c4775b60e3a178ba79a58f5d46e1faf740750dad130b8d0a6", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Next question . ", "start_char_idx": 407, "end_char_idx": 438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b78b9865-348f-4b1d-b537-9aea758349ff": {"__data__": {"id_": "b78b9865-348f-4b1d-b537-9aea758349ff", "embedding": null, "metadata": {"window": "Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n", "original_text": "Yes. ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d710224b-15a3-47e7-a057-83b0f0a90912", "node_type": "1", "metadata": {"window": "Lisa Gill:  Okay .  Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore . ", "original_text": "Jason Hollar:  Next question . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7257a96dcd0ed612942b8780ffaa86fbea9424094b3759a8aaf1e0e614db93d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5436a088-6bd8-428e-8f4a-4f35c6a81f6a", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys . ", "original_text": "Thanks.  \n \n"}, "hash": "426c668cdc3c6c7a2a5aad253bd6dfbcdcc051cfaddefc2973eac0b774353d08", "class_name": "RelatedNodeInfo"}}, "text": "Yes. ", "start_char_idx": 438, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5436a088-6bd8-428e-8f4a-4f35c6a81f6a": {"__data__": {"id_": "5436a088-6bd8-428e-8f4a-4f35c6a81f6a", "embedding": null, "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys . ", "original_text": "Thanks.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b78b9865-348f-4b1d-b537-9aea758349ff", "node_type": "1", "metadata": {"window": "Great .  Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n", "original_text": "Yes. ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df66ae8411db9137f955a1672b08464a7d83a54f4f630d8686061da718a2e79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e3568cc-32e4-4dd8-975e-b57c530dfea3", "node_type": "1", "metadata": {"window": "Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question . ", "original_text": "Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore . "}, "hash": "1c69df0aac9109687e3f0fac30d6da4747c97ffb81bc39e32247562e0f5ad82e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 443, "end_char_idx": 455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e3568cc-32e4-4dd8-975e-b57c530dfea3": {"__data__": {"id_": "3e3568cc-32e4-4dd8-975e-b57c530dfea3", "embedding": null, "metadata": {"window": "Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question . ", "original_text": "Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5436a088-6bd8-428e-8f4a-4f35c6a81f6a", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys . ", "original_text": "Thanks.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0e46a9fc033290e815ba86e14a594548b014cfdae8b539da8f0337d2364bbad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea3ca64d-53bd-4c32-bba0-f21c504ae65a", "node_type": "1", "metadata": {"window": "Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?  ", "original_text": "Please \ngo ahead.  \n \n"}, "hash": "d142fdd4cdc201412f979d1daad52a2398ddf07ccd1aa84b26b8c79fdaebcd37", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore . ", "start_char_idx": 455, "end_char_idx": 550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea3ca64d-53bd-4c32-bba0-f21c504ae65a": {"__data__": {"id_": "ea3ca64d-53bd-4c32-bba0-f21c504ae65a", "embedding": null, "metadata": {"window": "Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?  ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e3568cc-32e4-4dd8-975e-b57c530dfea3", "node_type": "1", "metadata": {"window": "Jason Hollar:  Next question .  Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question . ", "original_text": "Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f1a818b15e8e179f1d6240f5b5cdfbfec666a7c0ba416101cd0eac41ef3a41d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1570809f-877d-43d1-a307-c5dd1703cce8", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?  ", "original_text": "Elizabeth Anderson :  Hi, guys . "}, "hash": "7311fc11db0b791e49de8157e5fded809c30633359ef9bc5835e92c7c314139f", "class_name": "RelatedNodeInfo"}}, "text": "Please \ngo ahead.  \n \n", "start_char_idx": 550, "end_char_idx": 572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1570809f-877d-43d1-a307-c5dd1703cce8": {"__data__": {"id_": "1570809f-877d-43d1-a307-c5dd1703cce8", "embedding": null, "metadata": {"window": "Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?  ", "original_text": "Elizabeth Anderson :  Hi, guys . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea3ca64d-53bd-4c32-bba0-f21c504ae65a", "node_type": "1", "metadata": {"window": "Yes.  Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?  ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f50ad2aa0295ec4731a73e1715f04981753d1c09e96179d11a547ddb3f953fdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07008c2b-6931-4833-aee0-56be86c8e32b", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.  ", "original_text": "Thanks so much for the question . "}, "hash": "8079258d1a1c5ed7fcb5f60bcfd8d4bb9abfabfbe201dad67f679295ae6f6cc5", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson :  Hi, guys . ", "start_char_idx": 572, "end_char_idx": 605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07008c2b-6931-4833-aee0-56be86c8e32b": {"__data__": {"id_": "07008c2b-6931-4833-aee0-56be86c8e32b", "embedding": null, "metadata": {"window": "Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.  ", "original_text": "Thanks so much for the question . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1570809f-877d-43d1-a307-c5dd1703cce8", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?  ", "original_text": "Elizabeth Anderson :  Hi, guys . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0da4fcf7c1e78ce91ed9053a742f116e15fe21741729fd66974602e2200ffdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "791556e7-4643-401a-a8c1-f37b9b23806d", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense . ", "original_text": "I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?  "}, "hash": "0a8fb65ee9e27f69e5a050463175575e616d405444f1932a80918e7721568be6", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question . ", "start_char_idx": 605, "end_char_idx": 639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "791556e7-4643-401a-a8c1-f37b9b23806d": {"__data__": {"id_": "791556e7-4643-401a-a8c1-f37b9b23806d", "embedding": null, "metadata": {"window": "Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense . ", "original_text": "I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?  ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07008c2b-6931-4833-aee0-56be86c8e32b", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of Elizabeth Anderson calling from Evercore .  Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.  ", "original_text": "Thanks so much for the question . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ce72ff0fdfaa4b0e2f0a989e1a6def3e3952e2a8a6fb8750f305b7818d95233", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57b5687a-3e67-4732-8946-51ed601315d8", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?  ", "original_text": "Are you starting to get pricing in certain places where \nyou had before?  "}, "hash": "b2ab3e7ee72f5c6a7d3add2abea6678f1dac1742481bbdf909959a0ba61ed03a", "class_name": "RelatedNodeInfo"}}, "text": "I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?  ", "start_char_idx": 639, "end_char_idx": 945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57b5687a-3e67-4732-8946-51ed601315d8": {"__data__": {"id_": "57b5687a-3e67-4732-8946-51ed601315d8", "embedding": null, "metadata": {"window": "Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?  ", "original_text": "Are you starting to get pricing in certain places where \nyou had before?  ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "791556e7-4643-401a-a8c1-f37b9b23806d", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense . ", "original_text": "I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?  ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae4e622db593cef6403e7a0de280e389772961564ea1b56fabc4d8604106215e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a85309d5-d00b-4dc1-86e7-c3866f0e2d61", "node_type": "1", "metadata": {"window": "Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n", "original_text": "If you can help us kind of understand that mix.  "}, "hash": "40c409df64d408c86e49ca56b96659a2bc25b80a48fa2fc6ec8c4ef663fb18d2", "class_name": "RelatedNodeInfo"}}, "text": "Are you starting to get pricing in certain places where \nyou had before?  ", "start_char_idx": 945, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a85309d5-d00b-4dc1-86e7-c3866f0e2d61": {"__data__": {"id_": "a85309d5-d00b-4dc1-86e7-c3866f0e2d61", "embedding": null, "metadata": {"window": "Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n", "original_text": "If you can help us kind of understand that mix.  ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57b5687a-3e67-4732-8946-51ed601315d8", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?  ", "original_text": "Are you starting to get pricing in certain places where \nyou had before?  ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60c6c5cb4d50e8083551278a8b5c41045c4c8e97cab922b1bc2f00796ac23039", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b7a69f5-b7b9-4574-ad7c-31db049db412", "node_type": "1", "metadata": {"window": "I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah . ", "original_text": "And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense . "}, "hash": "807d78f297cc70d1c9bbaf37bcb39ee67dcf26f80f9d633303a6a128b755cc92", "class_name": "RelatedNodeInfo"}}, "text": "If you can help us kind of understand that mix.  ", "start_char_idx": 1019, "end_char_idx": 1068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b7a69f5-b7b9-4574-ad7c-31db049db412": {"__data__": {"id_": "9b7a69f5-b7b9-4574-ad7c-31db049db412", "embedding": null, "metadata": {"window": "I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah . ", "original_text": "And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a85309d5-d00b-4dc1-86e7-c3866f0e2d61", "node_type": "1", "metadata": {"window": "Thanks so much for the question .  I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n", "original_text": "If you can help us kind of understand that mix.  ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "037dfd88c2cf4b7ece4f296dac0bea135bb0e5dfcb5f47665f522b5bf0e04ff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8c75df8-3e9f-4f2e-8639-9075fffed053", "node_type": "1", "metadata": {"window": "Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it . ", "original_text": "So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?  "}, "hash": "fcdac376476ecaea9f1a0a166cc648604b03d412844be7fcdc0fea382f9a546e", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense . ", "start_char_idx": 1068, "end_char_idx": 1296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8c75df8-3e9f-4f2e-8639-9075fffed053": {"__data__": {"id_": "f8c75df8-3e9f-4f2e-8639-9075fffed053", "embedding": null, "metadata": {"window": "Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it . ", "original_text": "So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?  ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b7a69f5-b7b9-4574-ad7c-31db049db412", "node_type": "1", "metadata": {"window": "I was wondering if you could talk a \nlittle bit more about the Pharma improvement in the back half of the year and specifically like as you've \nhad time to sort of think through the Pharma reorgani zation , is there a  continued cost -cutting benefit, \nis that just improving the operating profit growth?   Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah . ", "original_text": "And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49c5371afbe31fcce883cbf00810d6445a0fc6b2faf657cfd429cdce3195bfdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cd80e16-b29b-4a9a-b7ff-4ce2cf0d7392", "node_type": "1", "metadata": {"window": "If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances . ", "original_text": "Thank \nyou. \n \n"}, "hash": "20e4df2675457f0ebc6ad8ab42b963e41fca820cd8efcf961a1338b32ab47dcb", "class_name": "RelatedNodeInfo"}}, "text": "So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?  ", "start_char_idx": 1296, "end_char_idx": 1431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cd80e16-b29b-4a9a-b7ff-4ce2cf0d7392": {"__data__": {"id_": "5cd80e16-b29b-4a9a-b7ff-4ce2cf0d7392", "embedding": null, "metadata": {"window": "If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances . ", "original_text": "Thank \nyou. \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8c75df8-3e9f-4f2e-8639-9075fffed053", "node_type": "1", "metadata": {"window": "Are you starting to get pricing in certain places where \nyou had before?   If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it . ", "original_text": "So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?  ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a2179cece0367433cb8a8f26fef8cb4a23b83ddcac6a407afb50ab52b2b766e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99354fc7-3e2e-4f71-8584-ffb506ee9f0f", "node_type": "1", "metadata": {"window": "And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side . ", "original_text": "Jason Hollar:  Yeah . "}, "hash": "fe9dfd1eefc2a2cea81548296dd0d7516c4670f4c7fd9cdcfc98bd54fd6d13a7", "class_name": "RelatedNodeInfo"}}, "text": "Thank \nyou. \n \n", "start_char_idx": 1431, "end_char_idx": 1446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99354fc7-3e2e-4f71-8584-ffb506ee9f0f": {"__data__": {"id_": "99354fc7-3e2e-4f71-8584-ffb506ee9f0f", "embedding": null, "metadata": {"window": "And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side . ", "original_text": "Jason Hollar:  Yeah . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cd80e16-b29b-4a9a-b7ff-4ce2cf0d7392", "node_type": "1", "metadata": {"window": "If you can help us kind of understand that mix.   And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances . ", "original_text": "Thank \nyou. \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da7d1a03bf322fd0a7e51d466bdaeade162589ea18e42e644bb7bbfadc2d2d28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c83ad98a-2a7e-49c4-8262-9f92c58cd150", "node_type": "1", "metadata": {"window": "So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back . ", "original_text": "I'll start with your second question there because you nailed it . "}, "hash": "1856d5c726e8a4cb4c2a6554de799441b3d03443e1937321414082407001197c", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah . ", "start_char_idx": 1446, "end_char_idx": 1468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c83ad98a-2a7e-49c4-8262-9f92c58cd150": {"__data__": {"id_": "c83ad98a-2a7e-49c4-8262-9f92c58cd150", "embedding": null, "metadata": {"window": "So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back . ", "original_text": "I'll start with your second question there because you nailed it . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99354fc7-3e2e-4f71-8584-ffb506ee9f0f", "node_type": "1", "metadata": {"window": "And then secondly, o n the interest \nexpense guide, it looks like the back half guide has a big sort of step -up versus what you did in the first \nquarter , or the first two quarters of the year , in terms of interest expense .  So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side . ", "original_text": "Jason Hollar:  Yeah . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb7e538a82557a7a6bf1236f1dd06c4983e722db8119e1da441d4649e6c1fce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6a32b6c-d583-45a1-a2fe-ef061fa33d3c", "node_type": "1", "metadata": {"window": "Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt . ", "original_text": "It's really about \ncash balances . "}, "hash": "b6bd29cf9b06b79a197c38e59539443331736edcfc71e324637e110694110243", "class_name": "RelatedNodeInfo"}}, "text": "I'll start with your second question there because you nailed it . ", "start_char_idx": 1468, "end_char_idx": 1535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6a32b6c-d583-45a1-a2fe-ef061fa33d3c": {"__data__": {"id_": "b6a32b6c-d583-45a1-a2fe-ef061fa33d3c", "embedding": null, "metadata": {"window": "Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt . ", "original_text": "It's really about \ncash balances . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c83ad98a-2a7e-49c4-8262-9f92c58cd150", "node_type": "1", "metadata": {"window": "So is that just sort of changes \nin cash balance in terms of the net interest contribution or are there other factors going on there?   Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back . ", "original_text": "I'll start with your second question there because you nailed it . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58bd9f50dbc534a6dc8927c6fcc581cc69c9b1795ec8ffbf01a15c2127a2e49b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "baa0fd75-bf02-41b9-a17d-3a4df94ac7db", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known . ", "original_text": "We don't anticipate there being significa nt differences in the interest side . "}, "hash": "ddc85b90abf6ef0f86b53eb5bb594d83983c707dc5bb88320aab766eaebe80d2", "class_name": "RelatedNodeInfo"}}, "text": "It's really about \ncash balances . ", "start_char_idx": 1535, "end_char_idx": 1570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "baa0fd75-bf02-41b9-a17d-3a4df94ac7db": {"__data__": {"id_": "baa0fd75-bf02-41b9-a17d-3a4df94ac7db", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known . ", "original_text": "We don't anticipate there being significa nt differences in the interest side . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6a32b6c-d583-45a1-a2fe-ef061fa33d3c", "node_type": "1", "metadata": {"window": "Thank \nyou. \n \n Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt . ", "original_text": "It's really about \ncash balances . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01cfbf95455b67b2762701d0cc8c7e4402b4b81ec5a57b43fab035dbe1ba754", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3f04ff5-46e6-47d9-aa1f-b533e49c517c", "node_type": "1", "metadata": {"window": "I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date . ", "original_text": "Let me just \nkind of step back . "}, "hash": "a22f07354355568a030aa15190cbac84b825e74b1201e9dbaf7e60d1fcd2cf70", "class_name": "RelatedNodeInfo"}}, "text": "We don't anticipate there being significa nt differences in the interest side . ", "start_char_idx": 1570, "end_char_idx": 1650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3f04ff5-46e6-47d9-aa1f-b533e49c517c": {"__data__": {"id_": "a3f04ff5-46e6-47d9-aa1f-b533e49c517c", "embedding": null, "metadata": {"window": "I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date . ", "original_text": "Let me just \nkind of step back . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "baa0fd75-bf02-41b9-a17d-3a4df94ac7db", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah .  I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known . ", "original_text": "We don't anticipate there being significa nt differences in the interest side . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b98b7a067ce24c37c012fde6b10fe22a34932bc947bdd5c341b97d827781694", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9bcf030-626c-4305-98e7-aaa99007a1e2", "node_type": "1", "metadata": {"window": "It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year . ", "original_text": "We have a very fixed interest expense for our debt . "}, "hash": "47d400e9129f7be1a3977e30726f64f0fd4085ecb7e2ad24a667328c0087622d", "class_name": "RelatedNodeInfo"}}, "text": "Let me just \nkind of step back . ", "start_char_idx": 1650, "end_char_idx": 1683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9bcf030-626c-4305-98e7-aaa99007a1e2": {"__data__": {"id_": "f9bcf030-626c-4305-98e7-aaa99007a1e2", "embedding": null, "metadata": {"window": "It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year . ", "original_text": "We have a very fixed interest expense for our debt . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3f04ff5-46e6-47d9-aa1f-b533e49c517c", "node_type": "1", "metadata": {"window": "I'll start with your second question there because you nailed it .  It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date . ", "original_text": "Let me just \nkind of step back . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c771aa864dbf63a2d2b5aa97a394e09853df946ba22e53a125395da84f7db82f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7357f2a-7855-4f48-ad9c-0bbafc0858bf", "node_type": "1", "metadata": {"window": "We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down . ", "original_text": "So our interest expense side is \nquite predictable and known . "}, "hash": "05de98d74cd6aee2a188c80c7273461cc7f2ee13351b1b9d571cab78656af094", "class_name": "RelatedNodeInfo"}}, "text": "We have a very fixed interest expense for our debt . ", "start_char_idx": 1683, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7357f2a-7855-4f48-ad9c-0bbafc0858bf": {"__data__": {"id_": "c7357f2a-7855-4f48-ad9c-0bbafc0858bf", "embedding": null, "metadata": {"window": "We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down . ", "original_text": "So our interest expense side is \nquite predictable and known . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9bcf030-626c-4305-98e7-aaa99007a1e2", "node_type": "1", "metadata": {"window": "It's really about \ncash balances .  We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year . ", "original_text": "We have a very fixed interest expense for our debt . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54882fcf8375be82036dbdbcb440f33d6dfec0e71400ea57552170bc6444d4ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df52489e-5dff-4303-aea9-d2c164b75905", "node_type": "1", "metadata": {"window": "Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well . ", "original_text": "It's really the interest income is the part that we've seen favorability in  \nyear to date . "}, "hash": "91f4f06b6f02091064eb15d7de6a989e0404559d7d1b1919a12167bdd61326b3", "class_name": "RelatedNodeInfo"}}, "text": "So our interest expense side is \nquite predictable and known . ", "start_char_idx": 1736, "end_char_idx": 1799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df52489e-5dff-4303-aea9-d2c164b75905": {"__data__": {"id_": "df52489e-5dff-4303-aea9-d2c164b75905", "embedding": null, "metadata": {"window": "Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well . ", "original_text": "It's really the interest income is the part that we've seen favorability in  \nyear to date . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7357f2a-7855-4f48-ad9c-0bbafc0858bf", "node_type": "1", "metadata": {"window": "We don't anticipate there being significa nt differences in the interest side .  Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down . ", "original_text": "So our interest expense side is \nquite predictable and known . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a530e5cafdd64e605a0e830b02dae056ead27e27bc13c7cf4f070f72f760ec6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9723b015-facd-4e2a-89d9-4881f6a7040e", "node_type": "1", "metadata": {"window": "We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half . ", "original_text": "And our cash balances were higher than anticipated over the first half of the year . "}, "hash": "627dacd5aee65ff785ccd301c988924d934678e284cf7989031b803e2a2e64a6", "class_name": "RelatedNodeInfo"}}, "text": "It's really the interest income is the part that we've seen favorability in  \nyear to date . ", "start_char_idx": 1799, "end_char_idx": 1892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9723b015-facd-4e2a-89d9-4881f6a7040e": {"__data__": {"id_": "9723b015-facd-4e2a-89d9-4881f6a7040e", "embedding": null, "metadata": {"window": "We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half . ", "original_text": "And our cash balances were higher than anticipated over the first half of the year . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df52489e-5dff-4303-aea9-d2c164b75905", "node_type": "1", "metadata": {"window": "Let me just \nkind of step back .  We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well . ", "original_text": "It's really the interest income is the part that we've seen favorability in  \nyear to date . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33dc1c120fcfc2804eb64223719ac17f109817752526df6d1f99f3b286462aa2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1f7f033-3952-4f59-8b3a-5827d7d2835c", "node_type": "1", "metadata": {"window": "So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n", "original_text": "We do \nhave the $550 million note coming due here in March and we anticipate to pay down . "}, "hash": "385187469bfe7d600e85366299422d503dee2e624a7822f8a0124cb0d0142f83", "class_name": "RelatedNodeInfo"}}, "text": "And our cash balances were higher than anticipated over the first half of the year . ", "start_char_idx": 1892, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1f7f033-3952-4f59-8b3a-5827d7d2835c": {"__data__": {"id_": "f1f7f033-3952-4f59-8b3a-5827d7d2835c", "embedding": null, "metadata": {"window": "So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n", "original_text": "We do \nhave the $550 million note coming due here in March and we anticipate to pay down . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9723b015-facd-4e2a-89d9-4881f6a7040e", "node_type": "1", "metadata": {"window": "We have a very fixed interest expense for our debt .  So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half . ", "original_text": "And our cash balances were higher than anticipated over the first half of the year . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c217ec2e661896472ea47bb814c9b474d6109c05725fcd3fbec67e3269e3c28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33996750-9bf5-49d8-82a4-7719c28f57af", "node_type": "1", "metadata": {"window": "It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else . ", "original_text": "And there's just \na seasonal aspect of our cash flow as well . "}, "hash": "d1334a2f8ffddd0411c1101bfabe1d196c7992da055ae60344ef3147ac98d004", "class_name": "RelatedNodeInfo"}}, "text": "We do \nhave the $550 million note coming due here in March and we anticipate to pay down . ", "start_char_idx": 1977, "end_char_idx": 2068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33996750-9bf5-49d8-82a4-7719c28f57af": {"__data__": {"id_": "33996750-9bf5-49d8-82a4-7719c28f57af", "embedding": null, "metadata": {"window": "It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else . ", "original_text": "And there's just \na seasonal aspect of our cash flow as well . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1f7f033-3952-4f59-8b3a-5827d7d2835c", "node_type": "1", "metadata": {"window": "So our interest expense side is \nquite predictable and known .  It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n", "original_text": "We do \nhave the $550 million note coming due here in March and we anticipate to pay down . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85c4170e80a45f45416c23117b3c128aeb3174851861e8db2619adeb23ad448e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3c06962-044e-4d3f-a166-916418f17a91", "node_type": "1", "metadata": {"window": "And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables . ", "original_text": "So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half . "}, "hash": "390a4022a35427ab4ff0ef8e76070dc5e1010e882728d0ecb0509f979c5b5934", "class_name": "RelatedNodeInfo"}}, "text": "And there's just \na seasonal aspect of our cash flow as well . ", "start_char_idx": 2068, "end_char_idx": 2131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3c06962-044e-4d3f-a166-916418f17a91": {"__data__": {"id_": "b3c06962-044e-4d3f-a166-916418f17a91", "embedding": null, "metadata": {"window": "And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables . ", "original_text": "So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33996750-9bf5-49d8-82a4-7719c28f57af", "node_type": "1", "metadata": {"window": "It's really the interest income is the part that we've seen favorability in  \nyear to date .  And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else . ", "original_text": "And there's just \na seasonal aspect of our cash flow as well . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93565a9bfaaeead3a5cb445976969d0697532775288c764736fb9ec969005a72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0893ad95-6a76-4bb5-a733-b2faaaced0f3", "node_type": "1", "metadata": {"window": "We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent. ", "original_text": "So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n"}, "hash": "f2e8a575f4385df624186a206705a872a1364df66d886e40364b1555338d5a8b", "class_name": "RelatedNodeInfo"}}, "text": "So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half . ", "start_char_idx": 2131, "end_char_idx": 2305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0893ad95-6a76-4bb5-a733-b2faaaced0f3": {"__data__": {"id_": "0893ad95-6a76-4bb5-a733-b2faaaced0f3", "embedding": null, "metadata": {"window": "We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent. ", "original_text": "So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3c06962-044e-4d3f-a166-916418f17a91", "node_type": "1", "metadata": {"window": "And our cash balances were higher than anticipated over the first half of the year .  We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables . ", "original_text": "So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02c8916d0bf8e3bad1a0c8384a086f073d2ea0feb1d6c115ac7ea8d6895ff120", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01624c07-a73c-4966-8342-ff544260e16b", "node_type": "1", "metadata": {"window": "And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength . ", "original_text": "As it relates to Pharma, it's really more about volume than anything else . "}, "hash": "9a62d736047144d19058d3a0d3e031468b84a01b5991569a03c42f9806e79d00", "class_name": "RelatedNodeInfo"}}, "text": "So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n", "start_char_idx": 2305, "end_char_idx": 2457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01624c07-a73c-4966-8342-ff544260e16b": {"__data__": {"id_": "01624c07-a73c-4966-8342-ff544260e16b", "embedding": null, "metadata": {"window": "And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength . ", "original_text": "As it relates to Pharma, it's really more about volume than anything else . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0893ad95-6a76-4bb5-a733-b2faaaced0f3", "node_type": "1", "metadata": {"window": "We do \nhave the $550 million note coming due here in March and we anticipate to pay down .  And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent. ", "original_text": "So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7775931f2b987d6441421ae88b650027bc88b02b5cd45fb3aaccce31f2e3f65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc5c3441-b354-474d-8696-1e507c9641e3", "node_type": "1", "metadata": {"window": "So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based . ", "original_text": "We're not seeing a lot of other \nkey variables . "}, "hash": "31771dc4a8d299d1080e79cd48fe5fc57262a82d9f6e239d21ee20eb43aa39c0", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to Pharma, it's really more about volume than anything else . ", "start_char_idx": 2457, "end_char_idx": 2533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc5c3441-b354-474d-8696-1e507c9641e3": {"__data__": {"id_": "bc5c3441-b354-474d-8696-1e507c9641e3", "embedding": null, "metadata": {"window": "So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based . ", "original_text": "We're not seeing a lot of other \nkey variables . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01624c07-a73c-4966-8342-ff544260e16b", "node_type": "1", "metadata": {"window": "And there's just \na seasonal aspect of our cash flow as well .  So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength . ", "original_text": "As it relates to Pharma, it's really more about volume than anything else . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d3a7a17012b34e115c8e1d366e08a2dd6f366555269bd07411c295d60342dcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a5e8671-57a8-4d6e-a3fb-9835a1f74ab8", "node_type": "1", "metadata": {"window": "So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics . ", "original_text": "Underlying  dynamics within the generics business continue to be very consist ent. "}, "hash": "f0206523e49f1f13b1e0232d9d9cf6d37e18aad00ae1c8a2dad9542696720a51", "class_name": "RelatedNodeInfo"}}, "text": "We're not seeing a lot of other \nkey variables . ", "start_char_idx": 2533, "end_char_idx": 2582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a5e8671-57a8-4d6e-a3fb-9835a1f74ab8": {"__data__": {"id_": "5a5e8671-57a8-4d6e-a3fb-9835a1f74ab8", "embedding": null, "metadata": {"window": "So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics . ", "original_text": "Underlying  dynamics within the generics business continue to be very consist ent. ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc5c3441-b354-474d-8696-1e507c9641e3", "node_type": "1", "metadata": {"window": "So we w ould not anticipate the same lower levels or say \nimproved interest income that reduces our interest expense in the second half like what we saw in the \nfirst half .  So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based . ", "original_text": "We're not seeing a lot of other \nkey variables . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8df5e1220d6daee3e99d3345061ee7c5ecdc978070e8817084560ef55214181d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbee6f12-8fe4-49e2-9988-88c52842bc85", "node_type": "1", "metadata": {"window": "As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that . ", "original_text": "We \ncontinue to see very broad -based volume strength . "}, "hash": "afe9d5916a2c0d7bdc96a32b2986a930f5e7efb1b734a27b0bd23a8890711cb4", "class_name": "RelatedNodeInfo"}}, "text": "Underlying  dynamics within the generics business continue to be very consist ent. ", "start_char_idx": 2582, "end_char_idx": 2665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbee6f12-8fe4-49e2-9988-88c52842bc85": {"__data__": {"id_": "bbee6f12-8fe4-49e2-9988-88c52842bc85", "embedding": null, "metadata": {"window": "As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that . ", "original_text": "We \ncontinue to see very broad -based volume strength . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a5e8671-57a8-4d6e-a3fb-9835a1f74ab8", "node_type": "1", "metadata": {"window": "So you should take away that we continue to have a very advantaged balance sheet, \nespecially as it relates to the fixed variable  mix of our debt.  \n \n As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics . ", "original_text": "Underlying  dynamics within the generics business continue to be very consist ent. ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e147d2415781f7a4f1aaadeb18dbaa49c2959be0a526b208b5a7dccd44dff975", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ebd6bfb-af36-428f-8b77-e7c177a5e762", "node_type": "1", "metadata": {"window": "We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear. ", "original_text": "Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based . "}, "hash": "a582dc6cb6cf3832a52036c0a8002a320a282bc31065998274ee4c84c122e726", "class_name": "RelatedNodeInfo"}}, "text": "We \ncontinue to see very broad -based volume strength . ", "start_char_idx": 2665, "end_char_idx": 2721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ebd6bfb-af36-428f-8b77-e7c177a5e762": {"__data__": {"id_": "7ebd6bfb-af36-428f-8b77-e7c177a5e762", "embedding": null, "metadata": {"window": "We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear. ", "original_text": "Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbee6f12-8fe4-49e2-9988-88c52842bc85", "node_type": "1", "metadata": {"window": "As it relates to Pharma, it's really more about volume than anything else .  We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that . ", "original_text": "We \ncontinue to see very broad -based volume strength . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8b5f0df73b05ee8b98569fd7c9638d257dc055d96d5b5314da382bc1ffb009a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cd67157-09d6-4d6a-b799-5949b2d05687", "node_type": "1", "metadata": {"window": "Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before . ", "original_text": "I referenced my comments between Trish and I, brand \nspecialty , as well as generics . "}, "hash": "f0dad0481cba9ca1bb0d566831f5bbad19bdf22889d4a98342b836cc1073fe45", "class_name": "RelatedNodeInfo"}}, "text": "Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based . ", "start_char_idx": 2721, "end_char_idx": 2817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cd67157-09d6-4d6a-b799-5949b2d05687": {"__data__": {"id_": "0cd67157-09d6-4d6a-b799-5949b2d05687", "embedding": null, "metadata": {"window": "Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before . ", "original_text": "I referenced my comments between Trish and I, brand \nspecialty , as well as generics . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ebd6bfb-af36-428f-8b77-e7c177a5e762", "node_type": "1", "metadata": {"window": "We're not seeing a lot of other \nkey variables .  Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear. ", "original_text": "Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8050a59fc1e7ee10bfde45c906f0dfed8b99a5217b89d8ca2221aa45be014c17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15129a88-67a3-4035-836c-11aeaceb295f", "node_type": "1", "metadata": {"window": "We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half . ", "original_text": "It is a lot of vo lume drivers within that . "}, "hash": "dda74f59a00dab28193381d4ac5ea3f8a0f106c6a95af9ec270cbe22d558ec17", "class_name": "RelatedNodeInfo"}}, "text": "I referenced my comments between Trish and I, brand \nspecialty , as well as generics . ", "start_char_idx": 2817, "end_char_idx": 2904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15129a88-67a3-4035-836c-11aeaceb295f": {"__data__": {"id_": "15129a88-67a3-4035-836c-11aeaceb295f", "embedding": null, "metadata": {"window": "We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half . ", "original_text": "It is a lot of vo lume drivers within that . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cd67157-09d6-4d6a-b799-5949b2d05687", "node_type": "1", "metadata": {"window": "Underlying  dynamics within the generics business continue to be very consist ent.  We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before . ", "original_text": "I referenced my comments between Trish and I, brand \nspecialty , as well as generics . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f044f9f90b149db113c82cc743bbcf5b7d39f9f354754b9dbf69c0141cf805d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdc05d53-75c7-4c8b-95ee-096b8070ffad", "node_type": "1", "metadata": {"window": "Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear. "}, "hash": "5970790ee1feb81fd0e1d8e948249d7b35d308c1de20d49d74d8e29732a43c54", "class_name": "RelatedNodeInfo"}}, "text": "It is a lot of vo lume drivers within that . ", "start_char_idx": 2904, "end_char_idx": 2949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdc05d53-75c7-4c8b-95ee-096b8070ffad": {"__data__": {"id_": "fdc05d53-75c7-4c8b-95ee-096b8070ffad", "embedding": null, "metadata": {"window": "Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear. ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15129a88-67a3-4035-836c-11aeaceb295f", "node_type": "1", "metadata": {"window": "We \ncontinue to see very broad -based volume strength .  Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half . ", "original_text": "It is a lot of vo lume drivers within that . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05724f0ac2be30e64cc0756c1743cec685c7b4ff2bc3d6aa901f17380b31c2fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72f6ae19-6f18-4b0f-9fed-838801e32e13", "node_type": "1", "metadata": {"window": "I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "So our second -half expectations remain consistent with what we had indicated before . "}, "hash": "bdf601420a3c225ecaea9245e89c90d9821221b4a1b2bfded17a9279d9978f8e", "class_name": "RelatedNodeInfo"}}, "text": "And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear. ", "start_char_idx": 2949, "end_char_idx": 3094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72f6ae19-6f18-4b0f-9fed-838801e32e13": {"__data__": {"id_": "72f6ae19-6f18-4b0f-9fed-838801e32e13", "embedding": null, "metadata": {"window": "I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "So our second -half expectations remain consistent with what we had indicated before . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdc05d53-75c7-4c8b-95ee-096b8070ffad", "node_type": "1", "metadata": {"window": "Q2 was certainly a very strong quarter as it relates \nto volume, and we saw that broad -based .  I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear. ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "004a89d1b9d5615d03b74b934a02236ddd1c37be36363eed25b2868a94916e08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc8e0605-9b46-468e-8bd9-34482accc5ec", "node_type": "1", "metadata": {"window": "It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half . "}, "hash": "b3a828883dc5602c4512226777116aa6985c046a9123ebdf1f5bada400d442b0", "class_name": "RelatedNodeInfo"}}, "text": "So our second -half expectations remain consistent with what we had indicated before . ", "start_char_idx": 3094, "end_char_idx": 3181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc8e0605-9b46-468e-8bd9-34482accc5ec": {"__data__": {"id_": "fc8e0605-9b46-468e-8bd9-34482accc5ec", "embedding": null, "metadata": {"window": "It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72f6ae19-6f18-4b0f-9fed-838801e32e13", "node_type": "1", "metadata": {"window": "I referenced my comments between Trish and I, brand \nspecialty , as well as generics .  It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "So our second -half expectations remain consistent with what we had indicated before . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34c290a2316e08120fc4c11ab2ceeb25e5def544edb2f27e4819678b0e7244d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c6de64a-f99d-4e72-9186-6e7368358a05", "node_type": "1", "metadata": {"window": "And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n "}, "hash": "20582ce8906667b044acb20b2825ce7b0ac0b5b33ec75ea5193ad6d5b7930642", "class_name": "RelatedNodeInfo"}}, "text": "A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half . ", "start_char_idx": 3181, "end_char_idx": 3396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c6de64a-f99d-4e72-9186-6e7368358a05": {"__data__": {"id_": "3c6de64a-f99d-4e72-9186-6e7368358a05", "embedding": null, "metadata": {"window": "And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273c9018dee76ee7823ab70243a39c24ecd6b5d959599da5286ff9c0e5eb06bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc8e0605-9b46-468e-8bd9-34482accc5ec", "node_type": "1", "metadata": {"window": "It is a lot of vo lume drivers within that .  And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db52597da6e9f1e8dbc57b3a31e395ba4d483ff78190cf15a5be8bffd93c90bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a223dec7-ba4d-4b0d-92fc-9e4d9ff13b89", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n", "original_text": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong . "}, "hash": "2031ca91fc7b91b603575c8e5ca6e2b70689f86a3579f57698abb596b6a28d57", "class_name": "RelatedNodeInfo"}}, "text": "But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "start_char_idx": 3396, "end_char_idx": 3554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a223dec7-ba4d-4b0d-92fc-9e4d9ff13b89": {"__data__": {"id_": "a223dec7-ba4d-4b0d-92fc-9e4d9ff13b89", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n", "original_text": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c6de64a-f99d-4e72-9186-6e7368358a05", "node_type": "1", "metadata": {"window": "And as we think about the growth \nin the second half of the year, it's very consistent with what we had indicated at the beginning of the \nyear.  So our second -half expectations remain consistent with what we had indicated before .  A little bit \nless growth than what we've seen in the first half and that's just a reflection of, again, Trish's comments \nthat we anticipate it being closer to more normali zed level of growth in the second half .  But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "original_text": "But if we \nmaintain the same level of strength t hat we've seen in the last couple of quarters and then there's some \nopportunity in the high end of that.  \n ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b346f9f8a21149630c2c0b67b77df012de2146a003ef1d52c5918a251f4e8fe1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "becef871-f08d-4675-9711-fee56f58d59b", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu . ", "original_text": "If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters . "}, "hash": "3a9b3fa1a48de888cfef4bb21aea125eeac524e7a624c55262f7d235140c8610", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong . ", "start_char_idx": 0, "end_char_idx": 88, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "becef871-f08d-4675-9711-fee56f58d59b": {"__data__": {"id_": "becef871-f08d-4675-9711-fee56f58d59b", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu . ", "original_text": "If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a223dec7-ba4d-4b0d-92fc-9e4d9ff13b89", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n", "original_text": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c9b7dfa8a3bd4a27fb61f1cf071cef3e4ba92f125b4252bf55d11660662d6b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6afc8418-8aa2-4275-8018-4b534800fb02", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year . ", "original_text": "But this \nwould be the last quarter until we start to lap that . "}, "hash": "3d48ed335692d1138f16431b5724965a0b028031fc8e9ca0d75ce3c0d589b05b", "class_name": "RelatedNodeInfo"}}, "text": "If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters . ", "start_char_idx": 88, "end_char_idx": 327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6afc8418-8aa2-4275-8018-4b534800fb02": {"__data__": {"id_": "6afc8418-8aa2-4275-8018-4b534800fb02", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year . ", "original_text": "But this \nwould be the last quarter until we start to lap that . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "becef871-f08d-4675-9711-fee56f58d59b", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu . ", "original_text": "If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "325ead9faa606137baa54c1c376c1ff09f9d045af1c95252c30d04457354dc96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "469ed938-c12c-451c-aa2d-c470c5c7df2a", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal . ", "original_text": "So that's part of the driver from a year -over-year \nperspective.  \n \n"}, "hash": "06e27a1902cd8d7a51bb4ee116e61f69afd661a261c10a60c0ca80abf5ffb3e7", "class_name": "RelatedNodeInfo"}}, "text": "But this \nwould be the last quarter until we start to lap that . ", "start_char_idx": 327, "end_char_idx": 392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "469ed938-c12c-451c-aa2d-c470c5c7df2a": {"__data__": {"id_": "469ed938-c12c-451c-aa2d-c470c5c7df2a", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal . ", "original_text": "So that's part of the driver from a year -over-year \nperspective.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6afc8418-8aa2-4275-8018-4b534800fb02", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year . ", "original_text": "But this \nwould be the last quarter until we start to lap that . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e11211324c1151b0436d62d25651590f5e4613974bdf9b986694c0561b82a03f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d10b5225-045f-4410-8001-d2a80f1a6a33", "node_type": "1", "metadata": {"window": "If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n", "original_text": "And then not significant, but there is an element of cough, cold, and flu . "}, "hash": "39fe4708e4a4455bee05622cafeb7759d4f63490ccc7ac3ce466659ab796e916", "class_name": "RelatedNodeInfo"}}, "text": "So that's part of the driver from a year -over-year \nperspective.  \n \n", "start_char_idx": 392, "end_char_idx": 462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d10b5225-045f-4410-8001-d2a80f1a6a33": {"__data__": {"id_": "d10b5225-045f-4410-8001-d2a80f1a6a33", "embedding": null, "metadata": {"window": "If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n", "original_text": "And then not significant, but there is an element of cough, cold, and flu . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "469ed938-c12c-451c-aa2d-c470c5c7df2a", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal . ", "original_text": "So that's part of the driver from a year -over-year \nperspective.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a57fbe49952572bb10922d2d1667f98987ea264fc8578033149fbea35c67e01f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b08a66eb-b0da-4979-804e-da6090d9e1d7", "node_type": "1", "metadata": {"window": "But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it. ", "original_text": "That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year . "}, "hash": "5a24fbac90c326c5e8815e238f1ed29f042f259dbe1d60f404cea29e7d2fc09b", "class_name": "RelatedNodeInfo"}}, "text": "And then not significant, but there is an element of cough, cold, and flu . ", "start_char_idx": 462, "end_char_idx": 538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b08a66eb-b0da-4979-804e-da6090d9e1d7": {"__data__": {"id_": "b08a66eb-b0da-4979-804e-da6090d9e1d7", "embedding": null, "metadata": {"window": "But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it. ", "original_text": "That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d10b5225-045f-4410-8001-d2a80f1a6a33", "node_type": "1", "metadata": {"window": "If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n", "original_text": "And then not significant, but there is an element of cough, cold, and flu . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bfd66c1fab81e8568c995617e1ff747bc47a409e0f7fcfa8a7bab10862f18aa8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26cb7d7c-971e-41d5-9997-b2154e09a3b0", "node_type": "1", "metadata": {"window": "So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n", "original_text": "In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal . "}, "hash": "4d1cfcebebe4b5938a440ab7e702b6e176155fcbdec900b204d97d55c8fad83f", "class_name": "RelatedNodeInfo"}}, "text": "That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year . ", "start_char_idx": 538, "end_char_idx": 665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26cb7d7c-971e-41d5-9997-b2154e09a3b0": {"__data__": {"id_": "26cb7d7c-971e-41d5-9997-b2154e09a3b0", "embedding": null, "metadata": {"window": "So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n", "original_text": "In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b08a66eb-b0da-4979-804e-da6090d9e1d7", "node_type": "1", "metadata": {"window": "But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it. ", "original_text": "That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5eb65af1fa994e0e07894bb71caedac59f055aa78b9d8eef03834ae5a664747", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffa24f4e-f832-45a8-b5da-5af6c0e2071b", "node_type": "1", "metadata": {"window": "And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n", "original_text": "So those are all the key moving pieces.  \n \n"}, "hash": "c4e80778b356f5a4fe624ab8d7e464c74dba453d05234fe7ab83d875e6595e5b", "class_name": "RelatedNodeInfo"}}, "text": "In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal . ", "start_char_idx": 665, "end_char_idx": 817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffa24f4e-f832-45a8-b5da-5af6c0e2071b": {"__data__": {"id_": "ffa24f4e-f832-45a8-b5da-5af6c0e2071b", "embedding": null, "metadata": {"window": "And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n", "original_text": "So those are all the key moving pieces.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26cb7d7c-971e-41d5-9997-b2154e09a3b0", "node_type": "1", "metadata": {"window": "So that's part of the driver from a year -over-year \nperspective.  \n \n And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n", "original_text": "In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99cbfa1251310b82f37ea487e450453c1cbc41d4e923e600df94e86e2a4833fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9956daf-cb97-41ad-aa82-6aef5a6c5c23", "node_type": "1", "metadata": {"window": "That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n", "original_text": "Elizabeth Anderson:  Got it. "}, "hash": "204799e274bdb9282bade16b004f7c8b26692d2b8b00b848b2e5bae46c5a4d88", "class_name": "RelatedNodeInfo"}}, "text": "So those are all the key moving pieces.  \n \n", "start_char_idx": 817, "end_char_idx": 861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9956daf-cb97-41ad-aa82-6aef5a6c5c23": {"__data__": {"id_": "c9956daf-cb97-41ad-aa82-6aef5a6c5c23", "embedding": null, "metadata": {"window": "That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n", "original_text": "Elizabeth Anderson:  Got it. ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffa24f4e-f832-45a8-b5da-5af6c0e2071b", "node_type": "1", "metadata": {"window": "And then not significant, but there is an element of cough, cold, and flu .  That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n", "original_text": "So those are all the key moving pieces.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50f2297b081f1b70f9ab083aad0dc86badc1b21edeae9fde7526b19193b0e172", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6ca408b-0626-4a99-b435-11a5f830e172", "node_type": "1", "metadata": {"window": "In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question . ", "original_text": "Thank you so much.  \n \n"}, "hash": "dd3907bea7710e8aa9a2eb0eb0795a197c1db884b20bbf8f96bff6b39428d41f", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson:  Got it. ", "start_char_idx": 861, "end_char_idx": 890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6ca408b-0626-4a99-b435-11a5f830e172": {"__data__": {"id_": "a6ca408b-0626-4a99-b435-11a5f830e172", "embedding": null, "metadata": {"window": "In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question . ", "original_text": "Thank you so much.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9956daf-cb97-41ad-aa82-6aef5a6c5c23", "node_type": "1", "metadata": {"window": "That's a nice little tailwind for \nthe quarter, but at this point, we don't anticipate that being a driver for the full year .  In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n", "original_text": "Elizabeth Anderson:  Got it. ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a407f50808e18dc2ae2f9b7e72a8a4bd78e8d9a88ab6265f1af0ec03a628e13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d33b4f7-78a6-495c-88eb-e69d9ea1f40c", "node_type": "1", "metadata": {"window": "So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit . ", "original_text": "Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n"}, "hash": "17aef8d50e7b33531b3371c5580c38c08d55fc3ba896e74c8c06c2d9dd704d1b", "class_name": "RelatedNodeInfo"}}, "text": "Thank you so much.  \n \n", "start_char_idx": 890, "end_char_idx": 913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d33b4f7-78a6-495c-88eb-e69d9ea1f40c": {"__data__": {"id_": "9d33b4f7-78a6-495c-88eb-e69d9ea1f40c", "embedding": null, "metadata": {"window": "So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit . ", "original_text": "Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6ca408b-0626-4a99-b435-11a5f830e172", "node_type": "1", "metadata": {"window": "In fact, this could \nbe a little bit  of a headwind as it relates to Q3 specifically, because it looks like the season is ending \nearlier than normal .  So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question . ", "original_text": "Thank you so much.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12069b18ec3d30ca8c5dd38528e2a5d740e3ebf8f6118a15bbb072bf9cc7c228", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c86163c-eb22-44af-87a1-17affd757718", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense . ", "original_text": "Please go ahead.  \n \n"}, "hash": "c07a0d13cda783ca686d9ed2ddd90bec5e0c15eaa1f74c42540a5ecd14fde213", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n", "start_char_idx": 913, "end_char_idx": 1013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c86163c-eb22-44af-87a1-17affd757718": {"__data__": {"id_": "6c86163c-eb22-44af-87a1-17affd757718", "embedding": null, "metadata": {"window": "Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense . ", "original_text": "Please go ahead.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d33b4f7-78a6-495c-88eb-e69d9ea1f40c", "node_type": "1", "metadata": {"window": "So those are all the key moving pieces.  \n \n Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit . ", "original_text": "Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bae6b357f8d1ce8b9636683db9b92f3961bcfd2ce0fc69f4ad68140c7c12c116", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7ccf4fc-8168-480e-848d-146a55795388", "node_type": "1", "metadata": {"window": "Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates . ", "original_text": "Michael Cherny:  Good morning and thanks for taking the question . "}, "hash": "42f4baf5c625ebc462a59c1d5342667bc774236b0c15b1bd3b55cba76f56a42b", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1013, "end_char_idx": 1034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7ccf4fc-8168-480e-848d-146a55795388": {"__data__": {"id_": "c7ccf4fc-8168-480e-848d-146a55795388", "embedding": null, "metadata": {"window": "Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates . ", "original_text": "Michael Cherny:  Good morning and thanks for taking the question . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c86163c-eb22-44af-87a1-17affd757718", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  Got it.  Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense . ", "original_text": "Please go ahead.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80c6c0624593686f131897df71d76df661238c75f83315806a93e13ed6be1750", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5adef5cc-5de6-4192-adf2-7a182e19cc11", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS . ", "original_text": "So just to parse through your \nnumbers a little bit . "}, "hash": "2941715784643f1622856f04d2343a923d433028c371405ab43dd18dc038e822", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny:  Good morning and thanks for taking the question . ", "start_char_idx": 1034, "end_char_idx": 1101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5adef5cc-5de6-4192-adf2-7a182e19cc11": {"__data__": {"id_": "5adef5cc-5de6-4192-adf2-7a182e19cc11", "embedding": null, "metadata": {"window": "Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS . ", "original_text": "So just to parse through your \nnumbers a little bit . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7ccf4fc-8168-480e-848d-146a55795388", "node_type": "1", "metadata": {"window": "Thank you so much.  \n \n Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates . ", "original_text": "Michael Cherny:  Good morning and thanks for taking the question . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a66bdd8cd28ed2b60c2d71d53edbbc3fd04754f168ee86afdbfaac4ab1b201", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39dcb5a9-6197-4ae9-811b-428cb4a94ec8", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range . ", "original_text": "I just want to get a sense . "}, "hash": "ada6dd39f2006a4b6d62441a9a1386eab3f44e30a56d1561cdbabc1b86cd9c87", "class_name": "RelatedNodeInfo"}}, "text": "So just to parse through your \nnumbers a little bit . ", "start_char_idx": 1101, "end_char_idx": 1155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39dcb5a9-6197-4ae9-811b-428cb4a94ec8": {"__data__": {"id_": "39dcb5a9-6197-4ae9-811b-428cb4a94ec8", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range . ", "original_text": "I just want to get a sense . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5adef5cc-5de6-4192-adf2-7a182e19cc11", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of M ichael Cherny calling from Bank of America . \n Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS . ", "original_text": "So just to parse through your \nnumbers a little bit . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adc4f4ba749855debee022a6d92a609c54bba8a4e2ec42bf46ac91d8eff1dfe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4cccf5f-6ceb-452e-83ae-aa85a83b5896", "node_type": "1", "metadata": {"window": "Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?  ", "original_text": "You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates . "}, "hash": "4026cb3dbf25efd0e572bf85a55b73c8ed4685524678b97b29346a50c09f61b9", "class_name": "RelatedNodeInfo"}}, "text": "I just want to get a sense . ", "start_char_idx": 1155, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4cccf5f-6ceb-452e-83ae-aa85a83b5896": {"__data__": {"id_": "d4cccf5f-6ceb-452e-83ae-aa85a83b5896", "embedding": null, "metadata": {"window": "Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?  ", "original_text": "You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39dcb5a9-6197-4ae9-811b-428cb4a94ec8", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range . ", "original_text": "I just want to get a sense . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86e2f06d014b21c7fab862f9f6ee1c47f6f270d7ab2128dbddbe2d6f60dac033", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85c5126f-8b70-40a0-9642-1a51b8bddc17", "node_type": "1", "metadata": {"window": "So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too . ", "original_text": "It seems like \nthere's more opportunity for upside on your EPS . "}, "hash": "a9d52299cd3f0aa4adcd89bf7668f5d57aecfb76090240a9982806e9017ce7be", "class_name": "RelatedNodeInfo"}}, "text": "You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates . ", "start_char_idx": 1184, "end_char_idx": 1328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85c5126f-8b70-40a0-9642-1a51b8bddc17": {"__data__": {"id_": "85c5126f-8b70-40a0-9642-1a51b8bddc17", "embedding": null, "metadata": {"window": "So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too . ", "original_text": "It seems like \nthere's more opportunity for upside on your EPS . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4cccf5f-6ceb-452e-83ae-aa85a83b5896", "node_type": "1", "metadata": {"window": "Michael Cherny:  Good morning and thanks for taking the question .  So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?  ", "original_text": "You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "356f579c4400d5fe59213bd37f78d49be767797493c3a2f855d97d58ef784248", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "220fb467-f16f-421f-aa22-5fbf822c7c2a", "node_type": "1", "metadata": {"window": "I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n", "original_text": "I know you talked about Medical basis, but you see \nnow coming at the low end of the range . "}, "hash": "d57b22a3b1dd00e4f4e03f150ba5d73ef50db760e7d30bc26be825599ba62576", "class_name": "RelatedNodeInfo"}}, "text": "It seems like \nthere's more opportunity for upside on your EPS . ", "start_char_idx": 1328, "end_char_idx": 1393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "220fb467-f16f-421f-aa22-5fbf822c7c2a": {"__data__": {"id_": "220fb467-f16f-421f-aa22-5fbf822c7c2a", "embedding": null, "metadata": {"window": "I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n", "original_text": "I know you talked about Medical basis, but you see \nnow coming at the low end of the range . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85c5126f-8b70-40a0-9642-1a51b8bddc17", "node_type": "1", "metadata": {"window": "So just to parse through your \nnumbers a little bit .  I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too . ", "original_text": "It seems like \nthere's more opportunity for upside on your EPS . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf5219815a100a82e414d9c179a6e4a87e5f840b5aead9ee724ba3e7e67a1fce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fed5e84c-2804-4db7-9495-17e54d08cd9c", "node_type": "1", "metadata": {"window": "You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah . ", "original_text": "But can you give us some of the other potential concerns or \nheadwinds that are built into this number?  "}, "hash": "fd4af5babc2f3dd9f5dfe7e50d76ac37518187b9ee297c1d04f11e33aab75cbb", "class_name": "RelatedNodeInfo"}}, "text": "I know you talked about Medical basis, but you see \nnow coming at the low end of the range . ", "start_char_idx": 1393, "end_char_idx": 1486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fed5e84c-2804-4db7-9495-17e54d08cd9c": {"__data__": {"id_": "fed5e84c-2804-4db7-9495-17e54d08cd9c", "embedding": null, "metadata": {"window": "You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah . ", "original_text": "But can you give us some of the other potential concerns or \nheadwinds that are built into this number?  ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "220fb467-f16f-421f-aa22-5fbf822c7c2a", "node_type": "1", "metadata": {"window": "I just want to get a sense .  You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n", "original_text": "I know you talked about Medical basis, but you see \nnow coming at the low end of the range . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ce2785c41b79b763b47fe85951b54f277d4ecedef37f6f9bcfd309268b0e8a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "031ad419-3264-4c18-9bb2-9bb69813d811", "node_type": "1", "metadata": {"window": "It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael . ", "original_text": "Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too . "}, "hash": "51330e9f44e04926a6edc14f79a05d68bf21991cff82c5e98cef7dca93de26ed", "class_name": "RelatedNodeInfo"}}, "text": "But can you give us some of the other potential concerns or \nheadwinds that are built into this number?  ", "start_char_idx": 1486, "end_char_idx": 1591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "031ad419-3264-4c18-9bb2-9bb69813d811": {"__data__": {"id_": "031ad419-3264-4c18-9bb2-9bb69813d811", "embedding": null, "metadata": {"window": "It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael . ", "original_text": "Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fed5e84c-2804-4db7-9495-17e54d08cd9c", "node_type": "1", "metadata": {"window": "You've had strong outperformance here to date based \non typical timing and annualization and what you're calling for relative to growth rates .  It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah . ", "original_text": "But can you give us some of the other potential concerns or \nheadwinds that are built into this number?  ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5919d44921fbe8798a2f3f8de604168ce4375781dab3ee0be0ccf3f2424bc03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06848ef4-da9c-40ce-9428-2d9ef5cd5fa4", "node_type": "1", "metadata": {"window": "I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n", "original_text": "So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n"}, "hash": "514b3cbe5eabe51c277f2d523ed88df07b5338c8964c76f93f244372c4d1e0e7", "class_name": "RelatedNodeInfo"}}, "text": "Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too . ", "start_char_idx": 1591, "end_char_idx": 1708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06848ef4-da9c-40ce-9428-2d9ef5cd5fa4": {"__data__": {"id_": "06848ef4-da9c-40ce-9428-2d9ef5cd5fa4", "embedding": null, "metadata": {"window": "I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n", "original_text": "So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "031ad419-3264-4c18-9bb2-9bb69813d811", "node_type": "1", "metadata": {"window": "It seems like \nthere's more opportunity for upside on your EPS .  I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael . ", "original_text": "Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85df3a49167c202591d45a713035a580462f037290d178e581ff765e3779d7fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f1efa0c-9715-47df-96d7-13eaf68a33af", "node_type": "1", "metadata": {"window": "But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher . ", "original_text": "Jason Hollar:  Yeah . "}, "hash": "dca7b93d4e10e20b92bbae23b56cfa95628bb2c68b65a75cc7ba7a175fbd8fc6", "class_name": "RelatedNodeInfo"}}, "text": "So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n", "start_char_idx": 1708, "end_char_idx": 1835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f1efa0c-9715-47df-96d7-13eaf68a33af": {"__data__": {"id_": "7f1efa0c-9715-47df-96d7-13eaf68a33af", "embedding": null, "metadata": {"window": "But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher . ", "original_text": "Jason Hollar:  Yeah . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06848ef4-da9c-40ce-9428-2d9ef5cd5fa4", "node_type": "1", "metadata": {"window": "I know you talked about Medical basis, but you see \nnow coming at the low end of the range .  But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n", "original_text": "So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c51b99f1644978db252b1178c465ac04a1999b739f08320f3e7629b16a299f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3546f48b-3cf2-4778-874c-4b02103b4c71", "node_type": "1", "metadata": {"window": "Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf. ", "original_text": "Thanks, Michael . "}, "hash": "22e74397ef17d633f56dfb39a2bfffb94d3098eb417f733eb4e2da2f71e257f0", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah . ", "start_char_idx": 1835, "end_char_idx": 1857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3546f48b-3cf2-4778-874c-4b02103b4c71": {"__data__": {"id_": "3546f48b-3cf2-4778-874c-4b02103b4c71", "embedding": null, "metadata": {"window": "Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf. ", "original_text": "Thanks, Michael . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f1efa0c-9715-47df-96d7-13eaf68a33af", "node_type": "1", "metadata": {"window": "But can you give us some of the other potential concerns or \nheadwinds that are built into this number?   Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher . ", "original_text": "Jason Hollar:  Yeah . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99ba82e0990fe70cf6e90210635b60b0b80bfb8f02623fd8baad9ac33d4e853e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "850b9995-4ad7-405e-9a8b-4b84cb04d7b3", "node_type": "1", "metadata": {"window": "So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n", "original_text": "First of all, overall, I think it's a balanced outlook that we have . \n"}, "hash": "d272ca95a0504dda8d332a2501bbbe9cfa6ac9c9b4dbc5d8f227cf02473ed5f5", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Michael . ", "start_char_idx": 1857, "end_char_idx": 1875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "850b9995-4ad7-405e-9a8b-4b84cb04d7b3": {"__data__": {"id_": "850b9995-4ad7-405e-9a8b-4b84cb04d7b3", "embedding": null, "metadata": {"window": "So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n", "original_text": "First of all, overall, I think it's a balanced outlook that we have . \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3546f48b-3cf2-4778-874c-4b02103b4c71", "node_type": "1", "metadata": {"window": "Mathematically, you could argue that your EPS baseline \nshould be higher, and annualising it, you'd get there, too .  So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf. ", "original_text": "Thanks, Michael . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e9b40e4c67b50024eece1707933a1a06152777262b66ace08828bcebd0f310b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e614fda0-35e8-42fd-a892-c8ca2c67143d", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll. ", "original_text": "I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher . "}, "hash": "48931983dc2e02ae314ad3552108798f5f923d82cb64640ae3e2b4742fc0d057", "class_name": "RelatedNodeInfo"}}, "text": "First of all, overall, I think it's a balanced outlook that we have . \n", "start_char_idx": 1875, "end_char_idx": 1946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e614fda0-35e8-42fd-a892-c8ca2c67143d": {"__data__": {"id_": "e614fda0-35e8-42fd-a892-c8ca2c67143d", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll. ", "original_text": "I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "850b9995-4ad7-405e-9a8b-4b84cb04d7b3", "node_type": "1", "metadata": {"window": "So I want to make sure I understand al l of \nthe I guess takes against the positive puts that you update in your guidance.  \n \n Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n", "original_text": "First of all, overall, I think it's a balanced outlook that we have . \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be32ffe99013a48bc40ee361931fc9a5e0e2fae7fb3b5ee89427ad7cdce537ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "243ef65e-9242-46e0-9dd1-e546c6e93e72", "node_type": "1", "metadata": {"window": "Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year . ", "original_text": "We expect it to be higher in the second \nhalf. "}, "hash": "58e469b1b7e2ef3a1f17ba7bf882028f08c3c03d600839f957d51b358188e0c1", "class_name": "RelatedNodeInfo"}}, "text": "I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher . ", "start_char_idx": 1946, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "243ef65e-9242-46e0-9dd1-e546c6e93e72": {"__data__": {"id_": "243ef65e-9242-46e0-9dd1-e546c6e93e72", "embedding": null, "metadata": {"window": "Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year . ", "original_text": "We expect it to be higher in the second \nhalf. ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e614fda0-35e8-42fd-a892-c8ca2c67143d", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah .  Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll. ", "original_text": "I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b37c90f7bba0bc53589625d22c00ba83c8fdc26a7848af31393a1c01d16de204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cccf96d8-0e2e-42c6-96a1-39a277695418", "node_type": "1", "metadata": {"window": "First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year . ", "original_text": "So that's one of the components you're thinking about from an EPS driver.  \n \n"}, "hash": "81d019758079b833d4d0c0db5c8d76d49a70d2a604ab5d6575b0663b0e6ca849", "class_name": "RelatedNodeInfo"}}, "text": "We expect it to be higher in the second \nhalf. ", "start_char_idx": 2112, "end_char_idx": 2159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cccf96d8-0e2e-42c6-96a1-39a277695418": {"__data__": {"id_": "cccf96d8-0e2e-42c6-96a1-39a277695418", "embedding": null, "metadata": {"window": "First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year . ", "original_text": "So that's one of the components you're thinking about from an EPS driver.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "243ef65e-9242-46e0-9dd1-e546c6e93e72", "node_type": "1", "metadata": {"window": "Thanks, Michael .  First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year . ", "original_text": "We expect it to be higher in the second \nhalf. ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18a54be1da5999440d765ca419a3b9323b47798063adfe86f2a1f125be8625b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "111b3192-da75-486d-b8ad-1eac52751347", "node_type": "1", "metadata": {"window": "I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic . ", "original_text": "And then Pharma is a key driver as we ll. "}, "hash": "2e13f8994e64daed1cfd7ce47c469d57f7c0d452010967851daa86c4f6a81028", "class_name": "RelatedNodeInfo"}}, "text": "So that's one of the components you're thinking about from an EPS driver.  \n \n", "start_char_idx": 2159, "end_char_idx": 2237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "111b3192-da75-486d-b8ad-1eac52751347": {"__data__": {"id_": "111b3192-da75-486d-b8ad-1eac52751347", "embedding": null, "metadata": {"window": "I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic . ", "original_text": "And then Pharma is a key driver as we ll. ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cccf96d8-0e2e-42c6-96a1-39a277695418", "node_type": "1", "metadata": {"window": "First of all, overall, I think it's a balanced outlook that we have . \n I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year . ", "original_text": "So that's one of the components you're thinking about from an EPS driver.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8aca7543569d616ce2ff48cdcdcf45f2cd03701fea9279f36d184fdd2784cb06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06885133-ba00-49ad-b9a4-883eb7a2e3ac", "node_type": "1", "metadata": {"window": "We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced . ", "original_text": "Still solid growth in the middle of that range that we had at \nthe beginning of the year . "}, "hash": "9e661514bddb2a64ea74047f3737110c4f1efdd617ce44d3a9519cae5b6f52e5", "class_name": "RelatedNodeInfo"}}, "text": "And then Pharma is a key driver as we ll. ", "start_char_idx": 2237, "end_char_idx": 2279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06885133-ba00-49ad-b9a4-883eb7a2e3ac": {"__data__": {"id_": "06885133-ba00-49ad-b9a4-883eb7a2e3ac", "embedding": null, "metadata": {"window": "We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced . ", "original_text": "Still solid growth in the middle of that range that we had at \nthe beginning of the year . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "111b3192-da75-486d-b8ad-1eac52751347", "node_type": "1", "metadata": {"window": "I think a couple of the key drivers of the first half, second hal f, I just went through on Elizabeth's \nquestion, you know, interest expense is going to be higher .  We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic . ", "original_text": "And then Pharma is a key driver as we ll. ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c15a89f9ea2a73f3ed6af17014e1a04c5b257d2957329a62e05928891c56f28f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5154d0de-65cc-421a-945a-072c43bec20e", "node_type": "1", "metadata": {"window": "So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation . ", "original_text": "Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year . "}, "hash": "475d72077588595dec9f7e509354271d1625b03617b4c36a259069e3c590d234", "class_name": "RelatedNodeInfo"}}, "text": "Still solid growth in the middle of that range that we had at \nthe beginning of the year . ", "start_char_idx": 2279, "end_char_idx": 2370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5154d0de-65cc-421a-945a-072c43bec20e": {"__data__": {"id_": "5154d0de-65cc-421a-945a-072c43bec20e", "embedding": null, "metadata": {"window": "So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation . ", "original_text": "Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06885133-ba00-49ad-b9a4-883eb7a2e3ac", "node_type": "1", "metadata": {"window": "We expect it to be higher in the second \nhalf.  So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced . ", "original_text": "Still solid growth in the middle of that range that we had at \nthe beginning of the year . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "049ef32c9f7aa0f8352e6c77280e40c71078898d63b2d9b5b3871f75715337d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5935cdb-1629-4aa0-bde2-1f359492f7a2", "node_type": "1", "metadata": {"window": "And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight . ", "original_text": "So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic . "}, "hash": "efe48fa028309947aef2be09f85129311b6c86255e51f34b6a9ac06a5cdc2852", "class_name": "RelatedNodeInfo"}}, "text": "Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year . ", "start_char_idx": 2370, "end_char_idx": 2581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5935cdb-1629-4aa0-bde2-1f359492f7a2": {"__data__": {"id_": "e5935cdb-1629-4aa0-bde2-1f359492f7a2", "embedding": null, "metadata": {"window": "And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight . ", "original_text": "So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5154d0de-65cc-421a-945a-072c43bec20e", "node_type": "1", "metadata": {"window": "So that's one of the components you're thinking about from an EPS driver.  \n \n And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation . ", "original_text": "Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e89433679f4c99ba8053c367df4136795b62b8b57e1fe854b393c2ea9792914d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59730801-8ae2-4246-8d31-de5764fc6e16", "node_type": "1", "metadata": {"window": "Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined . ", "original_text": "And we think overall that 's balanced . "}, "hash": "b49e8ef4f26e96f3c421e996be90322008ed9e8ae9e53653565710044ab21d76", "class_name": "RelatedNodeInfo"}}, "text": "So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic . ", "start_char_idx": 2581, "end_char_idx": 2771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59730801-8ae2-4246-8d31-de5764fc6e16": {"__data__": {"id_": "59730801-8ae2-4246-8d31-de5764fc6e16", "embedding": null, "metadata": {"window": "Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined . ", "original_text": "And we think overall that 's balanced . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5935cdb-1629-4aa0-bde2-1f359492f7a2", "node_type": "1", "metadata": {"window": "And then Pharma is a key driver as we ll.  Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight . ", "original_text": "So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b4d877514e5155622f6c867c8932f8d8dd6a61cb97fcf5c57d3de04536c6353", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52fa0572-2903-4fc8-83e2-dba261943491", "node_type": "1", "metadata": {"window": "Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n", "original_text": "Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation . "}, "hash": "a505dca68d937b3e890bf78900409af5204aa3817fa28d42610b92034012a8fc", "class_name": "RelatedNodeInfo"}}, "text": "And we think overall that 's balanced . ", "start_char_idx": 2771, "end_char_idx": 2811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52fa0572-2903-4fc8-83e2-dba261943491": {"__data__": {"id_": "52fa0572-2903-4fc8-83e2-dba261943491", "embedding": null, "metadata": {"window": "Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n", "original_text": "Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59730801-8ae2-4246-8d31-de5764fc6e16", "node_type": "1", "metadata": {"window": "Still solid growth in the middle of that range that we had at \nthe beginning of the year .  Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined . ", "original_text": "And we think overall that 's balanced . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bbc000f8b0fb97d6f23f80138ed7b5ed1047bc032ec1219c6b42aab8f3c0b3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff6e5005-b972-4c34-9f00-4ccafb875d9a", "node_type": "1", "metadata": {"window": "So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley . ", "original_text": "And the first instance we would expect of cost stepp ing down \nas it relates to the international freight . "}, "hash": "1b3a273b076fb318289013a81a3ef3a90b38b29737a249914709d57317c70ced", "class_name": "RelatedNodeInfo"}}, "text": "Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation . ", "start_char_idx": 2811, "end_char_idx": 3005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff6e5005-b972-4c34-9f00-4ccafb875d9a": {"__data__": {"id_": "ff6e5005-b972-4c34-9f00-4ccafb875d9a", "embedding": null, "metadata": {"window": "So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley . ", "original_text": "And the first instance we would expect of cost stepp ing down \nas it relates to the international freight . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52fa0572-2903-4fc8-83e2-dba261943491", "node_type": "1", "metadata": {"window": "Not at the same pace of growth that we had in the first half, but still growth \nand also just to kind of step back a little bit and we had a similar level of growth , about 5% growth in \nthe prior fiscal year .  So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n", "original_text": "Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7db04e19146d806387dd157d2ac7c6bf62afc0792ede4ce218747cdaf447df26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbc74f0a-16a5-4043-ba0b-ec515f127ee4", "node_type": "1", "metadata": {"window": "And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "But all the other drivers, I think are fairly consistent with what \nwe outlined . "}, "hash": "cafb231ad5260a0a870110e91818004ecae7452fdfb7246e29dcea80ec7e6232", "class_name": "RelatedNodeInfo"}}, "text": "And the first instance we would expect of cost stepp ing down \nas it relates to the international freight . ", "start_char_idx": 3005, "end_char_idx": 3113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbc74f0a-16a5-4043-ba0b-ec515f127ee4": {"__data__": {"id_": "cbc74f0a-16a5-4043-ba0b-ec515f127ee4", "embedding": null, "metadata": {"window": "And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "But all the other drivers, I think are fairly consistent with what \nwe outlined . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff6e5005-b972-4c34-9f00-4ccafb875d9a", "node_type": "1", "metadata": {"window": "So now we're on 18 to 24 months, a pretty consistent, stable, much more \npredictable type of growth that we've seen in that business as we step farther and farther away from \nthe pandemic .  And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley . ", "original_text": "And the first instance we would expect of cost stepp ing down \nas it relates to the international freight . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7bc0aea25f29a5b31d5b74631560a98bfb040226bd6c174c396b6086f1aa28d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68936f94-5472-49ff-b673-39a36faef873", "node_type": "1", "metadata": {"window": "Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "Next q uestion, please.  \n \n"}, "hash": "64f931b8c35e0f0e9fa8e37783ba1d98e7de2a7e525cd7a946248afc8b6dc6d8", "class_name": "RelatedNodeInfo"}}, "text": "But all the other drivers, I think are fairly consistent with what \nwe outlined . ", "start_char_idx": 3113, "end_char_idx": 3195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68936f94-5472-49ff-b673-39a36faef873": {"__data__": {"id_": "68936f94-5472-49ff-b673-39a36faef873", "embedding": null, "metadata": {"window": "Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "Next q uestion, please.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbc74f0a-16a5-4043-ba0b-ec515f127ee4", "node_type": "1", "metadata": {"window": "And we think overall that 's balanced .  Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "But all the other drivers, I think are fairly consistent with what \nwe outlined . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07c9f6f27240187c24e4040641b1f49329fea2e5f791ca0e55df534d46ea552d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d3f760c-aae6-46ba-b6f7-e4627b305245", "node_type": "1", "metadata": {"window": "And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley . "}, "hash": "0705f3ed85281bc0a29a4e7c1290d06fec9176db202b90871f7f1a4357bafa20", "class_name": "RelatedNodeInfo"}}, "text": "Next q uestion, please.  \n \n", "start_char_idx": 3195, "end_char_idx": 3223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d3f760c-aae6-46ba-b6f7-e4627b305245": {"__data__": {"id_": "7d3f760c-aae6-46ba-b6f7-e4627b305245", "embedding": null, "metadata": {"window": "And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68936f94-5472-49ff-b673-39a36faef873", "node_type": "1", "metadata": {"window": "Of course, in the second half of the year, there's \na meaningful step up in the Medical segment performance and that's, of course, being driven more \nthan anything by the pricing on inflation .  And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "Next q uestion, please.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0c0322d3efe8add528fa9e3d23206d4a7592f622451b29d073992b89606e844", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c975000f-a168-4cff-8112-24bd9173bc7a", "node_type": "1", "metadata": {"window": "But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "Please \ngo ahead.  \n "}, "hash": "8af0e0bcc87779a3b0525397f9976fb67c96b75dd3b672cef34911dda40d79c5", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley . ", "start_char_idx": 3223, "end_char_idx": 3318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c975000f-a168-4cff-8112-24bd9173bc7a": {"__data__": {"id_": "c975000f-a168-4cff-8112-24bd9173bc7a", "embedding": null, "metadata": {"window": "But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "Please \ngo ahead.  \n ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c12d09399da6fc28bfd781a543aa6f0023a553421eed1c2b13bcd337d26e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d3f760c-aae6-46ba-b6f7-e4627b305245", "node_type": "1", "metadata": {"window": "And the first instance we would expect of cost stepp ing down \nas it relates to the international freight .  But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34fbddd7a8472dd473a2addec03241f78384fa29f9b61c1833d6d3402118d22f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1435194-9a41-410f-ae56-5b2eb1eb7ef4", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?  ", "original_text": " \nPage 11 of 16 \n \nErin Wright:  Thanks . "}, "hash": "3010bc6aa776f587a2b2fd635965dbd866d3dec5881ec56b70beb966f82c4013", "class_name": "RelatedNodeInfo"}}, "text": "Please \ngo ahead.  \n ", "start_char_idx": 3318, "end_char_idx": 3339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1435194-9a41-410f-ae56-5b2eb1eb7ef4": {"__data__": {"id_": "c1435194-9a41-410f-ae56-5b2eb1eb7ef4", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?  ", "original_text": " \nPage 11 of 16 \n \nErin Wright:  Thanks . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c975000f-a168-4cff-8112-24bd9173bc7a", "node_type": "1", "metadata": {"window": "But all the other drivers, I think are fairly consistent with what \nwe outlined .  Next q uestion, please.  \n \n Operator:  The next question comes from the line of Erin W right calling from Morgan Stanley .  Please \ngo ahead.  \n ", "original_text": "Please \ngo ahead.  \n ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0073fd8f04d095c856ccb21c4255b593758acc1a791eed47673ee5e09aa30382", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7ae1e7e-6260-4352-b8bb-e2cd298c1d13", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n", "original_text": "So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there . "}, "hash": "8c3ef9a0e3ca38447faedd6da503e390b693a04190e720d8972bb0235f031dbd", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 16 \n \nErin Wright:  Thanks . ", "start_char_idx": 0, "end_char_idx": 42, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7ae1e7e-6260-4352-b8bb-e2cd298c1d13": {"__data__": {"id_": "e7ae1e7e-6260-4352-b8bb-e2cd298c1d13", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n", "original_text": "So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1435194-9a41-410f-ae56-5b2eb1eb7ef4", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?  ", "original_text": " \nPage 11 of 16 \n \nErin Wright:  Thanks . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5905e324915ac1e7214572a6bdeccb5951132d4b6fdfd9690b831cb099e56158", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6a1beb5-fbe5-4269-9c49-6cfd7f9d8d62", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin . ", "original_text": "But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?  "}, "hash": "98612fb7df0387b03d95a4b39fa20dfc971b03ea34dd5065f126ef176849a2b7", "class_name": "RelatedNodeInfo"}}, "text": "So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there . ", "start_char_idx": 42, "end_char_idx": 166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6a1beb5-fbe5-4269-9c49-6cfd7f9d8d62": {"__data__": {"id_": "e6a1beb5-fbe5-4269-9c49-6cfd7f9d8d62", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin . ", "original_text": "But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?  ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7ae1e7e-6260-4352-b8bb-e2cd298c1d13", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n", "original_text": "So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd79028e2af0767e2b4cfe53c107c0e179453bc9b1ad7f8302ea16ba4b68a91f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b99335b-ad31-4f71-81ea-1de759a4ecf6", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook . ", "original_text": "And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?  "}, "hash": "f681aecc37e5d3bf18c0277239637b3f2da8f0dfbba641e1c6eebf6e8f452716", "class_name": "RelatedNodeInfo"}}, "text": "But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?  ", "start_char_idx": 166, "end_char_idx": 288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b99335b-ad31-4f71-81ea-1de759a4ecf6": {"__data__": {"id_": "5b99335b-ad31-4f71-81ea-1de759a4ecf6", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook . ", "original_text": "And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?  ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6a1beb5-fbe5-4269-9c49-6cfd7f9d8d62", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin . ", "original_text": "But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?  ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ba36d2b0d3e97a7e026b88f6ff029bf6e5e7bdbe51051a1ba4f9886ff573ea8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "540753a0-940e-4cf4-b20e-c962947b3aac", "node_type": "1", "metadata": {"window": "So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets . ", "original_text": "Thanks.  \n \n"}, "hash": "262ffeafe56874d5198d6f9ea53ab224d23d2bab547868079e63eba66728f0fe", "class_name": "RelatedNodeInfo"}}, "text": "And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?  ", "start_char_idx": 288, "end_char_idx": 586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "540753a0-940e-4cf4-b20e-c962947b3aac": {"__data__": {"id_": "540753a0-940e-4cf4-b20e-c962947b3aac", "embedding": null, "metadata": {"window": "So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets . ", "original_text": "Thanks.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b99335b-ad31-4f71-81ea-1de759a4ecf6", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook . ", "original_text": "And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?  ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00b3fb40195f5384f7c2c2f99fa9c48b039dc68cecac46b4318d342cb80475bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f805ca83-5187-44e6-8879-dfaf54590c06", "node_type": "1", "metadata": {"window": "But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n", "original_text": "Jason Hollar:  Thanks, Erin . "}, "hash": "6d095d3acd32f2431e015447ffd92178bee56e8d2122526b4fb0ed56a90c8e11", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 586, "end_char_idx": 598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f805ca83-5187-44e6-8879-dfaf54590c06": {"__data__": {"id_": "f805ca83-5187-44e6-8879-dfaf54590c06", "embedding": null, "metadata": {"window": "But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n", "original_text": "Jason Hollar:  Thanks, Erin . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "540753a0-940e-4cf4-b20e-c962947b3aac", "node_type": "1", "metadata": {"window": "So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets . ", "original_text": "Thanks.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e801e1a8633e30adfcdfe92b389757a4ef14c861011d800cf24c79fbb216949", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f53d773-3600-45e3-9077-a2212e204849", "node_type": "1", "metadata": {"window": "And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets . ", "original_text": "Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook . "}, "hash": "56b02d990975695e6163c295fe836f63fdd7bcb8144a378c0f5679ae84431e4e", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Thanks, Erin . ", "start_char_idx": 598, "end_char_idx": 628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f53d773-3600-45e3-9077-a2212e204849": {"__data__": {"id_": "9f53d773-3600-45e3-9077-a2212e204849", "embedding": null, "metadata": {"window": "And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets . ", "original_text": "Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f805ca83-5187-44e6-8879-dfaf54590c06", "node_type": "1", "metadata": {"window": "But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n", "original_text": "Jason Hollar:  Thanks, Erin . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297cd502b979462f567de965b6740af634b4b9c18d31f5f1757f7594d413205f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62bd08d0-3559-43de-997f-198fe6a627bd", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct. ", "original_text": "Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets . "}, "hash": "3f02a49e4da514bbd82a5de7a7a6bca07c2382c4dfa0d27736da06969dd234f2", "class_name": "RelatedNodeInfo"}}, "text": "Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook . ", "start_char_idx": 628, "end_char_idx": 767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62bd08d0-3559-43de-997f-198fe6a627bd": {"__data__": {"id_": "62bd08d0-3559-43de-997f-198fe6a627bd", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct. ", "original_text": "Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f53d773-3600-45e3-9077-a2212e204849", "node_type": "1", "metadata": {"window": "And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?   Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets . ", "original_text": "Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a5a7aa37af2dea36ade554fb97242ee90848af3e8b71c439004b27f012f824a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb99ac05-1337-493a-a6be-3a6958f39740", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that . ", "original_text": "And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n"}, "hash": "2f6c9d2d76901143a63bb6d59cb601be17d575b03bd8d526364e5d4c579cb1d3", "class_name": "RelatedNodeInfo"}}, "text": "Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets . ", "start_char_idx": 767, "end_char_idx": 899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb99ac05-1337-493a-a6be-3a6958f39740": {"__data__": {"id_": "fb99ac05-1337-493a-a6be-3a6958f39740", "embedding": null, "metadata": {"window": "Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that . ", "original_text": "And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62bd08d0-3559-43de-997f-198fe6a627bd", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct. ", "original_text": "Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "708371464b83c675b04dcf1fd5e2d01911525307d4c4e473d9cff08b35537d28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "515b2e66-20fa-4024-9ce4-1f8ce607907a", "node_type": "1", "metadata": {"window": "Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation . ", "original_text": "The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets . "}, "hash": "dbaa990b458700a5880551469745c1ebd565270acc205432e2ee05bf2c43cd24", "class_name": "RelatedNodeInfo"}}, "text": "And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n", "start_char_idx": 899, "end_char_idx": 1066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "515b2e66-20fa-4024-9ce4-1f8ce607907a": {"__data__": {"id_": "515b2e66-20fa-4024-9ce4-1f8ce607907a", "embedding": null, "metadata": {"window": "Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation . ", "original_text": "The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb99ac05-1337-493a-a6be-3a6958f39740", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Erin .  Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that . ", "original_text": "And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67da1f9282d7a77efef33515cf4c1c5a1c09fde329604ef7d87666bc19cb283a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2de379e9-09de-4e98-b4bd-1ec709c42480", "node_type": "1", "metadata": {"window": "Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year . ", "original_text": "Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct. "}, "hash": "9ce07a2854cedfb8884e7b6d2d5f0d0dc015654eb290d90ac23b37fafe4bb693", "class_name": "RelatedNodeInfo"}}, "text": "The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets . ", "start_char_idx": 1066, "end_char_idx": 1179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2de379e9-09de-4e98-b4bd-1ec709c42480": {"__data__": {"id_": "2de379e9-09de-4e98-b4bd-1ec709c42480", "embedding": null, "metadata": {"window": "Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year . ", "original_text": "Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct. ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "515b2e66-20fa-4024-9ce4-1f8ce607907a", "node_type": "1", "metadata": {"window": "Overall, first of all, as I think about fiscal \u201823, it's a fairly normali zed level \nof performance that we have in our curren t outlook .  Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation . ", "original_text": "The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d148ec4608508c5843fe985122d4b8e10e2a919f80bf6ea6f28c2a89c827867b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42c5be59-6ff7-4aac-867d-c9631860be4e", "node_type": "1", "metadata": {"window": "And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n", "original_text": "We participated very little on any of that . "}, "hash": "a929a3969b79d65b71d029ff00be8e95f4800846c00420f3015aee10e040dad5", "class_name": "RelatedNodeInfo"}}, "text": "Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct. ", "start_char_idx": 1179, "end_char_idx": 1290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42c5be59-6ff7-4aac-867d-c9631860be4e": {"__data__": {"id_": "42c5be59-6ff7-4aac-867d-c9631860be4e", "embedding": null, "metadata": {"window": "And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n", "original_text": "We participated very little on any of that . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2de379e9-09de-4e98-b4bd-1ec709c42480", "node_type": "1", "metadata": {"window": "Again, growth for the reasons I highlighted, is a \nlittle bit stronger in the first half than what is in our longer -term targets .  And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year . ", "original_text": "Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct. ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "156207b1b8b9cf2eba915868acc1f90f545a44feb39be64a2be0cf2ac28d4e91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc4c5fe0-8603-4494-bc81-0030a4f86cae", "node_type": "1", "metadata": {"window": "The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year . ", "original_text": "Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation . "}, "hash": "ac9cc1963f08d977cd8f707a3e09274933e88270c753ebdecb59aa3828f6c033", "class_name": "RelatedNodeInfo"}}, "text": "We participated very little on any of that . ", "start_char_idx": 1290, "end_char_idx": 1335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc4c5fe0-8603-4494-bc81-0030a4f86cae": {"__data__": {"id_": "bc4c5fe0-8603-4494-bc81-0030a4f86cae", "embedding": null, "metadata": {"window": "The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year . ", "original_text": "Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42c5be59-6ff7-4aac-867d-c9631860be4e", "node_type": "1", "metadata": {"window": "And we \u2019ve seen  that very \nbroad strength that I would not expect to continue long term at that pace, especially when we \nconsider that incremental new customer.  \n \n The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n", "original_text": "We participated very little on any of that . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15de915aa51b4e3334865b20049ffb440813bde5fb41d8bea18649031b973c28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "344e6acd-2256-48c3-9f65-494cd51d3bb4", "node_type": "1", "metadata": {"window": "Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823. ", "original_text": "Of \ncourse, we're all the way through that at this point in time and have b een so for about a year . "}, "hash": "b129bc13c884e28fb5b426b66de703d3d4b986d6eb70e5592469d0a5b49eb8a8", "class_name": "RelatedNodeInfo"}}, "text": "Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation . ", "start_char_idx": 1335, "end_char_idx": 1472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "344e6acd-2256-48c3-9f65-494cd51d3bb4": {"__data__": {"id_": "344e6acd-2256-48c3-9f65-494cd51d3bb4", "embedding": null, "metadata": {"window": "Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823. ", "original_text": "Of \ncourse, we're all the way through that at this point in time and have b een so for about a year . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc4c5fe0-8603-4494-bc81-0030a4f86cae", "node_type": "1", "metadata": {"window": "The longer term, I think what this year reinforces is that we're on track for those long -term growth \ntargets .  Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year . ", "original_text": "Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c476dcd5aef32bba68ece74482234cfb0731397fdf84a0390e992846c7933a32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b67d4f2f-7a8d-4a3d-aba5-041d3e69c749", "node_type": "1", "metadata": {"window": "We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability . ", "original_text": "So \nwe're at a very normali zed level at this stage .  \n \n"}, "hash": "29239f6f3cf61dffddee946229afcd3fae60c69f7b7e0fde82437b232523c527", "class_name": "RelatedNodeInfo"}}, "text": "Of \ncourse, we're all the way through that at this point in time and have b een so for about a year . ", "start_char_idx": 1472, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b67d4f2f-7a8d-4a3d-aba5-041d3e69c749": {"__data__": {"id_": "b67d4f2f-7a8d-4a3d-aba5-041d3e69c749", "embedding": null, "metadata": {"window": "We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability . ", "original_text": "So \nwe're at a very normali zed level at this stage .  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "344e6acd-2256-48c3-9f65-494cd51d3bb4", "node_type": "1", "metadata": {"window": "Specifically to your question around COVID therapies and vaccines, you have it, your \ninclination is corre ct.  We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823. ", "original_text": "Of \ncourse, we're all the way through that at this point in time and have b een so for about a year . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f00dfe136d6d86ec40f503160f7feb0dea615ca710ba249dbcd22102f2a53e5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f91f5dbf-ebc2-46b9-af41-078a3260f1e3", "node_type": "1", "metadata": {"window": "Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that . ", "original_text": "As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year . "}, "hash": "b185f8b8adbac2dfd53bed2e8a2ebd5d6ab646bed61aa70c35ac3267fa64e6d9", "class_name": "RelatedNodeInfo"}}, "text": "So \nwe're at a very normali zed level at this stage .  \n \n", "start_char_idx": 1574, "end_char_idx": 1632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f91f5dbf-ebc2-46b9-af41-078a3260f1e3": {"__data__": {"id_": "f91f5dbf-ebc2-46b9-af41-078a3260f1e3", "embedding": null, "metadata": {"window": "Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that . ", "original_text": "As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b67d4f2f-7a8d-4a3d-aba5-041d3e69c749", "node_type": "1", "metadata": {"window": "We participated very little on any of that .  Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability . ", "original_text": "So \nwe're at a very normali zed level at this stage .  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "277997ca1a4bf70dbd6715f903d04643d7f663e519b66bbe76b1520c140eaaf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0752e085-1f39-4d98-aac0-2f66d5df6b30", "node_type": "1", "metadata": {"window": "Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.  ", "original_text": "So certainly no impacts for \u201823. "}, "hash": "98802d1a95142345365f9a149b1d68a986e0c19240b94fb3911b82a37882dfa6", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year . ", "start_char_idx": 1632, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0752e085-1f39-4d98-aac0-2f66d5df6b30": {"__data__": {"id_": "0752e085-1f39-4d98-aac0-2f66d5df6b30", "embedding": null, "metadata": {"window": "Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.  ", "original_text": "So certainly no impacts for \u201823. ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f91f5dbf-ebc2-46b9-af41-078a3260f1e3", "node_type": "1", "metadata": {"window": "Over the pandemic, frankly, we've had \nmore of a headwind than a tailwind because of the volume impacts on our underlying utili zation .  Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that . ", "original_text": "As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8f4e77112a9483f64cd05db047b21b0e2c32512e5031f2c7827bb6e5be1c0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bfb7098-4c78-4911-ac57-6a470f19e0d8", "node_type": "1", "metadata": {"window": "So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through . ", "original_text": "There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability . "}, "hash": "2b07db8f277d01ba5daf985540aff9f58c9470be1796f8636f95f9a3f07bb48a", "class_name": "RelatedNodeInfo"}}, "text": "So certainly no impacts for \u201823. ", "start_char_idx": 1772, "end_char_idx": 1805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bfb7098-4c78-4911-ac57-6a470f19e0d8": {"__data__": {"id_": "4bfb7098-4c78-4911-ac57-6a470f19e0d8", "embedding": null, "metadata": {"window": "So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through . ", "original_text": "There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0752e085-1f39-4d98-aac0-2f66d5df6b30", "node_type": "1", "metadata": {"window": "Of \ncourse, we're all the way through that at this point in time and have b een so for about a year .  So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.  ", "original_text": "So certainly no impacts for \u201823. ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b26b904e782a12d5608993e672b86c1bfd2c911e3b82e0261cff759dc695f3dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bbb7d85-691c-410f-aa74-795bc5b1f525", "node_type": "1", "metadata": {"window": "As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources . ", "original_text": "So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that . "}, "hash": "c8b85aa791a7076e1cf08b760a97a0ecd63303032f0aca78a34b2791fdebdd93", "class_name": "RelatedNodeInfo"}}, "text": "There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability . ", "start_char_idx": 1805, "end_char_idx": 2031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bbb7d85-691c-410f-aa74-795bc5b1f525": {"__data__": {"id_": "0bbb7d85-691c-410f-aa74-795bc5b1f525", "embedding": null, "metadata": {"window": "As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources . ", "original_text": "So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bfb7098-4c78-4911-ac57-6a470f19e0d8", "node_type": "1", "metadata": {"window": "So \nwe're at a very normali zed level at this stage .  \n \n As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through . ", "original_text": "There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f486c44509599c829cac013318b30d0a1b25fa8c75d8b1a16f8b1e2cd364845c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e1095e4-e7d5-4b15-a416-ef5caa089c87", "node_type": "1", "metadata": {"window": "So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n", "original_text": "So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.  "}, "hash": "e7b1426b15913cdc6311c1e9b47d6fe423234da9ef783599688bf477c5aa2497", "class_name": "RelatedNodeInfo"}}, "text": "So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that . ", "start_char_idx": 2031, "end_char_idx": 2267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e1095e4-e7d5-4b15-a416-ef5caa089c87": {"__data__": {"id_": "6e1095e4-e7d5-4b15-a416-ef5caa089c87", "embedding": null, "metadata": {"window": "So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n", "original_text": "So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.  ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bbb7d85-691c-410f-aa74-795bc5b1f525", "node_type": "1", "metadata": {"window": "As it relates to commerciali zation, I think all data points point to that beginning in the summertime, of \ncourse, after our fiscal year .  So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources . ", "original_text": "So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea3f7e15ae5de58d0a9c1c60a22ab6db433df8884bf2e1c97a32bb46134d4240", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae036f55-355c-4729-b77d-3b68d137baac", "node_type": "1", "metadata": {"window": "There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank . ", "original_text": "And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through . "}, "hash": "3b96cf93279c612b336155e6e6e916cec456068407289c215c12630420b2553d", "class_name": "RelatedNodeInfo"}}, "text": "So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.  ", "start_char_idx": 2267, "end_char_idx": 2441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae036f55-355c-4729-b77d-3b68d137baac": {"__data__": {"id_": "ae036f55-355c-4729-b77d-3b68d137baac", "embedding": null, "metadata": {"window": "There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank . ", "original_text": "And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e1095e4-e7d5-4b15-a416-ef5caa089c87", "node_type": "1", "metadata": {"window": "So certainly no impacts for \u201823.  There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n", "original_text": "So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.  ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "689b6c3c54c0afc40480075a7ac1e7e1cd0907032ed3d126e88c6b0729a4efcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10c25cc7-f610-4e0a-8ca5-8aca76d8ae98", "node_type": "1", "metadata": {"window": "So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n", "original_text": "So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources . "}, "hash": "47df20c8bf44d02ac96b1b910154b6b768840b4efcae7f36de088c8da66d16ce", "class_name": "RelatedNodeInfo"}}, "text": "And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through . ", "start_char_idx": 2441, "end_char_idx": 2709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10c25cc7-f610-4e0a-8ca5-8aca76d8ae98": {"__data__": {"id_": "10c25cc7-f610-4e0a-8ca5-8aca76d8ae98", "embedding": null, "metadata": {"window": "So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n", "original_text": "So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae036f55-355c-4729-b77d-3b68d137baac", "node_type": "1", "metadata": {"window": "There wo uld be some opportunities for \n\u201824 and beyond, however, I'd highlight the types of products and vaccines we're talking about, \nhistorically outside of the pandemic have not been significant drivers of profitability .  So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank . ", "original_text": "And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94058e3dc9d5887cb3d4de1ef48e359ebaa1b038bc5696d4a5dccc41967061b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1659e96c-1249-4f7f-a4b8-c45161884243", "node_type": "1", "metadata": {"window": "So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah . ", "original_text": "Next question, please.  \n \n"}, "hash": "a35ba67397406a5fc12f8f853a13ed0fce686adf9a879433b1162abc4c841794", "class_name": "RelatedNodeInfo"}}, "text": "So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources . ", "start_char_idx": 2709, "end_char_idx": 2831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1659e96c-1249-4f7f-a4b8-c45161884243": {"__data__": {"id_": "1659e96c-1249-4f7f-a4b8-c45161884243", "embedding": null, "metadata": {"window": "So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah . ", "original_text": "Next question, please.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10c25cc7-f610-4e0a-8ca5-8aca76d8ae98", "node_type": "1", "metadata": {"window": "So it's something \nthat should be a tailwin d, but I would not jump to the conclusion that it will be as significant as what \nwe've seen in the marketplace for others, given how the government had isolated that and procured \nfor that .  So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n", "original_text": "So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb94476fcd69ad09e610718872beadd8292b1605ab92f00c44ef2af71360c94b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17d2613d-5cf2-4190-8db4-dc26857f3bb5", "node_type": "1", "metadata": {"window": "And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question . ", "original_text": "Operator:  The next question comes from the line of George Hill calling from Deutsche Bank . "}, "hash": "e6f5f9ef2853fc06da301a003bd7627c7aa59788bf5239333eb6318cf77727cf", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n \n", "start_char_idx": 2831, "end_char_idx": 2858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17d2613d-5cf2-4190-8db4-dc26857f3bb5": {"__data__": {"id_": "17d2613d-5cf2-4190-8db4-dc26857f3bb5", "embedding": null, "metadata": {"window": "And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question . ", "original_text": "Operator:  The next question comes from the line of George Hill calling from Deutsche Bank . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1659e96c-1249-4f7f-a4b8-c45161884243", "node_type": "1", "metadata": {"window": "So something we'll keep an eye on and clearly something we'll be pr oviding some context for \nfurther as we understand it better and as we get closer at that point in time.   And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah . ", "original_text": "Next question, please.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c985fe720c037a815ba4b0e77f252508b550e402f5c4788b3d12863e2fc17a58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a8442e7-a61e-4358-a735-9bbe4a56128a", "node_type": "1", "metadata": {"window": "So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high . ", "original_text": "Please \ngo ahead.  \n \n"}, "hash": "d32aad29540ad74ac4e7b940e009045798e97b1d65d884f37007dc6f898a2c8b", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from the line of George Hill calling from Deutsche Bank . ", "start_char_idx": 2858, "end_char_idx": 2951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a8442e7-a61e-4358-a735-9bbe4a56128a": {"__data__": {"id_": "8a8442e7-a61e-4358-a735-9bbe4a56128a", "embedding": null, "metadata": {"window": "So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high . ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17d2613d-5cf2-4190-8db4-dc26857f3bb5", "node_type": "1", "metadata": {"window": "And the one final point on \nthat is even though the commerciali zation is scheduled for the summer, there is certainly a lot of \ndialogue and uncertainty a s to exactly how much is stockpiled within the government and how long \nwill it take for that to work through .  So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question . ", "original_text": "Operator:  The next question comes from the line of George Hill calling from Deutsche Bank . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd356fb6a1a30196eb3bc59166b0d07e07b248f731a44673af7712cd89a9993c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18285ec5-a5ab-4e52-ab3b-013bf8c90998", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n", "original_text": "George Hill:   Yeah . "}, "hash": "c1563c06e612247ded37ab3336369529d3f417af85ae0a4d00c86e2c129fdbef", "class_name": "RelatedNodeInfo"}}, "text": "Please \ngo ahead.  \n \n", "start_char_idx": 2951, "end_char_idx": 2973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18285ec5-a5ab-4e52-ab3b-013bf8c90998": {"__data__": {"id_": "18285ec5-a5ab-4e52-ab3b-013bf8c90998", "embedding": null, "metadata": {"window": "Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n", "original_text": "George Hill:   Yeah . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a8442e7-a61e-4358-a735-9bbe4a56128a", "node_type": "1", "metadata": {"window": "So while it may go commercial, it could take us some time to \nactually see a pull in terms of non -governmental sources .  Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high . ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "453446bc865fc0e35ac7c0d95e52224e6d1fabc40274bd9c778f7e24d0d4fed8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67d9fcd2-45ac-4a61-8d7e-e1de1296554f", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "Good morning, guys, and I appreciate you taking the question . "}, "hash": "a3b9b9f012cedba5f0e38062d9fa694acffca7c05724a4ea2f09f6f889b91a18", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:   Yeah . ", "start_char_idx": 2973, "end_char_idx": 2995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67d9fcd2-45ac-4a61-8d7e-e1de1296554f": {"__data__": {"id_": "67d9fcd2-45ac-4a61-8d7e-e1de1296554f", "embedding": null, "metadata": {"window": "Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "Good morning, guys, and I appreciate you taking the question . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18285ec5-a5ab-4e52-ab3b-013bf8c90998", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n", "original_text": "George Hill:   Yeah . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "063c1903b076a7bd63a089d912926df534b07f44c6ca0c9e8fc218fdb466a9e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcb28e19-ffb9-4988-b277-3e3daacbecf9", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high . "}, "hash": "242e9c8033b32a0600398129912e8b987ad8793addc0fb3b662f76c4ed357837", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, guys, and I appreciate you taking the question . ", "start_char_idx": 2995, "end_char_idx": 3058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcb28e19-ffb9-4988-b277-3e3daacbecf9": {"__data__": {"id_": "dcb28e19-ffb9-4988-b277-3e3daacbecf9", "embedding": null, "metadata": {"window": "Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67d9fcd2-45ac-4a61-8d7e-e1de1296554f", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of George Hill calling from Deutsche Bank .  Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "Good morning, guys, and I appreciate you taking the question . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e522ebfadb1094a798bf095f74331b0a77c44a415874966313312649c150a010", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68c10a50-b336-418a-9140-1cf5fe5bbd0b", "node_type": "1", "metadata": {"window": "George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n"}, "hash": "f7a9bad4a5b742104f77d40753df497aa287d34fc5cab4b5298bc3872d62ee9b", "class_name": "RelatedNodeInfo"}}, "text": "And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high . ", "start_char_idx": 3058, "end_char_idx": 3278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68c10a50-b336-418a-9140-1cf5fe5bbd0b": {"__data__": {"id_": "68c10a50-b336-418a-9140-1cf5fe5bbd0b", "embedding": null, "metadata": {"window": "George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcb28e19-ffb9-4988-b277-3e3daacbecf9", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ccab5354155e50bec7610cc6284c25d5f27552044dc5375a74ea9b648fffb20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "060834bb-cc73-4f2e-9f3b-8dde291c851c", "node_type": "1", "metadata": {"window": "Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n "}, "hash": "93b8438f9270332069e5086dd0afdab0a09e1aea920358bb8295ef38c56edc7f", "class_name": "RelatedNodeInfo"}}, "text": "So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n", "start_char_idx": 3278, "end_char_idx": 3391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "060834bb-cc73-4f2e-9f3b-8dde291c851c": {"__data__": {"id_": "060834bb-cc73-4f2e-9f3b-8dde291c851c", "embedding": null, "metadata": {"window": "Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "107b03a59bed83989468121f6228735f45067b64d1fcb2450b41040aa098014b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68c10a50-b336-418a-9140-1cf5fe5bbd0b", "node_type": "1", "metadata": {"window": "George Hill:   Yeah .  Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d0f2c63a11e9885f7ea9c6b54be5c3a21cfb2b9583701f3a2b2bdc691189c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d450eebc-72da-4267-9bdb-637491c3ec67", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year . ", "original_text": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael . "}, "hash": "2ebae8f4194f5980ce333395de83ff5b2bd95d8c46464c5206d113cbdefc6998", "class_name": "RelatedNodeInfo"}}, "text": "And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "start_char_idx": 3391, "end_char_idx": 3704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d450eebc-72da-4267-9bdb-637491c3ec67": {"__data__": {"id_": "d450eebc-72da-4267-9bdb-637491c3ec67", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year . ", "original_text": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "060834bb-cc73-4f2e-9f3b-8dde291c851c", "node_type": "1", "metadata": {"window": "Good morning, guys, and I appreciate you taking the question .  And I guess \nJason, my question is probably a derivative of Mike's  question, which is kind of given the guidance for \nthe year and the expectations of the back half, it would seem that the street is probably too high .  So I \nguess maybe could you talk about the big moving pieces just as it relates to the back half of the ye ar?  \n And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "original_text": "And should we think about the current guidance as probably a little bit on the conservative side or are \nthere real areas of weakness particularly in Medical, that we should be worried about in the back half \nof the year as it relates to where the compa ny plans to deliver results versus where the strain is?  \n ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "561a530175d938dac43f57f2515f050da8b8bfb442a687935364e36a2004be07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "493dc7c9-c089-4375-99ae-d973bbb4d0f2", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n", "original_text": "Again, I feel good about the balance that we have here . "}, "hash": "a01593d3a5a6896b441306ad26de6dd3018b6335b37d510fae3b9b54bb50187d", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael . ", "start_char_idx": 0, "end_char_idx": 134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "493dc7c9-c089-4375-99ae-d973bbb4d0f2": {"__data__": {"id_": "493dc7c9-c089-4375-99ae-d973bbb4d0f2", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n", "original_text": "Again, I feel good about the balance that we have here . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d450eebc-72da-4267-9bdb-637491c3ec67", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year . ", "original_text": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7609efe30e7181bfbf0579922854e4553766d83283fe156cc64ac9f6e6c2ef0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aef36892-bde4-4329-b428-1d87d6a96a53", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan . ", "original_text": "I feel very good about the pro gress \nto date . "}, "hash": "6ef983a3b742bf6848ad78f9e73f2c3942a2352bf57dc2929d4dc564e717b6fa", "class_name": "RelatedNodeInfo"}}, "text": "Again, I feel good about the balance that we have here . ", "start_char_idx": 134, "end_char_idx": 191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aef36892-bde4-4329-b428-1d87d6a96a53": {"__data__": {"id_": "aef36892-bde4-4329-b428-1d87d6a96a53", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan . ", "original_text": "I feel very good about the pro gress \nto date . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "493dc7c9-c089-4375-99ae-d973bbb4d0f2", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n", "original_text": "Again, I feel good about the balance that we have here . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65e9e138e6a854ccde74bb02acbcf3f050d4899b14608219e31bf2b3f8061456", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8211f7d6-649d-445d-9ccb-4d7578180711", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year . ", "original_text": "We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year . "}, "hash": "f33afbe62478bf40cdd55c049d73f4be6fdcfa3844e1fcca1a8d7040e1973ec1", "class_name": "RelatedNodeInfo"}}, "text": "I feel very good about the pro gress \nto date . ", "start_char_idx": 191, "end_char_idx": 239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8211f7d6-649d-445d-9ccb-4d7578180711": {"__data__": {"id_": "8211f7d6-649d-445d-9ccb-4d7578180711", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year . ", "original_text": "We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aef36892-bde4-4329-b428-1d87d6a96a53", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan . ", "original_text": "I feel very good about the pro gress \nto date . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00fd13614d17aa4d3d76c4a91887a505b31e163689dd8b6cf925f59ccc4c812d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "790db5ce-b3fd-4e76-8059-54c0e3134db5", "node_type": "1", "metadata": {"window": "Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes . ", "original_text": "So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n"}, "hash": "912c48590d2d987e09fd766e79d7843d153b46c7aa3bc67a629935a41d6b99de", "class_name": "RelatedNodeInfo"}}, "text": "We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year . ", "start_char_idx": 239, "end_char_idx": 342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "790db5ce-b3fd-4e76-8059-54c0e3134db5": {"__data__": {"id_": "790db5ce-b3fd-4e76-8059-54c0e3134db5", "embedding": null, "metadata": {"window": "Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes . ", "original_text": "So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8211f7d6-649d-445d-9ccb-4d7578180711", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year . ", "original_text": "We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f45a4459d74c63c19441d17ce5e933e211e91de01a70b6fc75bc795bc09b74f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27372dd7-1f77-4967-a29e-ed5ae892d9c6", "node_type": "1", "metadata": {"window": "I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter . ", "original_text": "On Medical, a lot has to occur still for us to execute upon our plan . "}, "hash": "15ea6b23e1dbc1fc1f4a62b7b2aea65ab01cfadc0ecb6380f70a10dc6ac16130", "class_name": "RelatedNodeInfo"}}, "text": "So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n", "start_char_idx": 342, "end_char_idx": 425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27372dd7-1f77-4967-a29e-ed5ae892d9c6": {"__data__": {"id_": "27372dd7-1f77-4967-a29e-ed5ae892d9c6", "embedding": null, "metadata": {"window": "I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter . ", "original_text": "On Medical, a lot has to occur still for us to execute upon our plan . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "790db5ce-b3fd-4e76-8059-54c0e3134db5", "node_type": "1", "metadata": {"window": "Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes . ", "original_text": "So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c07cfe6b32bf79bf5f3209c840e727f2f7b869dddd9e06bb0832fe110a332de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1d8ec53-3c18-47c9-ac84-4d0dbbda2bb2", "node_type": "1", "metadata": {"window": "We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation . ", "original_text": "It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year . "}, "hash": "c268f91465b84e883d39a0bb07a65f71747eb8b20c46de661eb795c1f0705bdd", "class_name": "RelatedNodeInfo"}}, "text": "On Medical, a lot has to occur still for us to execute upon our plan . ", "start_char_idx": 425, "end_char_idx": 496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1d8ec53-3c18-47c9-ac84-4d0dbbda2bb2": {"__data__": {"id_": "f1d8ec53-3c18-47c9-ac84-4d0dbbda2bb2", "embedding": null, "metadata": {"window": "We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation . ", "original_text": "It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27372dd7-1f77-4967-a29e-ed5ae892d9c6", "node_type": "1", "metadata": {"window": "I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter . ", "original_text": "On Medical, a lot has to occur still for us to execute upon our plan . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "795cba3f1f8556ae01c0a406e2173b276f63e34f67f80008f3ce7fa75bf14bb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3646b089-9ba6-4b5f-8c08-a0c0794a8afb", "node_type": "1", "metadata": {"window": "So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n", "original_text": "We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes . "}, "hash": "ce4e33c79b867256c027dfb4fbf0c1c520787f29377e012c53344a80d4b12030", "class_name": "RelatedNodeInfo"}}, "text": "It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year . ", "start_char_idx": 496, "end_char_idx": 673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3646b089-9ba6-4b5f-8c08-a0c0794a8afb": {"__data__": {"id_": "3646b089-9ba6-4b5f-8c08-a0c0794a8afb", "embedding": null, "metadata": {"window": "So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n", "original_text": "We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1d8ec53-3c18-47c9-ac84-4d0dbbda2bb2", "node_type": "1", "metadata": {"window": "We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year .  So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation . ", "original_text": "It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb2739ef7ff2be37a0e22a14a9d2ce9efdc504171944b4472a65e5be0d6867ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76906c52-f938-46f7-a44f-58880e691c87", "node_type": "1", "metadata": {"window": "On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere . ", "original_text": "But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter . "}, "hash": "d8e1632e594c88fb45ac2f8f1c8cd21d1bde8e73a5f361f5d502d64629ad0e5b", "class_name": "RelatedNodeInfo"}}, "text": "We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes . ", "start_char_idx": 673, "end_char_idx": 865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76906c52-f938-46f7-a44f-58880e691c87": {"__data__": {"id_": "76906c52-f938-46f7-a44f-58880e691c87", "embedding": null, "metadata": {"window": "On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere . ", "original_text": "But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3646b089-9ba6-4b5f-8c08-a0c0794a8afb", "node_type": "1", "metadata": {"window": "So if volumes continue at a more recent pace, then we'd have some opportunity.  \n \n On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n", "original_text": "We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4af0eba9717e36e36a8533c41ba762b72528c5283a30dfaa3fd18b32d6fb4ca7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bfd8291-9622-4eb7-b991-84595bc62b51", "node_type": "1", "metadata": {"window": "It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n", "original_text": "Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation . "}, "hash": "35e45e8903a5a66e70dd9a906ced3f87013e19da772b84a6851d24c1b74791f5", "class_name": "RelatedNodeInfo"}}, "text": "But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter . ", "start_char_idx": 865, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bfd8291-9622-4eb7-b991-84595bc62b51": {"__data__": {"id_": "5bfd8291-9622-4eb7-b991-84595bc62b51", "embedding": null, "metadata": {"window": "It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n", "original_text": "Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76906c52-f938-46f7-a44f-58880e691c87", "node_type": "1", "metadata": {"window": "On Medical, a lot has to occur still for us to execute upon our plan .  It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere . ", "original_text": "But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c3a4959d8947c4ccd7b22623e8caf05b04d5c449ae666fef6f1b4bfcd4e2ef0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15a2b4ef-4bc4-43ff-aa3a-05dd30f3bb21", "node_type": "1", "metadata": {"window": "We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter . ", "original_text": "So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n"}, "hash": "1b790e387c3b7d49f402b543c160a008b7e41a1c2e0d4b2a8f0ec67eb9305beb", "class_name": "RelatedNodeInfo"}}, "text": "Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation . ", "start_char_idx": 1182, "end_char_idx": 1308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15a2b4ef-4bc4-43ff-aa3a-05dd30f3bb21": {"__data__": {"id_": "15a2b4ef-4bc4-43ff-aa3a-05dd30f3bb21", "embedding": null, "metadata": {"window": "We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter . ", "original_text": "So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bfd8291-9622-4eb7-b991-84595bc62b51", "node_type": "1", "metadata": {"window": "It's very consistent with the plan, \nwe have good step up expected to continue .This guidance pro vides sequential improvement for each \nand every quarter throughout the year .  We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n", "original_text": "Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "955201bca268d618544787aeaba049cd6a9d548792e10e748015585db1f17b4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28d96ad7-f652-403b-a0f9-551a1a7aac58", "node_type": "1", "metadata": {"window": "But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth . ", "original_text": "And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere . "}, "hash": "0fc796d3d43d72aa61e3fad6a6132c35f4e11dfc24c63dda1b53bac408eca63d", "class_name": "RelatedNodeInfo"}}, "text": "So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n", "start_char_idx": 1308, "end_char_idx": 1393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28d96ad7-f652-403b-a0f9-551a1a7aac58": {"__data__": {"id_": "28d96ad7-f652-403b-a0f9-551a1a7aac58", "embedding": null, "metadata": {"window": "But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth . ", "original_text": "And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15a2b4ef-4bc4-43ff-aa3a-05dd30f3bb21", "node_type": "1", "metadata": {"window": "We would anticipate the next two quarters to have sequential \nimprovements as it relates to the ongoing pricing for inflation, the ongoing cost reductions, a gradual \nimprovement in volumes .  But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter . ", "original_text": "So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be962a6576ecde68c0f36cacd8f9738b00aa9242bb47d28194a6b7ae30bcd79b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3a24d5b-95c8-450f-9da6-805df4f66700", "node_type": "1", "metadata": {"window": "Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.  ", "original_text": "And I think the primary difference is related to the growth within Pharma still growing . \n"}, "hash": "f15d93df875548d03de8e4407d047194d5a083ebfd16d87214cb3828ee0c6248", "class_name": "RelatedNodeInfo"}}, "text": "And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere . ", "start_char_idx": 1393, "end_char_idx": 1502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3a24d5b-95c8-450f-9da6-805df4f66700": {"__data__": {"id_": "f3a24d5b-95c8-450f-9da6-805df4f66700", "embedding": null, "metadata": {"window": "Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.  ", "original_text": "And I think the primary difference is related to the growth within Pharma still growing . \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28d96ad7-f652-403b-a0f9-551a1a7aac58", "node_type": "1", "metadata": {"window": "But importantly, the big step up will be in the fourth quarter as we see \ninternational freight, whic h is a very high confidence element now given that we're now less than six \nmonths by the end of the year, these lower costs are almost certainly going to start to flow through \nour P&L here in the fourth quarter .  Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth . ", "original_text": "And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dee35e903a431ab6f1287c2a100d723027c50c37d93f5ecec3a9febe5eb27f4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6279037e-c89b-45d3-86bf-c1b2e7334435", "node_type": "1", "metadata": {"window": "So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at . ", "original_text": "And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter . "}, "hash": "c72b83ca306bb8faf3d8b1ba2749d337a91acf16677b9dd03e88fd12938e6199", "class_name": "RelatedNodeInfo"}}, "text": "And I think the primary difference is related to the growth within Pharma still growing . \n", "start_char_idx": 1502, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6279037e-c89b-45d3-86bf-c1b2e7334435": {"__data__": {"id_": "6279037e-c89b-45d3-86bf-c1b2e7334435", "embedding": null, "metadata": {"window": "So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at . ", "original_text": "And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3a24d5b-95c8-450f-9da6-805df4f66700", "node_type": "1", "metadata": {"window": "Still, at levels well below the pricing we'r e getting, but nonetheless, \nthat's a pretty well -known part of that equation .  So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.  ", "original_text": "And I think the primary difference is related to the growth within Pharma still growing . \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6c93d51cb4e552706a61abd783db1d76526ebc3ad6d8ea6948b5724dc9d40cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f70bc0d-4ca4-4bf9-94d7-9b1e07ffa849", "node_type": "1", "metadata": {"window": "And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations . ", "original_text": "We \nhad very strong growth . "}, "hash": "e91b805bcbb48a8317c60815bf890d8ed61e81dac820e3e044e3a386edac792a", "class_name": "RelatedNodeInfo"}}, "text": "And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter . ", "start_char_idx": 1593, "end_char_idx": 1686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f70bc0d-4ca4-4bf9-94d7-9b1e07ffa849": {"__data__": {"id_": "2f70bc0d-4ca4-4bf9-94d7-9b1e07ffa849", "embedding": null, "metadata": {"window": "And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations . ", "original_text": "We \nhad very strong growth . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6279037e-c89b-45d3-86bf-c1b2e7334435", "node_type": "1", "metadata": {"window": "So a lot of actions still in front of us, but the plan \nremains entirely intact.  \n \n And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at . ", "original_text": "And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e34ba284995eeb0ca254c6550e2115c0177926fe82447aa5df0f165db4f66b75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42ce350f-1a15-4e7a-b6ae-adaed7d427a4", "node_type": "1", "metadata": {"window": "And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n", "original_text": "It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.  "}, "hash": "2a83819e058973d7d769f4dd15c0bda913c41e260aedf5b3bf01a045bcbe1049", "class_name": "RelatedNodeInfo"}}, "text": "We \nhad very strong growth . ", "start_char_idx": 1686, "end_char_idx": 1715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42ce350f-1a15-4e7a-b6ae-adaed7d427a4": {"__data__": {"id_": "42ce350f-1a15-4e7a-b6ae-adaed7d427a4", "embedding": null, "metadata": {"window": "And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n", "original_text": "It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.  ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f70bc0d-4ca4-4bf9-94d7-9b1e07ffa849", "node_type": "1", "metadata": {"window": "And so when you talk about the first half, second half, you're implying there's some difference \nsomewhere .  And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations . ", "original_text": "We \nhad very strong growth . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d84ad057771cf918cb2b8b8420c46a35b459adddb26bdb5dc10a27a7217ab02e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff6f01c4-d111-4f48-bc99-a756521050ce", "node_type": "1", "metadata": {"window": "And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS . ", "original_text": "So we feel good about where \nwe're at . "}, "hash": "3f3bd0085f0024877e91225f68d3f388fc7f57e7860820e99f5b4a45fd7bc375", "class_name": "RelatedNodeInfo"}}, "text": "It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.  ", "start_char_idx": 1715, "end_char_idx": 1874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff6f01c4-d111-4f48-bc99-a756521050ce": {"__data__": {"id_": "ff6f01c4-d111-4f48-bc99-a756521050ce", "embedding": null, "metadata": {"window": "And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS . ", "original_text": "So we feel good about where \nwe're at . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42ce350f-1a15-4e7a-b6ae-adaed7d427a4", "node_type": "1", "metadata": {"window": "And I think the primary difference is related to the growth within Pharma still growing . \n And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n", "original_text": "It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.  ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8bd89b8dc0c039394d6c4e378c33c469a8a084ab36ece4ffc20bd15d6eec98b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e0feb91-1760-4ead-80b2-fd373f850dd8", "node_type": "1", "metadata": {"window": "We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n", "original_text": "There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations . "}, "hash": "cbd294c1200d4ab214104ef0bde1f8847d91a9112f796435bfa6251fa7b7b8aa", "class_name": "RelatedNodeInfo"}}, "text": "So we feel good about where \nwe're at . ", "start_char_idx": 1874, "end_char_idx": 1914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e0feb91-1760-4ead-80b2-fd373f850dd8": {"__data__": {"id_": "7e0feb91-1760-4ead-80b2-fd373f850dd8", "embedding": null, "metadata": {"window": "We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n", "original_text": "There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff6f01c4-d111-4f48-bc99-a756521050ce", "node_type": "1", "metadata": {"window": "And maybe one other point to remember Q4 of last year for Pharma was a very strong quarter .  We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS . ", "original_text": "So we feel good about where \nwe're at . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ffa40a69d60cac8959578408e171c81efd40338c79fd05e71f6ce0fe0a24c3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a6f4be8-698a-4647-b03d-cbf1b4d7d9ce", "node_type": "1", "metadata": {"window": "It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions . ", "original_text": "Next question, \nplease.  \n \n"}, "hash": "90be0bd519827abdd75969a785aa55bf022912e0b2d0795d9048a9d65069fb0b", "class_name": "RelatedNodeInfo"}}, "text": "There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations . ", "start_char_idx": 1914, "end_char_idx": 2091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a6f4be8-698a-4647-b03d-cbf1b4d7d9ce": {"__data__": {"id_": "6a6f4be8-698a-4647-b03d-cbf1b4d7d9ce", "embedding": null, "metadata": {"window": "It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions . ", "original_text": "Next question, \nplease.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e0feb91-1760-4ead-80b2-fd373f850dd8", "node_type": "1", "metadata": {"window": "We \nhad very strong growth .  It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n", "original_text": "There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4422b573eb8c1973b46146dc29df016e9a4b3c8e906a7853b0cc0396afa9a039", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "287c586e-556e-4c91-abab-21011d56a338", "node_type": "1", "metadata": {"window": "So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers . ", "original_text": "Operator:  The next question comes from the line of Andrea Alfonso calling from UBS . "}, "hash": "ad256c351549a442ce367dd1751725bb30fd46055856ea1ab8a6895e148f6bb8", "class_name": "RelatedNodeInfo"}}, "text": "Next question, \nplease.  \n \n", "start_char_idx": 2091, "end_char_idx": 2119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "287c586e-556e-4c91-abab-21011d56a338": {"__data__": {"id_": "287c586e-556e-4c91-abab-21011d56a338", "embedding": null, "metadata": {"window": "So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers . ", "original_text": "Operator:  The next question comes from the line of Andrea Alfonso calling from UBS . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a6f4be8-698a-4647-b03d-cbf1b4d7d9ce", "node_type": "1", "metadata": {"window": "It was a good quarter and that's one t hat we still anticipate there being growth \non top of that this year as well and that low to mid -single -digit range.   So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions . ", "original_text": "Next question, \nplease.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6829633502ccc87998abb2391160543e1200302ac31d859957622311ec3ea97c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a6b226d-d5ae-4a43-a9f6-5a516159a649", "node_type": "1", "metadata": {"window": "There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general . ", "original_text": "Please go \nahead.  \n \n"}, "hash": "2f2c7df72827d51c952b8b8a598b3b8bf8f2ae5ac866a31be3433f5ea220336a", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from the line of Andrea Alfonso calling from UBS . ", "start_char_idx": 2119, "end_char_idx": 2205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a6b226d-d5ae-4a43-a9f6-5a516159a649": {"__data__": {"id_": "5a6b226d-d5ae-4a43-a9f6-5a516159a649", "embedding": null, "metadata": {"window": "There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general . ", "original_text": "Please go \nahead.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "287c586e-556e-4c91-abab-21011d56a338", "node_type": "1", "metadata": {"window": "So we feel good about where \nwe're at .  There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers . ", "original_text": "Operator:  The next question comes from the line of Andrea Alfonso calling from UBS . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a45b6812e23e3ca04ca72be6a3a9773fbfd183b93df5eaf138f0aba1432c001", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd3363c6-64ca-4627-b189-4f6c02bfdf63", "node_type": "1", "metadata": {"window": "Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n", "original_text": "Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions . "}, "hash": "884e59384ab0acb692372c72f8abdc30feedb7fb1d7771e61b034baee17e03f1", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 2205, "end_char_idx": 2227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd3363c6-64ca-4627-b189-4f6c02bfdf63": {"__data__": {"id_": "fd3363c6-64ca-4627-b189-4f6c02bfdf63", "embedding": null, "metadata": {"window": "Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n", "original_text": "Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a6b226d-d5ae-4a43-a9f6-5a516159a649", "node_type": "1", "metadata": {"window": "There's opportunity in Pharma, there's some things we've got to watch out on Medical and \nwe continue t o execute all the below line items very consistent to our expectations .  Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general . ", "original_text": "Please go \nahead.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2bd7562b0fb62c3b683c724f48d82a38374ef45dc520e6f045e7d310779f110e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9522276-2584-4ea2-a4fb-875cd1552599", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals . ", "original_text": "So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers . "}, "hash": "2950e4d3d0c9d697e51a1347b8678608c8d9e78c5be068ddb30826f6eeb20e4d", "class_name": "RelatedNodeInfo"}}, "text": "Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions . ", "start_char_idx": 2227, "end_char_idx": 2323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9522276-2584-4ea2-a4fb-875cd1552599": {"__data__": {"id_": "a9522276-2584-4ea2-a4fb-875cd1552599", "embedding": null, "metadata": {"window": "Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals . ", "original_text": "So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd3363c6-64ca-4627-b189-4f6c02bfdf63", "node_type": "1", "metadata": {"window": "Next question, \nplease.  \n \n Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n", "original_text": "Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cded6d9ec804629f846b94590662b50551e15288b8ba2f139daef21160dcc97f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6801f78-81f2-49eb-af8f-a73d6bd11b23", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label? ", "original_text": "I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general . "}, "hash": "f8b189a109319f7d8f93e289e6083933b6491a1e1cc84fdf29e5832b646c52e8", "class_name": "RelatedNodeInfo"}}, "text": "So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers . ", "start_char_idx": 2323, "end_char_idx": 2503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6801f78-81f2-49eb-af8f-a73d6bd11b23": {"__data__": {"id_": "f6801f78-81f2-49eb-af8f-a73d6bd11b23", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label? ", "original_text": "I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9522276-2584-4ea2-a4fb-875cd1552599", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of Andrea Alfonso calling from UBS .  Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals . ", "original_text": "So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d00df4f7ab24137cb32bd04c142cc92990d611d960009ce8c05693a59b1533f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e65071-e63c-4dcc-b31c-61a12339501e", "node_type": "1", "metadata": {"window": "Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n", "original_text": "And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n"}, "hash": "21c0c6cdf14f062bdbe98c2d2f5f5344c1997c78e8f57e4ccb05e7131490adad", "class_name": "RelatedNodeInfo"}}, "text": "I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general . ", "start_char_idx": 2503, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4e65071-e63c-4dcc-b31c-61a12339501e": {"__data__": {"id_": "a4e65071-e63c-4dcc-b31c-61a12339501e", "embedding": null, "metadata": {"window": "Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n", "original_text": "And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6801f78-81f2-49eb-af8f-a73d6bd11b23", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label? ", "original_text": "I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "463600f17711a379818c90574e6391782bd3a2ffe7e1c716e3d28c3b37328cd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93ef1859-bf45-4f77-b85a-3358963fbb58", "node_type": "1", "metadata": {"window": "So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific . ", "original_text": "And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals . "}, "hash": "9da058a81b53709c75cf351b904fd7ecaf96a4f9f127c309bce7e6096ec56864", "class_name": "RelatedNodeInfo"}}, "text": "And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n", "start_char_idx": 2612, "end_char_idx": 2744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93ef1859-bf45-4f77-b85a-3358963fbb58": {"__data__": {"id_": "93ef1859-bf45-4f77-b85a-3358963fbb58", "embedding": null, "metadata": {"window": "So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific . ", "original_text": "And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4e65071-e63c-4dcc-b31c-61a12339501e", "node_type": "1", "metadata": {"window": "Andrea Alfonso :   Thank you so much, Trish and Jason, I a ppreciate you taking the questions .  So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n", "original_text": "And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7429ea0e64e5d699ee4b138088a9d83d0dcbb3e74009c7aac19d5b2fc89889c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "360c1e66-ea2c-446f-9875-9ec8a55f36ed", "node_type": "1", "metadata": {"window": "I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so . ", "original_text": "Have you observed changes and \njust the general appetite here for private label? "}, "hash": "1768ed273ed227c99c906ade8acc53d74de593c1dc54789bea58fb67c80e15d7", "class_name": "RelatedNodeInfo"}}, "text": "And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals . ", "start_char_idx": 2744, "end_char_idx": 2916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "360c1e66-ea2c-446f-9875-9ec8a55f36ed": {"__data__": {"id_": "360c1e66-ea2c-446f-9875-9ec8a55f36ed", "embedding": null, "metadata": {"window": "I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so . ", "original_text": "Have you observed changes and \njust the general appetite here for private label? ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93ef1859-bf45-4f77-b85a-3358963fbb58", "node_type": "1", "metadata": {"window": "So just \non the Med-surge side, again, you've discussed, you know, the different tranches of price increases \non the Med-surge side that you're going to be taking with customers .  I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific . ", "original_text": "And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3082480fc84b63bb3b0f3b9c4a97cda1c5a0cc8bae4b65ff4632e166d90259b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab57b38f-38e2-4e48-85df-e8eae647621c", "node_type": "1", "metadata": {"window": "And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822. ", "original_text": "Thanks so much for the question.  \n \n"}, "hash": "401d3421bb978b9ec28835612cfeaee95dafbbc1b1284e080d06a7bdd21878f3", "class_name": "RelatedNodeInfo"}}, "text": "Have you observed changes and \njust the general appetite here for private label? ", "start_char_idx": 2916, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab57b38f-38e2-4e48-85df-e8eae647621c": {"__data__": {"id_": "ab57b38f-38e2-4e48-85df-e8eae647621c", "embedding": null, "metadata": {"window": "And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822. ", "original_text": "Thanks so much for the question.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "360c1e66-ea2c-446f-9875-9ec8a55f36ed", "node_type": "1", "metadata": {"window": "I guess we just going to just love \nto get a qualitative update on GPO and customer receptivity in general .  And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so . ", "original_text": "Have you observed changes and \njust the general appetite here for private label? ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b74de0443a18dc36e2bfea92bb40573fba63ef981865326af71b4791e4e8ce5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6c33c5f-a2bc-4a06-9e9d-a317754a801a", "node_type": "1", "metadata": {"window": "And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year . ", "original_text": "Jason Hollar:  Sure, t errific . "}, "hash": "ca63e01c0fb4bb61dc73352e7ab4e380c7ad7bdcc98df6250ed223baf0b87104", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question.  \n \n", "start_char_idx": 2997, "end_char_idx": 3034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6c33c5f-a2bc-4a06-9e9d-a317754a801a": {"__data__": {"id_": "c6c33c5f-a2bc-4a06-9e9d-a317754a801a", "embedding": null, "metadata": {"window": "And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year . ", "original_text": "Jason Hollar:  Sure, t errific . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab57b38f-38e2-4e48-85df-e8eae647621c", "node_type": "1", "metadata": {"window": "And should we expect, as we \nthink about the cadence for the second half, those would more fully manifest in the numbers in 4Q?  \n \n And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822. ", "original_text": "Thanks so much for the question.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96059bf2f0556d0601b7517e9544cfff3b0ea70d751d5f0a635c618cef29b500", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "492ecb29-a04c-4ec2-8cf2-b5a97053a8bc", "node_type": "1", "metadata": {"window": "Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%. ", "original_text": "Happy to do so . "}, "hash": "8f3fe21eef1dc0e68f9cf1acd9581c0ac3f40f13d4e174287cc449a0a7537184", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure, t errific . ", "start_char_idx": 3034, "end_char_idx": 3067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "492ecb29-a04c-4ec2-8cf2-b5a97053a8bc": {"__data__": {"id_": "492ecb29-a04c-4ec2-8cf2-b5a97053a8bc", "embedding": null, "metadata": {"window": "Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%. ", "original_text": "Happy to do so . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6c33c5f-a2bc-4a06-9e9d-a317754a801a", "node_type": "1", "metadata": {"window": "And again, just as a corollary to that, you highlighted some inve stments around private label with the \ncurrent constraints and the purchasing environment for hospitals .  Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year . ", "original_text": "Jason Hollar:  Sure, t errific . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "829e013961d248193477f1017e1d23601d606a914ae1e586b857384710571086", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "365f9906-b475-4033-b53e-c37fa3292308", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step . ", "original_text": "So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822. "}, "hash": "88a98cce1619ad1d41c6bedc12af5dfdc1f6e4917817eaae616977c8c6b3a274", "class_name": "RelatedNodeInfo"}}, "text": "Happy to do so . ", "start_char_idx": 3067, "end_char_idx": 3084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "365f9906-b475-4033-b53e-c37fa3292308": {"__data__": {"id_": "365f9906-b475-4033-b53e-c37fa3292308", "embedding": null, "metadata": {"window": "Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step . ", "original_text": "So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822. ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "492ecb29-a04c-4ec2-8cf2-b5a97053a8bc", "node_type": "1", "metadata": {"window": "Have you observed changes and \njust the general appetite here for private label?  Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%. ", "original_text": "Happy to do so . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5bad7d8bd7d267685e12e08acfcfff9ca047d508064e2d719df8f650ecb9652", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "776a1407-aeb4-49fa-bebd-33a6a8a6e508", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n", "original_text": "So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year . "}, "hash": "85caf8e8aa4bf46e15b9dcfb2bc0ae4872271f536c7c2ae79fbda47c78a0d5e6", "class_name": "RelatedNodeInfo"}}, "text": "So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822. ", "start_char_idx": 3084, "end_char_idx": 3238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "776a1407-aeb4-49fa-bebd-33a6a8a6e508": {"__data__": {"id_": "776a1407-aeb4-49fa-bebd-33a6a8a6e508", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n", "original_text": "So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "365f9906-b475-4033-b53e-c37fa3292308", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  \n \n Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step . ", "original_text": "So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822. ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fbbb1f037eed419c34c5b9b6450f500415b890e0718c5133d4a79cb18328c566", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9471b91-81c1-4e00-8a85-a92d799a64fe", "node_type": "1", "metadata": {"window": "Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "And then now we are saying it's over \n30%. "}, "hash": "8427fe19e3b1eb6dbbcb0d932ab18b0aa2132d55c330d02c903c2e614c7b6cd4", "class_name": "RelatedNodeInfo"}}, "text": "So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year . ", "start_char_idx": 3238, "end_char_idx": 3424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9471b91-81c1-4e00-8a85-a92d799a64fe": {"__data__": {"id_": "e9471b91-81c1-4e00-8a85-a92d799a64fe", "embedding": null, "metadata": {"window": "Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "And then now we are saying it's over \n30%. ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "776a1407-aeb4-49fa-bebd-33a6a8a6e508", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure, t errific .  Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n", "original_text": "So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b606176c88288d2b66eb193d7dc9cbc8f936e8380ecd9c42e89bb956d70c2fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27bd0026-ab26-49f4-9519-a4feab5aa2ae", "node_type": "1", "metadata": {"window": "So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "So you can see that a fairly consistent stair step . "}, "hash": "a0b96d455e620a52d03afcaef645882d47fbd8d27baf901e8cd963a46e1a0cc4", "class_name": "RelatedNodeInfo"}}, "text": "And then now we are saying it's over \n30%. ", "start_char_idx": 3424, "end_char_idx": 3467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27bd0026-ab26-49f4-9519-a4feab5aa2ae": {"__data__": {"id_": "27bd0026-ab26-49f4-9519-a4feab5aa2ae", "embedding": null, "metadata": {"window": "So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "So you can see that a fairly consistent stair step . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9471b91-81c1-4e00-8a85-a92d799a64fe", "node_type": "1", "metadata": {"window": "Happy to do so .  So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "And then now we are saying it's over \n30%. ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb138084a82608966477a0a50d500312f02f8729a9e8ff681a119564ab6bd562", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc63f65e-0c60-417b-a0d3-7b917d0cc88d", "node_type": "1", "metadata": {"window": "So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "And that's how I think about the pricing side . \n"}, "hash": "6828472958ef3cfe37ddf51a43fab1fcbdfe3379cfba4793b87e7d85b9342a92", "class_name": "RelatedNodeInfo"}}, "text": "So you can see that a fairly consistent stair step . ", "start_char_idx": 3467, "end_char_idx": 3520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc63f65e-0c60-417b-a0d3-7b917d0cc88d": {"__data__": {"id_": "cc63f65e-0c60-417b-a0d3-7b917d0cc88d", "embedding": null, "metadata": {"window": "So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "And that's how I think about the pricing side . \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27bd0026-ab26-49f4-9519-a4feab5aa2ae", "node_type": "1", "metadata": {"window": "So on pricing, I would think about pricing as being a fairly \nstair-step process, beginning back with our first temporary price increase in March of \u201822.  So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "So you can see that a fairly consistent stair step . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e1442e3063e329d4b3d4ed0f97e3e4070e22a69587109b19edfc4c1faacd1b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "264efb91-5a5b-44cc-ae3e-4a4d3889fcae", "node_type": "1", "metadata": {"window": "And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "Less on the temporary price increases going forward and more on the rotation to more renewals as "}, "hash": "539285b76e8c693531833761ca6e9e80facea9260c8adce1d9257c42732c6111", "class_name": "RelatedNodeInfo"}}, "text": "And that's how I think about the pricing side . \n", "start_char_idx": 3520, "end_char_idx": 3569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "264efb91-5a5b-44cc-ae3e-4a4d3889fcae": {"__data__": {"id_": "264efb91-5a5b-44cc-ae3e-4a4d3889fcae", "embedding": null, "metadata": {"window": "And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "Less on the temporary price increases going forward and more on the rotation to more renewals as ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cbf8234f867f3dd46ba755fb4c89ba7e5e04ac68f66f72fd925f460c6d273d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc63f65e-0c60-417b-a0d3-7b917d0cc88d", "node_type": "1", "metadata": {"window": "So, what we \nhave and what we first shared was the 20% mitigation of inflation soon afte r in the fourth quarter of \nlast year, then that went to 25% in the first quarter of this year .  And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "And that's how I think about the pricing side . \n", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71c77f5b730947d00cd7ee4555803c95ac191a6784e3ab5a13c96ac5341ebf0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32e22566-68ff-4f3e-b12d-304537c3156e", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown . ", "original_text": " \nPage 13 of 16 \n \nthey come up . "}, "hash": "a61a083477bfa374bfbc99a0478128ff4e506c820e5c5af5cd47646d773cf496", "class_name": "RelatedNodeInfo"}}, "text": "Less on the temporary price increases going forward and more on the rotation to more renewals as ", "start_char_idx": 3569, "end_char_idx": 3666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32e22566-68ff-4f3e-b12d-304537c3156e": {"__data__": {"id_": "32e22566-68ff-4f3e-b12d-304537c3156e", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown . ", "original_text": " \nPage 13 of 16 \n \nthey come up . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "264efb91-5a5b-44cc-ae3e-4a4d3889fcae", "node_type": "1", "metadata": {"window": "And then now we are saying it's over \n30%.  So you can see that a fairly consistent stair step .  And that's how I think about the pricing side . \n Less on the temporary price increases going forward and more on the rotation to more renewals as ", "original_text": "Less on the temporary price increases going forward and more on the rotation to more renewals as ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22893a0294e1407bdef34e134bee375c643a2e7ceb96bb873066f350ac023fcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5d18cd4-1edd-4cca-9b03-870837c81cf8", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight . ", "original_text": "And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts. "}, "hash": "d15253894a62245400cd0c70c9a3c355d2f4a5922ba4ddd35a0c7f1aa40cb9d7", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 16 \n \nthey come up . ", "start_char_idx": 0, "end_char_idx": 34, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5d18cd4-1edd-4cca-9b03-870837c81cf8": {"__data__": {"id_": "d5d18cd4-1edd-4cca-9b03-870837c81cf8", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight . ", "original_text": "And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts. ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32e22566-68ff-4f3e-b12d-304537c3156e", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown . ", "original_text": " \nPage 13 of 16 \n \nthey come up . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650427b19d3f08d2c27542f2d9540be88f82f77d3a70d9a16a228938b7b77799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d4e19f7-972c-4ebb-be48-b4e5f61db4e8", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust . ", "original_text": "So a continuation of more of the same . \n \n"}, "hash": "5500120da9bcf2deba2c9fc480e160ba038a7bfb382ae5f8673cac2b7d0b3aae", "class_name": "RelatedNodeInfo"}}, "text": "And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts. ", "start_char_idx": 34, "end_char_idx": 186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d4e19f7-972c-4ebb-be48-b4e5f61db4e8": {"__data__": {"id_": "0d4e19f7-972c-4ebb-be48-b4e5f61db4e8", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust . ", "original_text": "So a continuation of more of the same . \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5d18cd4-1edd-4cca-9b03-870837c81cf8", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight . ", "original_text": "And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts. ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "200e3d498088ee5a2552bde2d2074e38e7074740488dd547099e8bcdb31e18b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "039a3021-e408-4b8d-b6c4-0acc833ededb", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n", "original_text": "How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown . "}, "hash": "3deb3110b78c16611d4b36182938aeb18bb479d33eb780e33ed75b52e134d4f4", "class_name": "RelatedNodeInfo"}}, "text": "So a continuation of more of the same . \n \n", "start_char_idx": 186, "end_char_idx": 229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "039a3021-e408-4b8d-b6c4-0acc833ededb": {"__data__": {"id_": "039a3021-e408-4b8d-b6c4-0acc833ededb", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n", "original_text": "How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d4e19f7-972c-4ebb-be48-b4e5f61db4e8", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust . ", "original_text": "So a continuation of more of the same . \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bd9b048b7b065ebf30154e2d396559c8b3707ce445d7c8d77e76b2ee6283514", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b42791dc-3bbd-415b-ae99-53e16f501e3d", "node_type": "1", "metadata": {"window": "And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers . ", "original_text": "So and again, that's largely focused on the international freight . "}, "hash": "1d77d226ba90cae5ee11e789ae762dedbdb00b31775345926233d3025c9d50cd", "class_name": "RelatedNodeInfo"}}, "text": "How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown . ", "start_char_idx": 229, "end_char_idx": 338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b42791dc-3bbd-415b-ae99-53e16f501e3d": {"__data__": {"id_": "b42791dc-3bbd-415b-ae99-53e16f501e3d", "embedding": null, "metadata": {"window": "And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers . ", "original_text": "So and again, that's largely focused on the international freight . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "039a3021-e408-4b8d-b6c4-0acc833ededb", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n", "original_text": "How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58d6fe53455131ef672a4f54f4440e5321d21fc2304728bee14fdcce856340e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61e5094a-c8d4-402f-9a33-04bd67e804c3", "node_type": "1", "metadata": {"window": "So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation . ", "original_text": "So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust . "}, "hash": "f32bd3df831c8a5fc6499709c2998922b0b51e54f001f1639ff47fc649dbc83b", "class_name": "RelatedNodeInfo"}}, "text": "So and again, that's largely focused on the international freight . ", "start_char_idx": 338, "end_char_idx": 406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61e5094a-c8d4-402f-9a33-04bd67e804c3": {"__data__": {"id_": "61e5094a-c8d4-402f-9a33-04bd67e804c3", "embedding": null, "metadata": {"window": "So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation . ", "original_text": "So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b42791dc-3bbd-415b-ae99-53e16f501e3d", "node_type": "1", "metadata": {"window": "And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers . ", "original_text": "So and again, that's largely focused on the international freight . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96e509493f8f70d6479d3fcc1ccbca5b31c52e1f2ed367ad6f8d7df92b2384ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "400bbfa3-a4b8-4932-954a-1fd834054df8", "node_type": "1", "metadata": {"window": "How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means . ", "original_text": "And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n"}, "hash": "c530f34cfb85858e90ffe8a60609c579b0aeceb042dde4737070a567b2e35e4a", "class_name": "RelatedNodeInfo"}}, "text": "So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust . ", "start_char_idx": 406, "end_char_idx": 562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "400bbfa3-a4b8-4932-954a-1fd834054df8": {"__data__": {"id_": "400bbfa3-a4b8-4932-954a-1fd834054df8", "embedding": null, "metadata": {"window": "How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means . ", "original_text": "And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61e5094a-c8d4-402f-9a33-04bd67e804c3", "node_type": "1", "metadata": {"window": "So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation . ", "original_text": "So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4313505d1cc38f8c41448f4d86ceeadd25d73aaa4f7fa93930bbaf70c76aa7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6a7a26e-22b0-414c-8675-cab268930e67", "node_type": "1", "metadata": {"window": "So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well . ", "original_text": "As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers . "}, "hash": "ff2453654c46a783466c60e66ad565abad5a9668cd5223a0a4337ea69b551701", "class_name": "RelatedNodeInfo"}}, "text": "And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n", "start_char_idx": 562, "end_char_idx": 663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6a7a26e-22b0-414c-8675-cab268930e67": {"__data__": {"id_": "b6a7a26e-22b0-414c-8675-cab268930e67", "embedding": null, "metadata": {"window": "So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well . ", "original_text": "As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "400bbfa3-a4b8-4932-954a-1fd834054df8", "node_type": "1", "metadata": {"window": "How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown .  So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means . ", "original_text": "And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec98027422a212e6f9296263e6821fa93e32affeb9820c921d2de8aa900127b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe9deae8-3212-48ee-a1d6-b42a7ca6b556", "node_type": "1", "metadata": {"window": "So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it . ", "original_text": "All of our customers are dealing with challenges beyond the \ninflation . "}, "hash": "0e88e54c5fcd8f3ef0f45f57a6de8426dad84d0ca792c640fe5bfe41f6fd653d", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers . ", "start_char_idx": 663, "end_char_idx": 805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe9deae8-3212-48ee-a1d6-b42a7ca6b556": {"__data__": {"id_": "fe9deae8-3212-48ee-a1d6-b42a7ca6b556", "embedding": null, "metadata": {"window": "So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it . ", "original_text": "All of our customers are dealing with challenges beyond the \ninflation . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6a7a26e-22b0-414c-8675-cab268930e67", "node_type": "1", "metadata": {"window": "So and again, that's largely focused on the international freight .  So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well . ", "original_text": "As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a61df573291d4bd744285fea977222f45a7f8e63275943392fda0a9d5bf5bc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "157cfac2-54ab-4976-8045-4a06193b268b", "node_type": "1", "metadata": {"window": "And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n", "original_text": "In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means . "}, "hash": "f31f922fd20df61ea7863ae4298de38e05f9f6fff7102ae8f0f808a8ed0564c1", "class_name": "RelatedNodeInfo"}}, "text": "All of our customers are dealing with challenges beyond the \ninflation . ", "start_char_idx": 805, "end_char_idx": 878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "157cfac2-54ab-4976-8045-4a06193b268b": {"__data__": {"id_": "157cfac2-54ab-4976-8045-4a06193b268b", "embedding": null, "metadata": {"window": "And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n", "original_text": "In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe9deae8-3212-48ee-a1d6-b42a7ca6b556", "node_type": "1", "metadata": {"window": "So pricing, I would expect to \njust c ontinue blocking and tackling all the way through to the end of fiscal \u201824 is where most of the \nprices will adjust .  And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it . ", "original_text": "All of our customers are dealing with challenges beyond the \ninflation . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e80f1a8f1e819b521f6de568703ed816e5b44f676d11873d03671ae216ea4a9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "209b0e73-a463-4536-997d-125c932aee2b", "node_type": "1", "metadata": {"window": "As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen. ", "original_text": "And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well . "}, "hash": "b756ceb65e593e99547e03ca5fee2c20a70c8172c26e1a67a97c07c8134218be", "class_name": "RelatedNodeInfo"}}, "text": "In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means . ", "start_char_idx": 878, "end_char_idx": 1286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "209b0e73-a463-4536-997d-125c932aee2b": {"__data__": {"id_": "209b0e73-a463-4536-997d-125c932aee2b", "embedding": null, "metadata": {"window": "As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen. ", "original_text": "And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "157cfac2-54ab-4976-8045-4a06193b268b", "node_type": "1", "metadata": {"window": "And that's why we indicate that we won't get to full mitigation until about that point in \ntime.  \n \n As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n", "original_text": "In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "918c472212630a3254f001a6ed41dd6bc6a1ea75b5da72a31379be0279c8d726", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3029b83e-c89f-4f0a-813c-9f6ce9b56a55", "node_type": "1", "metadata": {"window": "All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n", "original_text": "So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it . "}, "hash": "ec91b471a05da55d7d3dc0ce8f85320ed1a0741839a150ddb235a1a3163e7ba1", "class_name": "RelatedNodeInfo"}}, "text": "And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well . ", "start_char_idx": 1286, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3029b83e-c89f-4f0a-813c-9f6ce9b56a55": {"__data__": {"id_": "3029b83e-c89f-4f0a-813c-9f6ce9b56a55", "embedding": null, "metadata": {"window": "All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n", "original_text": "So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "209b0e73-a463-4536-997d-125c932aee2b", "node_type": "1", "metadata": {"window": "As it relates to private label, I think it 's an interesting related question to pricing, because, yes, we \nwant to work with our customers .  All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen. ", "original_text": "And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c67632a7b226a8991a3c73be37c540917c94fac2f8cd999b6b4cdc60ee11e5ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "678f8a05-1b07-4aba-a651-2828c036fde9", "node_type": "1", "metadata": {"window": "In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah . ", "original_text": "Next question, please.  \n \n"}, "hash": "382124a864e6e6ba6ffa0100cc172ae4750f9fd4f259e77bcde56715eec53ce1", "class_name": "RelatedNodeInfo"}}, "text": "So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it . ", "start_char_idx": 1541, "end_char_idx": 1653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "678f8a05-1b07-4aba-a651-2828c036fde9": {"__data__": {"id_": "678f8a05-1b07-4aba-a651-2828c036fde9", "embedding": null, "metadata": {"window": "In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah . ", "original_text": "Next question, please.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3029b83e-c89f-4f0a-813c-9f6ce9b56a55", "node_type": "1", "metadata": {"window": "All of our customers are dealing with challenges beyond the \ninflation .  In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n", "original_text": "So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0d990f5be13dfbc19317617fcdaef38d4b6d03fdccd8fc5a7cbccefce39e989", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ab9b04e-75bd-427c-9682-0e5d8b102711", "node_type": "1", "metadata": {"window": "And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys . ", "original_text": "Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen. "}, "hash": "dd723cc43a3994a77d752d4b6f5bb4736e3e60f45b95032fc982d60cd6754815", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n \n", "start_char_idx": 1653, "end_char_idx": 1680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ab9b04e-75bd-427c-9682-0e5d8b102711": {"__data__": {"id_": "2ab9b04e-75bd-427c-9682-0e5d8b102711", "embedding": null, "metadata": {"window": "And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys . ", "original_text": "Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen. ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "678f8a05-1b07-4aba-a651-2828c036fde9", "node_type": "1", "metadata": {"window": "In this category, they have actually much bigger challenges than other categories, and, you \nknow, the desire on our part is to work with them if there's a possible win -win to find value in other \nways, whether that is to more private label, it's, of course, we're doing everything we can to offset the \nincrease or the increases to start with, to  mitigate the inflation through other non -pricing means .  And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah . ", "original_text": "Next question, please.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2657b15c8361e31fe0dd8d418edc3a5657ba6d01d779ee60f14aa8d774757c9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e62a724-e8d6-42e3-8796-217bf742fa4f", "node_type": "1", "metadata": {"window": "So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first . ", "original_text": "Please go \nahead.  \n \n"}, "hash": "7973b53eabc4ab64985e5f0e92dc799c3cac9feb17ced23738fd7f31a1f44571", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen. ", "start_char_idx": 1680, "end_char_idx": 1768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e62a724-e8d6-42e3-8796-217bf742fa4f": {"__data__": {"id_": "7e62a724-e8d6-42e3-8796-217bf742fa4f", "embedding": null, "metadata": {"window": "So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first . ", "original_text": "Please go \nahead.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ab9b04e-75bd-427c-9682-0e5d8b102711", "node_type": "1", "metadata": {"window": "And \nof course, part of this is also working with the supply base and we indicated that we're working on the \ndistribution fees as well so that the supply base does their part, we do our part and our c ustomers are \ngoing to have to absorb this as well .  So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys . ", "original_text": "Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen. ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2ce65d78e4fd0f2ad856027fb23292b4bcd98d81965d45fc8f5864283aa0449", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f1bf703-5dfc-4c12-99e1-3edb7d4a4a9f", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere. ", "original_text": "Charles Rhyee:  Yeah . "}, "hash": "00012dd20f4ee93d64e0a3bc415e7f353acd145e3e155865e6dba133b61f2c70", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 1768, "end_char_idx": 1790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f1bf703-5dfc-4c12-99e1-3edb7d4a4a9f": {"__data__": {"id_": "6f1bf703-5dfc-4c12-99e1-3edb7d4a4a9f", "embedding": null, "metadata": {"window": "Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere. ", "original_text": "Charles Rhyee:  Yeah . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e62a724-e8d6-42e3-8796-217bf742fa4f", "node_type": "1", "metadata": {"window": "So it's a whole industry has to address this and that's the \ncollaborative approach that we're taking with it .  Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first . ", "original_text": "Please go \nahead.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efc55960377703861a00683832840756e2f395715ee005f17c850f6d56c8a1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c23dee31-6b64-4233-9081-952341ffbb58", "node_type": "1", "metadata": {"window": "Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality . ", "original_text": "Thanks for taking the questions, guys . "}, "hash": "0c28866b477fa7d9dd1ca67bb391d57af758f01d82de20251236ca1fea1d1742", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  Yeah . ", "start_char_idx": 1790, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c23dee31-6b64-4233-9081-952341ffbb58": {"__data__": {"id_": "c23dee31-6b64-4233-9081-952341ffbb58", "embedding": null, "metadata": {"window": "Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality . ", "original_text": "Thanks for taking the questions, guys . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f1bf703-5dfc-4c12-99e1-3edb7d4a4a9f", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere. ", "original_text": "Charles Rhyee:  Yeah . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb997358182f1a0d70d7abd0d5cb70c0024b67e9e700b6e5da869b34254981bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c17c3062-74cd-47cc-bb69-0be0182686e5", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n", "original_text": "Just two real quick ones, maybe on the \nmodel first . "}, "hash": "c2a9ade8221458059d67ef040eb3c258162b70fd995933b3685c154fe3e71d07", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the questions, guys . ", "start_char_idx": 1813, "end_char_idx": 1853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c17c3062-74cd-47cc-bb69-0be0182686e5": {"__data__": {"id_": "c17c3062-74cd-47cc-bb69-0be0182686e5", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n", "original_text": "Just two real quick ones, maybe on the \nmodel first . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c23dee31-6b64-4233-9081-952341ffbb58", "node_type": "1", "metadata": {"window": "Operator:   The next question comes from the line of Charles Rhyee call ing from Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality . ", "original_text": "Thanks for taking the questions, guys . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efb71a48d380800c9b64f12087a1ec25fb6ea5c2092b5d854346ded705cd3e1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e78b1639-1b47-470b-b889-e8e9ce09a9e0", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah . ", "original_text": "Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere. "}, "hash": "0c2bca17592e915e0a1cbf9aef85329ee266b38cec41855440942caf6085fa78", "class_name": "RelatedNodeInfo"}}, "text": "Just two real quick ones, maybe on the \nmodel first . ", "start_char_idx": 1853, "end_char_idx": 1907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e78b1639-1b47-470b-b889-e8e9ce09a9e0": {"__data__": {"id_": "e78b1639-1b47-470b-b889-e8e9ce09a9e0", "embedding": null, "metadata": {"window": "Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah . ", "original_text": "Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere. ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c17c3062-74cd-47cc-bb69-0be0182686e5", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n", "original_text": "Just two real quick ones, maybe on the \nmodel first . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca0f245737e639fb98d700157bb49f0985906db93893a88b69cf2ef8e1221937", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f99c38b8-c7ed-4b0c-b327-b66b1276251d", "node_type": "1", "metadata": {"window": "Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that . ", "original_text": "It's a little different than I think when you look back in normal seasonality . "}, "hash": "51ea0bff1763d890500b14bfaa13caae8bf8b151cbee927ddce2a0311a3ad056", "class_name": "RelatedNodeInfo"}}, "text": "Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere. ", "start_char_idx": 1907, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f99c38b8-c7ed-4b0c-b327-b66b1276251d": {"__data__": {"id_": "f99c38b8-c7ed-4b0c-b327-b66b1276251d", "embedding": null, "metadata": {"window": "Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that . ", "original_text": "It's a little different than I think when you look back in normal seasonality . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e78b1639-1b47-470b-b889-e8e9ce09a9e0", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yeah .  Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah . ", "original_text": "Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere. ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12183600a6a8180766e21e49341ee49c81ed28006680408a47d8b8693dfee1df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb85778d-3e4c-4171-8e58-3b8078c7caa1", "node_type": "1", "metadata": {"window": "Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year . ", "original_text": "Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n"}, "hash": "7b8f81f61f76242591e14a30da5aa6cdc1b87b1e70ec5edcd8f689247be0d21f", "class_name": "RelatedNodeInfo"}}, "text": "It's a little different than I think when you look back in normal seasonality . ", "start_char_idx": 2112, "end_char_idx": 2192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb85778d-3e4c-4171-8e58-3b8078c7caa1": {"__data__": {"id_": "bb85778d-3e4c-4171-8e58-3b8078c7caa1", "embedding": null, "metadata": {"window": "Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year . ", "original_text": "Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f99c38b8-c7ed-4b0c-b327-b66b1276251d", "node_type": "1", "metadata": {"window": "Thanks for taking the questions, guys .  Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that . ", "original_text": "It's a little different than I think when you look back in normal seasonality . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ec651f6e8a32a224ec75b9cc1774cf64ebc5f5a4e807e34b5ea1dea40aa3795", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7769a66-73f7-4ea9-9393-ba34254094c1", "node_type": "1", "metadata": {"window": "Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically . ", "original_text": "Jason Hollar:  Yeah . "}, "hash": "de77e5adc17dea2ac7b5eba955df6587be8b8cdb2d6ac86471ba2dac0889a78e", "class_name": "RelatedNodeInfo"}}, "text": "Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n", "start_char_idx": 2192, "end_char_idx": 2278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7769a66-73f7-4ea9-9393-ba34254094c1": {"__data__": {"id_": "b7769a66-73f7-4ea9-9393-ba34254094c1", "embedding": null, "metadata": {"window": "Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically . ", "original_text": "Jason Hollar:  Yeah . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb85778d-3e4c-4171-8e58-3b8078c7caa1", "node_type": "1", "metadata": {"window": "Just two real quick ones, maybe on the \nmodel first .  Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year . ", "original_text": "Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4bde2a54733c57127b1abdb2affa210e113a5a09fe28494bdba3e73f9db5aa2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4126702c-fb9d-4367-a078-ebefd584b191", "node_type": "1", "metadata": {"window": "It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter . ", "original_text": "Let me take that . "}, "hash": "4b1d701ebc4a50c9604a7da05fb3875e1cd79c9118a3fbb70ff569b32d486564", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah . ", "start_char_idx": 2278, "end_char_idx": 2300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4126702c-fb9d-4367-a078-ebefd584b191": {"__data__": {"id_": "4126702c-fb9d-4367-a078-ebefd584b191", "embedding": null, "metadata": {"window": "It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter . ", "original_text": "Let me take that . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7769a66-73f7-4ea9-9393-ba34254094c1", "node_type": "1", "metadata": {"window": "Trish, I think you talked about Pharma distribution, we should think about the , it sounds \nlike you kind of sa ying the contribution should be kind of even through the back half of the fiscal year \nhere.  It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically . ", "original_text": "Jason Hollar:  Yeah . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f386ad930c0dafbd14855dc20aaddf5fd54061554aec231eeb807771381f0bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63611da9-db92-4348-a12a-d035e2f5b669", "node_type": "1", "metadata": {"window": "Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit. ", "original_text": "So that comment was the growth rates were going to be even \nyear over year . "}, "hash": "79b475faea6219d4a70749362701b8f9a0bfc28ba1679d726fd3249a247f8b87", "class_name": "RelatedNodeInfo"}}, "text": "Let me take that . ", "start_char_idx": 2300, "end_char_idx": 2319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63611da9-db92-4348-a12a-d035e2f5b669": {"__data__": {"id_": "63611da9-db92-4348-a12a-d035e2f5b669", "embedding": null, "metadata": {"window": "Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit. ", "original_text": "So that comment was the growth rates were going to be even \nyear over year . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4126702c-fb9d-4367-a078-ebefd584b191", "node_type": "1", "metadata": {"window": "It's a little different than I think when you look back in normal seasonality .  Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter . ", "original_text": "Let me take that . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ecfe6f6106c8444000fb67bafaaa8beb73fc137a69e2b03fd2335ff69a5f3a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72400856-d3dd-49d5-9084-18f90a8756d1", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n", "original_text": "So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically . "}, "hash": "478033aa642013d3e0ad165493ca89a46646ebe7197c97fe076e94ad1817862f", "class_name": "RelatedNodeInfo"}}, "text": "So that comment was the growth rates were going to be even \nyear over year . ", "start_char_idx": 2319, "end_char_idx": 2396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72400856-d3dd-49d5-9084-18f90a8756d1": {"__data__": {"id_": "72400856-d3dd-49d5-9084-18f90a8756d1", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n", "original_text": "So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63611da9-db92-4348-a12a-d035e2f5b669", "node_type": "1", "metadata": {"window": "Anything specific that \nyou'd call out to, you know, why that might be this year?  \n \n Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit. ", "original_text": "So that comment was the growth rates were going to be even \nyear over year . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5a3cd8486a9685ed5874a008e95d19ff429e88b0aa00dc1d860d3a6e6456c9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daffc66c-16a6-4878-a781-d70d7a275e32", "node_type": "1", "metadata": {"window": "Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see . ", "original_text": "You know, we're still talking less than 5% contribution, but that is all in the third \nquarter . "}, "hash": "cf9d8d9e6cbc820bf51b5a7a54fddd3c40479753d400e4121a07b42fa75bf46f", "class_name": "RelatedNodeInfo"}}, "text": "So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically . ", "start_char_idx": 2396, "end_char_idx": 2601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daffc66c-16a6-4878-a781-d70d7a275e32": {"__data__": {"id_": "daffc66c-16a6-4878-a781-d70d7a275e32", "embedding": null, "metadata": {"window": "Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see . ", "original_text": "You know, we're still talking less than 5% contribution, but that is all in the third \nquarter . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72400856-d3dd-49d5-9084-18f90a8756d1", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah .  Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n", "original_text": "So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e0d369fd4d9b9336fb929ac3077021b113123aadf55875f5b2344b7418b6d36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0017eae-dffc-47ce-8e90-e90bc3c2a6ad", "node_type": "1", "metadata": {"window": "So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay . ", "original_text": "So sequentially, we would still expect the third quarter to have that element associated with \nit. "}, "hash": "e7d1f979c3e963b09803e92af54f9eb8e7dcac85ff71a22fdacf97ba24cfdb69", "class_name": "RelatedNodeInfo"}}, "text": "You know, we're still talking less than 5% contribution, but that is all in the third \nquarter . ", "start_char_idx": 2601, "end_char_idx": 2698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0017eae-dffc-47ce-8e90-e90bc3c2a6ad": {"__data__": {"id_": "e0017eae-dffc-47ce-8e90-e90bc3c2a6ad", "embedding": null, "metadata": {"window": "So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay . ", "original_text": "So sequentially, we would still expect the third quarter to have that element associated with \nit. ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daffc66c-16a6-4878-a781-d70d7a275e32", "node_type": "1", "metadata": {"window": "Let me take that .  So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see . ", "original_text": "You know, we're still talking less than 5% contribution, but that is all in the third \nquarter . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5c844c268a250a7010c867299a20ddf3ae9f2545b45abfd59254d42b0af1a14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d452036-43dc-4d86-a249-7538efdc5489", "node_type": "1", "metadata": {"window": "So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard . ", "original_text": "Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n"}, "hash": "d7359a51c78252ab04b97398ae12489487b2ca2ad04fbe627d3d215fa437c424", "class_name": "RelatedNodeInfo"}}, "text": "So sequentially, we would still expect the third quarter to have that element associated with \nit. ", "start_char_idx": 2698, "end_char_idx": 2797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d452036-43dc-4d86-a249-7538efdc5489": {"__data__": {"id_": "5d452036-43dc-4d86-a249-7538efdc5489", "embedding": null, "metadata": {"window": "So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard . ", "original_text": "Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0017eae-dffc-47ce-8e90-e90bc3c2a6ad", "node_type": "1", "metadata": {"window": "So that comment was the growth rates were going to be even \nyear over year .  So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay . ", "original_text": "So sequentially, we would still expect the third quarter to have that element associated with \nit. ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da35fea565dd351095290ccf6f69ae976b08f7594fcc6845c03d9cb0028cfbcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad8fe1e0-d707-4782-ae4c-d27d5754dee4", "node_type": "1", "metadata": {"window": "You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home. ", "original_text": "Charles Rhyee:  I see . "}, "hash": "658d6320f2cbef938bba7adb150bd2eb6356b04fde238c53ddfbe25afbbdbd13", "class_name": "RelatedNodeInfo"}}, "text": "Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n", "start_char_idx": 2797, "end_char_idx": 2930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad8fe1e0-d707-4782-ae4c-d27d5754dee4": {"__data__": {"id_": "ad8fe1e0-d707-4782-ae4c-d27d5754dee4", "embedding": null, "metadata": {"window": "You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home. ", "original_text": "Charles Rhyee:  I see . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d452036-43dc-4d86-a249-7538efdc5489", "node_type": "1", "metadata": {"window": "So you're exactly right, Charles, that there will continue to be the expectation of \nnormal seasonality that largely comes from the brand inflation, albeit much lower than what it has \nbeen historically .  You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard . ", "original_text": "Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d7c78010f13471a77652be6206f3e40d80ed7537aeca13458d8d3bf32341115", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85ecb61c-935f-4012-9912-aa07d0f3334d", "node_type": "1", "metadata": {"window": "So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry . ", "original_text": "Okay . "}, "hash": "13829fc7fb697e7f5d03f02285e6cd68fffb56f93b25dfe6bd68a4f355299d1d", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  I see . ", "start_char_idx": 2930, "end_char_idx": 2954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85ecb61c-935f-4012-9912-aa07d0f3334d": {"__data__": {"id_": "85ecb61c-935f-4012-9912-aa07d0f3334d", "embedding": null, "metadata": {"window": "So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry . ", "original_text": "Okay . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad8fe1e0-d707-4782-ae4c-d27d5754dee4", "node_type": "1", "metadata": {"window": "You know, we're still talking less than 5% contribution, but that is all in the third \nquarter .  So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home. ", "original_text": "Charles Rhyee:  I see . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de40e44e2b84588b7e0e0acb2f4f8f3913e44de3cd8a9e6ee1714de22ee3c54f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffc90a20-3964-4f21-a74b-a8498d69531c", "node_type": "1", "metadata": {"window": "Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver . ", "original_text": "I might have misheard . "}, "hash": "743797ed83afc22fafd0c5275c277590be80d44d07f390ca736fd14965fe7583", "class_name": "RelatedNodeInfo"}}, "text": "Okay . ", "start_char_idx": 2954, "end_char_idx": 2961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffc90a20-3964-4f21-a74b-a8498d69531c": {"__data__": {"id_": "ffc90a20-3964-4f21-a74b-a8498d69531c", "embedding": null, "metadata": {"window": "Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver . ", "original_text": "I might have misheard . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85ecb61c-935f-4012-9912-aa07d0f3334d", "node_type": "1", "metadata": {"window": "So sequentially, we would still expect the third quarter to have that element associated with \nit.  Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry . ", "original_text": "Okay . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6bd7ba88e356e5fb566ca95737b2b212e0fb595ecc892f0cef95d09e884db4a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d5d9725-13de-41b6-b36d-86f7aaee9c8d", "node_type": "1", "metadata": {"window": "Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness . ", "original_text": "Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home. "}, "hash": "513cbdd0f5565786ea68d7ace3d958000e6d546134cd8224fd04642ce9b91832", "class_name": "RelatedNodeInfo"}}, "text": "I might have misheard . ", "start_char_idx": 2961, "end_char_idx": 2985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d5d9725-13de-41b6-b36d-86f7aaee9c8d": {"__data__": {"id_": "3d5d9725-13de-41b6-b36d-86f7aaee9c8d", "embedding": null, "metadata": {"window": "Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness . ", "original_text": "Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home. ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffc90a20-3964-4f21-a74b-a8498d69531c", "node_type": "1", "metadata": {"window": "Trish's comments were specifically related to the year -over-year growth rates being relatively equal \nbetween the two quarters.  \n \n Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver . ", "original_text": "I might have misheard . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "890160b27b0adbc50d9b9fd11c8f1f5f7d182d9233c6128fa8f7b0d82cb745db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "901a2464-fe68-4acc-be13-1ce694854a46", "node_type": "1", "metadata": {"window": "Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n", "original_text": "I'm sorry . "}, "hash": "3cca0b1af3a1bd0d1b0bc951c4108d632bc6f907e9799eeb85c19259f1c9e8bf", "class_name": "RelatedNodeInfo"}}, "text": "Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home. ", "start_char_idx": 2985, "end_char_idx": 3068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "901a2464-fe68-4acc-be13-1ce694854a46": {"__data__": {"id_": "901a2464-fe68-4acc-be13-1ce694854a46", "embedding": null, "metadata": {"window": "Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n", "original_text": "I'm sorry . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d5d9725-13de-41b6-b36d-86f7aaee9c8d", "node_type": "1", "metadata": {"window": "Charles Rhyee:  I see .  Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness . ", "original_text": "Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home. ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6df0ec8d41b2a43570d5672c403644f6021d7e8d8bb31036bf0d7ab74f85737d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bf27700-81a3-4117-92b6-73e66fa7472d", "node_type": "1", "metadata": {"window": "I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure . ", "original_text": "You keep talking about at-Home solutions and how that's a \ngood growth driver . "}, "hash": "fe1a48afc4a6a0c5e701c8115dd3eb0e89c38b964ab9e759f83d0c39a83cac09", "class_name": "RelatedNodeInfo"}}, "text": "I'm sorry . ", "start_char_idx": 3068, "end_char_idx": 3080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bf27700-81a3-4117-92b6-73e66fa7472d": {"__data__": {"id_": "5bf27700-81a3-4117-92b6-73e66fa7472d", "embedding": null, "metadata": {"window": "I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure . ", "original_text": "You keep talking about at-Home solutions and how that's a \ngood growth driver . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "901a2464-fe68-4acc-be13-1ce694854a46", "node_type": "1", "metadata": {"window": "Okay .  I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n", "original_text": "I'm sorry . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf7c18f578126d167d0ef3e45bcbda375853eed435f92d7ef85936adab88a663", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "039804b1-2d98-47db-b5fe-e5d11e054183", "node_type": "1", "metadata": {"window": "Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah . ", "original_text": "In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness . "}, "hash": "d30b097bca5cc138427f72c9eacd429109602655b28d7aa8f5dce8923ea850b6", "class_name": "RelatedNodeInfo"}}, "text": "You keep talking about at-Home solutions and how that's a \ngood growth driver . ", "start_char_idx": 3080, "end_char_idx": 3160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "039804b1-2d98-47db-b5fe-e5d11e054183": {"__data__": {"id_": "039804b1-2d98-47db-b5fe-e5d11e054183", "embedding": null, "metadata": {"window": "Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah . ", "original_text": "In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bf27700-81a3-4117-92b6-73e66fa7472d", "node_type": "1", "metadata": {"window": "I might have misheard .  Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure . ", "original_text": "You keep talking about at-Home solutions and how that's a \ngood growth driver . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9660433a0669d8b1d23538f4e5840e7361f5cd0375bf14b38b350fc0d000c2d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c8f90e2-e68f-47fb-a297-579fa20cdf46", "node_type": "1", "metadata": {"window": "I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on . ", "original_text": "Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n"}, "hash": "b6d021f505330ea1410b3259dde95fc41f94c1d6bfb8f6271c210fc8260a8ee3", "class_name": "RelatedNodeInfo"}}, "text": "In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness . ", "start_char_idx": 3160, "end_char_idx": 3252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c8f90e2-e68f-47fb-a297-579fa20cdf46": {"__data__": {"id_": "5c8f90e2-e68f-47fb-a297-579fa20cdf46", "embedding": null, "metadata": {"window": "I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on . ", "original_text": "Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "039804b1-2d98-47db-b5fe-e5d11e054183", "node_type": "1", "metadata": {"window": "Maybe if I could just follow up on you know, you \nkeep talking about the a t-Home.  I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah . ", "original_text": "In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef3282d8ef4bf3201f2484847886c5e555363fdd43327c716899c87302c1cb00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1df31580-c67b-40a3-beb6-ff6003703457", "node_type": "1", "metadata": {"window": "You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "Jason Hollar:  Sure . "}, "hash": "e6bad0690b0245df94641fe51ce8901b2f4b13a33a8285b8a46846bfcd8d4028", "class_name": "RelatedNodeInfo"}}, "text": "Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n", "start_char_idx": 3252, "end_char_idx": 3421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1df31580-c67b-40a3-beb6-ff6003703457": {"__data__": {"id_": "1df31580-c67b-40a3-beb6-ff6003703457", "embedding": null, "metadata": {"window": "You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "Jason Hollar:  Sure . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c8f90e2-e68f-47fb-a297-579fa20cdf46", "node_type": "1", "metadata": {"window": "I'm sorry .  You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on . ", "original_text": "Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06399fbd7c6fa1603462ef31901cc2e541d3ebd166f23440e0bcf11d235cd5be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbb0423a-e878-432d-8f52-c3eccf99bcce", "node_type": "1", "metadata": {"window": "In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "Yeah . "}, "hash": "54b24f08035e5fa1b1c8c475657b6473ca0f318535c93c4bce26accf997f491f", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure . ", "start_char_idx": 3421, "end_char_idx": 3443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbb0423a-e878-432d-8f52-c3eccf99bcce": {"__data__": {"id_": "bbb0423a-e878-432d-8f52-c3eccf99bcce", "embedding": null, "metadata": {"window": "In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "Yeah . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1df31580-c67b-40a3-beb6-ff6003703457", "node_type": "1", "metadata": {"window": "You keep talking about at-Home solutions and how that's a \ngood growth driver .  In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "Jason Hollar:  Sure . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "229956380f9d1d22010ea5d82fa1607444958d228d5dc806792188ca0a3b03ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8c1a1b9-a24b-4161-a7d7-a81f77ffb668", "node_type": "1", "metadata": {"window": "Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on . "}, "hash": "cae72ec40265223ee505187924f68bf53811a31f75a13d8c5f029fe38ad5e4b5", "class_name": "RelatedNodeInfo"}}, "text": "Yeah . ", "start_char_idx": 1806, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8c1a1b9-a24b-4161-a7d7-a81f77ffb668": {"__data__": {"id_": "d8c1a1b9-a24b-4161-a7d7-a81f77ffb668", "embedding": null, "metadata": {"window": "Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbb0423a-e878-432d-8f52-c3eccf99bcce", "node_type": "1", "metadata": {"window": "In the past, you've kind of given a little bit of a breakout of the size of the \nbusiness .  Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "Yeah . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa6e218ba04ea63f961d5d79e8c174cbd3e565f910d2cd1e96bdddf868aacc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f1a2803-75b2-4314-bf22-7aa8472c50f7", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "And that business, I think "}, "hash": "4510e95c36c5f3b15c9f0da55a188c229d76d950dbaefc85720fefd8372a0e2b", "class_name": "RelatedNodeInfo"}}, "text": "You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on . ", "start_char_idx": 3450, "end_char_idx": 3590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f1a2803-75b2-4314-bf22-7aa8472c50f7": {"__data__": {"id_": "9f1a2803-75b2-4314-bf22-7aa8472c50f7", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "And that business, I think ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "294df374-c06a-492b-94ba-193af1a92c42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad045095a7fb91cba27887bebae9fe649bba51b3c8a3109a94831ea0a6340d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8c1a1b9-a24b-4161-a7d7-a81f77ffb668", "node_type": "1", "metadata": {"window": "Is there any kind of additional color you can give us here in terms of  sizing of this business, \nyou know, how much it's grown relative to the rest of the segment?  \n \n Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a2ee4c35ce48391ee57be28294bf7bdd77b0c5369ba14a31e681ee9451f972a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d95b88e-f611-4a42-aaf9-1307cfe44ce3", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n", "original_text": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue . "}, "hash": "9bcc1a7e357566d411d282d474f68845133818adfcb11fdd65e4a8fac2c7a995", "class_name": "RelatedNodeInfo"}}, "text": "And that business, I think ", "start_char_idx": 3590, "end_char_idx": 3617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d95b88e-f611-4a42-aaf9-1307cfe44ce3": {"__data__": {"id_": "6d95b88e-f611-4a42-aaf9-1307cfe44ce3", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n", "original_text": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f1a2803-75b2-4314-bf22-7aa8472c50f7", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure .  Yeah .  You can also go to our segment  foot note, this is one of the two \nbusinesses we every quarter provide incremental revenue information on .  And that business, I think ", "original_text": "And that business, I think ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a888101c520660dc91f2815f0b6d9d7cdadcf775b67d7e9587433c6145f8086", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "826c18d3-96a8-4e63-8fc7-fbc883300d82", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays . ", "original_text": "And I believe for both the first and second quarter, we grew it by \naround 9% . "}, "hash": "dcabf120f80a5c2f52876047efad8af096589013f9ae461c47ef2b3b353a387b", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue . ", "start_char_idx": 0, "end_char_idx": 59, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "826c18d3-96a8-4e63-8fc7-fbc883300d82": {"__data__": {"id_": "826c18d3-96a8-4e63-8fc7-fbc883300d82", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays . ", "original_text": "And I believe for both the first and second quarter, we grew it by \naround 9% . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d95b88e-f611-4a42-aaf9-1307cfe44ce3", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n", "original_text": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f26c31767defde17b8d8e81b25e4d20f75c0297677dfdda1d1fb53c19ef8238", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a138579e-010f-48e2-a288-303e695d0659", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n", "original_text": "But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n"}, "hash": "39055431788558df0eb9cb60c746e29ee20ba7125283ddcc82930d9e799d5742", "class_name": "RelatedNodeInfo"}}, "text": "And I believe for both the first and second quarter, we grew it by \naround 9% . ", "start_char_idx": 59, "end_char_idx": 139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a138579e-010f-48e2-a288-303e695d0659": {"__data__": {"id_": "a138579e-010f-48e2-a288-303e695d0659", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n", "original_text": "But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "826c18d3-96a8-4e63-8fc7-fbc883300d82", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays . ", "original_text": "And I believe for both the first and second quarter, we grew it by \naround 9% . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8096bbdf6cd0ca1a5a08dfd8a94e1a7b2e83a9234f9451c34199eb5ad1d4e363", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db473f30-37e5-4b3d-a549-d5c52408b74f", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great . ", "original_text": "Charles Rhyee:  Grea t, thank you.  \n \n"}, "hash": "0382d8a160e52efd5393d80d4ceced2091ac557e18bc325840607736eac217b5", "class_name": "RelatedNodeInfo"}}, "text": "But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n", "start_char_idx": 139, "end_char_idx": 234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db473f30-37e5-4b3d-a549-d5c52408b74f": {"__data__": {"id_": "db473f30-37e5-4b3d-a549-d5c52408b74f", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great . ", "original_text": "Charles Rhyee:  Grea t, thank you.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a138579e-010f-48e2-a288-303e695d0659", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n", "original_text": "But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad7a68e1f2354499771cc58a07e1946b876044f8099d0cf2340e6efb0c2d48fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70f4e11b-110d-4012-a513-979d7ce30e7c", "node_type": "1", "metadata": {"window": "And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks . ", "original_text": "Operator:  The next question comes from the line of Steven Valiquette calling from Barclays . "}, "hash": "6ecb16992ab367078f92a8e9a1dab436777caafe9d0f02bb80588ac0afbbfd53", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  Grea t, thank you.  \n \n", "start_char_idx": 234, "end_char_idx": 273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70f4e11b-110d-4012-a513-979d7ce30e7c": {"__data__": {"id_": "70f4e11b-110d-4012-a513-979d7ce30e7c", "embedding": null, "metadata": {"window": "And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks . ", "original_text": "Operator:  The next question comes from the line of Steven Valiquette calling from Barclays . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db473f30-37e5-4b3d-a549-d5c52408b74f", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great . ", "original_text": "Charles Rhyee:  Grea t, thank you.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07139d9c7a27c30fd0900497ad25804ecaf6046c8077f8763aaa6b12b4ce74e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d3f4226-b9a1-413d-b64f-2ab63909140f", "node_type": "1", "metadata": {"window": "But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone . ", "original_text": "Please \ngo ahead.  \n \n"}, "hash": "39381ff05ade9392b8142d694c43b938e56edf6d239cc26ec4441d42e88aefd7", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from the line of Steven Valiquette calling from Barclays . ", "start_char_idx": 273, "end_char_idx": 367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d3f4226-b9a1-413d-b64f-2ab63909140f": {"__data__": {"id_": "3d3f4226-b9a1-413d-b64f-2ab63909140f", "embedding": null, "metadata": {"window": "But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone . ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70f4e11b-110d-4012-a513-979d7ce30e7c", "node_type": "1", "metadata": {"window": "And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks . ", "original_text": "Operator:  The next question comes from the line of Steven Valiquette calling from Barclays . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "324bdcb6e43121f327f625583a5e7ba0f8b817828bc29e9874d02cb4625b855d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c141f2e-7449-426b-8c00-1fab9eabb506", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n", "original_text": "Steven Valiquette:   Great . "}, "hash": "9da0b2fb96997fb0a0ebbbeb0771cdde562cb5b38d48a4e086f73c75b5c36540", "class_name": "RelatedNodeInfo"}}, "text": "Please \ngo ahead.  \n \n", "start_char_idx": 367, "end_char_idx": 389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c141f2e-7449-426b-8c00-1fab9eabb506": {"__data__": {"id_": "2c141f2e-7449-426b-8c00-1fab9eabb506", "embedding": null, "metadata": {"window": "Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n", "original_text": "Steven Valiquette:   Great . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d3f4226-b9a1-413d-b64f-2ab63909140f", "node_type": "1", "metadata": {"window": "But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone . ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f413144cbd5a17dc7b89b2b47f7b7b3d35243442dff49be7d0927e03f22f3651", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d65e06c2-50d1-4743-806a-c99fc97433ca", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that . ", "original_text": "Thanks . "}, "hash": "2510518e4fa8587ba2e16b07ed197133baff2823572184243f33637f35e579d1", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette:   Great . ", "start_char_idx": 389, "end_char_idx": 418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d65e06c2-50d1-4743-806a-c99fc97433ca": {"__data__": {"id_": "d65e06c2-50d1-4743-806a-c99fc97433ca", "embedding": null, "metadata": {"window": "Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that . ", "original_text": "Thanks . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c141f2e-7449-426b-8c00-1fab9eabb506", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Grea t, thank you.  \n \n Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n", "original_text": "Steven Valiquette:   Great . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7374af3e136d0987247fd9057e3577d5aaf1597d5cef8191a0432597c95d11af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91e3a5d4-0e7f-483f-8508-af3991fa1bfa", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?  ", "original_text": "Good morning, everyone . "}, "hash": "18a3ce926b8e64137b6ce90f4e4eb6eef41972beff72f1a83903ecc8d1c4fca4", "class_name": "RelatedNodeInfo"}}, "text": "Thanks . ", "start_char_idx": 418, "end_char_idx": 427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91e3a5d4-0e7f-483f-8508-af3991fa1bfa": {"__data__": {"id_": "91e3a5d4-0e7f-483f-8508-af3991fa1bfa", "embedding": null, "metadata": {"window": "Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?  ", "original_text": "Good morning, everyone . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d65e06c2-50d1-4743-806a-c99fc97433ca", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of Steven Valiquette calling from Barclays .  Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that . ", "original_text": "Thanks . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eafcd8352212640c8c4a2daff12d46cee2d11430bbc963cb42c27f812848b5ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04f17601-578c-41d2-aaaa-41680e61939b", "node_type": "1", "metadata": {"window": "Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?  ", "original_text": "So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n"}, "hash": "55dcd81da31eb132c8bd2d18b1ea45154f22247a4abe2230bd714ba8dbaa2ac7", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, everyone . ", "start_char_idx": 427, "end_char_idx": 452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04f17601-578c-41d2-aaaa-41680e61939b": {"__data__": {"id_": "04f17601-578c-41d2-aaaa-41680e61939b", "embedding": null, "metadata": {"window": "Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?  ", "original_text": "So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91e3a5d4-0e7f-483f-8508-af3991fa1bfa", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?  ", "original_text": "Good morning, everyone . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50a84f4874bb7bc619cdee79b00ec02539a8f6d3c3fa9a1e78c1d476fe123c60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb1b05a8-0ecb-4a91-9f39-5644097a4140", "node_type": "1", "metadata": {"window": "Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well . ", "original_text": "So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that . "}, "hash": "fbf9c70c85c6ae21fe39895076ca2a79f27ebafb7bc4fe5c0da32b91a2059cd9", "class_name": "RelatedNodeInfo"}}, "text": "So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n", "start_char_idx": 452, "end_char_idx": 598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb1b05a8-0ecb-4a91-9f39-5644097a4140": {"__data__": {"id_": "fb1b05a8-0ecb-4a91-9f39-5644097a4140", "embedding": null, "metadata": {"window": "Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well . ", "original_text": "So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04f17601-578c-41d2-aaaa-41680e61939b", "node_type": "1", "metadata": {"window": "Steven Valiquette:   Great .  Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?  ", "original_text": "So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b1807d45dfaad5f875e6e9170881367b1578d7d186ff0b043079daafa4f3f6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c93b3335-b168-4002-9569-7d29ad7a725b", "node_type": "1", "metadata": {"window": "Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?  ", "original_text": "When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?  "}, "hash": "60b84000003b1aad3a77d74889f1ac1a2b080d126c9b1f17ad254e094910af63", "class_name": "RelatedNodeInfo"}}, "text": "So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that . ", "start_char_idx": 598, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c93b3335-b168-4002-9569-7d29ad7a725b": {"__data__": {"id_": "c93b3335-b168-4002-9569-7d29ad7a725b", "embedding": null, "metadata": {"window": "Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?  ", "original_text": "When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?  ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb1b05a8-0ecb-4a91-9f39-5644097a4140", "node_type": "1", "metadata": {"window": "Thanks .  Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well . ", "original_text": "So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a035ab5450e8956201251d437e0f76fc73e8fc83dba5e99550830f4c0f802c08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0c3ee60-fed9-4979-9b8d-ebdee76ae4b2", "node_type": "1", "metadata": {"window": "So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n", "original_text": "Or is it just better buying through Red Oak?  "}, "hash": "73efc2526aa85cca58414159d481d9917d028616d6e34c6addbfe0d81ecfe449", "class_name": "RelatedNodeInfo"}}, "text": "When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?  ", "start_char_idx": 724, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0c3ee60-fed9-4979-9b8d-ebdee76ae4b2": {"__data__": {"id_": "c0c3ee60-fed9-4979-9b8d-ebdee76ae4b2", "embedding": null, "metadata": {"window": "So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n", "original_text": "Or is it just better buying through Red Oak?  ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c93b3335-b168-4002-9569-7d29ad7a725b", "node_type": "1", "metadata": {"window": "Good morning, everyone .  So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?  ", "original_text": "When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?  ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2152e13bee8050079ba8af98debac0beb08cadb1a9a59d5022c979e93fd8cd8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0adc0a7f-317d-4396-bb4f-0173ec047bc4", "node_type": "1", "metadata": {"window": "So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure . ", "original_text": "And also, it's \nbeen really a much stronger new first -time generic launch calendar as well . "}, "hash": "5c47ab19ed152543a203c51c02fe66a9be2744627f8808e413b8dde60ba343d4", "class_name": "RelatedNodeInfo"}}, "text": "Or is it just better buying through Red Oak?  ", "start_char_idx": 845, "end_char_idx": 891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0adc0a7f-317d-4396-bb4f-0173ec047bc4": {"__data__": {"id_": "0adc0a7f-317d-4396-bb4f-0173ec047bc4", "embedding": null, "metadata": {"window": "So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure . ", "original_text": "And also, it's \nbeen really a much stronger new first -time generic launch calendar as well . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0c3ee60-fed9-4979-9b8d-ebdee76ae4b2", "node_type": "1", "metadata": {"window": "So on page five in the slide deck, you \ntalked about the quote -unquot e, you know, just generics program as one of the positive key variables . \n So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n", "original_text": "Or is it just better buying through Red Oak?  ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10fd0470967e5a0a08db1da247b116c90ab27eb846fb2f17240418840fd9fe41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dd6ae99-8dc9-458c-80d0-7f35f2cd0934", "node_type": "1", "metadata": {"window": "When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah . ", "original_text": "But just curious, what's \nthe biggest piece within your comm ent about just the generics program?  "}, "hash": "4acefd96a6a3da6ab57d76665787e714c941d535d458ee36555186f16e2a046e", "class_name": "RelatedNodeInfo"}}, "text": "And also, it's \nbeen really a much stronger new first -time generic launch calendar as well . ", "start_char_idx": 891, "end_char_idx": 985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dd6ae99-8dc9-458c-80d0-7f35f2cd0934": {"__data__": {"id_": "4dd6ae99-8dc9-458c-80d0-7f35f2cd0934", "embedding": null, "metadata": {"window": "When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah . ", "original_text": "But just curious, what's \nthe biggest piece within your comm ent about just the generics program?  ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0adc0a7f-317d-4396-bb4f-0173ec047bc4", "node_type": "1", "metadata": {"window": "So I just wanted to get a little more color just to confirm kind of what referring to as the biggest \ncomponent within that .  When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure . ", "original_text": "And also, it's \nbeen really a much stronger new first -time generic launch calendar as well . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8e44f552d3f7bf92a9337d64d40ccfdfd956213db5e48ba4eea5934c14bdfe2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0611d43-60cf-4713-bc05-0390e1eaf5e2", "node_type": "1", "metadata": {"window": "Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume . ", "original_text": "Thanks.  \n \n"}, "hash": "c2f41204dee7325c110affd1cd40c4d285b33965b93d10bcb485bc468d9df425", "class_name": "RelatedNodeInfo"}}, "text": "But just curious, what's \nthe biggest piece within your comm ent about just the generics program?  ", "start_char_idx": 985, "end_char_idx": 1084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0611d43-60cf-4713-bc05-0390e1eaf5e2": {"__data__": {"id_": "d0611d43-60cf-4713-bc05-0390e1eaf5e2", "embedding": null, "metadata": {"window": "Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume . ", "original_text": "Thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dd6ae99-8dc9-458c-80d0-7f35f2cd0934", "node_type": "1", "metadata": {"window": "When thinking about are you just referring to just better g eneric volume and \ngeneric compliance rates with customers?   Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah . ", "original_text": "But just curious, what's \nthe biggest piece within your comm ent about just the generics program?  ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8014c46398a824e959e6c8142c36b0b5e8dd01aafc4e40e55f5add00dacda3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f6c8f47-6197-4076-ac7f-f1bd37f1dc39", "node_type": "1", "metadata": {"window": "And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit . ", "original_text": "Jason Hollar:  Sure . "}, "hash": "aae401a90a612984d5060e1129a056fdbb6796cb7e865547643e600d782e3210", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1084, "end_char_idx": 1096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f6c8f47-6197-4076-ac7f-f1bd37f1dc39": {"__data__": {"id_": "3f6c8f47-6197-4076-ac7f-f1bd37f1dc39", "embedding": null, "metadata": {"window": "And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit . ", "original_text": "Jason Hollar:  Sure . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0611d43-60cf-4713-bc05-0390e1eaf5e2", "node_type": "1", "metadata": {"window": "Or is it just better buying through Red Oak?   And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume . ", "original_text": "Thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6b815c2285308d28a3a96f935b82fd9987328c65a10a55e08375128a0c61497", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93385183-1f82-4efc-964d-2ede51fca0c4", "node_type": "1", "metadata": {"window": "But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance . ", "original_text": "Yeah . "}, "hash": "5f0ff336395619cc61dc139a1a0a7d0f08caf9a44db4a840543a61abacfcbca6", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure . ", "start_char_idx": 1096, "end_char_idx": 1118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93385183-1f82-4efc-964d-2ede51fca0c4": {"__data__": {"id_": "93385183-1f82-4efc-964d-2ede51fca0c4", "embedding": null, "metadata": {"window": "But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance . ", "original_text": "Yeah . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f6c8f47-6197-4076-ac7f-f1bd37f1dc39", "node_type": "1", "metadata": {"window": "And also, it's \nbeen really a much stronger new first -time generic launch calendar as well .  But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit . ", "original_text": "Jason Hollar:  Sure . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f02774548013ea5ba5ff7a53e816a7a5f423d4854bf568e69dfff7065e9f661b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fad0dad-f103-4c45-97d8-3a08117a29a0", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty . ", "original_text": "Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume . "}, "hash": "324c5b3ebc3b9c63d9d4c16027768e9fe53adf7f935b740da580bc4c7ecbe374", "class_name": "RelatedNodeInfo"}}, "text": "Yeah . ", "start_char_idx": 1118, "end_char_idx": 1125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fad0dad-f103-4c45-97d8-3a08117a29a0": {"__data__": {"id_": "4fad0dad-f103-4c45-97d8-3a08117a29a0", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty . ", "original_text": "Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93385183-1f82-4efc-964d-2ede51fca0c4", "node_type": "1", "metadata": {"window": "But just curious, what's \nthe biggest piece within your comm ent about just the generics program?   Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance . ", "original_text": "Yeah . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1d85dada5cebb7cfe6ba413422f2bbaabe06f4ffa14a082cd271570969868f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6067434f-ebb1-40d3-a4de-1304d0006584", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n", "original_text": "I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit . "}, "hash": "124286f99f4a8b4f52ecd2ac7ecdc064819cd696fd5bab31ed5f5514b5aad514", "class_name": "RelatedNodeInfo"}}, "text": "Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume . ", "start_char_idx": 1125, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6067434f-ebb1-40d3-a4de-1304d0006584": {"__data__": {"id_": "6067434f-ebb1-40d3-a4de-1304d0006584", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n", "original_text": "I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fad0dad-f103-4c45-97d8-3a08117a29a0", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty . ", "original_text": "Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1da1a1ffbd7a98f935afc10abb727f9e3f71525c2feb82b96544870b401b115f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "362a4cb3-0e56-4729-825c-da89a740f1b3", "node_type": "1", "metadata": {"window": "Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic . ", "original_text": "Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance . "}, "hash": "cfcd50c2934c2ab2a62aac48f0ce2491ef6879bd53b8a3a06f378e8663a457f4", "class_name": "RelatedNodeInfo"}}, "text": "I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit . ", "start_char_idx": 1247, "end_char_idx": 1360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "362a4cb3-0e56-4729-825c-da89a740f1b3": {"__data__": {"id_": "362a4cb3-0e56-4729-825c-da89a740f1b3", "embedding": null, "metadata": {"window": "Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic . ", "original_text": "Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6067434f-ebb1-40d3-a4de-1304d0006584", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure .  Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n", "original_text": "I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c2ea9e89bbcdfc58596bce6fd832f1f464237e2c1133d23e1665f30ba7723eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac0edbd7-3ba0-4c52-8798-26f361ebb5ca", "node_type": "1", "metadata": {"window": "Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products . ", "original_text": "And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty . "}, "hash": "6c54e9c06ebb0f5e303985aab70f385520a3b70174f508f314ba22ed0e7cd8dc", "class_name": "RelatedNodeInfo"}}, "text": "Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance . ", "start_char_idx": 1360, "end_char_idx": 1461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac0edbd7-3ba0-4c52-8798-26f361ebb5ca": {"__data__": {"id_": "ac0edbd7-3ba0-4c52-8798-26f361ebb5ca", "embedding": null, "metadata": {"window": "Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products . ", "original_text": "And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "362a4cb3-0e56-4729-825c-da89a740f1b3", "node_type": "1", "metadata": {"window": "Yeah .  Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic . ", "original_text": "Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9adb963f4f88ac5f4ee6bc4abcded457bf637780b4d51fb43d2175dba1467172", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d22d18d-d5f1-4c36-a2a1-962ed6898d40", "node_type": "1", "metadata": {"window": "I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature . ", "original_text": "And so this particular quarter, we saw that as \nwell.  \n \n"}, "hash": "88a949cdbaa70c03ca2a709724f589c05f34b39d60ec8fbf4c0540ba35c68788", "class_name": "RelatedNodeInfo"}}, "text": "And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty . ", "start_char_idx": 1461, "end_char_idx": 1658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d22d18d-d5f1-4c36-a2a1-962ed6898d40": {"__data__": {"id_": "6d22d18d-d5f1-4c36-a2a1-962ed6898d40", "embedding": null, "metadata": {"window": "I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature . ", "original_text": "And so this particular quarter, we saw that as \nwell.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac0edbd7-3ba0-4c52-8798-26f361ebb5ca", "node_type": "1", "metadata": {"window": "Overall, the biggest component for this particular quarter and most \nquarters that we see more recently has been volume .  I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products . ", "original_text": "And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21f2296cb0c435a6fced97655cda7059950599ee2effb17ad1b197f9555e1e3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62be3b3f-66e1-48f2-b5db-b31d4dcb9266", "node_type": "1", "metadata": {"window": "Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well . ", "original_text": "Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic . "}, "hash": "a91e432f57bb28fb594e9fbde7d64c67b817922e24893f73d03683ad9ec35abb", "class_name": "RelatedNodeInfo"}}, "text": "And so this particular quarter, we saw that as \nwell.  \n \n", "start_char_idx": 1658, "end_char_idx": 1716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62be3b3f-66e1-48f2-b5db-b31d4dcb9266": {"__data__": {"id_": "62be3b3f-66e1-48f2-b5db-b31d4dcb9266", "embedding": null, "metadata": {"window": "Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well . ", "original_text": "Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d22d18d-d5f1-4c36-a2a1-962ed6898d40", "node_type": "1", "metadata": {"window": "I continue to use the statement consistent \nmarket dynamics that's referencing essentially the margin per unit .  Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature . ", "original_text": "And so this particular quarter, we saw that as \nwell.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04c4c384b3ff236a86968c2253c77791131d9adf4c7cc6258b66f6018bba0941", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8ca9968-dd9c-4b5f-9fde-70e92ca31fcd", "node_type": "1", "metadata": {"window": "And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix. ", "original_text": "They're more mature products . "}, "hash": "8486bdae77a9406e4865600c2dba6b68627140a011962af1a186f8d0d612ccd2", "class_name": "RelatedNodeInfo"}}, "text": "Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic . ", "start_char_idx": 1716, "end_char_idx": 1836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8ca9968-dd9c-4b5f-9fde-70e92ca31fcd": {"__data__": {"id_": "f8ca9968-dd9c-4b5f-9fde-70e92ca31fcd", "embedding": null, "metadata": {"window": "And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix. ", "original_text": "They're more mature products . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62be3b3f-66e1-48f2-b5db-b31d4dcb9266", "node_type": "1", "metadata": {"window": "Yes, there's ongoing deflation, but \nthe buy side sell -side continues to be relatively in balance .  And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well . ", "original_text": "Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7641036f74a58f412fa46df7df690bc5a7ca311ddeb4f17a8045379e11fbbe1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f91571cc-7f9e-4a39-959f-2165620b2aa0", "node_type": "1", "metadata": {"window": "And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n", "original_text": "So they do tend to carry with it a little bit lower margin \nprice points, things of that nature . "}, "hash": "8d290dfa84176d074a96df6836b114391d32e53b899cfd4a384b5b6ba2dafd7d", "class_name": "RelatedNodeInfo"}}, "text": "They're more mature products . ", "start_char_idx": 1836, "end_char_idx": 1867, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f91571cc-7f9e-4a39-959f-2165620b2aa0": {"__data__": {"id_": "f91571cc-7f9e-4a39-959f-2165620b2aa0", "embedding": null, "metadata": {"window": "And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n", "original_text": "So they do tend to carry with it a little bit lower margin \nprice points, things of that nature . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8ca9968-dd9c-4b5f-9fde-70e92ca31fcd", "node_type": "1", "metadata": {"window": "And so when we see a year -over-year \ndriver, it's driven often by volume and/or mix and we continu e to see very broad strength across all \nthe products, whether it be generics, brand specialty .  And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix. ", "original_text": "They're more mature products . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "700e521264c6699ec2af0ca638f6aac0ff7c3dba5b88287c28e12637f7474e86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b696808-da39-4619-b69e-1ea8341af1f1", "node_type": "1", "metadata": {"window": "Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it. ", "original_text": "But that would be a component as well . "}, "hash": "f6dac8394f9eb390453fe38ff029da92f51eac7b2aa0f47bfadf33ad48c1a2e0", "class_name": "RelatedNodeInfo"}}, "text": "So they do tend to carry with it a little bit lower margin \nprice points, things of that nature . ", "start_char_idx": 1867, "end_char_idx": 1965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b696808-da39-4619-b69e-1ea8341af1f1": {"__data__": {"id_": "4b696808-da39-4619-b69e-1ea8341af1f1", "embedding": null, "metadata": {"window": "Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it. ", "original_text": "But that would be a component as well . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f91571cc-7f9e-4a39-959f-2165620b2aa0", "node_type": "1", "metadata": {"window": "And so this particular quarter, we saw that as \nwell.  \n \n Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n", "original_text": "So they do tend to carry with it a little bit lower margin \nprice points, things of that nature . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26ddb98bba72947ba03f73d6821a17de999fbeb673a2f6b47325627e01a8ef9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7094295c-4479-48b7-bf43-03f776d382e2", "node_type": "1", "metadata": {"window": "They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n", "original_text": "But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix. "}, "hash": "10c8301b4568351110f299864639ae6934a0f6997c4c753adb19e2861687221a", "class_name": "RelatedNodeInfo"}}, "text": "But that would be a component as well . ", "start_char_idx": 1965, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7094295c-4479-48b7-bf43-03f776d382e2": {"__data__": {"id_": "7094295c-4479-48b7-bf43-03f776d382e2", "embedding": null, "metadata": {"window": "They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n", "original_text": "But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix. ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b696808-da39-4619-b69e-1ea8341af1f1", "node_type": "1", "metadata": {"window": "Again, not the biggest driver, but when I talk about cough, cold, and flu, a lot of those products have \ngone generic .  They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it. ", "original_text": "But that would be a component as well . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbbcf66a8bfa0581000dbae9be3f0f2426e6decd0664798baa25b576b61f23e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdb1876a-e1dc-4446-99b0-09d4db29b0e4", "node_type": "1", "metadata": {"window": "So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n", "original_text": "Next question.  \n \n"}, "hash": "58687dfa224e339fa51f24295dfb58020301ad32e00929064795ee7dc17daae9", "class_name": "RelatedNodeInfo"}}, "text": "But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix. ", "start_char_idx": 2005, "end_char_idx": 2178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdb1876a-e1dc-4446-99b0-09d4db29b0e4": {"__data__": {"id_": "bdb1876a-e1dc-4446-99b0-09d4db29b0e4", "embedding": null, "metadata": {"window": "So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n", "original_text": "Next question.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7094295c-4479-48b7-bf43-03f776d382e2", "node_type": "1", "metadata": {"window": "They're more mature products .  So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n", "original_text": "But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix. ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7209298f87d55fcfabf9f3ea539811f15031c8fa8b91dbe4b377eacd30f5315", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f6b55c0-13a1-4f15-b042-031c04ed013e", "node_type": "1", "metadata": {"window": "But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n", "original_text": "Steven Valiquette:   Got it. "}, "hash": "263b2d3cd9aacc40ace24015213bf5c9d3238a7585304883a8b9d43cb07db974", "class_name": "RelatedNodeInfo"}}, "text": "Next question.  \n \n", "start_char_idx": 2178, "end_char_idx": 2197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f6b55c0-13a1-4f15-b042-031c04ed013e": {"__data__": {"id_": "5f6b55c0-13a1-4f15-b042-031c04ed013e", "embedding": null, "metadata": {"window": "But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n", "original_text": "Steven Valiquette:   Got it. ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdb1876a-e1dc-4446-99b0-09d4db29b0e4", "node_type": "1", "metadata": {"window": "So they do tend to carry with it a little bit lower margin \nprice points, things of that nature .  But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n", "original_text": "Next question.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c794e9b23499daa9ae60e24f7045f68d42f546e92836dda3f0273bbc3dd57c53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77040772-f3fc-49cd-92e9-48ca85f3eed5", "node_type": "1", "metadata": {"window": "But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you . ", "original_text": "Okay, thanks.  \n \n"}, "hash": "9eab146bdffffadb670ebd417848a99633882b96716f2b6eb5f13d5dc7e08842", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette:   Got it. ", "start_char_idx": 2197, "end_char_idx": 2226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77040772-f3fc-49cd-92e9-48ca85f3eed5": {"__data__": {"id_": "77040772-f3fc-49cd-92e9-48ca85f3eed5", "embedding": null, "metadata": {"window": "But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you . ", "original_text": "Okay, thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f6b55c0-13a1-4f15-b042-031c04ed013e", "node_type": "1", "metadata": {"window": "But that would be a component as well .  But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n", "original_text": "Steven Valiquette:   Got it. ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea75213e39f94f6d8b9aa9282d67e37773372d13453fda3d53dc44a9432b8863", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b83b1eb-3e4b-4678-abb1-b37afe204bfd", "node_type": "1", "metadata": {"window": "Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?  ", "original_text": "Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n"}, "hash": "cb4f7d3cfb9b08bfb1ce6aa583f518db1b8a85ece4f5955792a586fbd702418f", "class_name": "RelatedNodeInfo"}}, "text": "Okay, thanks.  \n \n", "start_char_idx": 2226, "end_char_idx": 2244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b83b1eb-3e4b-4678-abb1-b37afe204bfd": {"__data__": {"id_": "2b83b1eb-3e4b-4678-abb1-b37afe204bfd", "embedding": null, "metadata": {"window": "Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?  ", "original_text": "Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77040772-f3fc-49cd-92e9-48ca85f3eed5", "node_type": "1", "metadata": {"window": "But again, I'm only \nhighlighting that given how many questions we get on the to pic, not that that's a significant driver, but \noverall the short answer is volume and mix.  Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you . ", "original_text": "Okay, thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efc4f7ef7aceeb1796e0aef9ae244e248f944d5edc3bdfbb735f087e0f5f0b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6adba9a8-1f04-4cfe-bb68-cc77a80093e7", "node_type": "1", "metadata": {"window": "Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n", "original_text": "Please go ahead.  \n \n"}, "hash": "65d7735e28496f2fa1796a47b4683e3910406eeb089ef58b97ca5672d0c585ed", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n", "start_char_idx": 2244, "end_char_idx": 2342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6adba9a8-1f04-4cfe-bb68-cc77a80093e7": {"__data__": {"id_": "6adba9a8-1f04-4cfe-bb68-cc77a80093e7", "embedding": null, "metadata": {"window": "Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n", "original_text": "Please go ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b83b1eb-3e4b-4678-abb1-b37afe204bfd", "node_type": "1", "metadata": {"window": "Next question.  \n \n Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?  ", "original_text": "Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a871288b21c3d6ccc01f755f169535d72de69470b29407979590e687f4c90a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "524f1ea1-0d05-47e5-97a3-e16b87d0121e", "node_type": "1", "metadata": {"window": "Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters . ", "original_text": "Eric Percher :  Thank you . "}, "hash": "f4c720763d15d9439a6a9e2e6f42e9c6bf90fb0dd12f7859dd993e4cca8c5a65", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 2342, "end_char_idx": 2363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "524f1ea1-0d05-47e5-97a3-e16b87d0121e": {"__data__": {"id_": "524f1ea1-0d05-47e5-97a3-e16b87d0121e", "embedding": null, "metadata": {"window": "Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters . ", "original_text": "Eric Percher :  Thank you . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6adba9a8-1f04-4cfe-bb68-cc77a80093e7", "node_type": "1", "metadata": {"window": "Steven Valiquette:   Got it.  Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n", "original_text": "Please go ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "760def281123d102cad9bb97be426dcb0363cfca032c7d5462104f1c018ca8ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb12cd5c-0047-4964-8d66-fc6724b7eb25", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase . ", "original_text": "A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?  "}, "hash": "9753bf330c4457577b4b25ac868e43ea4de6feec4df53f816918c7662334c662", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher :  Thank you . ", "start_char_idx": 2363, "end_char_idx": 2391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb12cd5c-0047-4964-8d66-fc6724b7eb25": {"__data__": {"id_": "cb12cd5c-0047-4964-8d66-fc6724b7eb25", "embedding": null, "metadata": {"window": "Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase . ", "original_text": "A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?  ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "524f1ea1-0d05-47e5-97a3-e16b87d0121e", "node_type": "1", "metadata": {"window": "Okay, thanks.  \n \n Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters . ", "original_text": "Eric Percher :  Thank you . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f63c060b3c5d18249a5e639d0ed9315cd6166c11aaa00fa3a1aaa0c42847e5b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75b010f4-f0fd-4d1f-ade1-d1f0a74919c4", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments . ", "original_text": "And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n"}, "hash": "843e71eb62d325ece9b68c02b40bfa055c838d45c13f02189a4f9ff5611a44a2", "class_name": "RelatedNodeInfo"}}, "text": "A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?  ", "start_char_idx": 2391, "end_char_idx": 2549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75b010f4-f0fd-4d1f-ade1-d1f0a74919c4": {"__data__": {"id_": "75b010f4-f0fd-4d1f-ade1-d1f0a74919c4", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments . ", "original_text": "And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb12cd5c-0047-4964-8d66-fc6724b7eb25", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of Eric Percher calling from Nephron Research . \n Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase . ", "original_text": "A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?  ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96a6d22fcc3b6cc1c638173bd9ff72c85164a523a8762358340a2da2ca51bc15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "815b0562-8ed1-4867-91dc-4c319fc7d411", "node_type": "1", "metadata": {"window": "Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters . "}, "hash": "c8f2f2f46cd53e35ff5e8f2b3d8933c8dc5d349b0c19d4dd09ce4840db18df7c", "class_name": "RelatedNodeInfo"}}, "text": "And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n", "start_char_idx": 2549, "end_char_idx": 2766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "815b0562-8ed1-4867-91dc-4c319fc7d411": {"__data__": {"id_": "815b0562-8ed1-4867-91dc-4c319fc7d411", "embedding": null, "metadata": {"window": "Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75b010f4-f0fd-4d1f-ade1-d1f0a74919c4", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments . ", "original_text": "And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "398f140884ec5777ad19ebf4daabacca1c036d7e7e1efd938811fe243714e560", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22937657-3124-4afb-b54b-8855eb6ee836", "node_type": "1", "metadata": {"window": "A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "So it's in the ramp -\nup phase . "}, "hash": "79c238838447f59bc7d5bcace3d0d229cbe7e77c775ba88f60807202fbbef6e6", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters . ", "start_char_idx": 2766, "end_char_idx": 2958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22937657-3124-4afb-b54b-8855eb6ee836": {"__data__": {"id_": "22937657-3124-4afb-b54b-8855eb6ee836", "embedding": null, "metadata": {"window": "A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "So it's in the ramp -\nup phase . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "815b0562-8ed1-4867-91dc-4c319fc7d411", "node_type": "1", "metadata": {"window": "Eric Percher :  Thank you .  A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2bc9e6c01430240ca4fce44d8fa1a23f0ae514b86764f3d662440ffec6e10898", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fd0c16b-8839-4c4b-a6fe-676609029edf", "node_type": "1", "metadata": {"window": "And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "So we are seeing positive returns already on those investments . "}, "hash": "9b820258cf97594e88b0e8d9e99a8613b7609362c56056f5c06b300aa7416902", "class_name": "RelatedNodeInfo"}}, "text": "So it's in the ramp -\nup phase . ", "start_char_idx": 2958, "end_char_idx": 2991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fd0c16b-8839-4c4b-a6fe-676609029edf": {"__data__": {"id_": "8fd0c16b-8839-4c4b-a6fe-676609029edf", "embedding": null, "metadata": {"window": "And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "So we are seeing positive returns already on those investments . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22937657-3124-4afb-b54b-8855eb6ee836", "node_type": "1", "metadata": {"window": "A question on nuclear or theranostics, can you remind us where your \ninvestments are targeted in \u201923, and where and when do we see ROI on those investments?   And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "So it's in the ramp -\nup phase . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61e933163f14aa6401184bf1f74db7d55cf9fad4cc0e24dde7e804e970d8633f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1248843-c736-4d81-9236-0c6c37ee6a3a", "node_type": "1", "metadata": {"window": "Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "This is a business case . "}, "hash": "d9ff356274c713b3962c15e7e8bc5474cf81187e186bb70b8bd345fffcc3822b", "class_name": "RelatedNodeInfo"}}, "text": "So we are seeing positive returns already on those investments . ", "start_char_idx": 2991, "end_char_idx": 3056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1248843-c736-4d81-9236-0c6c37ee6a3a": {"__data__": {"id_": "e1248843-c736-4d81-9236-0c6c37ee6a3a", "embedding": null, "metadata": {"window": "Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "This is a business case . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b25bb831728909c3035968dd64d2392df07da6df3a2f72eee7597f96c0a9c45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fd0c16b-8839-4c4b-a6fe-676609029edf", "node_type": "1", "metadata": {"window": "And \nthen given the developments around Alzheimer's tre atments, what are you looking for relative to \napproval or policy change on testing that could lead to more significant step up in demand in that \nbusiness?  \n \n Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "So we are seeing positive returns already on those investments . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41369aee0984b39b7108f2b74da017066b7c3c399475a7d1277e3e4a264dbefe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76af05d8-fe26-44ed-9ae1-f7617683e865", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that . ", "original_text": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business . "}, "hash": "893d38e69f776b9d0974aa26da4a7a623fdbcfb8aa318eac45b8f01041c3cd0c", "class_name": "RelatedNodeInfo"}}, "text": "This is a business case . ", "start_char_idx": 3056, "end_char_idx": 3082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76af05d8-fe26-44ed-9ae1-f7617683e865": {"__data__": {"id_": "76af05d8-fe26-44ed-9ae1-f7617683e865", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that . ", "original_text": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1248843-c736-4d81-9236-0c6c37ee6a3a", "node_type": "1", "metadata": {"window": "Jason Hollar:  S ure, so  the theranostics business launched sometime in the last six, nine months an d \nwe're starting to see now more of that contribution over the last couple of quarters .  So it's in the ramp -\nup phase .  So we are seeing positive returns already on those investments .  This is a business case . ", "original_text": "This is a business case . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a51ee8b723b8a82f531241c67832cf02cd14b561d6b53b84bb4c6a6862ea490f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d2226ee-73d7-4174-98fe-1d0eb4e42893", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome . ", "original_text": "It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n"}, "hash": "944fb415630913ee765a76872eb973b854bde9aa845aa9016f3a5fc2e20402c0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business . ", "start_char_idx": 0, "end_char_idx": 170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d2226ee-73d7-4174-98fe-1d0eb4e42893": {"__data__": {"id_": "4d2226ee-73d7-4174-98fe-1d0eb4e42893", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome . ", "original_text": "It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76af05d8-fe26-44ed-9ae1-f7617683e865", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that . ", "original_text": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5045077e65d1f76e49104cf42ae03e85b7181c31f6d57f3c4d74aa4bf00fd5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63b0cc4b-9e0b-48a6-8eb8-fffe9501de3b", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities . ", "original_text": "The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n"}, "hash": "387415bd74afb9ab01e0e45004d1bec8d67832d26d40bb32f4848cb7a990621f", "class_name": "RelatedNodeInfo"}}, "text": "It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n", "start_char_idx": 170, "end_char_idx": 291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63b0cc4b-9e0b-48a6-8eb8-fffe9501de3b": {"__data__": {"id_": "63b0cc4b-9e0b-48a6-8eb8-fffe9501de3b", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities . ", "original_text": "The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d2226ee-73d7-4174-98fe-1d0eb4e42893", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome . ", "original_text": "It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "555c2dc10e91afc4b3ce5f27161c9e7d2b212669bda15eede7d1d0c49b822131", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7140ddc2-c6fe-43a2-ac6a-80e8fb52732d", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area . ", "original_text": "As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that . "}, "hash": "dc419aaa83bfcf5a4236688726d85a42a6645b27593a84e9543e4ea96fd193fe", "class_name": "RelatedNodeInfo"}}, "text": "The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n", "start_char_idx": 291, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7140ddc2-c6fe-43a2-ac6a-80e8fb52732d": {"__data__": {"id_": "7140ddc2-c6fe-43a2-ac6a-80e8fb52732d", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area . ", "original_text": "As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63b0cc4b-9e0b-48a6-8eb8-fffe9501de3b", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities . ", "original_text": "The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cda5d3d7cf273a827dda1e4748fd298fd9801dcadf6f7f697299fd26b24d832", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fde66348-4850-4545-ac41-5777e0eeee02", "node_type": "1", "metadata": {"window": "It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum . ", "original_text": "I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome . "}, "hash": "1fd8421cd573f2661e27b40ec5334ced8d104c3dfcc4482756f49b9aa07d99d1", "class_name": "RelatedNodeInfo"}}, "text": "As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that . ", "start_char_idx": 525, "end_char_idx": 751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fde66348-4850-4545-ac41-5777e0eeee02": {"__data__": {"id_": "fde66348-4850-4545-ac41-5777e0eeee02", "embedding": null, "metadata": {"window": "It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum . ", "original_text": "I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7140ddc2-c6fe-43a2-ac6a-80e8fb52732d", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area . ", "original_text": "As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4179cfb0773e432161e891427c4aa3168c0a50b30dc2ce81ba77c914d56a233", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20e3c8c4-1806-42cd-a78b-ec61cf32fd9a", "node_type": "1", "metadata": {"window": "The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug . ", "original_text": "We have broad expertise capabilities . "}, "hash": "145390880a0706ee31819dd4e91c246b6355b98f6d3489871f95ac94516c74f9", "class_name": "RelatedNodeInfo"}}, "text": "I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome . ", "start_char_idx": 751, "end_char_idx": 903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20e3c8c4-1806-42cd-a78b-ec61cf32fd9a": {"__data__": {"id_": "20e3c8c4-1806-42cd-a78b-ec61cf32fd9a", "embedding": null, "metadata": {"window": "The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug . ", "original_text": "We have broad expertise capabilities . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fde66348-4850-4545-ac41-5777e0eeee02", "node_type": "1", "metadata": {"window": "It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum . ", "original_text": "I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ec4ebace677ef88635745dad99e52793ec049c2451ba37b6115f9966ea4c1d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6652d02f-9fd0-4876-aad4-72b99ee1185f", "node_type": "1", "metadata": {"window": "As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products . ", "original_text": "We \nare not dependent on any one particular area . "}, "hash": "18a5cff76a98ced340d41dbd497cd0bae8f314a7bbbde3d8f34a7bcc11072525", "class_name": "RelatedNodeInfo"}}, "text": "We have broad expertise capabilities . ", "start_char_idx": 903, "end_char_idx": 942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6652d02f-9fd0-4876-aad4-72b99ee1185f": {"__data__": {"id_": "6652d02f-9fd0-4876-aad4-72b99ee1185f", "embedding": null, "metadata": {"window": "As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products . ", "original_text": "We \nare not dependent on any one particular area . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20e3c8c4-1806-42cd-a78b-ec61cf32fd9a", "node_type": "1", "metadata": {"window": "The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug . ", "original_text": "We have broad expertise capabilities . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "289382a740a1b469c012a317c7c513106c9e9aeb7fd4207801fee17803a81610", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af9f64b8-c5cb-4051-83d9-a2e3e9e6162a", "node_type": "1", "metadata": {"window": "I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n", "original_text": "And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum . "}, "hash": "a47c778f987f560f366f6b1440fc844ab6ad4eab5044d4b9fc93575c46ec278d", "class_name": "RelatedNodeInfo"}}, "text": "We \nare not dependent on any one particular area . ", "start_char_idx": 942, "end_char_idx": 993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af9f64b8-c5cb-4051-83d9-a2e3e9e6162a": {"__data__": {"id_": "af9f64b8-c5cb-4051-83d9-a2e3e9e6162a", "embedding": null, "metadata": {"window": "I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n", "original_text": "And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6652d02f-9fd0-4876-aad4-72b99ee1185f", "node_type": "1", "metadata": {"window": "As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that .  I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products . ", "original_text": "We \nare not dependent on any one particular area . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd70feded51bfb687fc651552749f274cdceffef77ee7fab8fd53c2685d9504b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "667f4776-6340-41d1-b118-8f3998bce2c6", "node_type": "1", "metadata": {"window": "We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n", "original_text": "So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug . "}, "hash": "a17e1967a300f21563622ed07276c6fbdb739e2d88667fe8b86fbbda5bc32812", "class_name": "RelatedNodeInfo"}}, "text": "And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum . ", "start_char_idx": 993, "end_char_idx": 1253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "667f4776-6340-41d1-b118-8f3998bce2c6": {"__data__": {"id_": "667f4776-6340-41d1-b118-8f3998bce2c6", "embedding": null, "metadata": {"window": "We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n", "original_text": "So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af9f64b8-c5cb-4051-83d9-a2e3e9e6162a", "node_type": "1", "metadata": {"window": "I would say that the beauty of this business and the success of this business is that \nit's not directly linked to a very specific particular outcome .  We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n", "original_text": "And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ef716558635e698fb8fbdb6f9da27abe708d7005c933910391543caa40e0cc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19e8bc63-1aae-491a-8ad6-b5dd0528f0e6", "node_type": "1", "metadata": {"window": "We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies . ", "original_text": "So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products . "}, "hash": "95666c011a2323f9fb3887a0d2d0a00b1ebfd15535f0642b286f0ab24aded9c4", "class_name": "RelatedNodeInfo"}}, "text": "So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug . ", "start_char_idx": 1253, "end_char_idx": 1504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19e8bc63-1aae-491a-8ad6-b5dd0528f0e6": {"__data__": {"id_": "19e8bc63-1aae-491a-8ad6-b5dd0528f0e6", "embedding": null, "metadata": {"window": "We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies . ", "original_text": "So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "667f4776-6340-41d1-b118-8f3998bce2c6", "node_type": "1", "metadata": {"window": "We have broad expertise capabilities .  We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n", "original_text": "So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03446ea084eb46f34fce881d5c22559273b75b35b461b0aff90d2f798cff7e61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c4a2df2-5c0e-4cd4-843a-7c7c4f0ed22b", "node_type": "1", "metadata": {"window": "And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n", "original_text": "And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n"}, "hash": "67684073468f43d00a5b8da4271e642a88714b252299fb4ea225b033cd0d1993", "class_name": "RelatedNodeInfo"}}, "text": "So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products . ", "start_char_idx": 1504, "end_char_idx": 1609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c4a2df2-5c0e-4cd4-843a-7c7c4f0ed22b": {"__data__": {"id_": "3c4a2df2-5c0e-4cd4-843a-7c7c4f0ed22b", "embedding": null, "metadata": {"window": "And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n", "original_text": "And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19e8bc63-1aae-491a-8ad6-b5dd0528f0e6", "node_type": "1", "metadata": {"window": "We \nare not dependent on any one particular area .  And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies . ", "original_text": "So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48b92f53cc0ae28864cb79fe266e097e831df8e32854c9f959e39a3d0e07b4bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "372ef484-c8d2-45c0-8c6c-651596021083", "node_type": "1", "metadata": {"window": "So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you . ", "original_text": "Eric Percher:  Thank you .  \n \n"}, "hash": "b0df90f4c1d5d14f05d549429cbe7fbba37897219fcc2e29782f67a72a7f8f01", "class_name": "RelatedNodeInfo"}}, "text": "And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n", "start_char_idx": 1609, "end_char_idx": 1768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "372ef484-c8d2-45c0-8c6c-651596021083": {"__data__": {"id_": "372ef484-c8d2-45c0-8c6c-651596021083", "embedding": null, "metadata": {"window": "So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you . ", "original_text": "Eric Percher:  Thank you .  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c4a2df2-5c0e-4cd4-843a-7c7c4f0ed22b", "node_type": "1", "metadata": {"window": "And is that diversification of which we're seeing with \nthe theranostics expansion being even more accentuated becau se we get to work with so many more \nmanufacturers and partners that it just creates a broad opportunity for us to grow across the \nspectrum .  So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n", "original_text": "And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5de6ec2dccfaff6ed588d98ccdb62a43e7083d8629ca3730a81842d9a4053b56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64592f03-9d19-4453-bfab-9877a1d4f44c", "node_type": "1", "metadata": {"window": "So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian . ", "original_text": "Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies . "}, "hash": "806a305703034d58ab5f06bee6c377e00d276d960e3cfe26c3413aac02e5d43c", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:  Thank you .  \n \n", "start_char_idx": 1768, "end_char_idx": 1799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64592f03-9d19-4453-bfab-9877a1d4f44c": {"__data__": {"id_": "64592f03-9d19-4453-bfab-9877a1d4f44c", "embedding": null, "metadata": {"window": "So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian . ", "original_text": "Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "372ef484-c8d2-45c0-8c6c-651596021083", "node_type": "1", "metadata": {"window": "So our business case for continued growth, our goal of achieving a doubling of the profit in \nthis business from fisc al \u201821 to \u201826 is predicated on a lot of singles and doubles, not triples and home \nruns by attaching to a blockbuster type of drug .  So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you . ", "original_text": "Eric Percher:  Thank you .  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1376e3bd956502e356bcae5b7b0e96c68a03ccf719e0b4265b9a1aee28fbba51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c14317df-a163-4f90-b274-0052bac9f8f0", "node_type": "1", "metadata": {"window": "And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation . ", "original_text": "Please go \nahead.  \n \n"}, "hash": "57ecc42d7e9b52e348ad71e1c62bc609552d807a3386638f69bc6e5f414876ef", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies . ", "start_char_idx": 1799, "end_char_idx": 1892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c14317df-a163-4f90-b274-0052bac9f8f0": {"__data__": {"id_": "c14317df-a163-4f90-b274-0052bac9f8f0", "embedding": null, "metadata": {"window": "And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation . ", "original_text": "Please go \nahead.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64592f03-9d19-4453-bfab-9877a1d4f44c", "node_type": "1", "metadata": {"window": "So beyond that, you know, we don't talk about \nindividual drugs, individual manufacturers, or products .  And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian . ", "original_text": "Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff20a5e5d46b2ed605afc1e6c05a46ccfdba21ded5f69b4c7d6688b9161221b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a584d19-b756-4f22-b0f0-ab90a6d422ec", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n", "original_text": "Brian Tanquilut:  Thank you . "}, "hash": "cfbdc315b78f4b62b2cbe8b0beaeff9ac17231819d81cd69e45f7071dec451a7", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 1892, "end_char_idx": 1914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a584d19-b756-4f22-b0f0-ab90a6d422ec": {"__data__": {"id_": "7a584d19-b756-4f22-b0f0-ab90a6d422ec", "embedding": null, "metadata": {"window": "Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n", "original_text": "Brian Tanquilut:  Thank you . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c14317df-a163-4f90-b274-0052bac9f8f0", "node_type": "1", "metadata": {"window": "And so I would , but li ke I said, I just don't think \nthat that's the real draw for this business is the breadth that we have and the broad capabilities.  \n \n Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation . ", "original_text": "Please go \nahead.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f22391b6328f5aee40770d571a5d8188689532432ed024f0175abcd151514b1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b984cfc3-d191-469c-92a8-691d5921efe2", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity . ", "original_text": "You have [inaudible] on for Brian . "}, "hash": "c1a328ed605cad2af310814ab716a8e6b7e274a3ae2058819e4f16324780a670", "class_name": "RelatedNodeInfo"}}, "text": "Brian Tanquilut:  Thank you . ", "start_char_idx": 1914, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b984cfc3-d191-469c-92a8-691d5921efe2": {"__data__": {"id_": "b984cfc3-d191-469c-92a8-691d5921efe2", "embedding": null, "metadata": {"window": "Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity . ", "original_text": "You have [inaudible] on for Brian . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a584d19-b756-4f22-b0f0-ab90a6d422ec", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you .  \n \n Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n", "original_text": "Brian Tanquilut:  Thank you . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "909b4cda645e0843b53ad3a7ded17be975cf698629613db9c6a76fb257a73bd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5e2f90b-f377-4a5d-a8eb-ad5f30865bde", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components . ", "original_text": "So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation . "}, "hash": "0a6544cec90d77af7ab585dff9886443478f8b9f93683fb541b5aaa9ca720370", "class_name": "RelatedNodeInfo"}}, "text": "You have [inaudible] on for Brian . ", "start_char_idx": 1944, "end_char_idx": 1980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5e2f90b-f377-4a5d-a8eb-ad5f30865bde": {"__data__": {"id_": "c5e2f90b-f377-4a5d-a8eb-ad5f30865bde", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components . ", "original_text": "So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b984cfc3-d191-469c-92a8-691d5921efe2", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from the line of Brian Tanquilut calling from Jefferies .  Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity . ", "original_text": "You have [inaudible] on for Brian . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4375a9fbd7b3ac2ae26dd9cd160d83c4a0f56d9acf146ea9b0eb5c001c9e0c00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb9c3d17-8ee4-4a43-8633-6212214cda5a", "node_type": "1", "metadata": {"window": "Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain . ", "original_text": "Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n"}, "hash": "ad31fc184b099ba5fa1575ae53f70d98a8ec62265a2635aff7ba043af3b8e99e", "class_name": "RelatedNodeInfo"}}, "text": "So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation . ", "start_char_idx": 1980, "end_char_idx": 2092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb9c3d17-8ee4-4a43-8633-6212214cda5a": {"__data__": {"id_": "bb9c3d17-8ee4-4a43-8633-6212214cda5a", "embedding": null, "metadata": {"window": "Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain . ", "original_text": "Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5e2f90b-f377-4a5d-a8eb-ad5f30865bde", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components . ", "original_text": "So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfabe54366ae008e08be5ebbd5125a65fa32ef87b3e3cb4ca678aec8e3080058", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15548602-8581-4f3b-ac44-74a0eb58e76f", "node_type": "1", "metadata": {"window": "You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it . ", "original_text": "Jason Hollar:  Well, I wish I had more clarity . "}, "hash": "6da365feabe0170595bc62515d25d5d5b26a94c98d18a99e76f013a611269e6a", "class_name": "RelatedNodeInfo"}}, "text": "Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n", "start_char_idx": 2092, "end_char_idx": 2199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15548602-8581-4f3b-ac44-74a0eb58e76f": {"__data__": {"id_": "15548602-8581-4f3b-ac44-74a0eb58e76f", "embedding": null, "metadata": {"window": "You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it . ", "original_text": "Jason Hollar:  Well, I wish I had more clarity . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb9c3d17-8ee4-4a43-8633-6212214cda5a", "node_type": "1", "metadata": {"window": "Brian Tanquilut:  Thank you .  You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain . ", "original_text": "Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cafda29298cfdf7726eb0efaf2a4c1da324edc5286b36d531aaefb94691d2173", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1ed08bb-dfb1-441c-872b-5c9149225c23", "node_type": "1", "metadata": {"window": "So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that . ", "original_text": "I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components . "}, "hash": "955108409d38acd0ed50096817142b8d07765630244260cc25f10984561e01e7", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Well, I wish I had more clarity . ", "start_char_idx": 2199, "end_char_idx": 2248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1ed08bb-dfb1-441c-872b-5c9149225c23": {"__data__": {"id_": "f1ed08bb-dfb1-441c-872b-5c9149225c23", "embedding": null, "metadata": {"window": "So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that . ", "original_text": "I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15548602-8581-4f3b-ac44-74a0eb58e76f", "node_type": "1", "metadata": {"window": "You have [inaudible] on for Brian .  So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it . ", "original_text": "Jason Hollar:  Well, I wish I had more clarity . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bc6da4ad8d2fba3b37467cb8f2c89e68e5ec1215174fa435685c8fd46afd35a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aba89d2f-879b-44df-b6b0-a7f0bc8e6327", "node_type": "1", "metadata": {"window": "Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?  ", "original_text": "So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain . "}, "hash": "e8210a0b4ccf05da8ecd29793bfe40c7a895efd167c305d0a643741e6a6085d4", "class_name": "RelatedNodeInfo"}}, "text": "I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components . ", "start_char_idx": 2248, "end_char_idx": 2388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aba89d2f-879b-44df-b6b0-a7f0bc8e6327": {"__data__": {"id_": "aba89d2f-879b-44df-b6b0-a7f0bc8e6327", "embedding": null, "metadata": {"window": "Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?  ", "original_text": "So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1ed08bb-dfb1-441c-872b-5c9149225c23", "node_type": "1", "metadata": {"window": "So, you mentioned expecting \nstabili zation of supply chain headwinds, particularly in freight transportation .  Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that . ", "original_text": "I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aeb482623a67e67f5246775e6a21cf32ed10c6106cf20ce636a137fa2ba61a3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eee6670b-265c-46e7-9768-5aa5b03cd501", "node_type": "1", "metadata": {"window": "Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower . ", "original_text": "We need to be prepared for it . "}, "hash": "3d81731d8596d15b81ede8ab5d1a408beee3bcb8b1ea8b0f0ac5b3b7c48296de", "class_name": "RelatedNodeInfo"}}, "text": "So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain . ", "start_char_idx": 2388, "end_char_idx": 2511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eee6670b-265c-46e7-9768-5aa5b03cd501": {"__data__": {"id_": "eee6670b-265c-46e7-9768-5aa5b03cd501", "embedding": null, "metadata": {"window": "Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower . ", "original_text": "We need to be prepared for it . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aba89d2f-879b-44df-b6b0-a7f0bc8e6327", "node_type": "1", "metadata": {"window": "Can you just discuss any \nsense you might have around the cadence  of that improvement moving forward?  \n \n Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?  ", "original_text": "So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbb9d3dd79b18c1ba1305364ea88fed5fd874cab9b04293a4c84f172903a5fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5178e45d-c66f-497d-9bd1-eb9e04d20b2a", "node_type": "1", "metadata": {"window": "I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks . ", "original_text": "We've diversified our supply chain further as a result of living \nthrough that . "}, "hash": "eb906a3e4d1887f16daf7c4c485ad00e9b2f03d273d6342800159c5bbe1fb798", "class_name": "RelatedNodeInfo"}}, "text": "We need to be prepared for it . ", "start_char_idx": 2511, "end_char_idx": 2543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5178e45d-c66f-497d-9bd1-eb9e04d20b2a": {"__data__": {"id_": "5178e45d-c66f-497d-9bd1-eb9e04d20b2a", "embedding": null, "metadata": {"window": "I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks . ", "original_text": "We've diversified our supply chain further as a result of living \nthrough that . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eee6670b-265c-46e7-9768-5aa5b03cd501", "node_type": "1", "metadata": {"window": "Jason Hollar:  Well, I wish I had more clarity .  I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower . ", "original_text": "We need to be prepared for it . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a855db6d67f976874fac1e639f7bc8c9c5c3949aeb11fe0a110c2693a26fcf5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "449b0856-b7aa-4751-b608-336619d6ffc8", "node_type": "1", "metadata": {"window": "So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n", "original_text": "But where those costs are, and it's still elevated in certain ar eas, right?  "}, "hash": "76bac3ac64f0fe9c1152203bada748f3fb8e7667a246b0d18deca9b1938158ed", "class_name": "RelatedNodeInfo"}}, "text": "We've diversified our supply chain further as a result of living \nthrough that . ", "start_char_idx": 2543, "end_char_idx": 2624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "449b0856-b7aa-4751-b608-336619d6ffc8": {"__data__": {"id_": "449b0856-b7aa-4751-b608-336619d6ffc8", "embedding": null, "metadata": {"window": "So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n", "original_text": "But where those costs are, and it's still elevated in certain ar eas, right?  ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5178e45d-c66f-497d-9bd1-eb9e04d20b2a", "node_type": "1", "metadata": {"window": "I would say that it's a lot more stable than it has been \nover the last few years, and we have to break apart freight into the components .  So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks . ", "original_text": "We've diversified our supply chain further as a result of living \nthrough that . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c84caf3d3baba5ba7dac5ae86302452ae9ca559a507b1bf3db6ef3653816be00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0f6e58f-c0f4-4bb3-8df6-5177ffb4cb4d", "node_type": "1", "metadata": {"window": "We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage . ", "original_text": "The main China \nto North America channels are much , much lower . "}, "hash": "278aa801bb0371c4cb6a4129ef28b50d2d19f0b25370325380e9d24404cf4748", "class_name": "RelatedNodeInfo"}}, "text": "But where those costs are, and it's still elevated in certain ar eas, right?  ", "start_char_idx": 2624, "end_char_idx": 2702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0f6e58f-c0f4-4bb3-8df6-5177ffb4cb4d": {"__data__": {"id_": "a0f6e58f-c0f4-4bb3-8df6-5177ffb4cb4d", "embedding": null, "metadata": {"window": "We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage . ", "original_text": "The main China \nto North America channels are much , much lower . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "449b0856-b7aa-4751-b608-336619d6ffc8", "node_type": "1", "metadata": {"window": "So within \ninternational freight, that  I believe, was an anomaly that is unlikely to occur anytime soon, if ever \nagain .  We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n", "original_text": "But where those costs are, and it's still elevated in certain ar eas, right?  ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1107bb9731510b4caea99cb20526f3773a8b2a764a146264a947d2a539b7ec6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72da486a-4ebc-42d7-bec8-93c31b209aa4", "node_type": "1", "metadata": {"window": "We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation . ", "original_text": "But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks . "}, "hash": "caf4f2ec5f3bc12e0b89285a105f13095d335f69429aef97338404f3de8ecd64", "class_name": "RelatedNodeInfo"}}, "text": "The main China \nto North America channels are much , much lower . ", "start_char_idx": 2702, "end_char_idx": 2768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72da486a-4ebc-42d7-bec8-93c31b209aa4": {"__data__": {"id_": "72da486a-4ebc-42d7-bec8-93c31b209aa4", "embedding": null, "metadata": {"window": "We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation . ", "original_text": "But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0f6e58f-c0f4-4bb3-8df6-5177ffb4cb4d", "node_type": "1", "metadata": {"window": "We need to be prepared for it .  We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage . ", "original_text": "The main China \nto North America channels are much , much lower . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6a0d0d31b52d44d47e4b8ca50f21005bd59012a2eaf687dd3600abf41dd6e8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf4373fd-bcdb-4f4e-a04e-f078ef2627de", "node_type": "1", "metadata": {"window": "But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel . ", "original_text": "So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n"}, "hash": "b4b3da7b90bb2f77129f6a9e171b4cb5b23c819cee60b01b61079ccef8408633", "class_name": "RelatedNodeInfo"}}, "text": "But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks . ", "start_char_idx": 2768, "end_char_idx": 2901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf4373fd-bcdb-4f4e-a04e-f078ef2627de": {"__data__": {"id_": "bf4373fd-bcdb-4f4e-a04e-f078ef2627de", "embedding": null, "metadata": {"window": "But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel . ", "original_text": "So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72da486a-4ebc-42d7-bec8-93c31b209aa4", "node_type": "1", "metadata": {"window": "We've diversified our supply chain further as a result of living \nthrough that .  But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation . ", "original_text": "But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6abd2153fc22e5d8009c7c82872051a20fcf28906ce7a56beb2abd02a2cda3a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a0dce17-223b-4089-8937-9aa40d0eb65c", "node_type": "1", "metadata": {"window": "The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak . ", "original_text": "So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage . "}, "hash": "4c6117b26531a0b870edc75da5e4e7d556d17b791b588c30dc1a079ed5393aff", "class_name": "RelatedNodeInfo"}}, "text": "So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n", "start_char_idx": 2901, "end_char_idx": 3040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a0dce17-223b-4089-8937-9aa40d0eb65c": {"__data__": {"id_": "6a0dce17-223b-4089-8937-9aa40d0eb65c", "embedding": null, "metadata": {"window": "The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak . ", "original_text": "So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf4373fd-bcdb-4f4e-a04e-f078ef2627de", "node_type": "1", "metadata": {"window": "But where those costs are, and it's still elevated in certain ar eas, right?   The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel . ", "original_text": "So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fef48f54adc12cf95a79fea3921424be944be1b59535ed8d5ee19b44c92fbf9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0610b98-ce31-4862-b002-2b1c6ba09e22", "node_type": "1", "metadata": {"window": "But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic . ", "original_text": "The more elevated remains the  domestic transportation . "}, "hash": "e3af9a26c4ab82a0631f44b427b6627cd430996febfe47035b2c0d088cf4d32d", "class_name": "RelatedNodeInfo"}}, "text": "So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage . ", "start_char_idx": 3040, "end_char_idx": 3186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0610b98-ce31-4862-b002-2b1c6ba09e22": {"__data__": {"id_": "d0610b98-ce31-4862-b002-2b1c6ba09e22", "embedding": null, "metadata": {"window": "But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic . ", "original_text": "The more elevated remains the  domestic transportation . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a0dce17-223b-4089-8937-9aa40d0eb65c", "node_type": "1", "metadata": {"window": "The main China \nto North America channels are much , much lower .  But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak . ", "original_text": "So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8ad2b169082ee41b835012b185952d19130470787a3d72d9c5d5920afbf9f29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d162c96-991e-478b-bfb6-e66cec6f7ef3", "node_type": "1", "metadata": {"window": "So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here . ", "original_text": "It's \nalso down from its peak, especially as it relates to anything related to diesel fuel . "}, "hash": "d957d5a863cc787d6841922bafc8e3bad8fd9f8a6bcee0269228836aa7aa9a57", "class_name": "RelatedNodeInfo"}}, "text": "The more elevated remains the  domestic transportation . ", "start_char_idx": 3186, "end_char_idx": 3243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d162c96-991e-478b-bfb6-e66cec6f7ef3": {"__data__": {"id_": "5d162c96-991e-478b-bfb6-e66cec6f7ef3", "embedding": null, "metadata": {"window": "So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here . ", "original_text": "It's \nalso down from its peak, especially as it relates to anything related to diesel fuel . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0610b98-ce31-4862-b002-2b1c6ba09e22", "node_type": "1", "metadata": {"window": "But there is now a lot of sourcing through other \nparts of Asia that are higher than historical levels, but nowhere near the peaks .  So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic . ", "original_text": "The more elevated remains the  domestic transportation . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b300a9cdea40825932536fb97314d8963145045695febfef1cd81a70684603e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f56ab946-2bb5-46ff-afa0-501bc765fcc5", "node_type": "1", "metadata": {"window": "So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "So that's also off its \npeak . "}, "hash": "9b52e87ceb4cef56413b8f10d21a650df957bf0ffe875349430618507d9b4e51", "class_name": "RelatedNodeInfo"}}, "text": "It's \nalso down from its peak, especially as it relates to anything related to diesel fuel . ", "start_char_idx": 3243, "end_char_idx": 3336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f56ab946-2bb5-46ff-afa0-501bc765fcc5": {"__data__": {"id_": "f56ab946-2bb5-46ff-afa0-501bc765fcc5", "embedding": null, "metadata": {"window": "So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "So that's also off its \npeak . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d162c96-991e-478b-bfb6-e66cec6f7ef3", "node_type": "1", "metadata": {"window": "So we're clearly \nseeing at least an 80% reduction  of what those were at the peak and certainly much closer to pre -\npandemic levels.  \n \n So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here . ", "original_text": "It's \nalso down from its peak, especially as it relates to anything related to diesel fuel . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "277b11d29ca46acd6374bb0502a8ed3dbd31801c7168023ca872d727f7e66ec5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccd7ea31-7887-4a1c-b3b7-75ac0aae4ee9", "node_type": "1", "metadata": {"window": "The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic . "}, "hash": "6469dfb31801a2840f0a03a7ea0ef47981e2a7806076341ee476266d8329ae43", "class_name": "RelatedNodeInfo"}}, "text": "So that's also off its \npeak . ", "start_char_idx": 3336, "end_char_idx": 3367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccd7ea31-7887-4a1c-b3b7-75ac0aae4ee9": {"__data__": {"id_": "ccd7ea31-7887-4a1c-b3b7-75ac0aae4ee9", "embedding": null, "metadata": {"window": "The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f56ab946-2bb5-46ff-afa0-501bc765fcc5", "node_type": "1", "metadata": {"window": "So as relates to international freight, it's not my big worry at this point and it's one that we have to \ncontinue to keep an eye on and manage .  The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "So that's also off its \npeak . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8366f0131d0a45781de3228de8a4f43812f739ce11acf8066cd1dc71017d25e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "249bb9b7-e1bb-4ee2-bbe7-2b12d27260f7", "node_type": "1", "metadata": {"window": "It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "And th ere I have less confidence that it's going to materially reduce from here . "}, "hash": "acd68dd5b156db4337afaa9df6a62fabc96b17bbaa4ab21bd4266f36e8fa0eea", "class_name": "RelatedNodeInfo"}}, "text": "And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic . ", "start_char_idx": 3367, "end_char_idx": 3474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "249bb9b7-e1bb-4ee2-bbe7-2b12d27260f7": {"__data__": {"id_": "249bb9b7-e1bb-4ee2-bbe7-2b12d27260f7", "embedding": null, "metadata": {"window": "It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "And th ere I have less confidence that it's going to materially reduce from here . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccd7ea31-7887-4a1c-b3b7-75ac0aae4ee9", "node_type": "1", "metadata": {"window": "The more elevated remains the  domestic transportation .  It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "700f88fd0be22178e3f1fd2150f1ff8cfb4e24ca2df698947244c4f49b69df58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34608af1-71e5-40d0-bb1f-6b1014bf4ed1", "node_type": "1", "metadata": {"window": "So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "There's a "}, "hash": "61efd51d09e0936af651c2200a5652328040194c6eb323d36eb957a552f79280", "class_name": "RelatedNodeInfo"}}, "text": "And th ere I have less confidence that it's going to materially reduce from here . ", "start_char_idx": 3474, "end_char_idx": 3557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34608af1-71e5-40d0-bb1f-6b1014bf4ed1": {"__data__": {"id_": "34608af1-71e5-40d0-bb1f-6b1014bf4ed1", "embedding": null, "metadata": {"window": "So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "There's a ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f80e702b-d364-4eea-81d4-23a0966f4aec", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275103c26ff2a0bc260e0a41ff248820c986a172bd787f904d053031f2abf8ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "249bb9b7-e1bb-4ee2-bbe7-2b12d27260f7", "node_type": "1", "metadata": {"window": "It's \nalso down from its peak, especially as it relates to anything related to diesel fuel .  So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "And th ere I have less confidence that it's going to materially reduce from here . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f864d5ad7ebd5ee7399fda136575f2ce952993d6f9525edca8403cc08d4bff6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3466554-4242-4138-ad80-42c733ed41e5", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component. ", "original_text": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel . "}, "hash": "afea0d98f6b71b02bee2b4df61756f898dd6ce16623e98f5fa5cda6f02837e15", "class_name": "RelatedNodeInfo"}}, "text": "There's a ", "start_char_idx": 3557, "end_char_idx": 3567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3466554-4242-4138-ad80-42c733ed41e5": {"__data__": {"id_": "e3466554-4242-4138-ad80-42c733ed41e5", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component. ", "original_text": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34608af1-71e5-40d0-bb1f-6b1014bf4ed1", "node_type": "1", "metadata": {"window": "So that's also off its \npeak .  And we're seeing certain pockets of improvement, but it's still very elevated compared to pre -\npandemic .  And th ere I have less confidence that it's going to materially reduce from here .  There's a ", "original_text": "There's a ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed62f2b729a550e6d9d799d7c70203d239992cbfefb0458f8d54b4ea5ed950bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1593b5a0-3c0b-4c8c-ab8c-89e76809e4c4", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter . ", "original_text": "You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon . "}, "hash": "5091a318e13bd1225d8fea1ff28b7aef59c958ed9dc13c9509073f1b33b9ae12", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel . ", "start_char_idx": 0, "end_char_idx": 91, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1593b5a0-3c0b-4c8c-ab8c-89e76809e4c4": {"__data__": {"id_": "1593b5a0-3c0b-4c8c-ab8c-89e76809e4c4", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter . ", "original_text": "You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3466554-4242-4138-ad80-42c733ed41e5", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component. ", "original_text": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db76601d4e345d354f559d2e0f965defa8c5ea5245e8af591209ed28b34021f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d21f074-0129-400e-b91b-e4fe099d03ab", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated . ", "original_text": "So I expect domestic transportation to be higher longer, perhaps forever . "}, "hash": "1b8f441761756e43d381af03faa09ae7f321788ac7cbf4cf541d4f898351c054", "class_name": "RelatedNodeInfo"}}, "text": "You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon . ", "start_char_idx": 91, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d21f074-0129-400e-b91b-e4fe099d03ab": {"__data__": {"id_": "5d21f074-0129-400e-b91b-e4fe099d03ab", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated . ", "original_text": "So I expect domestic transportation to be higher longer, perhaps forever . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1593b5a0-3c0b-4c8c-ab8c-89e76809e4c4", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter . ", "original_text": "You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4c7c92e888d42f49f33f5e7c8257e0917583ce79efaecbe895494ffed0c2cad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47ad4671-0554-45f6-ae1e-0bdf2a35dc63", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n", "original_text": "And it's why we \nneed to have permanent pricing because of that component. "}, "hash": "420a037339af07c5a4067849b7c3fb27cb8a1f7aaed856dab01662c2c5c2259b", "class_name": "RelatedNodeInfo"}}, "text": "So I expect domestic transportation to be higher longer, perhaps forever . ", "start_char_idx": 238, "end_char_idx": 313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47ad4671-0554-45f6-ae1e-0bdf2a35dc63": {"__data__": {"id_": "47ad4671-0554-45f6-ae1e-0bdf2a35dc63", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n", "original_text": "And it's why we \nneed to have permanent pricing because of that component. ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d21f074-0129-400e-b91b-e4fe099d03ab", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated . ", "original_text": "So I expect domestic transportation to be higher longer, perhaps forever . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15545ac25c60b6449b61671ee53e0f5768902a662b06d08ac49ee2a616beea84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2eb6ddd4-28b3-4658-b126-d1faab1c3a9d", "node_type": "1", "metadata": {"window": "You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J . ", "original_text": "But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter . "}, "hash": "cbc7bfda1d843552623734c45e553cafa01ba173a47b22eda81ee6aa4fbcba52", "class_name": "RelatedNodeInfo"}}, "text": "And it's why we \nneed to have permanent pricing because of that component. ", "start_char_idx": 313, "end_char_idx": 388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2eb6ddd4-28b3-4658-b126-d1faab1c3a9d": {"__data__": {"id_": "2eb6ddd4-28b3-4658-b126-d1faab1c3a9d", "embedding": null, "metadata": {"window": "You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J . ", "original_text": "But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47ad4671-0554-45f6-ae1e-0bdf2a35dc63", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n", "original_text": "And it's why we \nneed to have permanent pricing because of that component. ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adbf2f3503f454487c1362e060b4c55e18c121fb90646587c69f72fd442b8ef1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88e4d535-4878-4b09-91e1-48ef7a19d3e9", "node_type": "1", "metadata": {"window": "So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse . ", "original_text": "And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated . "}, "hash": "3e83491958eeac0f9553ef4f9277c06df090a45bb25b445e80e4940a9ba72630", "class_name": "RelatedNodeInfo"}}, "text": "But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter . ", "start_char_idx": 388, "end_char_idx": 577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88e4d535-4878-4b09-91e1-48ef7a19d3e9": {"__data__": {"id_": "88e4d535-4878-4b09-91e1-48ef7a19d3e9", "embedding": null, "metadata": {"window": "So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse . ", "original_text": "And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2eb6ddd4-28b3-4658-b126-d1faab1c3a9d", "node_type": "1", "metadata": {"window": "You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J . ", "original_text": "But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28e57172a0b24102ded9f8005d662f57c2125008cb08dce22ad1ccc0dd97031b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b90d5bd-5e8d-4136-89a2-da3580cad9c3", "node_type": "1", "metadata": {"window": "And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n", "original_text": "Next \nquestion, please.  \n \n"}, "hash": "5c422b9c3049c4c150863f2fc177428d9214ac0f50afdb6db169da672879c806", "class_name": "RelatedNodeInfo"}}, "text": "And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated . ", "start_char_idx": 577, "end_char_idx": 738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b90d5bd-5e8d-4136-89a2-da3580cad9c3": {"__data__": {"id_": "3b90d5bd-5e8d-4136-89a2-da3580cad9c3", "embedding": null, "metadata": {"window": "And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n", "original_text": "Next \nquestion, please.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88e4d535-4878-4b09-91e1-48ef7a19d3e9", "node_type": "1", "metadata": {"window": "So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse . ", "original_text": "And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a7aa8a56c7b80b6cf2975a66c9c4fef3b8f1bf3cf115debda85ffed478f7858", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22db8857-9e0a-48b8-9db6-fae1fc8d455b", "node_type": "1", "metadata": {"window": "But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J. ", "original_text": "Operator:  And our final question comes from the line of A.J . "}, "hash": "8877fe4dc400f9d59e3ee7df98691fdaf6951dafd79d3f8f2d5984c98aa9bd49", "class_name": "RelatedNodeInfo"}}, "text": "Next \nquestion, please.  \n \n", "start_char_idx": 738, "end_char_idx": 766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22db8857-9e0a-48b8-9db6-fae1fc8d455b": {"__data__": {"id_": "22db8857-9e0a-48b8-9db6-fae1fc8d455b", "embedding": null, "metadata": {"window": "But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J. ", "original_text": "Operator:  And our final question comes from the line of A.J . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b90d5bd-5e8d-4136-89a2-da3580cad9c3", "node_type": "1", "metadata": {"window": "And it's why we \nneed to have permanent pricing because of that component.  But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n", "original_text": "Next \nquestion, please.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78de5238100523786ee8ca29fb002ce84c6c6cde0a8e4ee152c2d0478ae39b0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0ed527e-1fc7-4e74-a1ed-4b4b41781985", "node_type": "1", "metadata": {"window": "And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes. ", "original_text": "Rice calling from Credit Suisse . "}, "hash": "3cfaa72c2af548cc654f838d3df1406941610e2a229d5efed350163334fe92c0", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And our final question comes from the line of A.J . ", "start_char_idx": 766, "end_char_idx": 829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0ed527e-1fc7-4e74-a1ed-4b4b41781985": {"__data__": {"id_": "f0ed527e-1fc7-4e74-a1ed-4b4b41781985", "embedding": null, "metadata": {"window": "And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes. ", "original_text": "Rice calling from Credit Suisse . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22db8857-9e0a-48b8-9db6-fae1fc8d455b", "node_type": "1", "metadata": {"window": "But on the international freight side, that \nis why we are n ot pushing for faster price increases right now is because we believe that will be \ncoming down on our P&Ls this next quarter .  And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J. ", "original_text": "Operator:  And our final question comes from the line of A.J . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa2a851aa351f180a729b007b66f30e1ac25f6b1ac8ec466674384a35e65ab75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "142a0d69-79e9-4c72-90db-7d361fab24e5", "node_type": "1", "metadata": {"window": "Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot . ", "original_text": "Please \ngo ahead.  \n \n"}, "hash": "1b73d30e80788f2f20fc1f6f6584d519540672f06b0356fd98b6aa031819176b", "class_name": "RelatedNodeInfo"}}, "text": "Rice calling from Credit Suisse . ", "start_char_idx": 829, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "142a0d69-79e9-4c72-90db-7d361fab24e5": {"__data__": {"id_": "142a0d69-79e9-4c72-90db-7d361fab24e5", "embedding": null, "metadata": {"window": "Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot . ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0ed527e-1fc7-4e74-a1ed-4b4b41781985", "node_type": "1", "metadata": {"window": "And as we get through fiscal \u201824 those two lines, the \nprice line and the cost line , will finally intersect and we can see that tha t will be fully mitigated .  Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes. ", "original_text": "Rice calling from Credit Suisse . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b31d19ac90734c9c58df99b482fdb8f336cc9be71642c9c594db05ce0bf821e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "214f2b3a-89a1-473a-bb11-68f131ca2b0d", "node_type": "1", "metadata": {"window": "Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out . ", "original_text": "A.J. "}, "hash": "48b002b6578b6535eb1fe04567f5e09b88cc711a768c1e312e75214222975f9e", "class_name": "RelatedNodeInfo"}}, "text": "Please \ngo ahead.  \n \n", "start_char_idx": 863, "end_char_idx": 885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "214f2b3a-89a1-473a-bb11-68f131ca2b0d": {"__data__": {"id_": "214f2b3a-89a1-473a-bb11-68f131ca2b0d", "embedding": null, "metadata": {"window": "Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out . ", "original_text": "A.J. ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "142a0d69-79e9-4c72-90db-7d361fab24e5", "node_type": "1", "metadata": {"window": "Next \nquestion, please.  \n \n Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot . ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e86f64d065ebf1c2cf6f9967b302566a286cb67e8183ee5f6ace034010ff087", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a91214b-0154-460a-85ae-e32b8037f555", "node_type": "1", "metadata": {"window": "Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there . ", "original_text": "Rice :  Yes. "}, "hash": "42b37e081c40902624cea1ba7e9855581f98396b9285ee0d4ad52a869116db7a", "class_name": "RelatedNodeInfo"}}, "text": "A.J. ", "start_char_idx": 885, "end_char_idx": 890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a91214b-0154-460a-85ae-e32b8037f555": {"__data__": {"id_": "3a91214b-0154-460a-85ae-e32b8037f555", "embedding": null, "metadata": {"window": "Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there . ", "original_text": "Rice :  Yes. ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "214f2b3a-89a1-473a-bb11-68f131ca2b0d", "node_type": "1", "metadata": {"window": "Operator:  And our final question comes from the line of A.J .  Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out . ", "original_text": "A.J. ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea8db34743c8b778b1f77932f7787ad0e024cbfb7cf55236d8b9d005c9928272", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22ca1f9b-3bba-4662-a0d1-dd15dfd08f6a", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?  ", "original_text": "Thanks a lot . "}, "hash": "f8ec29b3941c85dc6950008bef9e8bfb7e8533240ad423434447b945877dc0b9", "class_name": "RelatedNodeInfo"}}, "text": "Rice :  Yes. ", "start_char_idx": 890, "end_char_idx": 903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22ca1f9b-3bba-4662-a0d1-dd15dfd08f6a": {"__data__": {"id_": "22ca1f9b-3bba-4662-a0d1-dd15dfd08f6a", "embedding": null, "metadata": {"window": "Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?  ", "original_text": "Thanks a lot . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a91214b-0154-460a-85ae-e32b8037f555", "node_type": "1", "metadata": {"window": "Rice calling from Credit Suisse .  Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there . ", "original_text": "Rice :  Yes. ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea43d3fef17bd0252cb3ab1d0c6d475a28ac6ab06527038bb958ef5a3be4121c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d4c7df1-a8d7-4b0c-8402-1d6f26be6bf2", "node_type": "1", "metadata": {"window": "A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?  ", "original_text": "I know growing specialty has been a priority for the company as this \nmanagement team set out . "}, "hash": "f821396bfc3b4532c512e64170493901c868539172a839f531f97090ad8d2ca9", "class_name": "RelatedNodeInfo"}}, "text": "Thanks a lot . ", "start_char_idx": 903, "end_char_idx": 918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d4c7df1-a8d7-4b0c-8402-1d6f26be6bf2": {"__data__": {"id_": "4d4c7df1-a8d7-4b0c-8402-1d6f26be6bf2", "embedding": null, "metadata": {"window": "A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?  ", "original_text": "I know growing specialty has been a priority for the company as this \nmanagement team set out . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22ca1f9b-3bba-4662-a0d1-dd15dfd08f6a", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?  ", "original_text": "Thanks a lot . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df532d5a7a9625e05dad458642bcbaaf5d8010d6c997bd720a4bfabc478212ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fe072c6-45a1-4cd0-aea4-b77e98d3bedd", "node_type": "1", "metadata": {"window": "Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n", "original_text": "And you've mentioned, again today that you're having progress there . "}, "hash": "bc113b1bc34b042aad5ce931da478bb15479f5a348a25557167b659d34d7b3fb", "class_name": "RelatedNodeInfo"}}, "text": "I know growing specialty has been a priority for the company as this \nmanagement team set out . ", "start_char_idx": 918, "end_char_idx": 1014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fe072c6-45a1-4cd0-aea4-b77e98d3bedd": {"__data__": {"id_": "7fe072c6-45a1-4cd0-aea4-b77e98d3bedd", "embedding": null, "metadata": {"window": "Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n", "original_text": "And you've mentioned, again today that you're having progress there . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d4c7df1-a8d7-4b0c-8402-1d6f26be6bf2", "node_type": "1", "metadata": {"window": "A.J.  Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?  ", "original_text": "I know growing specialty has been a priority for the company as this \nmanagement team set out . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10a7453cc89a476d013037f2ee1a68f9b5b89cb8a35cdb5f4622253dbdfb995", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faf500de-a404-436a-a824-740419968fb0", "node_type": "1", "metadata": {"window": "Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations . ", "original_text": "I \nguess can you just maybe tell us where you're seeing success in the specialty area?  "}, "hash": "fdc6ac11a222a64ae999c32f61e8a7a46f8ca6a9f808e198bf6bc411abb0d7c9", "class_name": "RelatedNodeInfo"}}, "text": "And you've mentioned, again today that you're having progress there . ", "start_char_idx": 1014, "end_char_idx": 1084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faf500de-a404-436a-a824-740419968fb0": {"__data__": {"id_": "faf500de-a404-436a-a824-740419968fb0", "embedding": null, "metadata": {"window": "Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations . ", "original_text": "I \nguess can you just maybe tell us where you're seeing success in the specialty area?  ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fe072c6-45a1-4cd0-aea4-b77e98d3bedd", "node_type": "1", "metadata": {"window": "Rice :  Yes.  Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n", "original_text": "And you've mentioned, again today that you're having progress there . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8a4b49cd59d8376da5d0578f55fac01261dab61ac67db058f9bc4656fc10158", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27ec8d71-06bf-4788-a122-8db748fa2ae6", "node_type": "1", "metadata": {"window": "I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter . ", "original_text": "And is the plan \nprogressing as expected as it was talked about over  the last year or so?  "}, "hash": "893d8394394a7b269e62feca8aebd3ac65d8424a7d87409a49aa96a7c37dbf0a", "class_name": "RelatedNodeInfo"}}, "text": "I \nguess can you just maybe tell us where you're seeing success in the specialty area?  ", "start_char_idx": 1084, "end_char_idx": 1172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27ec8d71-06bf-4788-a122-8db748fa2ae6": {"__data__": {"id_": "27ec8d71-06bf-4788-a122-8db748fa2ae6", "embedding": null, "metadata": {"window": "I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter . ", "original_text": "And is the plan \nprogressing as expected as it was talked about over  the last year or so?  ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faf500de-a404-436a-a824-740419968fb0", "node_type": "1", "metadata": {"window": "Thanks a lot .  I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations . ", "original_text": "I \nguess can you just maybe tell us where you're seeing success in the specialty area?  ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4304beb12652e312454e4a6050fe83b4ca79095e35c924bc69097802b33f2369", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdfbc346-2a71-43f1-80fd-4ba588bc8f62", "node_type": "1", "metadata": {"window": "And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers . ", "original_text": "Or is that an area of \noutperformance for you or how would you describe that?   \n \n"}, "hash": "2433f3d1e45374462231ff9782b6357f848cc96f23ee7b2da17df7767a94291d", "class_name": "RelatedNodeInfo"}}, "text": "And is the plan \nprogressing as expected as it was talked about over  the last year or so?  ", "start_char_idx": 1172, "end_char_idx": 1264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdfbc346-2a71-43f1-80fd-4ba588bc8f62": {"__data__": {"id_": "bdfbc346-2a71-43f1-80fd-4ba588bc8f62", "embedding": null, "metadata": {"window": "And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers . ", "original_text": "Or is that an area of \noutperformance for you or how would you describe that?   \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27ec8d71-06bf-4788-a122-8db748fa2ae6", "node_type": "1", "metadata": {"window": "I know growing specialty has been a priority for the company as this \nmanagement team set out .  And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter . ", "original_text": "And is the plan \nprogressing as expected as it was talked about over  the last year or so?  ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27d29de6f39018b2ad4f042f1f497abae60db14a0d0d738ee6b6a3dffb811e8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21b96769-c1f6-4874-b86e-677dfed76554", "node_type": "1", "metadata": {"window": "I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty . ", "original_text": "Jason Hollar:  Sure, it's absolutely meeting our expectations . "}, "hash": "c88602f65c30f4530ec6b7e07a8f4f9977a9c82b680a1b0b19cbce48c92fa1bd", "class_name": "RelatedNodeInfo"}}, "text": "Or is that an area of \noutperformance for you or how would you describe that?   \n \n", "start_char_idx": 1264, "end_char_idx": 1347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21b96769-c1f6-4874-b86e-677dfed76554": {"__data__": {"id_": "21b96769-c1f6-4874-b86e-677dfed76554", "embedding": null, "metadata": {"window": "I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty . ", "original_text": "Jason Hollar:  Sure, it's absolutely meeting our expectations . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdfbc346-2a71-43f1-80fd-4ba588bc8f62", "node_type": "1", "metadata": {"window": "And you've mentioned, again today that you're having progress there .  I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers . ", "original_text": "Or is that an area of \noutperformance for you or how would you describe that?   \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1d0a5c1d47639e57835b97a370cd478480e9a3e5ddd6d3d61a67602ce3a7ca4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f5c4638-27e6-40bf-898d-531cab4ba047", "node_type": "1", "metadata": {"window": "And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely . ", "original_text": "It was a call out in terms of the broad \nvolume that we had this last quarter . "}, "hash": "f7f2e598974b8f1f83cd3a8e90dc671b65d5fe7620d6488ca094cb0b14615bf0", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure, it's absolutely meeting our expectations . ", "start_char_idx": 1347, "end_char_idx": 1411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f5c4638-27e6-40bf-898d-531cab4ba047": {"__data__": {"id_": "8f5c4638-27e6-40bf-898d-531cab4ba047", "embedding": null, "metadata": {"window": "And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely . ", "original_text": "It was a call out in terms of the broad \nvolume that we had this last quarter . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21b96769-c1f6-4874-b86e-677dfed76554", "node_type": "1", "metadata": {"window": "I \nguess can you just maybe tell us where you're seeing success in the specialty area?   And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty . ", "original_text": "Jason Hollar:  Sure, it's absolutely meeting our expectations . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb6a28dc8b54fb33e658af9b958ca17678db739c96abd30b26a6259a542362c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc0d8a2c-77ab-452b-97c3-594765893bed", "node_type": "1", "metadata": {"window": "Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver . ", "original_text": "So we had st rength across a number of many different \ncategories and customers . "}, "hash": "8cc1055d718b834a902641e2fd687ced749a74208875d4c622224f5d516ece6c", "class_name": "RelatedNodeInfo"}}, "text": "It was a call out in terms of the broad \nvolume that we had this last quarter . ", "start_char_idx": 1411, "end_char_idx": 1491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc0d8a2c-77ab-452b-97c3-594765893bed": {"__data__": {"id_": "cc0d8a2c-77ab-452b-97c3-594765893bed", "embedding": null, "metadata": {"window": "Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver . ", "original_text": "So we had st rength across a number of many different \ncategories and customers . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f5c4638-27e6-40bf-898d-531cab4ba047", "node_type": "1", "metadata": {"window": "And is the plan \nprogressing as expected as it was talked about over  the last year or so?   Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely . ", "original_text": "It was a call out in terms of the broad \nvolume that we had this last quarter . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb9f5a3a99dd0b957875572de9ec9bb8007a4add5dd3375e8c0cc11f84d75be3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78ba5c2f-21f1-4f4f-955d-db4de2b799c8", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n", "original_text": "We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty . "}, "hash": "0a3f3dd5cc323b5327efe0cc23b93e2c47c155486249635fadfcbaeb46d9b905", "class_name": "RelatedNodeInfo"}}, "text": "So we had st rength across a number of many different \ncategories and customers . ", "start_char_idx": 1491, "end_char_idx": 1573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78ba5c2f-21f1-4f4f-955d-db4de2b799c8": {"__data__": {"id_": "78ba5c2f-21f1-4f4f-955d-db4de2b799c8", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n", "original_text": "We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc0d8a2c-77ab-452b-97c3-594765893bed", "node_type": "1", "metadata": {"window": "Or is that an area of \noutperformance for you or how would you describe that?   \n \n Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver . ", "original_text": "So we had st rength across a number of many different \ncategories and customers . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02cfd3fa93936b2051a748a0bbf8b957b64297a48f974a80ecae1ff7b2aa3552", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b507281c-861b-4d13-aa9d-946abb2473c8", "node_type": "1", "metadata": {"window": "It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform . ", "original_text": "So \nthe business i s strong, it's large, it's growing nicely . "}, "hash": "016e96b983b99eb41006a173f68f8ec6fa162106f54474f37255cce2bb059706", "class_name": "RelatedNodeInfo"}}, "text": "We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty . ", "start_char_idx": 1573, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b507281c-861b-4d13-aa9d-946abb2473c8": {"__data__": {"id_": "b507281c-861b-4d13-aa9d-946abb2473c8", "embedding": null, "metadata": {"window": "It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform . ", "original_text": "So \nthe business i s strong, it's large, it's growing nicely . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78ba5c2f-21f1-4f4f-955d-db4de2b799c8", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure, it's absolutely meeting our expectations .  It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n", "original_text": "We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebbdebe9ba828fffb48191cc8ff6a90054cf759f39ee353cd8b5b6709bcf4c53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f89d09d-58e1-435e-b2a2-8d4d386e6860", "node_type": "1", "metadata": {"window": "So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll. ", "original_text": "You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver . "}, "hash": "a112205afeecdf1fbe4ae46a206016d5e6ab5466756b0597faf455eefbac6fb9", "class_name": "RelatedNodeInfo"}}, "text": "So \nthe business i s strong, it's large, it's growing nicely . ", "start_char_idx": 1735, "end_char_idx": 1798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f89d09d-58e1-435e-b2a2-8d4d386e6860": {"__data__": {"id_": "4f89d09d-58e1-435e-b2a2-8d4d386e6860", "embedding": null, "metadata": {"window": "So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll. ", "original_text": "You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b507281c-861b-4d13-aa9d-946abb2473c8", "node_type": "1", "metadata": {"window": "It was a call out in terms of the broad \nvolume that we had this last quarter .  So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform . ", "original_text": "So \nthe business i s strong, it's large, it's growing nicely . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a3be28409d95e02aaf1bb5912fe99c3229d61c7112263345d5e7d3065ac47df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25e98902-e55e-4838-974f-05c30849572c", "node_type": "1", "metadata": {"window": "We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth . ", "original_text": "Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n"}, "hash": "e0d539bd603b3198a44687bfc58392e2f2afefb6668c5c3d0c228d8ab733d263", "class_name": "RelatedNodeInfo"}}, "text": "You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver . ", "start_char_idx": 1798, "end_char_idx": 1963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25e98902-e55e-4838-974f-05c30849572c": {"__data__": {"id_": "25e98902-e55e-4838-974f-05c30849572c", "embedding": null, "metadata": {"window": "We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth . ", "original_text": "Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f89d09d-58e1-435e-b2a2-8d4d386e6860", "node_type": "1", "metadata": {"window": "So we had st rength across a number of many different \ncategories and customers .  We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll. ", "original_text": "You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "336ce1c683f33fba13c96d9d10264f5fca96aca6b74145a854480325412638ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3e63db3-ef9b-4d11-aadf-048cc9e8751e", "node_type": "1", "metadata": {"window": "So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question . ", "original_text": "Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform . "}, "hash": "6b3f25a0922b54abfaff6d0d638b4efc0a2de09842c2dcc96cce5589843ead24", "class_name": "RelatedNodeInfo"}}, "text": "Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n", "start_char_idx": 1963, "end_char_idx": 2170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3e63db3-ef9b-4d11-aadf-048cc9e8751e": {"__data__": {"id_": "c3e63db3-ef9b-4d11-aadf-048cc9e8751e", "embedding": null, "metadata": {"window": "So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question . ", "original_text": "Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25e98902-e55e-4838-974f-05c30849572c", "node_type": "1", "metadata": {"window": "We also called out double -digit growth within ou r sourcing and \nmanufacturi er services group, which is a key component of the upstream elements of specialty .  So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth . ", "original_text": "Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d67b0d37ac93e1388ae7a3f2d1d68668962f36052322ad733af559ea52335dbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60cfb81a-f6ef-4547-a852-8dd6395f55f1", "node_type": "1", "metadata": {"window": "You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes. ", "original_text": "So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll. "}, "hash": "d3578edff17b2f52d8c73e60965c56e32f1a5169f9ccb059901463675cdd1198", "class_name": "RelatedNodeInfo"}}, "text": "Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform . ", "start_char_idx": 2170, "end_char_idx": 2283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60cfb81a-f6ef-4547-a852-8dd6395f55f1": {"__data__": {"id_": "60cfb81a-f6ef-4547-a852-8dd6395f55f1", "embedding": null, "metadata": {"window": "You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes. ", "original_text": "So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll. ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3e63db3-ef9b-4d11-aadf-048cc9e8751e", "node_type": "1", "metadata": {"window": "So \nthe business i s strong, it's large, it's growing nicely .  You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question . ", "original_text": "Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8515658ffa91d0534e7272a82eda1cbf610d331a0da698edd757142997f03342", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "749c8528-187d-4b36-bab2-e22e93a51429", "node_type": "1", "metadata": {"window": "Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n", "original_text": "So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth . "}, "hash": "f2eb66ffb5c52025520beef72eb0f3bdcfbbe3551cf934fb91a61f061a354cdd", "class_name": "RelatedNodeInfo"}}, "text": "So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll. ", "start_char_idx": 2283, "end_char_idx": 2528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "749c8528-187d-4b36-bab2-e22e93a51429": {"__data__": {"id_": "749c8528-187d-4b36-bab2-e22e93a51429", "embedding": null, "metadata": {"window": "Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n", "original_text": "So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60cfb81a-f6ef-4547-a852-8dd6395f55f1", "node_type": "1", "metadata": {"window": "You know, we have I think like the rest of the \nindustry, biosimilars is a nice tailwind that we're seeing , not large enough to call out as an individual \ndriver .  Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes. ", "original_text": "So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll. ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6be7849836fdc2e15b61cfeb04ef327c18ee7c47fdd0a197a917266122a81b64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32e68f3b-7c14-4032-804f-aaebfca67fa4", "node_type": "1", "metadata": {"window": "Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick . ", "original_text": "I believe that was our last question . "}, "hash": "e0d670e00295afd26915111247a168e5583f2d8ad5c756f522071b03be2292c1", "class_name": "RelatedNodeInfo"}}, "text": "So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth . ", "start_char_idx": 2528, "end_char_idx": 2729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32e68f3b-7c14-4032-804f-aaebfca67fa4": {"__data__": {"id_": "32e68f3b-7c14-4032-804f-aaebfca67fa4", "embedding": null, "metadata": {"window": "Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick . ", "original_text": "I believe that was our last question . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "749c8528-187d-4b36-bab2-e22e93a51429", "node_type": "1", "metadata": {"window": "Our 3PL business, especially with the regulatory approvals being a little bit more normali zed, is \nwell positioned and we're continuing to invest in areas that will be growth opportunities in the future . \n Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n", "original_text": "So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9d2302c0023d3ecbef29776d6572d7009b57edf686fc29583460076c550582d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "821c151f-9f93-479f-874f-1bf56c36333e", "node_type": "1", "metadata": {"window": "So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n", "original_text": "Yes. "}, "hash": "49acf5b7a489423f6979eef4f6dad5d6dc70738f8c43ec39fe8ba87a96208980", "class_name": "RelatedNodeInfo"}}, "text": "I believe that was our last question . ", "start_char_idx": 2729, "end_char_idx": 2768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "821c151f-9f93-479f-874f-1bf56c36333e": {"__data__": {"id_": "821c151f-9f93-479f-874f-1bf56c36333e", "embedding": null, "metadata": {"window": "So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n", "original_text": "Yes. ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32e68f3b-7c14-4032-804f-aaebfca67fa4", "node_type": "1", "metadata": {"window": "Whether that be cell and gene or just where value -based care is going, where we have our Navista \nTS platform .  So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick . ", "original_text": "I believe that was our last question . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1caac3c46dd5d1b83dcf0fe386d1a5c9a8d44e3d6995e059b9711da521159556", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32fadebb-23ec-4de1-bec7-d284dc82fd65", "node_type": "1", "metadata": {"window": "So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah . ", "original_text": "Thank you . \n"}, "hash": "dfeea04c10cd870bb60816e66047a063f3a215300f6b8fe3707ba4d38d8d8a54", "class_name": "RelatedNodeInfo"}}, "text": "Yes. ", "start_char_idx": 898, "end_char_idx": 903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32fadebb-23ec-4de1-bec7-d284dc82fd65": {"__data__": {"id_": "32fadebb-23ec-4de1-bec7-d284dc82fd65", "embedding": null, "metadata": {"window": "So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah . ", "original_text": "Thank you . \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "821c151f-9f93-479f-874f-1bf56c36333e", "node_type": "1", "metadata": {"window": "So we're investing organically and of course, within our inorganic, we've had a nice \nsuccess with our Bendcare GPO, and the investment in the MSO , that I think has given us some \nadditional opportunities to think about in the future as we ll.  So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n", "original_text": "Yes. ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b28ad34c46c86914d9c7ee74726a701a0672b7dbe80cb1499727c79cd87f899d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0869f6e8-59b3-4c15-bcb2-3f45b81335e2", "node_type": "1", "metadata": {"window": "I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n", "original_text": "And I'll wrap it up here real quick . "}, "hash": "276db094f1df46d734cacdba83ae9eda99aa1b5cafb55fdbac853a0e3d769855", "class_name": "RelatedNodeInfo"}}, "text": "Thank you . \n", "start_char_idx": 2773, "end_char_idx": 2786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0869f6e8-59b3-4c15-bcb2-3f45b81335e2": {"__data__": {"id_": "0869f6e8-59b3-4c15-bcb2-3f45b81335e2", "embedding": null, "metadata": {"window": "I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n", "original_text": "And I'll wrap it up here real quick . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32fadebb-23ec-4de1-bec7-d284dc82fd65", "node_type": "1", "metadata": {"window": "So not any one item to highlight, but there \nis a strong breadth across many different pillars of the specialty business that we feel good is a very \nstrong foundation and platform for future growth .  I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah . ", "original_text": "Thank you . \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95eba5d6fa91a643f93b3b6b405e4f5ab44fcd8dadfb3f0ad7d36f3221a5c00a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b0783fb-0f0d-490c-8c6b-2b4af219cf0f", "node_type": "1", "metadata": {"window": "Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks . ", "original_text": "Yes. \n \n"}, "hash": "ff5fc205ed579bac60d2cfcc506582ed648e241fb0ede3bbbec40e43fcde78e9", "class_name": "RelatedNodeInfo"}}, "text": "And I'll wrap it up here real quick . ", "start_char_idx": 2786, "end_char_idx": 2824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b0783fb-0f0d-490c-8c6b-2b4af219cf0f": {"__data__": {"id_": "7b0783fb-0f0d-490c-8c6b-2b4af219cf0f", "embedding": null, "metadata": {"window": "Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks . ", "original_text": "Yes. \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0869f6e8-59b3-4c15-bcb2-3f45b81335e2", "node_type": "1", "metadata": {"window": "I believe that was our last question .  Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n", "original_text": "And I'll wrap it up here real quick . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc187797e57c95f9ee9b2eabf629a71b3c40e76260849baffc974ac2e15575de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e8d5d92-1a22-4a71-973a-26f04e0f3787", "node_type": "1", "metadata": {"window": "Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that . ", "original_text": "Operator:  Yeah . "}, "hash": "ca3f0fc1fc4e211c708ea4e38a77a3c44dca334cf536cb377852b8403088062a", "class_name": "RelatedNodeInfo"}}, "text": "Yes. \n \n", "start_char_idx": 2824, "end_char_idx": 2832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e8d5d92-1a22-4a71-973a-26f04e0f3787": {"__data__": {"id_": "1e8d5d92-1a22-4a71-973a-26f04e0f3787", "embedding": null, "metadata": {"window": "Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that . ", "original_text": "Operator:  Yeah . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b0783fb-0f0d-490c-8c6b-2b4af219cf0f", "node_type": "1", "metadata": {"window": "Yes.  Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks . ", "original_text": "Yes. \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5de46c872f52e60a36c6a991a76e8ffe5426d34a3b66d21c55901b73bd1a394", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4862379a-9f2a-4268-bc29-db176533ecd3", "node_type": "1", "metadata": {"window": "And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business . ", "original_text": "There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n"}, "hash": "4c266bda74b854009802c6d4829f5cd6147c2962f783a5aad41882860891a675", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Yeah . ", "start_char_idx": 2832, "end_char_idx": 2850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4862379a-9f2a-4268-bc29-db176533ecd3": {"__data__": {"id_": "4862379a-9f2a-4268-bc29-db176533ecd3", "embedding": null, "metadata": {"window": "And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business . ", "original_text": "There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e8d5d92-1a22-4a71-973a-26f04e0f3787", "node_type": "1", "metadata": {"window": "Thank you . \n And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that . ", "original_text": "Operator:  Yeah . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "905bd98f71ec6dccf5fc0adaac4528fbfd752ed98ccfba21346ce491988c0ff6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5913b7f8-e23d-4f0e-a24a-1df012ddab37", "node_type": "1", "metadata": {"window": "Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation . ", "original_text": "Jason Hollar:  Yeah, thanks . "}, "hash": "905d146aebc000587f485415f7799082c0b27d7095d0e3b269f9539d45fc43ee", "class_name": "RelatedNodeInfo"}}, "text": "There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n", "start_char_idx": 2850, "end_char_idx": 2959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5913b7f8-e23d-4f0e-a24a-1df012ddab37": {"__data__": {"id_": "5913b7f8-e23d-4f0e-a24a-1df012ddab37", "embedding": null, "metadata": {"window": "Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation . ", "original_text": "Jason Hollar:  Yeah, thanks . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4862379a-9f2a-4268-bc29-db176533ecd3", "node_type": "1", "metadata": {"window": "And I'll wrap it up here real quick .  Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business . ", "original_text": "There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "911cef048bf61fb1d17a3decce77b74244e0d48c3312c7accde294b7a5d5f141", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f191ba1-8183-4791-9af6-dbc8935f0f89", "node_type": "1", "metadata": {"window": "Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n", "original_text": "I appreciate that . "}, "hash": "e15fbc747b0b40b1119cda47f427723ae06cb8fc86a8f34a5dd77edbb56ad3e3", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah, thanks . ", "start_char_idx": 2959, "end_char_idx": 2989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f191ba1-8183-4791-9af6-dbc8935f0f89": {"__data__": {"id_": "5f191ba1-8183-4791-9af6-dbc8935f0f89", "embedding": null, "metadata": {"window": "Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n", "original_text": "I appreciate that . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5913b7f8-e23d-4f0e-a24a-1df012ddab37", "node_type": "1", "metadata": {"window": "Yes. \n \n Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation . ", "original_text": "Jason Hollar:  Yeah, thanks . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a76370b9fd40ea3357a37d6d2ea322d3e37ad5d6fde31b924123fb861ffa43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71772b30-5457-4276-9b1b-e2be64614ffd", "node_type": "1", "metadata": {"window": "There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call . ", "original_text": "Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business . "}, "hash": "3276d4729a10b48c889d753a33d6f3b571da312588572876ec7e82db5d68fb3c", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate that . ", "start_char_idx": 2989, "end_char_idx": 3009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71772b30-5457-4276-9b1b-e2be64614ffd": {"__data__": {"id_": "71772b30-5457-4276-9b1b-e2be64614ffd", "embedding": null, "metadata": {"window": "There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call . ", "original_text": "Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f191ba1-8183-4791-9af6-dbc8935f0f89", "node_type": "1", "metadata": {"window": "Operator:  Yeah .  There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n", "original_text": "I appreciate that . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f011bd6ee784f0eeec047c92e95800000f742f3af7736adf7bb70420cbc2f3c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ec7b3df-1344-4327-b24a-619e19f808ba", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect . ", "original_text": "We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation . "}, "hash": "7059d6671e61416299ca205ef0265946bfb8a38e9c6c307721541b57d8ee34d7", "class_name": "RelatedNodeInfo"}}, "text": "Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business . ", "start_char_idx": 3009, "end_char_idx": 3194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ec7b3df-1344-4327-b24a-619e19f808ba": {"__data__": {"id_": "8ec7b3df-1344-4327-b24a-619e19f808ba", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect . ", "original_text": "We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71772b30-5457-4276-9b1b-e2be64614ffd", "node_type": "1", "metadata": {"window": "There are no further  questions , so I would hand you back to your host to conclude \ntoday's conference.  \n \n Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call . ", "original_text": "Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d54180188a254bb6f39ac8432b846ec64c1ba20fa09811f97b1847e84563c19f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9621562-3e0b-489e-a8e0-472d14cce89a", "node_type": "1", "metadata": {"window": "I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect .  Host, please stay connected \non the line.  ", "original_text": "So with that, thank you, and have a \ngreat day.  \n \n"}, "hash": "1b789d64f6d39dbd2f7587257ff80f554a8d4ccaf1d11ca5b58f8a0539867d36", "class_name": "RelatedNodeInfo"}}, "text": "We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation . ", "start_char_idx": 3194, "end_char_idx": 3322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9621562-3e0b-489e-a8e0-472d14cce89a": {"__data__": {"id_": "b9621562-3e0b-489e-a8e0-472d14cce89a", "embedding": null, "metadata": {"window": "I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect .  Host, please stay connected \non the line.  ", "original_text": "So with that, thank you, and have a \ngreat day.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ec7b3df-1344-4327-b24a-619e19f808ba", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, thanks .  I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect . ", "original_text": "We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b20a4f0557d9ce0bc6c713dc398b13608a8f7166b6b04862d2c9b39f3e275c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ffc54f0-c7ef-4948-82da-7887a76dc00a", "node_type": "1", "metadata": {"window": "Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect .  Host, please stay connected \non the line.  ", "original_text": "Operator:  Thank you for joining today's call . "}, "hash": "d27870e4cf8ef21ccd018b23feb790ec6740f1e11b8883c59aeadcd45992d8a2", "class_name": "RelatedNodeInfo"}}, "text": "So with that, thank you, and have a \ngreat day.  \n \n", "start_char_idx": 3322, "end_char_idx": 3374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ffc54f0-c7ef-4948-82da-7887a76dc00a": {"__data__": {"id_": "6ffc54f0-c7ef-4948-82da-7887a76dc00a", "embedding": null, "metadata": {"window": "Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect .  Host, please stay connected \non the line.  ", "original_text": "Operator:  Thank you for joining today's call . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9621562-3e0b-489e-a8e0-472d14cce89a", "node_type": "1", "metadata": {"window": "I appreciate that .  Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect .  Host, please stay connected \non the line.  ", "original_text": "So with that, thank you, and have a \ngreat day.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bb6ceefbe95b2fcb5540f1b3514ee943f215d713ffd1d6d88dc2cc46e11d42d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3b212a7-2ccc-4841-a4b8-24045b45b309", "node_type": "1", "metadata": {"window": "We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect .  Host, please stay connected \non the line.  ", "original_text": "You may now disconnect . "}, "hash": "14cdcbbe5cd7e90a69fff9df86eb19e2c3cebd4e12ce43f4c2839083875a26e7", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you for joining today's call . ", "start_char_idx": 3374, "end_char_idx": 3422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3b212a7-2ccc-4841-a4b8-24045b45b309": {"__data__": {"id_": "d3b212a7-2ccc-4841-a4b8-24045b45b309", "embedding": null, "metadata": {"window": "We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect .  Host, please stay connected \non the line.  ", "original_text": "You may now disconnect . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ffc54f0-c7ef-4948-82da-7887a76dc00a", "node_type": "1", "metadata": {"window": "Just to summarise real quick, I'm pleased with the \ncontinued stability in Pharma, as we just discussed here today, as well as the progress that we're \nmaking in the Medical business .  We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect .  Host, please stay connected \non the line.  ", "original_text": "Operator:  Thank you for joining today's call . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ded1aa144cc5b5b307c96272a0cab3a7c2c568a8f160549cfabd6b3dbbdb5dec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad40ac1c-08a6-4aab-8970-33d264cd9ca7", "node_type": "1", "metadata": {"window": "So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect .  Host, please stay connected \non the line.  ", "original_text": "Host, please stay connected \non the line.  "}, "hash": "da5dc1918782caf7abeffc35007ecef1dd9c4fe1111ebe2e97844e8a2d7d4a49", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect . ", "start_char_idx": 3422, "end_char_idx": 3447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad40ac1c-08a6-4aab-8970-33d264cd9ca7": {"__data__": {"id_": "ad40ac1c-08a6-4aab-8970-33d264cd9ca7", "embedding": null, "metadata": {"window": "So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect .  Host, please stay connected \non the line.  ", "original_text": "Host, please stay connected \non the line.  ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "258eaa664f1fcd4730725adc04db6c18aedd5c6c0b443cbb244ff4e0c08fb125", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3b212a7-2ccc-4841-a4b8-24045b45b309", "node_type": "1", "metadata": {"window": "We are committed to executing on our key priorities, including \nmaintaining  a relentless focus on shareholder value creation .  So with that, thank you, and have a \ngreat day.  \n \n Operator:  Thank you for joining today's call .  You may now disconnect .  Host, please stay connected \non the line.  ", "original_text": "You may now disconnect . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "348def134b2f64184d3c834da1be3aa0b29ec06187d6d39f2541076c0029a384", "class_name": "RelatedNodeInfo"}}, "text": "Host, please stay connected \non the line.  ", "start_char_idx": 3447, "end_char_idx": 3490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"40c59cb6-ec27-4d2d-862a-c3f6edc23738": {"doc_hash": "3262c248f76bbce871a924fe0fbe347fe50b19c42b6b4afc05ebda50e8a5c832", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "65f1f320-e7bb-45f1-904f-79ff82bd6bf7": {"doc_hash": "1886c5bd7e3511ab6c88bc201c7d7ecf1cf3eab98078b0ba8b0937e52609c1b5", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "4f5a7aeb-ba46-4be2-8782-6976e4f59d70": {"doc_hash": "d52f028d0099afe0cc81b1918abf37b69f89546e1099bed0b61d9e29dc4b022f", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "b77c5f9f-c8c9-45af-9287-e8df0b9ac0ff": {"doc_hash": "9d8a1320bd29b78b042687c7b5eb1a03302a61a8f816f14cc98ce795568345d0", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "3092d54a-59d3-4c8d-ac78-5ad0e3d469f0": {"doc_hash": "7c90c96da86b9da24dbc9cf44ca4e6234eb8c30f3a0a5d337ec0a74907f0e3e0", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "1e029378-f87d-4f5c-901f-7208f3569a00": {"doc_hash": "51507e72123946941acb4b18342a6f58ff732d495ab6f3dfc36c2e7e469a780c", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "c18cc781-3496-47eb-94c9-f5ccbcc3aed5": {"doc_hash": "64cd4e5f72b564e24a1870ef0c9abbeac7dfdae6b5fcde9f4975e49a7d4dfa29", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "66634b70-d7ee-43ee-9f66-0bbff9cd7545": {"doc_hash": "84568d6e13447de8da53b24ce957c4f2a53685da07ff940f07076438305a9123", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "6fd068f4-e07e-4a32-b36d-8a1607040c04": {"doc_hash": "a37a69229db6869ca56e73871d575c3553918467e94b6fb64cc6dee2c96ebeb5", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "327584de-bd37-4cda-90f3-cd945b22e8a8": {"doc_hash": "72567de9d22d8a2bed0acf90e3a626d29d0095ec67d881f7ea9e87ff5d9eefd1", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "1e9141bc-fa23-4b4b-bce8-ceed288e1403": {"doc_hash": "84ecda873240d3c978373755ba06fa6975d9e74c0213f49b6e4dd38ca420e511", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "8d28c4d5-fd9c-4c14-b1c4-5efb1331ef65": {"doc_hash": "5fb8053f5b081c51d5cf2a7ebb01f1e7473275e00a3938ee872cdd053923a4ed", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "ccdc05ae-47c7-4b56-9864-a40bb13cf39f": {"doc_hash": "ec6bfa10371798460b91552137d13c2330ea3be0b8ee1d2e09177d567f99311e", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "ab5a43fe-253f-4033-a688-baa0511dcb18": {"doc_hash": "b70295c61b00dff79db547bf910a2b5e2ef6d415123a53b98a98d1d764fecb60", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "51630290-54e3-4395-afe8-60b311f5b2ac": {"doc_hash": "a46f3d8d2a0007d85b3ba975875d5905378bc8f14a4876c5e121b507a38417ec", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "c6f62471-5cb3-420b-8696-0272130e7647": {"doc_hash": "2f42ec17a0d24b4df7f35aec207e201d9bb4c6a0ef7c81386835d70e813a7336", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "dd452422-4bea-41e0-bc92-4d82791f9128": {"doc_hash": "ff2bf5722a87c1c4fade8b4b392b6cbfd4c2ca4606cfb640c78eb6c2cffa756a", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "4dd9cdc7-705d-451b-8ecd-b8874433755e": {"doc_hash": "6c64b494a4c65d35b4e8c359b4dc0ce673069b070b3807ece93793d2a09de53f", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "48d74772-2354-4594-ba84-029550fa729b": {"doc_hash": "6bd7e2172161aee4f4597c694fc69de0ea4d831b8e73b13f971263102c619cfd", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "4f7f06fa-6cce-4390-9709-8b98134db78c": {"doc_hash": "b69aa2fa2ad97bbfe0d35e063dd8c30c48a16ac9dfc41c128518cc279685640c", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "0215de7a-f500-43ef-99f4-2d6b0cb67192": {"doc_hash": "beca412527546008e7108cdc4bb9793e54c294540b8a12b159352976091f75d6", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "f8905862-e7fa-47d7-a7a5-3689acaea323": {"doc_hash": "ed56c0d799bdb89979e0c640ab19f2f4ec83d33992111e74aedc40f7e07dc1be", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "aca04cea-8371-4a36-89aa-31c9a069b388": {"doc_hash": "d0de4418a1ffb28984b6aecbe677374de8e1521090dfacc09da0002f3bb6c300", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "a7f9ab1a-88fb-4c59-b9df-f7eb9d241148": {"doc_hash": "d916c503982ddebb6973769d27d75c5dcc59c276dcd387754c8ce015dfa5ca7e", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "3421c8f5-d2ae-4e3a-a1db-9b2b870cac48": {"doc_hash": "e90fde5f27d7d17e5364938b03da54a8a2d33795ef6e2114f7daa65084ee17de", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "0c688c43-7107-4c63-b440-d3d8f758e413": {"doc_hash": "825b23198b06c62ae81a4649d844014669225d105f3b19ae54f61f5e405542c4", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "b613e4fc-d8ac-4aad-bc4e-d2eaa77247a6": {"doc_hash": "040676bc7231bf31c469f0bb610258607391e34b9799e754f7f863c9621f5054", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "7ef9cba6-7404-4ced-a52d-d32c58de4552": {"doc_hash": "ba7751e02d19604e7cb831004b43cd9025660e15d727f9abc4d47c3184eac33d", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "f7a0ad06-b541-49b7-83c2-fbea7acbf26f": {"doc_hash": "64e8f8d9eb7b2e970cf75a69e9efb16ec5eea34ab7fadcbc755fcf79caf78569", "ref_doc_id": "8c6d82a3-2491-4948-aa5b-cb1424e06db0"}, "0a5e9ae7-34a0-4abf-9608-9a58ff73b2fe": {"doc_hash": "3f7dc4cb379562b3ac91174e2427df33569db82887e26bfeed81e1462b83a093", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "6216ea0d-a1a1-477b-abc5-75d59248bc35": {"doc_hash": "f770c31bde10fa7c76940fdf1d6cc34f6e0cf40a2eec1e15257a3fdc8d5790d2", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "af5be324-9283-45b0-9557-e3eddcb186a6": {"doc_hash": "77d5c09e9eec7758baccb479c6cebb6b7f364239a6fc5a0f91a52405cba4e44e", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "8e0ae0dc-ae82-44f8-9640-fa9be3ffaf44": {"doc_hash": "9d240f9885b3cfef4fc02a1ef852dd51367bb2a9925641193e91ad592750762b", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "d0c33dc3-6892-4e23-aac2-f055042a787d": {"doc_hash": "003ee957b8ea578c922f4bd64dea954f23f6ee890d3be2bc254e62326f5fce29", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "21436b26-d3f9-476b-8dad-ac6f91cada08": {"doc_hash": "70da2ad7a42709724a98c80179c5e368a4182191aebccad08bb3c8eaa085717e", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "9d18904c-7613-4a5c-a0de-d36740f8efea": {"doc_hash": "9939625f21c169f4bbf8f498d25be283999725edba5903251f50c93d4730b60d", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "b6584d86-8286-4e51-a68d-588d345c3428": {"doc_hash": "5e42d5b03c7e2cb64d59c41dfe660aa74bf1c6bffac88ff9b66a65ef2126ca3d", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "6b84cb09-5b78-43a1-bef5-be35831cec0f": {"doc_hash": "529158c1b9619a30c6dd3f285e65f36d44a3101c7281fb6dbbb2c31f4e98b877", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "3b680782-520d-4109-8858-dc28d749c731": {"doc_hash": "bf4735dc43b9fcf2c36f5c981e851a9ffaf76f065c01182b48181152d7a32f03", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "7f1a02fc-5157-4f98-93f2-c24942e8666b": {"doc_hash": "3f91ca226b84219725ddbe7bc1f3efb5f043b53343a037f3e934f42b96f57589", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "523b4030-9f3e-483a-90b2-a1d988e23a22": {"doc_hash": "7fb8e5a2aa5c75e0e84c3c26db5c66da0ff88b90694c9defe3d25087f0b52cc3", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "5643e2ee-f753-4aac-a16a-9470e73bedab": {"doc_hash": "e11c4dc0737ce04fd00af56a4d3cc3ff65fa1d106bbf10ee22e43632235f04e0", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "1f80f571-e349-4aab-8fcc-ff505c3eee90": {"doc_hash": "690724b2621310fbe6e4151d1447bd4d91c86e475c1fac4aa2ce944dffa5a039", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "09da0c1c-c13a-4a99-bebb-260822d605f2": {"doc_hash": "ecf83318daf0ea6f449bb482ae32a5e2f84439e376250154e1fd4741c29dc7c0", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "f54df3e5-0cf3-4996-aa36-02cb3f66e2ed": {"doc_hash": "da2827241eef00b87f79d8758834d9598b665668e62b16f9dacf857aa6aa9945", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "f84405eb-697f-4502-a4c8-1371425e5040": {"doc_hash": "15c27b8bd73f45e1aa20f80122aee5492ceab64a37eb9aa0ece709c6790b4486", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "ad8d91a4-d0f1-49b9-aaaf-dc21900eeb9b": {"doc_hash": "bed3577d4804bcca8fbfb5b77cab1043663f19d32346b1e81ea173e6decbac5b", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "c2f83f2d-324a-46b3-a618-03e1631e93c0": {"doc_hash": "cabddecc1a5077eeda4589efec34dc3e62552c4e4ba963506f835becfd6f98e9", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "37827ad2-2771-459b-9bdb-3d7af386f114": {"doc_hash": "b70a3507d3d5abeed9f2e0a12eb175554485751e7248c850059b14fcd12e8f13", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "6c848f86-91d8-4805-a57f-f1887839c574": {"doc_hash": "adb95af90ffe906bce17fa3c6b3f84d9dbc5548ff2fe751f35bb2b5653d5d600", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "d0f443ac-ab7e-41bf-8bb4-28e945fe228d": {"doc_hash": "0dd5e277308167de6b0f6665f0b97fe389f0da23c9df260835611a8ea6ad636e", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "6cee39c0-b8f5-45c1-9375-882ac0fa3885": {"doc_hash": "17f1090d906ce949216d405f2aff2c8cb8c36e8bd7e210081af13a22269767dc", "ref_doc_id": "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04"}, "57fdb6c8-d778-40f6-8431-ff97bca14fe6": {"doc_hash": "ab85305b76364e876392464437b72debacafcd7f70c1207e68e64d081e012304", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "c5f71a49-d78e-40cf-b65c-0a15b0d8a3ca": {"doc_hash": "dfce9784943270371ea5bf1b2d7f03b87a6ee22b3f80759d6271f4d56727c4fd", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "2c8592bc-b53e-40ce-b8c8-88dcb4606d0d": {"doc_hash": "849f33a807625f0977797d225adf3cb333e22631af5370edda111d4304836d11", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "9590ccac-c9dc-4044-b261-e6a2ed1be82b": {"doc_hash": "4313eafb2bed0564c611aaac77eaff688c2b6bf382199bd2b35d1a15bc850b7b", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "4642057c-f645-4349-a396-423b72f23210": {"doc_hash": "5ce3f79fe7f30cda1bebf9b9a903ecdd811396a74facedf0deb4fdb3fd28002d", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "1a021d24-0fd7-4634-bd17-e222dd4bbadf": {"doc_hash": "a2237ae9ac27edf6d7aa3901c73f98cb6b5f3b300fed396a0ce94de7c51f289c", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "256e1646-68a5-4e23-95bc-a212d7d7d1b3": {"doc_hash": "fcc9bc623940dbda5e52cf331d8c3d882a00d481ee1fe218ddf0fe6be0b564ac", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "21109ba3-58e9-402c-bf6f-e83f6debc7c1": {"doc_hash": "affb8d18a1a7b92559906b8deece40d28fdcd445c90de95373bed40f0f85c29b", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "1c2063ac-0f43-42ed-8769-d5e19bc07f6a": {"doc_hash": "2d0f26936f4e777798d2762406759b0b5ac40c3930ffde47ad5ec58b5c7b3c99", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "d659da2a-e8a9-472c-b4ad-5b979a55f6fd": {"doc_hash": "22411ff9104957154940f96b48a955e97a1f2cf1076d8df331ea28df9ce21b3a", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "d5664932-6758-4b77-968f-1602a93a275c": {"doc_hash": "f190c3e6278078739c45607cbdaae4a61c86baa92e6c08abac58c00162dba46a", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "01f491f1-bc53-4186-96db-051bac17ecbc": {"doc_hash": "ae089258c301b9abce668b2a292590d1bd95d868d692e98ee5b3ff29a0344b6a", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "8353d0d2-8500-4562-a842-a71e4a85cc91": {"doc_hash": "50aa1df360b920cc8369cdf7890c5b47e12a1ce20955c8632b4ee56d3c0b93e9", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "fc67ec20-c3d3-4f5b-82d3-4deed5a83dcf": {"doc_hash": "5125999c9aca860dec0112089de3941eb51322de85f01521699204a85858512b", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "fe60aac3-518b-4a4c-9465-6412b30dd445": {"doc_hash": "1e6aafb7027050365176e86662738276db68fea2dd10451f8777f73d6542c0e6", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "e0203552-2471-42ec-988d-fd2869f56716": {"doc_hash": "43d700ea9cf58f58008316227eef560c9aab5c540383348e80678900d6794ffd", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "9db249a5-5189-43ec-ae02-b4e9aad440fe": {"doc_hash": "edf2580d044f83c442d3e7eb555599a9d72c766828474d6551a639d1964145f2", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "df2b96da-a907-4687-bc98-5408fb1ab9ef": {"doc_hash": "c061886413f7bae3838979adcddd358b339c11c01135588ad750778c0598eadb", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "654da6f2-b92c-46f5-954d-0d593f1ab661": {"doc_hash": "0b477478fbcf22226486c232d7b8cc3982eaa8d36b2dda882923b98f5a755f61", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "7e7bd50b-5e4a-4d08-949e-4c6ca1762aa1": {"doc_hash": "c0a9e4e047adb34e812dd576eab5c455043fbc00de4e632f47fb219fc40fb757", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "06f06375-6dd0-4783-9af9-e30e2c2f9898": {"doc_hash": "0ef55f88bbca9aeae36164a34439d0c1f62f6e96a84ad0fc7fc7192df7711aa7", "ref_doc_id": "f3b09b99-f8e9-4090-b58b-3a3930852e37"}, "07f7976b-8381-4ac3-8044-ea96eae61cf0": {"doc_hash": "952f6194a7a5338cde838d49fec7c20da1f3848448a695a29e5d7a60c6d2210f", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "e4f0c547-fb2a-4acf-85af-26e2db6e1f3a": {"doc_hash": "6e3d7a2ee7e8b1793462f0368e918075f7ff79ce610c19b61ccfebce11710c45", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "f8a290a8-5600-4387-9daf-2998f2979f5e": {"doc_hash": "c1e4905f7d0a834b654bb57d738b492cc4362298cea94b5bd7fa68420b753792", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "5a5dabdb-86b1-46e6-9720-48e3769551bd": {"doc_hash": "d820e91588905384f85caa52358b0bca7fc765deb2a9deaaeb5df96a8688839f", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "a823d1a7-207f-475c-ae36-585b8c4526d7": {"doc_hash": "24e60b9052fa6c96cee8092983b42d370dfaff3f61f7f0235eea257b2d16d658", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "263cc231-0ec0-4b80-9144-0b977789828e": {"doc_hash": "bafdcd7dd894733172e0c7cff897deae0b275fba279516a420d5d57ed193f2a1", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "1bbbe9d9-bf2b-4f0f-aa8a-25a305abf750": {"doc_hash": "7b6f9b98dc7cb64fa8410bf329eb47e090d1c33a2ca2324da1f091bda1733f43", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "21890191-b2d1-4082-804c-a998555ec57f": {"doc_hash": "3b865c79fff651675bc6691a0569ee6024a924838fa6b687a66bd22ae034c820", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "8b246986-fb7a-4093-ac84-2ebed5cbecfd": {"doc_hash": "a96fb8e0719430fe923e01edfdaa81df891b62513c865b813241088c81475f08", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "936a0f96-edc3-411a-91a3-29acdc2b6f53": {"doc_hash": "33c4540f770e68a1e9440f2545f71b6e7a783b27e2a389263774837ea5575279", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "5a553583-21e5-4dc6-b3d0-f7e81ce98301": {"doc_hash": "39780979a2955e531e47023fcd3a375c6cf98eb2ebd4929def61de34697e5c56", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "ed047fb5-e536-40b0-a889-55346ed34b02": {"doc_hash": "15787633e6088c0d5d58ce2c14b9280c23b617a32962dfb57848ea1a0b9d68d6", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "a5095139-98fd-4c19-aab0-83928355305f": {"doc_hash": "914b015c3ee4f1552b513e0e8d6b789f1c10f1cc724680beb74d943716c2bea6", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "c68d6749-2db6-4031-84b2-3d1a51e9c91c": {"doc_hash": "336aa7c81001ea502fafa8be033a5b2e4899de6b01f3446aed929cf2ca044073", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "cd86546a-3178-4f37-9e3f-256b67157ae9": {"doc_hash": "61e7f3cfdff8a4bfe32679df456ac744bc4d6b1e3e45d1bb3e7a2167dff81a6d", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "571ed69f-f46d-4897-a4f2-53fb0379031a": {"doc_hash": "e35356bfc15f63cbbe9a7addacbb59e39e1d6cdf38316b6cb09d5eed74ebf16d", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "95759236-358f-40ba-b4a3-ba5a3c3c9123": {"doc_hash": "affc6a47f19b24a2e5ad7f7e42a17ba79e9049c699b46ab76ab56d3568be5d12", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "e50899a3-adee-48a2-88fb-e8b699b1e638": {"doc_hash": "078c7ff92cf2ff399cb2f576982c3e0639dcc962a424adfc4ec682e52674843e", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "779e1dcd-3f69-4c5c-8d89-90b5ab667ea2": {"doc_hash": "df9adee5c4f2417e5d85a21ce54f68e55f29b951f91915de5deb73de8f4f3e39", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "1bc40fd3-7fc9-4419-8052-c519a93196fd": {"doc_hash": "cf66ce65801297b21bbc29c98b89e3b2347129e91152f91b536e71b86308b797", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "c4220628-6ad6-4ec2-8404-1e1ea7f2703f": {"doc_hash": "3b9d33e402d1af581165fc7dfcd0c4b2d016897dc598fdcdbe804b6f4aef549b", "ref_doc_id": "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7"}, "85c52a78-3f76-4cca-b0e0-740e26a9bc4f": {"doc_hash": "e20cfbdcdb402218bfd0fea44ece5958abd0d2dad29b56a9e79500aefbac23b0", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "287c82ee-1617-4c71-b4c6-4711a50bb580": {"doc_hash": "87ec32f230bb306b0030afaf6ccbb944bd24a4770ad256f78ca1f010a3536849", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "944d0c3a-4aa3-4038-86e3-f5d3f650a975": {"doc_hash": "6322659f4f59a87e9b754f78530bfdccdc3bf725cae7e5c7aed6a47e29ba9441", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "7dd4a69a-8d82-4c07-b1db-8469c9e53644": {"doc_hash": "4b6a5eb058204385501ee891075bb621c9c197079a72619d56cac97699724f6d", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "466706cd-33a1-4107-9d50-5e8f4d4218d2": {"doc_hash": "f1e4eda3c9cce42297958c88e462f5238d53b81a3898d665b05562bf059ac900", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "9c6e2e84-2507-460d-9e41-d2a17818d7ea": {"doc_hash": "a36fbccb5097cd22a710959ec2c43025c2ac9b432eed5d883917c8a3e910dd8b", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "a37ca68f-869d-4c30-a713-80404760763a": {"doc_hash": "36b3446e715212274a3373328cca3bcfa9921c6bb69195df1690fc2f93ea8d84", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "c6665a55-482f-431d-bd48-a1d100368f9b": {"doc_hash": "d29b6e64943832b9f6d7c2681d2c11143a008da48cf8bf4861c83c3fdab1bcd9", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "2965d487-b0c1-4bd0-8467-f1baf24379ea": {"doc_hash": "77f071d16c1f1a5546741bc2bd6c1e8ade2104690be25c61a7b4fae2693f63df", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "aefce484-dc81-4e96-a21e-32da3a72ebf7": {"doc_hash": "be4eb43a703da1417c9417fa5146d5acd81f5866a747b8c9459bd4fe17aa0e9e", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "211a0c81-5ea9-46ab-a1b7-799fd5012dec": {"doc_hash": "c065e3703dd7cd0bf7eb844c919e24be062441f1e7b480db3fabd734513e9171", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "0abf00a4-e2dc-4ac9-a518-874739a105c3": {"doc_hash": "1036a52cf390fad94d2c61eda8f5878042e9724b2f2c30b4025e851e37e11ed3", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "8c0a1095-05f5-404c-97bd-c3b5cc93df7b": {"doc_hash": "29c8f99b0a7269e688b3d909028e5f726e622445f7beb282ec5699804f3dd2d1", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "6c82249a-d493-44f7-af17-aee950329313": {"doc_hash": "ad3baa400b77bfddefe64d013868efea6f51108628b2e55c4238df1f8e6ec9fa", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "2cb36767-7ed1-46fd-ad59-02adb2f18414": {"doc_hash": "0b3b8660cd040b7d1733a3c0ddf1504a58e288a052bc314393ab2df4a96108ff", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "2433049a-7780-4c3f-a414-9bb22ab40dc3": {"doc_hash": "48992c0b319c3a1dd01214956a924169eda4e71076153c307a15129557d7dfc3", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "b66430dd-3355-4498-bd7d-42b493f8a2a1": {"doc_hash": "62043d64a16e873178273600d78d8f80c6cbe0d0d07f34e5944d6d9bd9eae4a9", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "a2bd6145-5347-4685-9657-1f327e6f97b1": {"doc_hash": "351e9e953ace99776e6fdcb6eaa3fdbd9d07a17e086681ba14880371cd0f907a", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "8bb2278b-a1f6-4f1a-b8bc-373de35e3043": {"doc_hash": "6643d346be1eb5bb96eb1b3cd05d05e4680955144ae7069d085835ad8420689a", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "a7f03c2e-efcb-4bbc-b5e7-0a5745be9f00": {"doc_hash": "798c6059a00bed7b7ec25dff8df3799ac83ec7cb385f243f418bd6a0cc93cddc", "ref_doc_id": "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67"}, "ed36ceba-aab9-4fbe-8a2c-e97fdf49464a": {"doc_hash": "a33eefc2e7f6271e531ee4e951ba89de1a16796ab5f80f045ac6c8bcc60fb011", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "4ad1bc6f-ed62-4a31-bc7f-38cdcf4d6999": {"doc_hash": "1664c3c19ea21bebb8c7a9fc6de65ad44d7b61e121dccc04a008329fb46c2892", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "e1eaba84-7ad9-4af0-9bad-5a7b8cc8038f": {"doc_hash": "ee55be9da5361d7c2b7f2706bfa9e26d73778f54aa6ed392551aeddd9662c0ae", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "b730af6f-5a0e-49f3-b4a6-d2a12b0aef6b": {"doc_hash": "19cc49318ebfa0252b402536107b6456b82f6b3a8c74bf56504992d71cfcb013", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "6e3a9a0c-00cb-4928-82ec-8a3d7758c719": {"doc_hash": "392729fde9cf0e95b6e2db9a3672017f1e685eed95f77bb477b8a59562d95f00", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "924c03aa-07ff-4159-93c2-241784d61c3b": {"doc_hash": "4842266a9e075c13b8d0551260474de3f58a016145a7c244b81a44b293616e73", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "7c7856f1-d33e-41cc-bb1d-e520f514261a": {"doc_hash": "6750a0ddddcad704bd46887936e16eac7750370fb29c00da89984ea5b8b84ae9", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "93c54aad-3982-4ee2-9382-6f65bced9545": {"doc_hash": "120d033b8e3bdfb655c29b5d08cba4258241b34e9a15db49c4adb4f8184566a3", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "3346f407-38d4-4d9a-a40b-169687e229f7": {"doc_hash": "d1421ac1def0161069ab994276fbe3f2f83678882dbb0cfedaca749b42effa10", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "d8494921-a3b5-4c25-90bc-f81a979d5811": {"doc_hash": "5f9bcef07df1bfcea18c4b9a68f16fed3a87232a27dfe1e74e4be87b9fc2e8e3", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "949e6cdf-8cf4-4503-94fb-6b743c041c93": {"doc_hash": "7e02e4e91670dc0b101bcc29cbb2783ec1aecd61dbdc5f8081a337aee1415d0b", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "7075fef9-e235-48e6-a65a-6e2ffa6cdc93": {"doc_hash": "96af6f5eabfbfe16a92510af2dcf8b10e0a48b9c6cda3e7647ffc189e929b3d2", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "663d233b-7f87-433d-bc28-da6c3c3d7e35": {"doc_hash": "d53fe0a99bffd940cb1d85b53ad5ed835cd3cb3e22a5aa737f4b7eb5fde4597c", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "033d60d5-f355-4342-a8ae-41ec3a7048d1": {"doc_hash": "3636982eaa259dacc06d461cc5c1bdd8b959afbe47852f473fcdae91a14fba6c", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "053d3036-b3d5-47cc-82fb-2e55064f2eab": {"doc_hash": "d27b3063e0e16d10837164c667e89c346936a09d77c00dc6316ccbf138b57684", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "0b1cada1-b67c-427a-9346-670f171b5831": {"doc_hash": "2bf0c486425ab359c118d8f4630453946f0cab2220b4d26e5b094b88e2fe575c", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "273820e0-3cff-4f91-b748-088ca15fb25c": {"doc_hash": "b0bdbf65ccf0f571ed79732744c8eac3cdb309e0f3dcd497c350dca1e0bb54dd", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "11028dd9-6e17-4b45-8ec4-73cb4bbb5c34": {"doc_hash": "5279c761e8a16ff148a97f81a4cb45ecd62c59180b2ccdabb2fe55c476df3196", "ref_doc_id": "36c518d4-1e39-4a53-bd58-f66f0fa4581a"}, "d5703d9b-ec88-477d-b8f9-3e137197953f": {"doc_hash": "4878a09ee4a2ddbd2a67b545d0a2b4c0716b845cf4190a0f8dc88777a7ae7a43", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "c323ff84-04ee-4db5-b6eb-282cf0a2c0b7": {"doc_hash": "ce6e8720022ebd532c290a33e301e07e1efc303daf6551a79ca4b291d6e244c6", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "65f3e828-8259-4b84-b961-851a56b1aef6": {"doc_hash": "b80d28958dbaa769dc446c4124e97d04861c833c5ab98ee7322f766a38c05050", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "90d4a0ba-76a2-439d-a8ce-2ab638a5cbed": {"doc_hash": "79100a31251dd9548e11c3e30e7c7ef87a12f0bf40420bdaa3acf9c9ad2e6c05", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "e94d6552-dd70-4495-874c-b72b8e16863c": {"doc_hash": "174d33d9416c92e7233ac03987e8ef1dc5a8a91f30492d1aaf69083297df6921", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "f2b9229b-df27-4253-8be5-c6f805db1efa": {"doc_hash": "7eb87050379db5891a37b32d4f9cacd1dcd06c306305896174cece5dd5d9e869", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "ed36589b-eadc-458e-82d3-2ee48ebcfd47": {"doc_hash": "ccca4b5b5ecdfd5a9b2f5021eaaa1921b16beb858bda5ec58f195b7841719408", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "1d6f587d-4722-41ea-adfe-81917db4ea69": {"doc_hash": "f0d2728d7e01146b1701472434813baf3a39c836b6ef0fa3aedf7e7f99bdbd54", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "9353a27a-4114-402a-bde3-6654432552b8": {"doc_hash": "3dc6ef5861a550ed5add670d7eab1497d784f53a6bd11d8b42c946ffc5a7ed33", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "a917898a-2a78-4453-b477-1875fa2eb444": {"doc_hash": "834cd9ece2be5d63f10a1e00d5f5d25b1a4f72a7cb10ea5d6d5e14b5083aa2d3", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "797c013e-6e12-4392-89a4-b600fe5ed5e3": {"doc_hash": "f1efa81577973109533dbe91a4e94238b8a2eb671aa4e6c425d10f353f59c037", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "828a1472-664d-4af4-b05c-e935801f5491": {"doc_hash": "a99565946083c51f88406ed5b29f3a0d72f9d13a1c61e8db0a1ade7b7d1fc4a3", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "81bbaad6-0194-4231-a967-834aba4722cf": {"doc_hash": "9eceed3b38146967596619afd5100425bd891914a6ea9cba6d9d8431f2d5bd9b", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "8f5cc462-bc27-466d-9cf1-1e0916f6a17a": {"doc_hash": "94b02de4ed577745b445f571ff905d8a554ee4d062e58140efa54dd3b9b8b85b", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "f53742c4-df74-4fe2-89ad-e4295126752a": {"doc_hash": "ef8cf7d9c03a0994e515b374a7d989e2e74f5f36f87e145169f890fa47b0e179", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "bb261727-b74b-4314-b7fe-f19ff1d8c521": {"doc_hash": "6071f89f9f0d72fb2453955a62567c44f4a9fb1007d1df38005a83bbdfc5396d", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "bc70c947-66bd-4575-9feb-92c59e505791": {"doc_hash": "5d2ef99d8b11db4a6ead1784bb85366e167e048c4150aa27213e3050c6d6f5dd", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "3d29562e-1275-4a96-a72a-85abf8241d2c": {"doc_hash": "75c128130110d63739ef2a022789c8cc1b9532ba0259c6aa559628197530cf1e", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "5a17554f-6a4e-45b9-b097-84ed38e083d6": {"doc_hash": "f5f2ec611318e1fe45b1fa711a15a21dd3585e07cc16cb04481b808addc3417d", "ref_doc_id": "8c71bed9-073f-4af1-9867-c47cb7248707"}, "b1e82e1d-7bb7-47b9-b522-96ab989e300f": {"doc_hash": "94c596bcf59404df1471eaee7e5b413c837f8446755dcc67d09963e926c75856", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "0fd4e993-9e9f-472f-9834-49e53f4c9609": {"doc_hash": "ec514b6be485e2e210bc5549c577e82cd87120f375d713da8a0f3d1532b74509", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "11b284ec-3c0b-4288-b530-57b6c0654ee5": {"doc_hash": "9b889f8e04029c2cdf9f27f6a659418772d3b51ad3900c10eb80abdead04889d", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "b8202855-051e-4406-91c6-c1222deebe83": {"doc_hash": "d8cd06f926966ee8f39e2859ce3a8bfdc3a9051d4829bab3b5d3189c8a753180", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "b3d4cebe-aa1b-4340-a4e3-1f546bcde761": {"doc_hash": "bde6be100ac5b3bbbd8a9b27480365cb97ff89f4aa80d6c63db7fe81b44bdc02", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "221af547-cafc-4819-b5ad-166a417c435b": {"doc_hash": "5f1884e0a6296ef5e72f5f66756eb61b641963cb2ff2ce8ccecba4bd3c4ec330", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "b176d3b1-f42b-42e4-ad6e-069df00a74f0": {"doc_hash": "131e2134dfbf6414c17b8ceea895fe533e782d06b083572c1a344dd6158ff516", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "588b7cc8-29d9-4dc0-847f-c8ea801bd283": {"doc_hash": "7d7165770fc6d9ec8f26549fac1fd756c1a6b311b651f21cb7b2cd169dc35757", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "e67499bc-1870-496b-9ac7-8ffb440f6efc": {"doc_hash": "c0d199a7dc367aef8c7eeeee94e2db6d6313a28b0124e26d19561831af68cdd1", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "bf75db4f-3d0a-4d0d-980c-fab8ed025023": {"doc_hash": "edd668d4605a325efcd5776941efc087007114eea23e365bd8abff0ebee46fa5", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "b5d1cc88-a2fa-4393-ad3d-a94bc32c2098": {"doc_hash": "7976d8b3f7774ec96071510efa63a2560183bc0da91ef98bf645634ae99c3c14", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "cd41bb40-f23d-497d-9588-f9f2d7b218cd": {"doc_hash": "85a54fc8f9c76bb81e6f867aebf653450b6d2fd72d5cc095a26f0244ab627d27", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "9ef5d208-2079-47ec-8d1b-45c94831cd98": {"doc_hash": "898bf89a7b2cb2461cddc0675a550e81ffd596be4a09735f8d49d34f7f896c42", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "a2865a0f-51e8-46cc-87e1-27d671f2dc6c": {"doc_hash": "a8c112cba6287380f41cce8290cab2231a3e9b267ac856f4e56b742f775ed5fc", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "9a993f51-f564-4c7d-8cd7-64b0bd2fcf30": {"doc_hash": "1c6c6ca85fd5d1f7d8ae715af36db4ffb1f9572922d33d216ea1479c1e4eb17b", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "b9a5e6df-d0e0-47cf-9ca5-61c994339900": {"doc_hash": "ae275daf2ed67a0403e395323f3d8f866fb3a82608219c595b15b71580736cb0", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "76fbe46f-c81b-43db-981b-1f2dabd55772": {"doc_hash": "b82bed8b47adf7b80714193c2270592590b569f8b4bde658d93b0981014808d9", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "d5a255fd-5513-40a3-bec7-33d50138a758": {"doc_hash": "a877dd1293ebe47425718a89691a9ed0500b690c3211bf8cb09f3cf761fd8f45", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "b0db8a74-78fe-4504-8572-794ae9f5f831": {"doc_hash": "fba8fe4257743ac40ff9b23b290452a5d9d7db5cdb81240b6f8d665180d66028", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "a1c303e0-c318-42eb-aff3-e67d24603458": {"doc_hash": "faf292e13a1e0f86d74e77badbc90335958cb3b304f28f12cdf1f2827613d6ca", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "a0f1636f-bc0f-45bb-842f-9204888e486f": {"doc_hash": "2c1cf0e66aaee8fa672903689c88d14e4e554bf5a6ff1dc06d79c5703d7c883c", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "bc0bcc7d-e973-4983-92a2-ebc0c7a89529": {"doc_hash": "064358e5399ff4eb1501516ecd7499504be7b10ee69e47fe29793ae18937efaf", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "da32364a-e8c4-4d25-8891-1a852d61662e": {"doc_hash": "75e1fb81685810d7822ed40d6f824776fd69f1f99c38324d1b7be857826f6fcb", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "8a80b0cc-ee8a-4ece-a85c-0816b9506876": {"doc_hash": "64a74ed8bc075a89852f1e0ec9a370edc7d794410e0a24b101a53f8191fa1dab", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "44d8c1e0-ad7a-4bc9-934c-933a355ce64a": {"doc_hash": "dfe5f36554d7149e22d19867a3bdaa5112b9544798d6c26cd71bf485ea34a6f7", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "c1f9ee80-8845-4a07-91b7-67c937172d7e": {"doc_hash": "fac345a56f3a6098b5c1155d0b9a1c824c516ad71c023dc147612fa01e0c9fd8", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "3e369788-8113-4fdb-b896-557ea220a626": {"doc_hash": "a225151a84481c4555a397f0c1318647e40b0ed7a405012e8564e9e5974efdc1", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "433dd27c-cdc7-419d-86b0-bc795da8364c": {"doc_hash": "3b75391285df0bf5e525cdfeb9d73d3f3d22467bf395b3fdb84bd9f0c0301168", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "2e3afc69-e76f-45d1-b80d-da255c82a459": {"doc_hash": "e5518fb349ba456f6e6acc4d10eee86e817a8377f07026eb3fa296053eb41277", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "0000b7fd-6042-46b3-b6e2-6b3ff445a27c": {"doc_hash": "744c73f9cc1c61c59de55af7e84fe5bbc9e9f656cd2e8204fa10573d05df5e2b", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "4faaf20e-f4a4-456f-bbb7-6d6a2d96838f": {"doc_hash": "517a4712c5081e0c5aedfc4161e9d7962ab55d1bb741c05b5fac59f7326edc5d", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "a921f115-5d6b-4372-bf99-6f35e38530a7": {"doc_hash": "0db0f36dec0cec56edea1fe1674aa361b1d2f9f702336e579af18e91d6ee92a4", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "1d9f792f-bec8-4b35-bed5-88dc22faf274": {"doc_hash": "f11a96fd85c2f47f38a36d7df9eec26e56988e70631dd25577a0f09d29ebb2d1", "ref_doc_id": "7df6ad5f-8465-48b7-b28f-41a819c1dfb8"}, "67def20d-9ea9-4e7d-b4ae-89c5aad6203a": {"doc_hash": "4fa025e720670e9227d29e73ac0b747e9f408c5c9d2717186cfa8ec6dd0d74f6", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "de78e4c8-32f0-4440-933d-5b3a9f4ab736": {"doc_hash": "5b382a2a5f6c5fe3e88cb7a457b8d05525edf76f3bf9c22fa150a3f622706319", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "302df498-ad0e-47d0-bb98-83f8ee0569b4": {"doc_hash": "a678bbcb80d7ddf0f3af3c317fb9bf50b7c3c675c18975a4fdc6556b53afdf61", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "c4d4ee26-2813-4158-ac1b-749b4d9fcf20": {"doc_hash": "55da03fa6860a716fe0ea36404f396ecd757e868da8c22f9535726b799afce14", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "8ace5f03-e90a-4ee9-bfe6-ca5a25f45e00": {"doc_hash": "6a60a4e69122f3cfe634b2d604fbffd2199ee160ae7b15d2559f82b31a7fa4de", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "d710224b-15a3-47e7-a057-83b0f0a90912": {"doc_hash": "7257a96dcd0ed612942b8780ffaa86fbea9424094b3759a8aaf1e0e614db93d8", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "b78b9865-348f-4b1d-b537-9aea758349ff": {"doc_hash": "5df66ae8411db9137f955a1672b08464a7d83a54f4f630d8686061da718a2e79", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "5436a088-6bd8-428e-8f4a-4f35c6a81f6a": {"doc_hash": "c0e46a9fc033290e815ba86e14a594548b014cfdae8b539da8f0337d2364bbad", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "3e3568cc-32e4-4dd8-975e-b57c530dfea3": {"doc_hash": "4f1a818b15e8e179f1d6240f5b5cdfbfec666a7c0ba416101cd0eac41ef3a41d", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "ea3ca64d-53bd-4c32-bba0-f21c504ae65a": {"doc_hash": "f50ad2aa0295ec4731a73e1715f04981753d1c09e96179d11a547ddb3f953fdb", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "1570809f-877d-43d1-a307-c5dd1703cce8": {"doc_hash": "d0da4fcf7c1e78ce91ed9053a742f116e15fe21741729fd66974602e2200ffdd", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "07008c2b-6931-4833-aee0-56be86c8e32b": {"doc_hash": "1ce72ff0fdfaa4b0e2f0a989e1a6def3e3952e2a8a6fb8750f305b7818d95233", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "791556e7-4643-401a-a8c1-f37b9b23806d": {"doc_hash": "ae4e622db593cef6403e7a0de280e389772961564ea1b56fabc4d8604106215e", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "57b5687a-3e67-4732-8946-51ed601315d8": {"doc_hash": "60c6c5cb4d50e8083551278a8b5c41045c4c8e97cab922b1bc2f00796ac23039", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "a85309d5-d00b-4dc1-86e7-c3866f0e2d61": {"doc_hash": "037dfd88c2cf4b7ece4f296dac0bea135bb0e5dfcb5f47665f522b5bf0e04ff5", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "9b7a69f5-b7b9-4574-ad7c-31db049db412": {"doc_hash": "49c5371afbe31fcce883cbf00810d6445a0fc6b2faf657cfd429cdce3195bfdd", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "f8c75df8-3e9f-4f2e-8639-9075fffed053": {"doc_hash": "4a2179cece0367433cb8a8f26fef8cb4a23b83ddcac6a407afb50ab52b2b766e", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "5cd80e16-b29b-4a9a-b7ff-4ce2cf0d7392": {"doc_hash": "da7d1a03bf322fd0a7e51d466bdaeade162589ea18e42e644bb7bbfadc2d2d28", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "99354fc7-3e2e-4f71-8584-ffb506ee9f0f": {"doc_hash": "eb7e538a82557a7a6bf1236f1dd06c4983e722db8119e1da441d4649e6c1fce9", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "c83ad98a-2a7e-49c4-8262-9f92c58cd150": {"doc_hash": "58bd9f50dbc534a6dc8927c6fcc581cc69c9b1795ec8ffbf01a15c2127a2e49b", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "b6a32b6c-d583-45a1-a2fe-ef061fa33d3c": {"doc_hash": "c01cfbf95455b67b2762701d0cc8c7e4402b4b81ec5a57b43fab035dbe1ba754", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "baa0fd75-bf02-41b9-a17d-3a4df94ac7db": {"doc_hash": "1b98b7a067ce24c37c012fde6b10fe22a34932bc947bdd5c341b97d827781694", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "a3f04ff5-46e6-47d9-aa1f-b533e49c517c": {"doc_hash": "c771aa864dbf63a2d2b5aa97a394e09853df946ba22e53a125395da84f7db82f", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "f9bcf030-626c-4305-98e7-aaa99007a1e2": {"doc_hash": "54882fcf8375be82036dbdbcb440f33d6dfec0e71400ea57552170bc6444d4ef", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "c7357f2a-7855-4f48-ad9c-0bbafc0858bf": {"doc_hash": "0a530e5cafdd64e605a0e830b02dae056ead27e27bc13c7cf4f070f72f760ec6", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "df52489e-5dff-4303-aea9-d2c164b75905": {"doc_hash": "33dc1c120fcfc2804eb64223719ac17f109817752526df6d1f99f3b286462aa2", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "9723b015-facd-4e2a-89d9-4881f6a7040e": {"doc_hash": "5c217ec2e661896472ea47bb814c9b474d6109c05725fcd3fbec67e3269e3c28", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "f1f7f033-3952-4f59-8b3a-5827d7d2835c": {"doc_hash": "85c4170e80a45f45416c23117b3c128aeb3174851861e8db2619adeb23ad448e", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "33996750-9bf5-49d8-82a4-7719c28f57af": {"doc_hash": "93565a9bfaaeead3a5cb445976969d0697532775288c764736fb9ec969005a72", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "b3c06962-044e-4d3f-a166-916418f17a91": {"doc_hash": "02c8916d0bf8e3bad1a0c8384a086f073d2ea0feb1d6c115ac7ea8d6895ff120", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "0893ad95-6a76-4bb5-a733-b2faaaced0f3": {"doc_hash": "b7775931f2b987d6441421ae88b650027bc88b02b5cd45fb3aaccce31f2e3f65", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "01624c07-a73c-4966-8342-ff544260e16b": {"doc_hash": "6d3a7a17012b34e115c8e1d366e08a2dd6f366555269bd07411c295d60342dcd", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "bc5c3441-b354-474d-8696-1e507c9641e3": {"doc_hash": "8df5e1220d6daee3e99d3345061ee7c5ecdc978070e8817084560ef55214181d", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "5a5e8671-57a8-4d6e-a3fb-9835a1f74ab8": {"doc_hash": "e147d2415781f7a4f1aaadeb18dbaa49c2959be0a526b208b5a7dccd44dff975", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "bbee6f12-8fe4-49e2-9988-88c52842bc85": {"doc_hash": "d8b5f0df73b05ee8b98569fd7c9638d257dc055d96d5b5314da382bc1ffb009a", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "7ebd6bfb-af36-428f-8b77-e7c177a5e762": {"doc_hash": "8050a59fc1e7ee10bfde45c906f0dfed8b99a5217b89d8ca2221aa45be014c17", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "0cd67157-09d6-4d6a-b799-5949b2d05687": {"doc_hash": "1f044f9f90b149db113c82cc743bbcf5b7d39f9f354754b9dbf69c0141cf805d", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "15129a88-67a3-4035-836c-11aeaceb295f": {"doc_hash": "05724f0ac2be30e64cc0756c1743cec685c7b4ff2bc3d6aa901f17380b31c2fd", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "fdc05d53-75c7-4c8b-95ee-096b8070ffad": {"doc_hash": "004a89d1b9d5615d03b74b934a02236ddd1c37be36363eed25b2868a94916e08", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "72f6ae19-6f18-4b0f-9fed-838801e32e13": {"doc_hash": "34c290a2316e08120fc4c11ab2ceeb25e5def544edb2f27e4819678b0e7244d3", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "fc8e0605-9b46-468e-8bd9-34482accc5ec": {"doc_hash": "db52597da6e9f1e8dbc57b3a31e395ba4d483ff78190cf15a5be8bffd93c90bf", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "3c6de64a-f99d-4e72-9186-6e7368358a05": {"doc_hash": "b346f9f8a21149630c2c0b67b77df012de2146a003ef1d52c5918a251f4e8fe1", "ref_doc_id": "dd429be4-daeb-4b7f-9e42-f01187bcd097"}, "a223dec7-ba4d-4b0d-92fc-9e4d9ff13b89": {"doc_hash": "3c9b7dfa8a3bd4a27fb61f1cf071cef3e4ba92f125b4252bf55d11660662d6b7", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "becef871-f08d-4675-9711-fee56f58d59b": {"doc_hash": "325ead9faa606137baa54c1c376c1ff09f9d045af1c95252c30d04457354dc96", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "6afc8418-8aa2-4275-8018-4b534800fb02": {"doc_hash": "e11211324c1151b0436d62d25651590f5e4613974bdf9b986694c0561b82a03f", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "469ed938-c12c-451c-aa2d-c470c5c7df2a": {"doc_hash": "a57fbe49952572bb10922d2d1667f98987ea264fc8578033149fbea35c67e01f", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "d10b5225-045f-4410-8001-d2a80f1a6a33": {"doc_hash": "bfd66c1fab81e8568c995617e1ff747bc47a409e0f7fcfa8a7bab10862f18aa8", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "b08a66eb-b0da-4979-804e-da6090d9e1d7": {"doc_hash": "c5eb65af1fa994e0e07894bb71caedac59f055aa78b9d8eef03834ae5a664747", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "26cb7d7c-971e-41d5-9997-b2154e09a3b0": {"doc_hash": "99cbfa1251310b82f37ea487e450453c1cbc41d4e923e600df94e86e2a4833fe", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "ffa24f4e-f832-45a8-b5da-5af6c0e2071b": {"doc_hash": "50f2297b081f1b70f9ab083aad0dc86badc1b21edeae9fde7526b19193b0e172", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "c9956daf-cb97-41ad-aa82-6aef5a6c5c23": {"doc_hash": "9a407f50808e18dc2ae2f9b7e72a8a4bd78e8d9a88ab6265f1af0ec03a628e13", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "a6ca408b-0626-4a99-b435-11a5f830e172": {"doc_hash": "12069b18ec3d30ca8c5dd38528e2a5d740e3ebf8f6118a15bbb072bf9cc7c228", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "9d33b4f7-78a6-495c-88eb-e69d9ea1f40c": {"doc_hash": "bae6b357f8d1ce8b9636683db9b92f3961bcfd2ce0fc69f4ad68140c7c12c116", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "6c86163c-eb22-44af-87a1-17affd757718": {"doc_hash": "80c6c0624593686f131897df71d76df661238c75f83315806a93e13ed6be1750", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "c7ccf4fc-8168-480e-848d-146a55795388": {"doc_hash": "30a66bdd8cd28ed2b60c2d71d53edbbc3fd04754f168ee86afdbfaac4ab1b201", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "5adef5cc-5de6-4192-adf2-7a182e19cc11": {"doc_hash": "adc4f4ba749855debee022a6d92a609c54bba8a4e2ec42bf46ac91d8eff1dfe7", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "39dcb5a9-6197-4ae9-811b-428cb4a94ec8": {"doc_hash": "86e2f06d014b21c7fab862f9f6ee1c47f6f270d7ab2128dbddbe2d6f60dac033", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "d4cccf5f-6ceb-452e-83ae-aa85a83b5896": {"doc_hash": "356f579c4400d5fe59213bd37f78d49be767797493c3a2f855d97d58ef784248", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "85c5126f-8b70-40a0-9642-1a51b8bddc17": {"doc_hash": "cf5219815a100a82e414d9c179a6e4a87e5f840b5aead9ee724ba3e7e67a1fce", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "220fb467-f16f-421f-aa22-5fbf822c7c2a": {"doc_hash": "8ce2785c41b79b763b47fe85951b54f277d4ecedef37f6f9bcfd309268b0e8a4", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "fed5e84c-2804-4db7-9495-17e54d08cd9c": {"doc_hash": "d5919d44921fbe8798a2f3f8de604168ce4375781dab3ee0be0ccf3f2424bc03", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "031ad419-3264-4c18-9bb2-9bb69813d811": {"doc_hash": "85df3a49167c202591d45a713035a580462f037290d178e581ff765e3779d7fd", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "06848ef4-da9c-40ce-9428-2d9ef5cd5fa4": {"doc_hash": "3c51b99f1644978db252b1178c465ac04a1999b739f08320f3e7629b16a299f4", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "7f1efa0c-9715-47df-96d7-13eaf68a33af": {"doc_hash": "99ba82e0990fe70cf6e90210635b60b0b80bfb8f02623fd8baad9ac33d4e853e", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "3546f48b-3cf2-4778-874c-4b02103b4c71": {"doc_hash": "7e9b40e4c67b50024eece1707933a1a06152777262b66ace08828bcebd0f310b", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "850b9995-4ad7-405e-9a8b-4b84cb04d7b3": {"doc_hash": "be32ffe99013a48bc40ee361931fc9a5e0e2fae7fb3b5ee89427ad7cdce537ba", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "e614fda0-35e8-42fd-a892-c8ca2c67143d": {"doc_hash": "b37c90f7bba0bc53589625d22c00ba83c8fdc26a7848af31393a1c01d16de204", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "243ef65e-9242-46e0-9dd1-e546c6e93e72": {"doc_hash": "18a54be1da5999440d765ca419a3b9323b47798063adfe86f2a1f125be8625b9", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "cccf96d8-0e2e-42c6-96a1-39a277695418": {"doc_hash": "8aca7543569d616ce2ff48cdcdcf45f2cd03701fea9279f36d184fdd2784cb06", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "111b3192-da75-486d-b8ad-1eac52751347": {"doc_hash": "c15a89f9ea2a73f3ed6af17014e1a04c5b257d2957329a62e05928891c56f28f", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "06885133-ba00-49ad-b9a4-883eb7a2e3ac": {"doc_hash": "049ef32c9f7aa0f8352e6c77280e40c71078898d63b2d9b5b3871f75715337d9", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "5154d0de-65cc-421a-945a-072c43bec20e": {"doc_hash": "e89433679f4c99ba8053c367df4136795b62b8b57e1fe854b393c2ea9792914d", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "e5935cdb-1629-4aa0-bde2-1f359492f7a2": {"doc_hash": "0b4d877514e5155622f6c867c8932f8d8dd6a61cb97fcf5c57d3de04536c6353", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "59730801-8ae2-4246-8d31-de5764fc6e16": {"doc_hash": "5bbc000f8b0fb97d6f23f80138ed7b5ed1047bc032ec1219c6b42aab8f3c0b3e", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "52fa0572-2903-4fc8-83e2-dba261943491": {"doc_hash": "7db04e19146d806387dd157d2ac7c6bf62afc0792ede4ce218747cdaf447df26", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "ff6e5005-b972-4c34-9f00-4ccafb875d9a": {"doc_hash": "b7bc0aea25f29a5b31d5b74631560a98bfb040226bd6c174c396b6086f1aa28d", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "cbc74f0a-16a5-4043-ba0b-ec515f127ee4": {"doc_hash": "07c9f6f27240187c24e4040641b1f49329fea2e5f791ca0e55df534d46ea552d", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "68936f94-5472-49ff-b673-39a36faef873": {"doc_hash": "d0c0322d3efe8add528fa9e3d23206d4a7592f622451b29d073992b89606e844", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "7d3f760c-aae6-46ba-b6f7-e4627b305245": {"doc_hash": "34fbddd7a8472dd473a2addec03241f78384fa29f9b61c1833d6d3402118d22f", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "c975000f-a168-4cff-8112-24bd9173bc7a": {"doc_hash": "0073fd8f04d095c856ccb21c4255b593758acc1a791eed47673ee5e09aa30382", "ref_doc_id": "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93"}, "c1435194-9a41-410f-ae56-5b2eb1eb7ef4": {"doc_hash": "5905e324915ac1e7214572a6bdeccb5951132d4b6fdfd9690b831cb099e56158", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "e7ae1e7e-6260-4352-b8bb-e2cd298c1d13": {"doc_hash": "cd79028e2af0767e2b4cfe53c107c0e179453bc9b1ad7f8302ea16ba4b68a91f", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "e6a1beb5-fbe5-4269-9c49-6cfd7f9d8d62": {"doc_hash": "1ba36d2b0d3e97a7e026b88f6ff029bf6e5e7bdbe51051a1ba4f9886ff573ea8", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "5b99335b-ad31-4f71-81ea-1de759a4ecf6": {"doc_hash": "00b3fb40195f5384f7c2c2f99fa9c48b039dc68cecac46b4318d342cb80475bd", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "540753a0-940e-4cf4-b20e-c962947b3aac": {"doc_hash": "6e801e1a8633e30adfcdfe92b389757a4ef14c861011d800cf24c79fbb216949", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "f805ca83-5187-44e6-8879-dfaf54590c06": {"doc_hash": "297cd502b979462f567de965b6740af634b4b9c18d31f5f1757f7594d413205f", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "9f53d773-3600-45e3-9077-a2212e204849": {"doc_hash": "4a5a7aa37af2dea36ade554fb97242ee90848af3e8b71c439004b27f012f824a", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "62bd08d0-3559-43de-997f-198fe6a627bd": {"doc_hash": "708371464b83c675b04dcf1fd5e2d01911525307d4c4e473d9cff08b35537d28", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "fb99ac05-1337-493a-a6be-3a6958f39740": {"doc_hash": "67da1f9282d7a77efef33515cf4c1c5a1c09fde329604ef7d87666bc19cb283a", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "515b2e66-20fa-4024-9ce4-1f8ce607907a": {"doc_hash": "d148ec4608508c5843fe985122d4b8e10e2a919f80bf6ea6f28c2a89c827867b", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "2de379e9-09de-4e98-b4bd-1ec709c42480": {"doc_hash": "156207b1b8b9cf2eba915868acc1f90f545a44feb39be64a2be0cf2ac28d4e91", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "42c5be59-6ff7-4aac-867d-c9631860be4e": {"doc_hash": "15de915aa51b4e3334865b20049ffb440813bde5fb41d8bea18649031b973c28", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "bc4c5fe0-8603-4494-bc81-0030a4f86cae": {"doc_hash": "c476dcd5aef32bba68ece74482234cfb0731397fdf84a0390e992846c7933a32", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "344e6acd-2256-48c3-9f65-494cd51d3bb4": {"doc_hash": "f00dfe136d6d86ec40f503160f7feb0dea615ca710ba249dbcd22102f2a53e5e", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "b67d4f2f-7a8d-4a3d-aba5-041d3e69c749": {"doc_hash": "277997ca1a4bf70dbd6715f903d04643d7f663e519b66bbe76b1520c140eaaf8", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "f91f5dbf-ebc2-46b9-af41-078a3260f1e3": {"doc_hash": "db8f4e77112a9483f64cd05db047b21b0e2c32512e5031f2c7827bb6e5be1c0d", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "0752e085-1f39-4d98-aac0-2f66d5df6b30": {"doc_hash": "b26b904e782a12d5608993e672b86c1bfd2c911e3b82e0261cff759dc695f3dd", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "4bfb7098-4c78-4911-ac57-6a470f19e0d8": {"doc_hash": "f486c44509599c829cac013318b30d0a1b25fa8c75d8b1a16f8b1e2cd364845c", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "0bbb7d85-691c-410f-aa74-795bc5b1f525": {"doc_hash": "ea3f7e15ae5de58d0a9c1c60a22ab6db433df8884bf2e1c97a32bb46134d4240", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "6e1095e4-e7d5-4b15-a416-ef5caa089c87": {"doc_hash": "689b6c3c54c0afc40480075a7ac1e7e1cd0907032ed3d126e88c6b0729a4efcd", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "ae036f55-355c-4729-b77d-3b68d137baac": {"doc_hash": "94058e3dc9d5887cb3d4de1ef48e359ebaa1b038bc5696d4a5dccc41967061b7", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "10c25cc7-f610-4e0a-8ca5-8aca76d8ae98": {"doc_hash": "fb94476fcd69ad09e610718872beadd8292b1605ab92f00c44ef2af71360c94b", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "1659e96c-1249-4f7f-a4b8-c45161884243": {"doc_hash": "c985fe720c037a815ba4b0e77f252508b550e402f5c4788b3d12863e2fc17a58", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "17d2613d-5cf2-4190-8db4-dc26857f3bb5": {"doc_hash": "bd356fb6a1a30196eb3bc59166b0d07e07b248f731a44673af7712cd89a9993c", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "8a8442e7-a61e-4358-a735-9bbe4a56128a": {"doc_hash": "453446bc865fc0e35ac7c0d95e52224e6d1fabc40274bd9c778f7e24d0d4fed8", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "18285ec5-a5ab-4e52-ab3b-013bf8c90998": {"doc_hash": "063c1903b076a7bd63a089d912926df534b07f44c6ca0c9e8fc218fdb466a9e6", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "67d9fcd2-45ac-4a61-8d7e-e1de1296554f": {"doc_hash": "e522ebfadb1094a798bf095f74331b0a77c44a415874966313312649c150a010", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "dcb28e19-ffb9-4988-b277-3e3daacbecf9": {"doc_hash": "7ccab5354155e50bec7610cc6284c25d5f27552044dc5375a74ea9b648fffb20", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "68c10a50-b336-418a-9140-1cf5fe5bbd0b": {"doc_hash": "45d0f2c63a11e9885f7ea9c6b54be5c3a21cfb2b9583701f3a2b2bdc691189c5", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "060834bb-cc73-4f2e-9f3b-8dde291c851c": {"doc_hash": "561a530175d938dac43f57f2515f050da8b8bfb442a687935364e36a2004be07", "ref_doc_id": "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc"}, "d450eebc-72da-4267-9bdb-637491c3ec67": {"doc_hash": "7609efe30e7181bfbf0579922854e4553766d83283fe156cc64ac9f6e6c2ef0c", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "493dc7c9-c089-4375-99ae-d973bbb4d0f2": {"doc_hash": "65e9e138e6a854ccde74bb02acbcf3f050d4899b14608219e31bf2b3f8061456", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "aef36892-bde4-4329-b428-1d87d6a96a53": {"doc_hash": "00fd13614d17aa4d3d76c4a91887a505b31e163689dd8b6cf925f59ccc4c812d", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "8211f7d6-649d-445d-9ccb-4d7578180711": {"doc_hash": "f45a4459d74c63c19441d17ce5e933e211e91de01a70b6fc75bc795bc09b74f5", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "790db5ce-b3fd-4e76-8059-54c0e3134db5": {"doc_hash": "9c07cfe6b32bf79bf5f3209c840e727f2f7b869dddd9e06bb0832fe110a332de", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "27372dd7-1f77-4967-a29e-ed5ae892d9c6": {"doc_hash": "795cba3f1f8556ae01c0a406e2173b276f63e34f67f80008f3ce7fa75bf14bb5", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "f1d8ec53-3c18-47c9-ac84-4d0dbbda2bb2": {"doc_hash": "fb2739ef7ff2be37a0e22a14a9d2ce9efdc504171944b4472a65e5be0d6867ec", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "3646b089-9ba6-4b5f-8c08-a0c0794a8afb": {"doc_hash": "4af0eba9717e36e36a8533c41ba762b72528c5283a30dfaa3fd18b32d6fb4ca7", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "76906c52-f938-46f7-a44f-58880e691c87": {"doc_hash": "0c3a4959d8947c4ccd7b22623e8caf05b04d5c449ae666fef6f1b4bfcd4e2ef0", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "5bfd8291-9622-4eb7-b991-84595bc62b51": {"doc_hash": "955201bca268d618544787aeaba049cd6a9d548792e10e748015585db1f17b4c", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "15a2b4ef-4bc4-43ff-aa3a-05dd30f3bb21": {"doc_hash": "be962a6576ecde68c0f36cacd8f9738b00aa9242bb47d28194a6b7ae30bcd79b", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "28d96ad7-f652-403b-a0f9-551a1a7aac58": {"doc_hash": "dee35e903a431ab6f1287c2a100d723027c50c37d93f5ecec3a9febe5eb27f4e", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "f3a24d5b-95c8-450f-9da6-805df4f66700": {"doc_hash": "a6c93d51cb4e552706a61abd783db1d76526ebc3ad6d8ea6948b5724dc9d40cb", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "6279037e-c89b-45d3-86bf-c1b2e7334435": {"doc_hash": "e34ba284995eeb0ca254c6550e2115c0177926fe82447aa5df0f165db4f66b75", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "2f70bc0d-4ca4-4bf9-94d7-9b1e07ffa849": {"doc_hash": "d84ad057771cf918cb2b8b8420c46a35b459adddb26bdb5dc10a27a7217ab02e", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "42ce350f-1a15-4e7a-b6ae-adaed7d427a4": {"doc_hash": "e8bd89b8dc0c039394d6c4e378c33c469a8a084ab36ece4ffc20bd15d6eec98b", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "ff6f01c4-d111-4f48-bc99-a756521050ce": {"doc_hash": "7ffa40a69d60cac8959578408e171c81efd40338c79fd05e71f6ce0fe0a24c3c", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "7e0feb91-1760-4ead-80b2-fd373f850dd8": {"doc_hash": "4422b573eb8c1973b46146dc29df016e9a4b3c8e906a7853b0cc0396afa9a039", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "6a6f4be8-698a-4647-b03d-cbf1b4d7d9ce": {"doc_hash": "6829633502ccc87998abb2391160543e1200302ac31d859957622311ec3ea97c", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "287c586e-556e-4c91-abab-21011d56a338": {"doc_hash": "9a45b6812e23e3ca04ca72be6a3a9773fbfd183b93df5eaf138f0aba1432c001", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "5a6b226d-d5ae-4a43-a9f6-5a516159a649": {"doc_hash": "2bd7562b0fb62c3b683c724f48d82a38374ef45dc520e6f045e7d310779f110e", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "fd3363c6-64ca-4627-b189-4f6c02bfdf63": {"doc_hash": "cded6d9ec804629f846b94590662b50551e15288b8ba2f139daef21160dcc97f", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "a9522276-2584-4ea2-a4fb-875cd1552599": {"doc_hash": "8d00df4f7ab24137cb32bd04c142cc92990d611d960009ce8c05693a59b1533f", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "f6801f78-81f2-49eb-af8f-a73d6bd11b23": {"doc_hash": "463600f17711a379818c90574e6391782bd3a2ffe7e1c716e3d28c3b37328cd5", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "a4e65071-e63c-4dcc-b31c-61a12339501e": {"doc_hash": "7429ea0e64e5d699ee4b138088a9d83d0dcbb3e74009c7aac19d5b2fc89889c3", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "93ef1859-bf45-4f77-b85a-3358963fbb58": {"doc_hash": "3082480fc84b63bb3b0f3b9c4a97cda1c5a0cc8bae4b65ff4632e166d90259b5", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "360c1e66-ea2c-446f-9875-9ec8a55f36ed": {"doc_hash": "4b74de0443a18dc36e2bfea92bb40573fba63ef981865326af71b4791e4e8ce5", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "ab57b38f-38e2-4e48-85df-e8eae647621c": {"doc_hash": "96059bf2f0556d0601b7517e9544cfff3b0ea70d751d5f0a635c618cef29b500", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "c6c33c5f-a2bc-4a06-9e9d-a317754a801a": {"doc_hash": "829e013961d248193477f1017e1d23601d606a914ae1e586b857384710571086", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "492ecb29-a04c-4ec2-8cf2-b5a97053a8bc": {"doc_hash": "c5bad7d8bd7d267685e12e08acfcfff9ca047d508064e2d719df8f650ecb9652", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "365f9906-b475-4033-b53e-c37fa3292308": {"doc_hash": "fbbb1f037eed419c34c5b9b6450f500415b890e0718c5133d4a79cb18328c566", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "776a1407-aeb4-49fa-bebd-33a6a8a6e508": {"doc_hash": "1b606176c88288d2b66eb193d7dc9cbc8f936e8380ecd9c42e89bb956d70c2fb", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "e9471b91-81c1-4e00-8a85-a92d799a64fe": {"doc_hash": "bb138084a82608966477a0a50d500312f02f8729a9e8ff681a119564ab6bd562", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "27bd0026-ab26-49f4-9519-a4feab5aa2ae": {"doc_hash": "6e1442e3063e329d4b3d4ed0f97e3e4070e22a69587109b19edfc4c1faacd1b5", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "cc63f65e-0c60-417b-a0d3-7b917d0cc88d": {"doc_hash": "71c77f5b730947d00cd7ee4555803c95ac191a6784e3ab5a13c96ac5341ebf0d", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "264efb91-5a5b-44cc-ae3e-4a4d3889fcae": {"doc_hash": "22893a0294e1407bdef34e134bee375c643a2e7ceb96bb873066f350ac023fcf", "ref_doc_id": "25253565-00d3-4e8f-97ca-9f7f17a34a4d"}, "32e22566-68ff-4f3e-b12d-304537c3156e": {"doc_hash": "650427b19d3f08d2c27542f2d9540be88f82f77d3a70d9a16a228938b7b77799", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "d5d18cd4-1edd-4cca-9b03-870837c81cf8": {"doc_hash": "200e3d498088ee5a2552bde2d2074e38e7074740488dd547099e8bcdb31e18b4", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "0d4e19f7-972c-4ebb-be48-b4e5f61db4e8": {"doc_hash": "7bd9b048b7b065ebf30154e2d396559c8b3707ce445d7c8d77e76b2ee6283514", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "039a3021-e408-4b8d-b6c4-0acc833ededb": {"doc_hash": "58d6fe53455131ef672a4f54f4440e5321d21fc2304728bee14fdcce856340e2", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "b42791dc-3bbd-415b-ae99-53e16f501e3d": {"doc_hash": "96e509493f8f70d6479d3fcc1ccbca5b31c52e1f2ed367ad6f8d7df92b2384ec", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "61e5094a-c8d4-402f-9a33-04bd67e804c3": {"doc_hash": "e4313505d1cc38f8c41448f4d86ceeadd25d73aaa4f7fa93930bbaf70c76aa7e", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "400bbfa3-a4b8-4932-954a-1fd834054df8": {"doc_hash": "ec98027422a212e6f9296263e6821fa93e32affeb9820c921d2de8aa900127b8", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "b6a7a26e-22b0-414c-8675-cab268930e67": {"doc_hash": "1a61df573291d4bd744285fea977222f45a7f8e63275943392fda0a9d5bf5bc8", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "fe9deae8-3212-48ee-a1d6-b42a7ca6b556": {"doc_hash": "e80f1a8f1e819b521f6de568703ed816e5b44f676d11873d03671ae216ea4a9b", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "157cfac2-54ab-4976-8045-4a06193b268b": {"doc_hash": "918c472212630a3254f001a6ed41dd6bc6a1ea75b5da72a31379be0279c8d726", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "209b0e73-a463-4536-997d-125c932aee2b": {"doc_hash": "c67632a7b226a8991a3c73be37c540917c94fac2f8cd999b6b4cdc60ee11e5ff", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "3029b83e-c89f-4f0a-813c-9f6ce9b56a55": {"doc_hash": "e0d990f5be13dfbc19317617fcdaef38d4b6d03fdccd8fc5a7cbccefce39e989", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "678f8a05-1b07-4aba-a651-2828c036fde9": {"doc_hash": "2657b15c8361e31fe0dd8d418edc3a5657ba6d01d779ee60f14aa8d774757c9b", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "2ab9b04e-75bd-427c-9682-0e5d8b102711": {"doc_hash": "b2ce65d78e4fd0f2ad856027fb23292b4bcd98d81965d45fc8f5864283aa0449", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "7e62a724-e8d6-42e3-8796-217bf742fa4f": {"doc_hash": "8efc55960377703861a00683832840756e2f395715ee005f17c850f6d56c8a1f", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "6f1bf703-5dfc-4c12-99e1-3edb7d4a4a9f": {"doc_hash": "eb997358182f1a0d70d7abd0d5cb70c0024b67e9e700b6e5da869b34254981bb", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "c23dee31-6b64-4233-9081-952341ffbb58": {"doc_hash": "efb71a48d380800c9b64f12087a1ec25fb6ea5c2092b5d854346ded705cd3e1f", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "c17c3062-74cd-47cc-bb69-0be0182686e5": {"doc_hash": "ca0f245737e639fb98d700157bb49f0985906db93893a88b69cf2ef8e1221937", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "e78b1639-1b47-470b-b889-e8e9ce09a9e0": {"doc_hash": "12183600a6a8180766e21e49341ee49c81ed28006680408a47d8b8693dfee1df", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "f99c38b8-c7ed-4b0c-b327-b66b1276251d": {"doc_hash": "7ec651f6e8a32a224ec75b9cc1774cf64ebc5f5a4e807e34b5ea1dea40aa3795", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "bb85778d-3e4c-4171-8e58-3b8078c7caa1": {"doc_hash": "4bde2a54733c57127b1abdb2affa210e113a5a09fe28494bdba3e73f9db5aa2c", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "b7769a66-73f7-4ea9-9393-ba34254094c1": {"doc_hash": "0f386ad930c0dafbd14855dc20aaddf5fd54061554aec231eeb807771381f0bf", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "4126702c-fb9d-4367-a078-ebefd584b191": {"doc_hash": "4ecfe6f6106c8444000fb67bafaaa8beb73fc137a69e2b03fd2335ff69a5f3a0", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "63611da9-db92-4348-a12a-d035e2f5b669": {"doc_hash": "a5a3cd8486a9685ed5874a008e95d19ff429e88b0aa00dc1d860d3a6e6456c9b", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "72400856-d3dd-49d5-9084-18f90a8756d1": {"doc_hash": "2e0d369fd4d9b9336fb929ac3077021b113123aadf55875f5b2344b7418b6d36", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "daffc66c-16a6-4878-a781-d70d7a275e32": {"doc_hash": "f5c844c268a250a7010c867299a20ddf3ae9f2545b45abfd59254d42b0af1a14", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "e0017eae-dffc-47ce-8e90-e90bc3c2a6ad": {"doc_hash": "da35fea565dd351095290ccf6f69ae976b08f7594fcc6845c03d9cb0028cfbcc", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "5d452036-43dc-4d86-a249-7538efdc5489": {"doc_hash": "6d7c78010f13471a77652be6206f3e40d80ed7537aeca13458d8d3bf32341115", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "ad8fe1e0-d707-4782-ae4c-d27d5754dee4": {"doc_hash": "de40e44e2b84588b7e0e0acb2f4f8f3913e44de3cd8a9e6ee1714de22ee3c54f", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "85ecb61c-935f-4012-9912-aa07d0f3334d": {"doc_hash": "6bd7ba88e356e5fb566ca95737b2b212e0fb595ecc892f0cef95d09e884db4a0", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "ffc90a20-3964-4f21-a74b-a8498d69531c": {"doc_hash": "890160b27b0adbc50d9b9fd11c8f1f5f7d182d9233c6128fa8f7b0d82cb745db", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "3d5d9725-13de-41b6-b36d-86f7aaee9c8d": {"doc_hash": "6df0ec8d41b2a43570d5672c403644f6021d7e8d8bb31036bf0d7ab74f85737d", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "901a2464-fe68-4acc-be13-1ce694854a46": {"doc_hash": "bf7c18f578126d167d0ef3e45bcbda375853eed435f92d7ef85936adab88a663", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "5bf27700-81a3-4117-92b6-73e66fa7472d": {"doc_hash": "9660433a0669d8b1d23538f4e5840e7361f5cd0375bf14b38b350fc0d000c2d9", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "039804b1-2d98-47db-b5fe-e5d11e054183": {"doc_hash": "ef3282d8ef4bf3201f2484847886c5e555363fdd43327c716899c87302c1cb00", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "5c8f90e2-e68f-47fb-a297-579fa20cdf46": {"doc_hash": "06399fbd7c6fa1603462ef31901cc2e541d3ebd166f23440e0bcf11d235cd5be", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "1df31580-c67b-40a3-beb6-ff6003703457": {"doc_hash": "229956380f9d1d22010ea5d82fa1607444958d228d5dc806792188ca0a3b03ed", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "bbb0423a-e878-432d-8f52-c3eccf99bcce": {"doc_hash": "0fa6e218ba04ea63f961d5d79e8c174cbd3e565f910d2cd1e96bdddf868aacc5", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "d8c1a1b9-a24b-4161-a7d7-a81f77ffb668": {"doc_hash": "3a2ee4c35ce48391ee57be28294bf7bdd77b0c5369ba14a31e681ee9451f972a", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "9f1a2803-75b2-4314-bf22-7aa8472c50f7": {"doc_hash": "2a888101c520660dc91f2815f0b6d9d7cdadcf775b67d7e9587433c6145f8086", "ref_doc_id": "294df374-c06a-492b-94ba-193af1a92c42"}, "6d95b88e-f611-4a42-aaf9-1307cfe44ce3": {"doc_hash": "8f26c31767defde17b8d8e81b25e4d20f75c0297677dfdda1d1fb53c19ef8238", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "826c18d3-96a8-4e63-8fc7-fbc883300d82": {"doc_hash": "8096bbdf6cd0ca1a5a08dfd8a94e1a7b2e83a9234f9451c34199eb5ad1d4e363", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "a138579e-010f-48e2-a288-303e695d0659": {"doc_hash": "ad7a68e1f2354499771cc58a07e1946b876044f8099d0cf2340e6efb0c2d48fc", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "db473f30-37e5-4b3d-a549-d5c52408b74f": {"doc_hash": "07139d9c7a27c30fd0900497ad25804ecaf6046c8077f8763aaa6b12b4ce74e4", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "70f4e11b-110d-4012-a513-979d7ce30e7c": {"doc_hash": "324bdcb6e43121f327f625583a5e7ba0f8b817828bc29e9874d02cb4625b855d", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "3d3f4226-b9a1-413d-b64f-2ab63909140f": {"doc_hash": "f413144cbd5a17dc7b89b2b47f7b7b3d35243442dff49be7d0927e03f22f3651", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "2c141f2e-7449-426b-8c00-1fab9eabb506": {"doc_hash": "7374af3e136d0987247fd9057e3577d5aaf1597d5cef8191a0432597c95d11af", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "d65e06c2-50d1-4743-806a-c99fc97433ca": {"doc_hash": "eafcd8352212640c8c4a2daff12d46cee2d11430bbc963cb42c27f812848b5ee", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "91e3a5d4-0e7f-483f-8508-af3991fa1bfa": {"doc_hash": "50a84f4874bb7bc619cdee79b00ec02539a8f6d3c3fa9a1e78c1d476fe123c60", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "04f17601-578c-41d2-aaaa-41680e61939b": {"doc_hash": "8b1807d45dfaad5f875e6e9170881367b1578d7d186ff0b043079daafa4f3f6f", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "fb1b05a8-0ecb-4a91-9f39-5644097a4140": {"doc_hash": "a035ab5450e8956201251d437e0f76fc73e8fc83dba5e99550830f4c0f802c08", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "c93b3335-b168-4002-9569-7d29ad7a725b": {"doc_hash": "2152e13bee8050079ba8af98debac0beb08cadb1a9a59d5022c979e93fd8cd8e", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "c0c3ee60-fed9-4979-9b8d-ebdee76ae4b2": {"doc_hash": "10fd0470967e5a0a08db1da247b116c90ab27eb846fb2f17240418840fd9fe41", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "0adc0a7f-317d-4396-bb4f-0173ec047bc4": {"doc_hash": "e8e44f552d3f7bf92a9337d64d40ccfdfd956213db5e48ba4eea5934c14bdfe2", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "4dd6ae99-8dc9-458c-80d0-7f35f2cd0934": {"doc_hash": "e8014c46398a824e959e6c8142c36b0b5e8dd01aafc4e40e55f5add00dacda3b", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "d0611d43-60cf-4713-bc05-0390e1eaf5e2": {"doc_hash": "b6b815c2285308d28a3a96f935b82fd9987328c65a10a55e08375128a0c61497", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "3f6c8f47-6197-4076-ac7f-f1bd37f1dc39": {"doc_hash": "f02774548013ea5ba5ff7a53e816a7a5f423d4854bf568e69dfff7065e9f661b", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "93385183-1f82-4efc-964d-2ede51fca0c4": {"doc_hash": "c1d85dada5cebb7cfe6ba413422f2bbaabe06f4ffa14a082cd271570969868f9", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "4fad0dad-f103-4c45-97d8-3a08117a29a0": {"doc_hash": "1da1a1ffbd7a98f935afc10abb727f9e3f71525c2feb82b96544870b401b115f", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "6067434f-ebb1-40d3-a4de-1304d0006584": {"doc_hash": "1c2ea9e89bbcdfc58596bce6fd832f1f464237e2c1133d23e1665f30ba7723eb", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "362a4cb3-0e56-4729-825c-da89a740f1b3": {"doc_hash": "9adb963f4f88ac5f4ee6bc4abcded457bf637780b4d51fb43d2175dba1467172", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "ac0edbd7-3ba0-4c52-8798-26f361ebb5ca": {"doc_hash": "21f2296cb0c435a6fced97655cda7059950599ee2effb17ad1b197f9555e1e3f", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "6d22d18d-d5f1-4c36-a2a1-962ed6898d40": {"doc_hash": "04c4c384b3ff236a86968c2253c77791131d9adf4c7cc6258b66f6018bba0941", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "62be3b3f-66e1-48f2-b5db-b31d4dcb9266": {"doc_hash": "7641036f74a58f412fa46df7df690bc5a7ca311ddeb4f17a8045379e11fbbe1e", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "f8ca9968-dd9c-4b5f-9fde-70e92ca31fcd": {"doc_hash": "700e521264c6699ec2af0ca638f6aac0ff7c3dba5b88287c28e12637f7474e86", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "f91571cc-7f9e-4a39-959f-2165620b2aa0": {"doc_hash": "26ddb98bba72947ba03f73d6821a17de999fbeb673a2f6b47325627e01a8ef9d", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "4b696808-da39-4619-b69e-1ea8341af1f1": {"doc_hash": "dbbcf66a8bfa0581000dbae9be3f0f2426e6decd0664798baa25b576b61f23e1", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "7094295c-4479-48b7-bf43-03f776d382e2": {"doc_hash": "f7209298f87d55fcfabf9f3ea539811f15031c8fa8b91dbe4b377eacd30f5315", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "bdb1876a-e1dc-4446-99b0-09d4db29b0e4": {"doc_hash": "c794e9b23499daa9ae60e24f7045f68d42f546e92836dda3f0273bbc3dd57c53", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "5f6b55c0-13a1-4f15-b042-031c04ed013e": {"doc_hash": "ea75213e39f94f6d8b9aa9282d67e37773372d13453fda3d53dc44a9432b8863", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "77040772-f3fc-49cd-92e9-48ca85f3eed5": {"doc_hash": "6efc4f7ef7aceeb1796e0aef9ae244e248f944d5edc3bdfbb735f087e0f5f0b7", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "2b83b1eb-3e4b-4678-abb1-b37afe204bfd": {"doc_hash": "3a871288b21c3d6ccc01f755f169535d72de69470b29407979590e687f4c90a7", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "6adba9a8-1f04-4cfe-bb68-cc77a80093e7": {"doc_hash": "760def281123d102cad9bb97be426dcb0363cfca032c7d5462104f1c018ca8ba", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "524f1ea1-0d05-47e5-97a3-e16b87d0121e": {"doc_hash": "f63c060b3c5d18249a5e639d0ed9315cd6166c11aaa00fa3a1aaa0c42847e5b3", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "cb12cd5c-0047-4964-8d66-fc6724b7eb25": {"doc_hash": "96a6d22fcc3b6cc1c638173bd9ff72c85164a523a8762358340a2da2ca51bc15", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "75b010f4-f0fd-4d1f-ade1-d1f0a74919c4": {"doc_hash": "398f140884ec5777ad19ebf4daabacca1c036d7e7e1efd938811fe243714e560", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "815b0562-8ed1-4867-91dc-4c319fc7d411": {"doc_hash": "2bc9e6c01430240ca4fce44d8fa1a23f0ae514b86764f3d662440ffec6e10898", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "22937657-3124-4afb-b54b-8855eb6ee836": {"doc_hash": "61e933163f14aa6401184bf1f74db7d55cf9fad4cc0e24dde7e804e970d8633f", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "8fd0c16b-8839-4c4b-a6fe-676609029edf": {"doc_hash": "41369aee0984b39b7108f2b74da017066b7c3c399475a7d1277e3e4a264dbefe", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "e1248843-c736-4d81-9236-0c6c37ee6a3a": {"doc_hash": "a51ee8b723b8a82f531241c67832cf02cd14b561d6b53b84bb4c6a6862ea490f", "ref_doc_id": "f6793a06-9bf8-4999-90fb-a228792d9b4c"}, "76af05d8-fe26-44ed-9ae1-f7617683e865": {"doc_hash": "a5045077e65d1f76e49104cf42ae03e85b7181c31f6d57f3c4d74aa4bf00fd5b", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "4d2226ee-73d7-4174-98fe-1d0eb4e42893": {"doc_hash": "555c2dc10e91afc4b3ce5f27161c9e7d2b212669bda15eede7d1d0c49b822131", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "63b0cc4b-9e0b-48a6-8eb8-fffe9501de3b": {"doc_hash": "6cda5d3d7cf273a827dda1e4748fd298fd9801dcadf6f7f697299fd26b24d832", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "7140ddc2-c6fe-43a2-ac6a-80e8fb52732d": {"doc_hash": "d4179cfb0773e432161e891427c4aa3168c0a50b30dc2ce81ba77c914d56a233", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "fde66348-4850-4545-ac41-5777e0eeee02": {"doc_hash": "6ec4ebace677ef88635745dad99e52793ec049c2451ba37b6115f9966ea4c1d7", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "20e3c8c4-1806-42cd-a78b-ec61cf32fd9a": {"doc_hash": "289382a740a1b469c012a317c7c513106c9e9aeb7fd4207801fee17803a81610", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "6652d02f-9fd0-4876-aad4-72b99ee1185f": {"doc_hash": "bd70feded51bfb687fc651552749f274cdceffef77ee7fab8fd53c2685d9504b", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "af9f64b8-c5cb-4051-83d9-a2e3e9e6162a": {"doc_hash": "8ef716558635e698fb8fbdb6f9da27abe708d7005c933910391543caa40e0cc1", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "667f4776-6340-41d1-b118-8f3998bce2c6": {"doc_hash": "03446ea084eb46f34fce881d5c22559273b75b35b461b0aff90d2f798cff7e61", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "19e8bc63-1aae-491a-8ad6-b5dd0528f0e6": {"doc_hash": "48b92f53cc0ae28864cb79fe266e097e831df8e32854c9f959e39a3d0e07b4bf", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "3c4a2df2-5c0e-4cd4-843a-7c7c4f0ed22b": {"doc_hash": "5de6ec2dccfaff6ed588d98ccdb62a43e7083d8629ca3730a81842d9a4053b56", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "372ef484-c8d2-45c0-8c6c-651596021083": {"doc_hash": "1376e3bd956502e356bcae5b7b0e96c68a03ccf719e0b4265b9a1aee28fbba51", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "64592f03-9d19-4453-bfab-9877a1d4f44c": {"doc_hash": "ff20a5e5d46b2ed605afc1e6c05a46ccfdba21ded5f69b4c7d6688b9161221b5", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "c14317df-a163-4f90-b274-0052bac9f8f0": {"doc_hash": "f22391b6328f5aee40770d571a5d8188689532432ed024f0175abcd151514b1f", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "7a584d19-b756-4f22-b0f0-ab90a6d422ec": {"doc_hash": "909b4cda645e0843b53ad3a7ded17be975cf698629613db9c6a76fb257a73bd2", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "b984cfc3-d191-469c-92a8-691d5921efe2": {"doc_hash": "4375a9fbd7b3ac2ae26dd9cd160d83c4a0f56d9acf146ea9b0eb5c001c9e0c00", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "c5e2f90b-f377-4a5d-a8eb-ad5f30865bde": {"doc_hash": "cfabe54366ae008e08be5ebbd5125a65fa32ef87b3e3cb4ca678aec8e3080058", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "bb9c3d17-8ee4-4a43-8633-6212214cda5a": {"doc_hash": "cafda29298cfdf7726eb0efaf2a4c1da324edc5286b36d531aaefb94691d2173", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "15548602-8581-4f3b-ac44-74a0eb58e76f": {"doc_hash": "7bc6da4ad8d2fba3b37467cb8f2c89e68e5ec1215174fa435685c8fd46afd35a", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "f1ed08bb-dfb1-441c-872b-5c9149225c23": {"doc_hash": "aeb482623a67e67f5246775e6a21cf32ed10c6106cf20ce636a137fa2ba61a3e", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "aba89d2f-879b-44df-b6b0-a7f0bc8e6327": {"doc_hash": "fcbb9d3dd79b18c1ba1305364ea88fed5fd874cab9b04293a4c84f172903a5fc", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "eee6670b-265c-46e7-9768-5aa5b03cd501": {"doc_hash": "a855db6d67f976874fac1e639f7bc8c9c5c3949aeb11fe0a110c2693a26fcf5d", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "5178e45d-c66f-497d-9bd1-eb9e04d20b2a": {"doc_hash": "c84caf3d3baba5ba7dac5ae86302452ae9ca559a507b1bf3db6ef3653816be00", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "449b0856-b7aa-4751-b608-336619d6ffc8": {"doc_hash": "1107bb9731510b4caea99cb20526f3773a8b2a764a146264a947d2a539b7ec6f", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "a0f6e58f-c0f4-4bb3-8df6-5177ffb4cb4d": {"doc_hash": "a6a0d0d31b52d44d47e4b8ca50f21005bd59012a2eaf687dd3600abf41dd6e8c", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "72da486a-4ebc-42d7-bec8-93c31b209aa4": {"doc_hash": "6abd2153fc22e5d8009c7c82872051a20fcf28906ce7a56beb2abd02a2cda3a9", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "bf4373fd-bcdb-4f4e-a04e-f078ef2627de": {"doc_hash": "fef48f54adc12cf95a79fea3921424be944be1b59535ed8d5ee19b44c92fbf9d", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "6a0dce17-223b-4089-8937-9aa40d0eb65c": {"doc_hash": "f8ad2b169082ee41b835012b185952d19130470787a3d72d9c5d5920afbf9f29", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "d0610b98-ce31-4862-b002-2b1c6ba09e22": {"doc_hash": "6b300a9cdea40825932536fb97314d8963145045695febfef1cd81a70684603e", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "5d162c96-991e-478b-bfb6-e66cec6f7ef3": {"doc_hash": "277b11d29ca46acd6374bb0502a8ed3dbd31801c7168023ca872d727f7e66ec5", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "f56ab946-2bb5-46ff-afa0-501bc765fcc5": {"doc_hash": "b8366f0131d0a45781de3228de8a4f43812f739ce11acf8066cd1dc71017d25e", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "ccd7ea31-7887-4a1c-b3b7-75ac0aae4ee9": {"doc_hash": "700f88fd0be22178e3f1fd2150f1ff8cfb4e24ca2df698947244c4f49b69df58", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "249bb9b7-e1bb-4ee2-bbe7-2b12d27260f7": {"doc_hash": "6f864d5ad7ebd5ee7399fda136575f2ce952993d6f9525edca8403cc08d4bff6", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "34608af1-71e5-40d0-bb1f-6b1014bf4ed1": {"doc_hash": "ed62f2b729a550e6d9d799d7c70203d239992cbfefb0458f8d54b4ea5ed950bd", "ref_doc_id": "f80e702b-d364-4eea-81d4-23a0966f4aec"}, "e3466554-4242-4138-ad80-42c733ed41e5": {"doc_hash": "db76601d4e345d354f559d2e0f965defa8c5ea5245e8af591209ed28b34021f4", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "1593b5a0-3c0b-4c8c-ab8c-89e76809e4c4": {"doc_hash": "f4c7c92e888d42f49f33f5e7c8257e0917583ce79efaecbe895494ffed0c2cad", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "5d21f074-0129-400e-b91b-e4fe099d03ab": {"doc_hash": "15545ac25c60b6449b61671ee53e0f5768902a662b06d08ac49ee2a616beea84", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "47ad4671-0554-45f6-ae1e-0bdf2a35dc63": {"doc_hash": "adbf2f3503f454487c1362e060b4c55e18c121fb90646587c69f72fd442b8ef1", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "2eb6ddd4-28b3-4658-b126-d1faab1c3a9d": {"doc_hash": "28e57172a0b24102ded9f8005d662f57c2125008cb08dce22ad1ccc0dd97031b", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "88e4d535-4878-4b09-91e1-48ef7a19d3e9": {"doc_hash": "1a7aa8a56c7b80b6cf2975a66c9c4fef3b8f1bf3cf115debda85ffed478f7858", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "3b90d5bd-5e8d-4136-89a2-da3580cad9c3": {"doc_hash": "78de5238100523786ee8ca29fb002ce84c6c6cde0a8e4ee152c2d0478ae39b0b", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "22db8857-9e0a-48b8-9db6-fae1fc8d455b": {"doc_hash": "aa2a851aa351f180a729b007b66f30e1ac25f6b1ac8ec466674384a35e65ab75", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "f0ed527e-1fc7-4e74-a1ed-4b4b41781985": {"doc_hash": "b31d19ac90734c9c58df99b482fdb8f336cc9be71642c9c594db05ce0bf821e6", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "142a0d69-79e9-4c72-90db-7d361fab24e5": {"doc_hash": "4e86f64d065ebf1c2cf6f9967b302566a286cb67e8183ee5f6ace034010ff087", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "214f2b3a-89a1-473a-bb11-68f131ca2b0d": {"doc_hash": "ea8db34743c8b778b1f77932f7787ad0e024cbfb7cf55236d8b9d005c9928272", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "3a91214b-0154-460a-85ae-e32b8037f555": {"doc_hash": "ea43d3fef17bd0252cb3ab1d0c6d475a28ac6ab06527038bb958ef5a3be4121c", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "22ca1f9b-3bba-4662-a0d1-dd15dfd08f6a": {"doc_hash": "df532d5a7a9625e05dad458642bcbaaf5d8010d6c997bd720a4bfabc478212ad", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "4d4c7df1-a8d7-4b0c-8402-1d6f26be6bf2": {"doc_hash": "b10a7453cc89a476d013037f2ee1a68f9b5b89cb8a35cdb5f4622253dbdfb995", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "7fe072c6-45a1-4cd0-aea4-b77e98d3bedd": {"doc_hash": "f8a4b49cd59d8376da5d0578f55fac01261dab61ac67db058f9bc4656fc10158", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "faf500de-a404-436a-a824-740419968fb0": {"doc_hash": "4304beb12652e312454e4a6050fe83b4ca79095e35c924bc69097802b33f2369", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "27ec8d71-06bf-4788-a122-8db748fa2ae6": {"doc_hash": "27d29de6f39018b2ad4f042f1f497abae60db14a0d0d738ee6b6a3dffb811e8d", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "bdfbc346-2a71-43f1-80fd-4ba588bc8f62": {"doc_hash": "c1d0a5c1d47639e57835b97a370cd478480e9a3e5ddd6d3d61a67602ce3a7ca4", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "21b96769-c1f6-4874-b86e-677dfed76554": {"doc_hash": "cb6a28dc8b54fb33e658af9b958ca17678db739c96abd30b26a6259a542362c7", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "8f5c4638-27e6-40bf-898d-531cab4ba047": {"doc_hash": "fb9f5a3a99dd0b957875572de9ec9bb8007a4add5dd3375e8c0cc11f84d75be3", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "cc0d8a2c-77ab-452b-97c3-594765893bed": {"doc_hash": "02cfd3fa93936b2051a748a0bbf8b957b64297a48f974a80ecae1ff7b2aa3552", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "78ba5c2f-21f1-4f4f-955d-db4de2b799c8": {"doc_hash": "ebbdebe9ba828fffb48191cc8ff6a90054cf759f39ee353cd8b5b6709bcf4c53", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "b507281c-861b-4d13-aa9d-946abb2473c8": {"doc_hash": "0a3be28409d95e02aaf1bb5912fe99c3229d61c7112263345d5e7d3065ac47df", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "4f89d09d-58e1-435e-b2a2-8d4d386e6860": {"doc_hash": "336ce1c683f33fba13c96d9d10264f5fca96aca6b74145a854480325412638ad", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "25e98902-e55e-4838-974f-05c30849572c": {"doc_hash": "d67b0d37ac93e1388ae7a3f2d1d68668962f36052322ad733af559ea52335dbe", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "c3e63db3-ef9b-4d11-aadf-048cc9e8751e": {"doc_hash": "8515658ffa91d0534e7272a82eda1cbf610d331a0da698edd757142997f03342", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "60cfb81a-f6ef-4547-a852-8dd6395f55f1": {"doc_hash": "6be7849836fdc2e15b61cfeb04ef327c18ee7c47fdd0a197a917266122a81b64", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "749c8528-187d-4b36-bab2-e22e93a51429": {"doc_hash": "f9d2302c0023d3ecbef29776d6572d7009b57edf686fc29583460076c550582d", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "32e68f3b-7c14-4032-804f-aaebfca67fa4": {"doc_hash": "1caac3c46dd5d1b83dcf0fe386d1a5c9a8d44e3d6995e059b9711da521159556", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "821c151f-9f93-479f-874f-1bf56c36333e": {"doc_hash": "b28ad34c46c86914d9c7ee74726a701a0672b7dbe80cb1499727c79cd87f899d", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "32fadebb-23ec-4de1-bec7-d284dc82fd65": {"doc_hash": "95eba5d6fa91a643f93b3b6b405e4f5ab44fcd8dadfb3f0ad7d36f3221a5c00a", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "0869f6e8-59b3-4c15-bcb2-3f45b81335e2": {"doc_hash": "dc187797e57c95f9ee9b2eabf629a71b3c40e76260849baffc974ac2e15575de", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "7b0783fb-0f0d-490c-8c6b-2b4af219cf0f": {"doc_hash": "c5de46c872f52e60a36c6a991a76e8ffe5426d34a3b66d21c55901b73bd1a394", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "1e8d5d92-1a22-4a71-973a-26f04e0f3787": {"doc_hash": "905bd98f71ec6dccf5fc0adaac4528fbfd752ed98ccfba21346ce491988c0ff6", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "4862379a-9f2a-4268-bc29-db176533ecd3": {"doc_hash": "911cef048bf61fb1d17a3decce77b74244e0d48c3312c7accde294b7a5d5f141", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "5913b7f8-e23d-4f0e-a24a-1df012ddab37": {"doc_hash": "10a76370b9fd40ea3357a37d6d2ea322d3e37ad5d6fde31b924123fb861ffa43", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "5f191ba1-8183-4791-9af6-dbc8935f0f89": {"doc_hash": "f011bd6ee784f0eeec047c92e95800000f742f3af7736adf7bb70420cbc2f3c0", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "71772b30-5457-4276-9b1b-e2be64614ffd": {"doc_hash": "d54180188a254bb6f39ac8432b846ec64c1ba20fa09811f97b1847e84563c19f", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "8ec7b3df-1344-4327-b24a-619e19f808ba": {"doc_hash": "1b20a4f0557d9ce0bc6c713dc398b13608a8f7166b6b04862d2c9b39f3e275c8", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "b9621562-3e0b-489e-a8e0-472d14cce89a": {"doc_hash": "5bb6ceefbe95b2fcb5540f1b3514ee943f215d713ffd1d6d88dc2cc46e11d42d", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "6ffc54f0-c7ef-4948-82da-7887a76dc00a": {"doc_hash": "ded1aa144cc5b5b307c96272a0cab3a7c2c568a8f160549cfabd6b3dbbdb5dec", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "d3b212a7-2ccc-4841-a4b8-24045b45b309": {"doc_hash": "348def134b2f64184d3c834da1be3aa0b29ec06187d6d39f2541076c0029a384", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}, "ad40ac1c-08a6-4aab-8970-33d264cd9ca7": {"doc_hash": "bce221138edee511321f1c40845b1f55904d600c48d2a7bf1552ebe558e81243", "ref_doc_id": "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3"}}, "docstore/ref_doc_info": {"8c6d82a3-2491-4948-aa5b-cb1424e06db0": {"node_ids": ["40c59cb6-ec27-4d2d-862a-c3f6edc23738", "65f1f320-e7bb-45f1-904f-79ff82bd6bf7", "4f5a7aeb-ba46-4be2-8782-6976e4f59d70", "b77c5f9f-c8c9-45af-9287-e8df0b9ac0ff", "3092d54a-59d3-4c8d-ac78-5ad0e3d469f0", "1e029378-f87d-4f5c-901f-7208f3569a00", "c18cc781-3496-47eb-94c9-f5ccbcc3aed5", "66634b70-d7ee-43ee-9f66-0bbff9cd7545", "6fd068f4-e07e-4a32-b36d-8a1607040c04", "327584de-bd37-4cda-90f3-cd945b22e8a8", "1e9141bc-fa23-4b4b-bce8-ceed288e1403", "8d28c4d5-fd9c-4c14-b1c4-5efb1331ef65", "ccdc05ae-47c7-4b56-9864-a40bb13cf39f", "ab5a43fe-253f-4033-a688-baa0511dcb18", "51630290-54e3-4395-afe8-60b311f5b2ac", "c6f62471-5cb3-420b-8696-0272130e7647", "dd452422-4bea-41e0-bc92-4d82791f9128", "4dd9cdc7-705d-451b-8ecd-b8874433755e", "48d74772-2354-4594-ba84-029550fa729b", "4f7f06fa-6cce-4390-9709-8b98134db78c", "0215de7a-f500-43ef-99f4-2d6b0cb67192", "f8905862-e7fa-47d7-a7a5-3689acaea323", "aca04cea-8371-4a36-89aa-31c9a069b388", "a7f9ab1a-88fb-4c59-b9df-f7eb9d241148", "3421c8f5-d2ae-4e3a-a1db-9b2b870cac48", "0c688c43-7107-4c63-b440-d3d8f758e413", "b613e4fc-d8ac-4aad-bc4e-d2eaa77247a6", "7ef9cba6-7404-4ced-a52d-d32c58de4552", "f7a0ad06-b541-49b7-83c2-fbea7acbf26f"], "metadata": {"window": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 2 , 2023, 8:30AM Eastern  \n \nOperator :   Hello and welcome to the second quarter FY 2023, Cardinal Health Earning Conference \nCall.  Please note, this call is being recorded and for the duration of the call, your lines will be on listen \nonly.  However, you will have the opportunity to ask questions at the end of the call . ", "original_text": " \nPage 1 of 16 \n \nQ2 FY23 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "41a38b33-7ebc-4fcf-bb1c-a5f021d23b04": {"node_ids": ["0a5e9ae7-34a0-4abf-9608-9a58ff73b2fe", "6216ea0d-a1a1-477b-abc5-75d59248bc35", "af5be324-9283-45b0-9557-e3eddcb186a6", "8e0ae0dc-ae82-44f8-9640-fa9be3ffaf44", "d0c33dc3-6892-4e23-aac2-f055042a787d", "21436b26-d3f9-476b-8dad-ac6f91cada08", "9d18904c-7613-4a5c-a0de-d36740f8efea", "b6584d86-8286-4e51-a68d-588d345c3428", "6b84cb09-5b78-43a1-bef5-be35831cec0f", "3b680782-520d-4109-8858-dc28d749c731", "7f1a02fc-5157-4f98-93f2-c24942e8666b", "523b4030-9f3e-483a-90b2-a1d988e23a22", "5643e2ee-f753-4aac-a16a-9470e73bedab", "1f80f571-e349-4aab-8fcc-ff505c3eee90", "09da0c1c-c13a-4a99-bebb-260822d605f2", "f54df3e5-0cf3-4996-aa36-02cb3f66e2ed", "f84405eb-697f-4502-a4c8-1371425e5040", "ad8d91a4-d0f1-49b9-aaaf-dc21900eeb9b", "c2f83f2d-324a-46b3-a618-03e1631e93c0", "37827ad2-2771-459b-9bdb-3d7af386f114", "6c848f86-91d8-4805-a57f-f1887839c574", "d0f443ac-ab7e-41bf-8bb4-28e945fe228d", "6cee39c0-b8f5-45c1-9375-882ac0fa3885"], "metadata": {"window": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n I look forward to interacting with you all further in the weeks and months to come as I continue to \nramp up.  \n \n Jason Hollar:   Thanks, Aaron.  Now let\u2019s begin with some high -level perspectives on the second \nquarter.  \n \n", "original_text": " \nPage 2 of 16 \n \ndays for me, I can already tell that while there is work to do, Jason and the team have a plan and \nthere are significant opportunities for value c reation in front of us .  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f3b09b99-f8e9-4090-b58b-3a3930852e37": {"node_ids": ["57fdb6c8-d778-40f6-8431-ff97bca14fe6", "c5f71a49-d78e-40cf-b65c-0a15b0d8a3ca", "2c8592bc-b53e-40ce-b8c8-88dcb4606d0d", "9590ccac-c9dc-4044-b261-e6a2ed1be82b", "4642057c-f645-4349-a396-423b72f23210", "1a021d24-0fd7-4634-bd17-e222dd4bbadf", "256e1646-68a5-4e23-95bc-a212d7d7d1b3", "21109ba3-58e9-402c-bf6f-e83f6debc7c1", "1c2063ac-0f43-42ed-8769-d5e19bc07f6a", "d659da2a-e8a9-472c-b4ad-5b979a55f6fd", "d5664932-6758-4b77-968f-1602a93a275c", "01f491f1-bc53-4186-96db-051bac17ecbc", "8353d0d2-8500-4562-a842-a71e4a85cc91", "fc67ec20-c3d3-4f5b-82d3-4deed5a83dcf", "fe60aac3-518b-4a4c-9465-6412b30dd445", "e0203552-2471-42ec-988d-fd2869f56716", "9db249a5-5189-43ec-ae02-b4e9aad440fe", "df2b96da-a907-4687-bc98-5408fb1ab9ef", "654da6f2-b92c-46f5-954d-0d593f1ab661", "7e7bd50b-5e4a-4d08-949e-4c6ca1762aa1", "06f06375-6dd0-4783-9af9-e30e2c2f9898"], "metadata": {"window": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs.  Benefits from \nour enterprise -wide cost savings initiatives offset some of this increase.  \n \n Operating earnings of $467 million  dollars  were in -line with the second quarter of last year.  This \nreflects growth in Pharma segment profit, offset by the decline in Medical segment profit, which was \nanticipated.  \n \n", "original_text": " \nPage 3 of 16 \n \nConsolidated SG&A increased 4 %, primarily reflecting inflationary supply chain costs. ", "page_label": "3", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c9498d0c-58a6-430e-8fcd-e4d4bd3e59b7": {"node_ids": ["07f7976b-8381-4ac3-8044-ea96eae61cf0", "e4f0c547-fb2a-4acf-85af-26e2db6e1f3a", "f8a290a8-5600-4387-9daf-2998f2979f5e", "5a5dabdb-86b1-46e6-9720-48e3769551bd", "a823d1a7-207f-475c-ae36-585b8c4526d7", "263cc231-0ec0-4b80-9144-0b977789828e", "1bbbe9d9-bf2b-4f0f-aa8a-25a305abf750", "21890191-b2d1-4082-804c-a998555ec57f", "8b246986-fb7a-4093-ac84-2ebed5cbecfd", "936a0f96-edc3-411a-91a3-29acdc2b6f53", "5a553583-21e5-4dc6-b3d0-f7e81ce98301", "ed047fb5-e536-40b0-a889-55346ed34b02", "a5095139-98fd-4c19-aab0-83928355305f", "c68d6749-2db6-4031-84b2-3d1a51e9c91c", "cd86546a-3178-4f37-9e3f-256b67157ae9", "571ed69f-f46d-4897-a4f2-53fb0379031a", "95759236-358f-40ba-b4a3-ba5a3c3c9123", "e50899a3-adee-48a2-88fb-e8b699b1e638", "779e1dcd-3f69-4c5c-8d89-90b5ab667ea2", "1bc40fd3-7fc9-4419-8052-c519a93196fd", "c4220628-6ad6-4ec2-8404-1e1ea7f2703f"], "metadata": {"window": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see.  This includes strong performance from Red Oak Sourcing, not only \ncontrolling costs but also in maximizing serv ice delivery for our customers.  \n \n Within our supply chain, we continue to effectively manage through the industry -wide inflationary \ncosts seen in the areas of transportation and labor.  In the second quarter, these inflationary impacts \nwere generally consis tent with our expectations. ", "original_text": " \nPage 4 of 16 \n \nRegarding our generics program, we are pleased with the solid execution and consistent market \ndynamics we continue to see. ", "page_label": "4", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bfae3958-bb2a-4ddb-b268-3e8a46bb7d67": {"node_ids": ["85c52a78-3f76-4cca-b0e0-740e26a9bc4f", "287c82ee-1617-4c71-b4c6-4711a50bb580", "944d0c3a-4aa3-4038-86e3-f5d3f650a975", "7dd4a69a-8d82-4c07-b1db-8469c9e53644", "466706cd-33a1-4107-9d50-5e8f4d4218d2", "9c6e2e84-2507-460d-9e41-d2a17818d7ea", "a37ca68f-869d-4c30-a713-80404760763a", "c6665a55-482f-431d-bd48-a1d100368f9b", "2965d487-b0c1-4bd0-8467-f1baf24379ea", "aefce484-dc81-4e96-a21e-32da3a72ebf7", "211a0c81-5ea9-46ab-a1b7-799fd5012dec", "0abf00a4-e2dc-4ac9-a518-874739a105c3", "8c0a1095-05f5-404c-97bd-c3b5cc93df7b", "6c82249a-d493-44f7-af17-aee950329313", "2cb36767-7ed1-46fd-ad59-02adb2f18414", "2433049a-7780-4c3f-a414-9bb22ab40dc3", "b66430dd-3355-4498-bd7d-42b493f8a2a1", "a2bd6145-5347-4685-9657-1f327e6f97b1", "8bb2278b-a1f6-4f1a-b8bc-373de35e3043", "a7f03c2e-efcb-4bbc-b5e7-0a5745be9f00"], "metadata": {"window": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n As we look to the second half in Pharma, we anticipate the year -over-year profit growth to be fairly \nbalanced between the  third and fourth quarters.  \n \n Turning to Medical...we continue to expect a revenue decline of 3 to 6% and segment profit ranging \nfrom flat to a decline of 20 %.  \n \n With respect to inflation and our mitigation actions, we continue to expect a net impact of \napproximately $300 million dollars in fiscal \u201823, or a minimal year -over-year impact.  \n \n", "original_text": " \nPage 5 of 16 \n \nTurning to slide 9 and the Pharmaceutical segment\u2026we are raising our outlook for revenue to a new \nrange of 1 3 to 15% growth and for segment profit to a new range of 4 to 6 .5% growth, both of which \nprimarily reflect our strong first half performance.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "36c518d4-1e39-4a53-bd58-f66f0fa4581a": {"node_ids": ["ed36ceba-aab9-4fbe-8a2c-e97fdf49464a", "4ad1bc6f-ed62-4a31-bc7f-38cdcf4d6999", "e1eaba84-7ad9-4af0-9bad-5a7b8cc8038f", "b730af6f-5a0e-49f3-b4a6-d2a12b0aef6b", "6e3a9a0c-00cb-4928-82ec-8a3d7758c719", "924c03aa-07ff-4159-93c2-241784d61c3b", "7c7856f1-d33e-41cc-bb1d-e520f514261a", "93c54aad-3982-4ee2-9382-6f65bced9545", "3346f407-38d4-4d9a-a40b-169687e229f7", "d8494921-a3b5-4c25-90bc-f81a979d5811", "949e6cdf-8cf4-4503-94fb-6b743c041c93", "7075fef9-e235-48e6-a65a-6e2ffa6cdc93", "663d233b-7f87-433d-bc28-da6c3c3d7e35", "033d60d5-f355-4342-a8ae-41ec3a7048d1", "053d3036-b3d5-47cc-82fb-2e55064f2eab", "0b1cada1-b67c-427a-9346-670f171b5831", "273820e0-3cff-4f91-b748-088ca15fb25c", "11028dd9-6e17-4b45-8ec4-73cb4bbb5c34"], "metadata": {"window": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories.  We\u2019ve also executed \nsupplier distributi on fee increases to offset higher transportation, labor, and fuel costs, and continue \nto explore other opportunities for further offsets with urgency.  \n \n We will continue to monitor cost trends and work with our industry partners to make pricing \nadjustments that are reflective of current market conditions.  Because we have taken a transparent \napproach working collaboratively with our partners, we continue to make progress on this front by \nsuccessfully adjusting product contracts as they renew. ", "original_text": " \nPage 6 of 16 \n \nTaking a step back, over the past 9 months we have made a series of widespread temporary price \nincreases across nearly all of our Cardinal Health brand product categories. ", "page_label": "6", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8c71bed9-073f-4af1-9867-c47cb7248707": {"node_ids": ["d5703d9b-ec88-477d-b8f9-3e137197953f", "c323ff84-04ee-4db5-b6eb-282cf0a2c0b7", "65f3e828-8259-4b84-b961-851a56b1aef6", "90d4a0ba-76a2-439d-a8ce-2ab638a5cbed", "e94d6552-dd70-4495-874c-b72b8e16863c", "f2b9229b-df27-4253-8be5-c6f805db1efa", "ed36589b-eadc-458e-82d3-2ee48ebcfd47", "1d6f587d-4722-41ea-adfe-81917db4ea69", "9353a27a-4114-402a-bde3-6654432552b8", "a917898a-2a78-4453-b477-1875fa2eb444", "797c013e-6e12-4392-89a4-b600fe5ed5e3", "828a1472-664d-4af4-b05c-e935801f5491", "81bbaad6-0194-4231-a967-834aba4722cf", "8f5cc462-bc27-466d-9cf1-1e0916f6a17a", "f53742c4-df74-4fe2-89ad-e4295126752a", "bb261727-b74b-4314-b7fe-f19ff1d8c521", "bc70c947-66bd-4575-9feb-92c59e505791", "3d29562e-1275-4a96-a72a-85abf8241d2c", "5a17554f-6a4e-45b9-b097-84ed38e083d6"], "metadata": {"window": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships.  This includes strategic sourcing,  along with the high \ndemand area of manufac turer services.  In Q2, we saw double -digit growth from manufacturer \nservices, where we continue to invest to build upon our capabilities, such as our leading Specialty \n3PL and Sonexus, our access and patient support portal.  And, in the area of cell and gen e therapy, \nwe are excited about the work we are doing in this emerging space across all of our service offerings, \nexpanding our capabilities and the opportunities we see in the future.  \n \n", "original_text": " \nPage 7 of 16 \n \nAs part of the recent segment organizational  changes, we also created a new Sourcing and \nManufacturer Services organization, enabling a more holistic approach to enhance our strong \npharmaceutical manufacturer partnerships. ", "page_label": "7", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7df6ad5f-8465-48b7-b28f-41a819c1dfb8": {"node_ids": ["b1e82e1d-7bb7-47b9-b522-96ab989e300f", "0fd4e993-9e9f-472f-9834-49e53f4c9609", "11b284ec-3c0b-4288-b530-57b6c0654ee5", "b8202855-051e-4406-91c6-c1222deebe83", "b3d4cebe-aa1b-4340-a4e3-1f546bcde761", "221af547-cafc-4819-b5ad-166a417c435b", "b176d3b1-f42b-42e4-ad6e-069df00a74f0", "588b7cc8-29d9-4dc0-847f-c8ea801bd283", "e67499bc-1870-496b-9ac7-8ffb440f6efc", "bf75db4f-3d0a-4d0d-980c-fab8ed025023", "b5d1cc88-a2fa-4393-ad3d-a94bc32c2098", "cd41bb40-f23d-497d-9588-f9f2d7b218cd", "9ef5d208-2079-47ec-8d1b-45c94831cd98", "a2865a0f-51e8-46cc-87e1-27d671f2dc6c", "9a993f51-f564-4c7d-8cd7-64b0bd2fcf30", "b9a5e6df-d0e0-47cf-9ca5-61c994339900", "76fbe46f-c81b-43db-981b-1f2dabd55772", "d5a255fd-5513-40a3-bec7-33d50138a758", "b0db8a74-78fe-4504-8572-794ae9f5f831", "a1c303e0-c318-42eb-aff3-e67d24603458", "a0f1636f-bc0f-45bb-842f-9204888e486f", "bc0bcc7d-e973-4983-92a2-ebc0c7a89529", "da32364a-e8c4-4d25-8891-1a852d61662e", "8a80b0cc-ee8a-4ece-a85c-0816b9506876", "44d8c1e0-ad7a-4bc9-934c-933a355ce64a", "c1f9ee80-8845-4a07-91b7-67c937172d7e", "3e369788-8113-4fdb-b896-557ea220a626", "433dd27c-cdc7-419d-86b0-bc795da8364c", "2e3afc69-e76f-45d1-b80d-da255c82a459", "0000b7fd-6042-46b3-b6e2-6b3ff445a27c", "4faaf20e-f4a4-456f-bbb7-6d6a2d96838f", "a921f115-5d6b-4372-bf99-6f35e38530a7", "1d9f792f-bec8-4b35-bed5-88dc22faf274"], "metadata": {"window": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n With that, we will take your questions.  \n \n Operator :   As a reminder, if you would like to ask a question, please press star one on your telephone \nkeypad.  To withdraw your question, plea se press star two. ", "original_text": " \nPage 8 of 16 \n \nare driving the execution of these critical priorities and who keep  our customers and their patients at \nthe center of everything they do.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "dd429be4-daeb-4b7f-9e42-f01187bcd097": {"node_ids": ["67def20d-9ea9-4e7d-b4ae-89c5aad6203a", "de78e4c8-32f0-4440-933d-5b3a9f4ab736", "302df498-ad0e-47d0-bb98-83f8ee0569b4", "c4d4ee26-2813-4158-ac1b-749b4d9fcf20", "8ace5f03-e90a-4ee9-bfe6-ca5a25f45e00", "d710224b-15a3-47e7-a057-83b0f0a90912", "b78b9865-348f-4b1d-b537-9aea758349ff", "5436a088-6bd8-428e-8f4a-4f35c6a81f6a", "3e3568cc-32e4-4dd8-975e-b57c530dfea3", "ea3ca64d-53bd-4c32-bba0-f21c504ae65a", "1570809f-877d-43d1-a307-c5dd1703cce8", "07008c2b-6931-4833-aee0-56be86c8e32b", "791556e7-4643-401a-a8c1-f37b9b23806d", "57b5687a-3e67-4732-8946-51ed601315d8", "a85309d5-d00b-4dc1-86e7-c3866f0e2d61", "9b7a69f5-b7b9-4574-ad7c-31db049db412", "f8c75df8-3e9f-4f2e-8639-9075fffed053", "5cd80e16-b29b-4a9a-b7ff-4ce2cf0d7392", "99354fc7-3e2e-4f71-8584-ffb506ee9f0f", "c83ad98a-2a7e-49c4-8262-9f92c58cd150", "b6a32b6c-d583-45a1-a2fe-ef061fa33d3c", "baa0fd75-bf02-41b9-a17d-3a4df94ac7db", "a3f04ff5-46e6-47d9-aa1f-b533e49c517c", "f9bcf030-626c-4305-98e7-aaa99007a1e2", "c7357f2a-7855-4f48-ad9c-0bbafc0858bf", "df52489e-5dff-4303-aea9-d2c164b75905", "9723b015-facd-4e2a-89d9-4881f6a7040e", "f1f7f033-3952-4f59-8b3a-5827d7d2835c", "33996750-9bf5-49d8-82a4-7719c28f57af", "b3c06962-044e-4d3f-a166-916418f17a91", "0893ad95-6a76-4bb5-a733-b2faaaced0f3", "01624c07-a73c-4966-8342-ff544260e16b", "bc5c3441-b354-474d-8696-1e507c9641e3", "5a5e8671-57a8-4d6e-a3fb-9835a1f74ab8", "bbee6f12-8fe4-49e2-9988-88c52842bc85", "7ebd6bfb-af36-428f-8b77-e7c177a5e762", "0cd67157-09d6-4d6a-b799-5949b2d05687", "15129a88-67a3-4035-836c-11aeaceb295f", "fdc05d53-75c7-4c8b-95ee-096b8070ffad", "72f6ae19-6f18-4b0f-9fed-838801e32e13", "fc8e0605-9b46-468e-8bd9-34482accc5ec", "3c6de64a-f99d-4e72-9186-6e7368358a05"], "metadata": {"window": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears .  So presuming that that maintains, then that's the range that we should be thinking about, but if \nwe get back to an increased level of volatility, which at this t ime we don't foresee, but that's certainly a \npossibility as well.  \n \n Lisa Gill:  Okay .  Great . ", "original_text": " \nPage 9 of 16 \n \nconsistent type s of volumes, but even that's a bit of an anomaly from what we've had over the last few \nyears . ", "page_label": "9", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ad811cbd-25ae-466d-95f2-d0b9bb5b9a93": {"node_ids": ["a223dec7-ba4d-4b0d-92fc-9e4d9ff13b89", "becef871-f08d-4675-9711-fee56f58d59b", "6afc8418-8aa2-4275-8018-4b534800fb02", "469ed938-c12c-451c-aa2d-c470c5c7df2a", "d10b5225-045f-4410-8001-d2a80f1a6a33", "b08a66eb-b0da-4979-804e-da6090d9e1d7", "26cb7d7c-971e-41d5-9997-b2154e09a3b0", "ffa24f4e-f832-45a8-b5da-5af6c0e2071b", "c9956daf-cb97-41ad-aa82-6aef5a6c5c23", "a6ca408b-0626-4a99-b435-11a5f830e172", "9d33b4f7-78a6-495c-88eb-e69d9ea1f40c", "6c86163c-eb22-44af-87a1-17affd757718", "c7ccf4fc-8168-480e-848d-146a55795388", "5adef5cc-5de6-4192-adf2-7a182e19cc11", "39dcb5a9-6197-4ae9-811b-428cb4a94ec8", "d4cccf5f-6ceb-452e-83ae-aa85a83b5896", "85c5126f-8b70-40a0-9642-1a51b8bddc17", "220fb467-f16f-421f-aa22-5fbf822c7c2a", "fed5e84c-2804-4db7-9495-17e54d08cd9c", "031ad419-3264-4c18-9bb2-9bb69813d811", "06848ef4-da9c-40ce-9428-2d9ef5cd5fa4", "7f1efa0c-9715-47df-96d7-13eaf68a33af", "3546f48b-3cf2-4778-874c-4b02103b4c71", "850b9995-4ad7-405e-9a8b-4b84cb04d7b3", "e614fda0-35e8-42fd-a892-c8ca2c67143d", "243ef65e-9242-46e0-9dd1-e546c6e93e72", "cccf96d8-0e2e-42c6-96a1-39a277695418", "111b3192-da75-486d-b8ad-1eac52751347", "06885133-ba00-49ad-b9a4-883eb7a2e3ac", "5154d0de-65cc-421a-945a-072c43bec20e", "e5935cdb-1629-4aa0-bde2-1f359492f7a2", "59730801-8ae2-4246-8d31-de5764fc6e16", "52fa0572-2903-4fc8-83e2-dba261943491", "ff6e5005-b972-4c34-9f00-4ccafb875d9a", "cbc74f0a-16a5-4043-ba0b-ec515f127ee4", "68936f94-5472-49ff-b673-39a36faef873", "7d3f760c-aae6-46ba-b6f7-e4627b305245", "c975000f-a168-4cff-8112-24bd9173bc7a"], "metadata": {"window": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong .  If you're thinking about it from a \nyear-over-a-year perspective, we also just have the added points that we did introduce a new customer \nin the third quarter of last year and that has been a nice tailwind for us the last four quarters .  But this \nwould be the last quarter until we start to lap that .  So that's part of the driver from a year -over-year \nperspective.  \n \n", "original_text": " \nPage 10 of 16 \n \nAnd then just one other comment about the Q2, why it was so strong . ", "page_label": "10", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f8bf8a8d-f6a5-42aa-a73b-469edfe275bc": {"node_ids": ["c1435194-9a41-410f-ae56-5b2eb1eb7ef4", "e7ae1e7e-6260-4352-b8bb-e2cd298c1d13", "e6a1beb5-fbe5-4269-9c49-6cfd7f9d8d62", "5b99335b-ad31-4f71-81ea-1de759a4ecf6", "540753a0-940e-4cf4-b20e-c962947b3aac", "f805ca83-5187-44e6-8879-dfaf54590c06", "9f53d773-3600-45e3-9077-a2212e204849", "62bd08d0-3559-43de-997f-198fe6a627bd", "fb99ac05-1337-493a-a6be-3a6958f39740", "515b2e66-20fa-4024-9ce4-1f8ce607907a", "2de379e9-09de-4e98-b4bd-1ec709c42480", "42c5be59-6ff7-4aac-867d-c9631860be4e", "bc4c5fe0-8603-4494-bc81-0030a4f86cae", "344e6acd-2256-48c3-9f65-494cd51d3bb4", "b67d4f2f-7a8d-4a3d-aba5-041d3e69c749", "f91f5dbf-ebc2-46b9-af41-078a3260f1e3", "0752e085-1f39-4d98-aac0-2f66d5df6b30", "4bfb7098-4c78-4911-ac57-6a470f19e0d8", "0bbb7d85-691c-410f-aa74-795bc5b1f525", "6e1095e4-e7d5-4b15-a416-ef5caa089c87", "ae036f55-355c-4729-b77d-3b68d137baac", "10c25cc7-f610-4e0a-8ca5-8aca76d8ae98", "1659e96c-1249-4f7f-a4b8-c45161884243", "17d2613d-5cf2-4190-8db4-dc26857f3bb5", "8a8442e7-a61e-4358-a735-9bbe4a56128a", "18285ec5-a5ab-4e52-ab3b-013bf8c90998", "67d9fcd2-45ac-4a61-8d7e-e1de1296554f", "dcb28e19-ffb9-4988-b277-3e3daacbecf9", "68c10a50-b336-418a-9140-1cf5fe5bbd0b", "060834bb-cc73-4f2e-9f3b-8dde291c851c"], "metadata": {"window": " \nPage 11 of 16 \n \nErin Wright:  Thanks .  So, you haven't really participated much in COVID treatment or vaccines \nobviously, with the contracts that are out there .  But as those open up to the private market, could that \nprovide a n opportunity for you as we're looking into next year?   And maybe thinking about some of \nthose other anomalies kind of into next year, what are some things that you're thinking about in terms \nof opportunity across that core Pharma segment as well in terms of drivers, or is it a continuation of \nthe same in terms of specialty drivers and other wise?  ", "original_text": " \nPage 11 of 16 \n \nErin Wright:  Thanks . ", "page_label": "11", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "25253565-00d3-4e8f-97ca-9f7f17a34a4d": {"node_ids": ["d450eebc-72da-4267-9bdb-637491c3ec67", "493dc7c9-c089-4375-99ae-d973bbb4d0f2", "aef36892-bde4-4329-b428-1d87d6a96a53", "8211f7d6-649d-445d-9ccb-4d7578180711", "790db5ce-b3fd-4e76-8059-54c0e3134db5", "27372dd7-1f77-4967-a29e-ed5ae892d9c6", "f1d8ec53-3c18-47c9-ac84-4d0dbbda2bb2", "3646b089-9ba6-4b5f-8c08-a0c0794a8afb", "76906c52-f938-46f7-a44f-58880e691c87", "5bfd8291-9622-4eb7-b991-84595bc62b51", "15a2b4ef-4bc4-43ff-aa3a-05dd30f3bb21", "28d96ad7-f652-403b-a0f9-551a1a7aac58", "f3a24d5b-95c8-450f-9da6-805df4f66700", "6279037e-c89b-45d3-86bf-c1b2e7334435", "2f70bc0d-4ca4-4bf9-94d7-9b1e07ffa849", "42ce350f-1a15-4e7a-b6ae-adaed7d427a4", "ff6f01c4-d111-4f48-bc99-a756521050ce", "7e0feb91-1760-4ead-80b2-fd373f850dd8", "6a6f4be8-698a-4647-b03d-cbf1b4d7d9ce", "287c586e-556e-4c91-abab-21011d56a338", "5a6b226d-d5ae-4a43-a9f6-5a516159a649", "fd3363c6-64ca-4627-b189-4f6c02bfdf63", "a9522276-2584-4ea2-a4fb-875cd1552599", "f6801f78-81f2-49eb-af8f-a73d6bd11b23", "a4e65071-e63c-4dcc-b31c-61a12339501e", "93ef1859-bf45-4f77-b85a-3358963fbb58", "360c1e66-ea2c-446f-9875-9ec8a55f36ed", "ab57b38f-38e2-4e48-85df-e8eae647621c", "c6c33c5f-a2bc-4a06-9e9d-a317754a801a", "492ecb29-a04c-4ec2-8cf2-b5a97053a8bc", "365f9906-b475-4033-b53e-c37fa3292308", "776a1407-aeb4-49fa-bebd-33a6a8a6e508", "e9471b91-81c1-4e00-8a85-a92d799a64fe", "27bd0026-ab26-49f4-9519-a4feab5aa2ae", "cc63f65e-0c60-417b-a0d3-7b917d0cc88d", "264efb91-5a5b-44cc-ae3e-4a4d3889fcae"], "metadata": {"window": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael .  Again, I feel good about the balance that we have here .  I feel very good about the pro gress \nto date .  We have growth, implied growth in the middle of the range for Pharma in the second half of \nthe year . ", "original_text": " \nPage 12 of 16 \n \nJason Hollar:  Sure, I'll try George, but I'm afraid it's going to sound very similar to what I said to \nMichael . ", "page_label": "12", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "294df374-c06a-492b-94ba-193af1a92c42": {"node_ids": ["32e22566-68ff-4f3e-b12d-304537c3156e", "d5d18cd4-1edd-4cca-9b03-870837c81cf8", "0d4e19f7-972c-4ebb-be48-b4e5f61db4e8", "039a3021-e408-4b8d-b6c4-0acc833ededb", "b42791dc-3bbd-415b-ae99-53e16f501e3d", "61e5094a-c8d4-402f-9a33-04bd67e804c3", "400bbfa3-a4b8-4932-954a-1fd834054df8", "b6a7a26e-22b0-414c-8675-cab268930e67", "fe9deae8-3212-48ee-a1d6-b42a7ca6b556", "157cfac2-54ab-4976-8045-4a06193b268b", "209b0e73-a463-4536-997d-125c932aee2b", "3029b83e-c89f-4f0a-813c-9f6ce9b56a55", "678f8a05-1b07-4aba-a651-2828c036fde9", "2ab9b04e-75bd-427c-9682-0e5d8b102711", "7e62a724-e8d6-42e3-8796-217bf742fa4f", "6f1bf703-5dfc-4c12-99e1-3edb7d4a4a9f", "c23dee31-6b64-4233-9081-952341ffbb58", "c17c3062-74cd-47cc-bb69-0be0182686e5", "e78b1639-1b47-470b-b889-e8e9ce09a9e0", "f99c38b8-c7ed-4b0c-b327-b66b1276251d", "bb85778d-3e4c-4171-8e58-3b8078c7caa1", "b7769a66-73f7-4ea9-9393-ba34254094c1", "4126702c-fb9d-4367-a078-ebefd584b191", "63611da9-db92-4348-a12a-d035e2f5b669", "72400856-d3dd-49d5-9084-18f90a8756d1", "daffc66c-16a6-4878-a781-d70d7a275e32", "e0017eae-dffc-47ce-8e90-e90bc3c2a6ad", "5d452036-43dc-4d86-a249-7538efdc5489", "ad8fe1e0-d707-4782-ae4c-d27d5754dee4", "85ecb61c-935f-4012-9912-aa07d0f3334d", "ffc90a20-3964-4f21-a74b-a8498d69531c", "3d5d9725-13de-41b6-b36d-86f7aaee9c8d", "901a2464-fe68-4acc-be13-1ce694854a46", "5bf27700-81a3-4117-92b6-73e66fa7472d", "039804b1-2d98-47db-b5fe-e5d11e054183", "5c8f90e2-e68f-47fb-a297-579fa20cdf46", "1df31580-c67b-40a3-beb6-ff6003703457", "bbb0423a-e878-432d-8f52-c3eccf99bcce", "d8c1a1b9-a24b-4161-a7d7-a81f77ffb668", "9f1a2803-75b2-4314-bf22-7aa8472c50f7"], "metadata": {"window": " \nPage 13 of 16 \n \nthey come up .  And that's just a natural function of where we're at in this process as we get farther \naway from the initiation of those temporary price adjustme nts.  So a continuation of more of the same . \n \n How you get to a widening of that 30% to 50% by end of the fiscal year  is the cost starting to come \ndown . ", "original_text": " \nPage 13 of 16 \n \nthey come up . ", "page_label": "13", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f6793a06-9bf8-4999-90fb-a228792d9b4c": {"node_ids": ["6d95b88e-f611-4a42-aaf9-1307cfe44ce3", "826c18d3-96a8-4e63-8fc7-fbc883300d82", "a138579e-010f-48e2-a288-303e695d0659", "db473f30-37e5-4b3d-a549-d5c52408b74f", "70f4e11b-110d-4012-a513-979d7ce30e7c", "3d3f4226-b9a1-413d-b64f-2ab63909140f", "2c141f2e-7449-426b-8c00-1fab9eabb506", "d65e06c2-50d1-4743-806a-c99fc97433ca", "91e3a5d4-0e7f-483f-8508-af3991fa1bfa", "04f17601-578c-41d2-aaaa-41680e61939b", "fb1b05a8-0ecb-4a91-9f39-5644097a4140", "c93b3335-b168-4002-9569-7d29ad7a725b", "c0c3ee60-fed9-4979-9b8d-ebdee76ae4b2", "0adc0a7f-317d-4396-bb4f-0173ec047bc4", "4dd6ae99-8dc9-458c-80d0-7f35f2cd0934", "d0611d43-60cf-4713-bc05-0390e1eaf5e2", "3f6c8f47-6197-4076-ac7f-f1bd37f1dc39", "93385183-1f82-4efc-964d-2ede51fca0c4", "4fad0dad-f103-4c45-97d8-3a08117a29a0", "6067434f-ebb1-40d3-a4de-1304d0006584", "362a4cb3-0e56-4729-825c-da89a740f1b3", "ac0edbd7-3ba0-4c52-8798-26f361ebb5ca", "6d22d18d-d5f1-4c36-a2a1-962ed6898d40", "62be3b3f-66e1-48f2-b5db-b31d4dcb9266", "f8ca9968-dd9c-4b5f-9fde-70e92ca31fcd", "f91571cc-7f9e-4a39-959f-2165620b2aa0", "4b696808-da39-4619-b69e-1ea8341af1f1", "7094295c-4479-48b7-bf43-03f776d382e2", "bdb1876a-e1dc-4446-99b0-09d4db29b0e4", "5f6b55c0-13a1-4f15-b042-031c04ed013e", "77040772-f3fc-49cd-92e9-48ca85f3eed5", "2b83b1eb-3e4b-4678-abb1-b37afe204bfd", "6adba9a8-1f04-4cfe-bb68-cc77a80093e7", "524f1ea1-0d05-47e5-97a3-e16b87d0121e", "cb12cd5c-0047-4964-8d66-fc6724b7eb25", "75b010f4-f0fd-4d1f-ade1-d1f0a74919c4", "815b0562-8ed1-4867-91dc-4c319fc7d411", "22937657-3124-4afb-b54b-8855eb6ee836", "8fd0c16b-8839-4c4b-a6fe-676609029edf", "e1248843-c736-4d81-9236-0c6c37ee6a3a"], "metadata": {"window": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue .  And I believe for both the first and second quarter, we grew it by \naround 9% .  But again, you can look to the segment to get the precise numbers each and every \nquarter.  \n \n Charles Rhyee:  Grea t, thank you.  \n \n", "original_text": " \nPage 14 of 16 \n \nlast year was $2.4 billion of revenue . ", "page_label": "14", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f80e702b-d364-4eea-81d4-23a0966f4aec": {"node_ids": ["76af05d8-fe26-44ed-9ae1-f7617683e865", "4d2226ee-73d7-4174-98fe-1d0eb4e42893", "63b0cc4b-9e0b-48a6-8eb8-fffe9501de3b", "7140ddc2-c6fe-43a2-ac6a-80e8fb52732d", "fde66348-4850-4545-ac41-5777e0eeee02", "20e3c8c4-1806-42cd-a78b-ec61cf32fd9a", "6652d02f-9fd0-4876-aad4-72b99ee1185f", "af9f64b8-c5cb-4051-83d9-a2e3e9e6162a", "667f4776-6340-41d1-b118-8f3998bce2c6", "19e8bc63-1aae-491a-8ad6-b5dd0528f0e6", "3c4a2df2-5c0e-4cd4-843a-7c7c4f0ed22b", "372ef484-c8d2-45c0-8c6c-651596021083", "64592f03-9d19-4453-bfab-9877a1d4f44c", "c14317df-a163-4f90-b274-0052bac9f8f0", "7a584d19-b756-4f22-b0f0-ab90a6d422ec", "b984cfc3-d191-469c-92a8-691d5921efe2", "c5e2f90b-f377-4a5d-a8eb-ad5f30865bde", "bb9c3d17-8ee4-4a43-8633-6212214cda5a", "15548602-8581-4f3b-ac44-74a0eb58e76f", "f1ed08bb-dfb1-441c-872b-5c9149225c23", "aba89d2f-879b-44df-b6b0-a7f0bc8e6327", "eee6670b-265c-46e7-9768-5aa5b03cd501", "5178e45d-c66f-497d-9bd1-eb9e04d20b2a", "449b0856-b7aa-4751-b608-336619d6ffc8", "a0f6e58f-c0f4-4bb3-8df6-5177ffb4cb4d", "72da486a-4ebc-42d7-bec8-93c31b209aa4", "bf4373fd-bcdb-4f4e-a04e-f078ef2627de", "6a0dce17-223b-4089-8937-9aa40d0eb65c", "d0610b98-ce31-4862-b002-2b1c6ba09e22", "5d162c96-991e-478b-bfb6-e66cec6f7ef3", "f56ab946-2bb5-46ff-afa0-501bc765fcc5", "ccd7ea31-7887-4a1c-b3b7-75ac0aae4ee9", "249bb9b7-e1bb-4ee2-bbe7-2b12d27260f7", "34608af1-71e5-40d0-bb1f-6b1014bf4ed1"], "metadata": {"window": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business .  It means that we have good visibility long term, but also \nmeans that we have to wait until we can get that benefit.  \n \n The theranostics has been something we' ve been working on since well before I arrived here in the \norganization three years ago, and it's one that we're now seeing the fruits of all those investments \nand efforts from that team.  \n \n As relates to the second part of your question, Eric, I get lots o f questions around trying to link our \nbusiness, our nuclear business, to specific approval, specific other drugs, and therapies and how we \ncan attach that . ", "original_text": " \nPage 15 of 16 \n \nThe thing with the nuclear business that is both wonderful and also at times a little bit frustrating is \nthat the business is a long -term business . ", "page_label": "15", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f71f1bc5-814d-4077-9dfe-712cfeeb4ea3": {"node_ids": ["e3466554-4242-4138-ad80-42c733ed41e5", "1593b5a0-3c0b-4c8c-ab8c-89e76809e4c4", "5d21f074-0129-400e-b91b-e4fe099d03ab", "47ad4671-0554-45f6-ae1e-0bdf2a35dc63", "2eb6ddd4-28b3-4658-b126-d1faab1c3a9d", "88e4d535-4878-4b09-91e1-48ef7a19d3e9", "3b90d5bd-5e8d-4136-89a2-da3580cad9c3", "22db8857-9e0a-48b8-9db6-fae1fc8d455b", "f0ed527e-1fc7-4e74-a1ed-4b4b41781985", "142a0d69-79e9-4c72-90db-7d361fab24e5", "214f2b3a-89a1-473a-bb11-68f131ca2b0d", "3a91214b-0154-460a-85ae-e32b8037f555", "22ca1f9b-3bba-4662-a0d1-dd15dfd08f6a", "4d4c7df1-a8d7-4b0c-8402-1d6f26be6bf2", "7fe072c6-45a1-4cd0-aea4-b77e98d3bedd", "faf500de-a404-436a-a824-740419968fb0", "27ec8d71-06bf-4788-a122-8db748fa2ae6", "bdfbc346-2a71-43f1-80fd-4ba588bc8f62", "21b96769-c1f6-4874-b86e-677dfed76554", "8f5c4638-27e6-40bf-898d-531cab4ba047", "cc0d8a2c-77ab-452b-97c3-594765893bed", "78ba5c2f-21f1-4f4f-955d-db4de2b799c8", "b507281c-861b-4d13-aa9d-946abb2473c8", "4f89d09d-58e1-435e-b2a2-8d4d386e6860", "25e98902-e55e-4838-974f-05c30849572c", "c3e63db3-ef9b-4d11-aadf-048cc9e8751e", "60cfb81a-f6ef-4547-a852-8dd6395f55f1", "749c8528-187d-4b36-bab2-e22e93a51429", "32e68f3b-7c14-4032-804f-aaebfca67fa4", "821c151f-9f93-479f-874f-1bf56c36333e", "32fadebb-23ec-4de1-bec7-d284dc82fd65", "0869f6e8-59b3-4c15-bcb2-3f45b81335e2", "7b0783fb-0f0d-490c-8c6b-2b4af219cf0f", "1e8d5d92-1a22-4a71-973a-26f04e0f3787", "4862379a-9f2a-4268-bc29-db176533ecd3", "5913b7f8-e23d-4f0e-a24a-1df012ddab37", "5f191ba1-8183-4791-9af6-dbc8935f0f89", "71772b30-5457-4276-9b1b-e2be64614ffd", "8ec7b3df-1344-4327-b24a-619e19f808ba", "b9621562-3e0b-489e-a8e0-472d14cce89a", "6ffc54f0-c7ef-4948-82da-7887a76dc00a", "d3b212a7-2ccc-4841-a4b8-24045b45b309", "ad40ac1c-08a6-4aab-8970-33d264cd9ca7"], "metadata": {"window": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel .  You have, you know, the equipment \nand the drivers, all of which, you know, are higher cost and they're not expected to come down any \ntime soon .  So I expect domestic transportation to be higher longer, perhaps forever .  And it's why we \nneed to have permanent pricing because of that component. ", "original_text": " \nPage 16 of 16 \n \nlot of inputs that go into transportation other than just diesel fuel . ", "page_label": "16", "file_name": "CAH-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 197693, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}